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Abstract 
With one third of the world's population infected with tuberculosis, and 8 
million new cases of active disease estimated annually, tuberculosis has been declared a 
global health emergency. Of particular concern has been the finding that drug 
resistance has developed in every country surveyed, and has reached high levels in a 
number of settings. Treatment of resistant cases, which require costly and difficult 
specialized regimens, has added considerable strain to health programs. Crucial 
questions in the global control of tuberculosis are raised, including where and to what 
extent will resistance emerge? And, can current control programs adequately manage 
resistance or are modifications needed? This problem is addressed in this thesis at 
three levels: the emergence, transmission and control of resistance. 
Emergence and transmission 
Drug resistance is a man made problem which first emerges by the acquisition 
of drug resistance mutations during the treatment of a drug sensitive case. This 
acquired resistance can then be transmitted to new susceptible individuals in the 
population, who are said to develop primary resistance. A mathematical model for the 
transmission of tuberculosis was developed on the basis of current understanding of the 
epidemiology of TB. The structure of the model includes the emergence of acquired 
and the transmission of primary resistance, in the context of a drug sensitive epidemic. 
Drug resistance was shown to emerge in a series of linked sub-epidemics following the 
start of treatment of a sensitive epidemic. Poor control practices, including a low 
treatment cure rate and a high acquired resistance rate, allows for the development of a 
high prevalence of resistance. 
Control 
In order to consider the impact of different control strategies, the model was 
expanded to incorporate elements of first and second line control, including case 
detection, treatment cure rates, drug susceptibility testing, and specialized resistance 
regimens. In addition, the importance of waiting times to treatment and return of drug 
susceptibility tests was examined. Case detection and treatment was found to be the 
most important control measure for reducing disease levels. For controlling resistance, 
the cure and drug susceptibility testing rates were most important. In high burden 
countries, control priorities should focus on increasing the case detection and cure 
rates. In areas where poor treatment practices have already resulted in a high 
prevalence of resistance, control measures should be first improved before expanding 
the program. In regions of low incidence, control measures should be improved 
through detection and treatment of latent infection. 
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"There is a dread disease which so prepares its victim, as 
it were, for death; which so refines it of its grosser aspect, 
and throws around familiar looks, unearthly indications 
of the coming change—a dread disease, in which the 
struggle between soul and body is so gradual, quiet, and 
solemn, and the result so sure, that day by day, and grain 
by grain, the mortal part wastes and withers away, so that 
the spirit grows light and sanguine with its lightening 
load, and, feeling immortality at hand, deems it but a new 
term of mortal life; a disease in which death and life are 
so strangely blended that death takes the glow and hue of 
life, and life the gaunt and grisly form of death; a disease 
which medicine never cured, wealth never warded off, or 
poverty could boast exemption from; which sometimes 
moves in giant strides, and sometimes at a tardy sluggish 
pace, but, slow or quick, is ever sure and certain." 
— Charles Dickens, in Nicholas Nickleby 
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Introduction 
"Twenty years ago, tuberculosis, even in its most 
dangerous form, consumption, was still not considered 
infectious. Of course, the work of Villemin and the 
experimental investigations by Cohnheim and 
Salomonsen had already provided certain clues which 
suggested that this conception was false. But it was only 
with the discovery of the tubercle bacillus that the 
aetiology of tuberculosis was placed on a firm footing, 
and the conviction gained that this is a parasitic disease, 
i.e. an infectious, but also avoidable one." 
— Robert Koch - Nobel Lecture , 
"The Current State of the Struggle against Tuberculosis" 
"Nobel Lecture, December 12, 1905 
Tuberculosis, an infectious disease caused by Mycobacterium tuberculosis, 
currently causes more deaths than any other single infectious disease. In 2003, the 
World Health Organization (WHO) reported a global incidence of 8.5 million new 
cases and 3 million deaths attributable to tuberculosis. One-third of the world's 
population is infected with M. tuberculosis, although only 1 in 10 of those infected will 
ever progress to active tuberculosis disease. Tuberculosis is particularly concentrated 
in the developing world, which suffers from 95% of all cases and 98% of deaths. 
Treatment of the high burden of tuberculosis in the developing world is complicated by 
poverty and under funded health control programs. (Dye, Scheele et al. 1999; WHO 
2000; WHO 2001; Mathers, Stein et al. 2002; WHO 2002; WHO 2003; WHO 2003) 
Throughout most of the 19"^  and 20"^ centuries, tuberculosis has remained a 
widespread and deadly disease. Improved living and social conditions, as well as 
isolation in sanatoria, led to reduced incidence and mortality through the early 1900s. 
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With the introduction of effective chemotherapy in the 1950s, there was an accelerated 
decline in both incidence and mortality rates. However, by the early 1990s, there were 
notable increases in tuberculosis epidemics worldwide. A number of factors are 
believed to have contributed to the resurgence of tuberculosis, including degradation in 
program management and funding for tuberculosis and the HIV epidemic. In 1993, the 
World Health Organization (WHO) declared that tuberculosis posed a global health 
emergency. (Grzybowski 1991; Styblo 1991; Sudre, ten Dam et al. 1992; Dolin, 
Raviglione et al. 1994; Kochi 1994; Kochi 1994; Murray and Lopez 1994; Murray, 
Lopez et al. 1994; Raviglione, Rieder et al. 1994; Raviglione, Snider et al. 1995) 
The emergence of drug resistant strains has further complicated control of the 
resurging epidemic of tuberculosis. In particular, multiple drug resistant (MDR) 
tuberculosis poses a significant challenge for control programs, as these cases are 
significantly more difficult and expensive to treat. Epidemics of MDR tuberculosis 
have been reported, most notably in local outbreaks in New York and the former Soviet 
Union. (Frieden, Sterling et al. 1993; Viljanen, Vyshnevskiy et al. 1998; Yerokhin, 
Punga et al. 2001; Munsiff Bassoff et al. 2002) Recent surveillance has shown that 
resistance to commonly used anti-tuberculosis drugs have emerged under every 
treatment program examined. Local hotspots of resistance, with a resistance prevalence 
of over 30%, were found in several regions. This has alerted concern as to the future 
course of resistance epidemics, and the potential threat resistance poses to the control of 
tuberculosis. This has also led to growing concern about the management of resistant 
cases within program conditions. (WHO/IUATLD 1997; Espinal, Kim et al. 2000; 
WHO/IUATLD 2000; Davies 2001; Espinal, Laszio et al. 2001; Raviglione, Gupta et 
al. 2001) 
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In this thesis, the concern over resistance within tuberculosis epidemics is 
addressed at two general levels: emergence and control. First, the conditions under 
which resistance emerges to high levels are considered. Mathematical models for the 
emergence and transmission of resistance are analyzed to identify the conditions which 
allow for the greatest selection for resistance. Questions posed in this section include 
where does resistance emerge to high levels, and under what situations is there a threat 
of the emergence of self-sustaining resistant epidemics? When is there cause for 
concern that resistance levels will continue to increase and interfere with control 
efforts? 
Secondly, the strategies for control of resistance within tuberculosis epidemics 
are considered. With resistance observed within every region surveyed, what 
approaches are advisable for management of these resistant cases and prevention of 
spread of resistance? Finally, how should combined priorities of reducing disease 
levels and prevention of resistance be incorporated into current programs? 
In Chapters 1 to 4 the literature on tuberculosis is reviewed. In Chapter 1 the 
epidemiology of tuberculosis is presented. The first section of Chapter 1 focuses on the 
global burden of disease and current practices in surveillance. The second section 
focuses on resistance, including trends in resistance and observations from recent 
surveillance of resistance. 
In Chapter 2, the molecular biology of tuberculosis is reviewed. This chapter 
focuses on the properties, lifecycle, transmission, and virulence of Mycobacterium 
tuberculosis. 
In Chapter 3, the treatment of tuberculosis is reviewed. The history of the 
treatment of tuberculosis is followed through the development of effective 
chemotherapy regimens. The current recommended regimens are explained, as well as 
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the structure of global control programs, mechanisms for case detection, and tests for 
diagnosis. In a related chapter placed as Appendix 4, there is a more complete review 
of the drugs commonly used in current chemotherapy regimens. 
In Chapter 4, the contribution of mathematical models to the study of 
tuberculosis is reviewed. This chapter examines models which have contributed to the 
understanding of the natural history, the epidemiology, and the intrinsic dynamics of 
tuberculosis. In the second section, models which examine resistance are presented. 
The third section includes recent models which are based on the molecular 
epidemiology of tuberculosis. 
In Chapter 5, a mathematical model for the emergence and transmission of 
resistant tuberculosis is developed. The model construction is explained, the 
parameters described and sources for parameter estimates given. Appendix 1 provides 
a more detailed description of the model, including a parameter table, model outline, 
and the set of differential equations used to define the basic model. 
In Chapter 6, the dynamics for the emergence and spread of resistance within 
TB epidemics are examined using the model presented in the previous chapter. A 
detailed sensitivity analysis is performed to identify the parameters which most 
influence model predictions and to characterize the relationship between uncertainty in 
parameter estimates and model outcome. Appendix 3 provides full details for the 
sensitivity analyses, and presentation of the simulations not shown within the summary 
of sensitivity analyses in Chapter 6. 
In Chapter 7, the model presented earlier is further developed to include more 
specific aspects of tuberculosis treatment, to provide a framework to consider the 
control of tuberculosis and resistance. Appendix 2 provides a more detailed description 
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of this model, including a parameter table, model outline, and the set of differential 
equations used to define the basic model. 
In Chapter 8, the model is used to examine the impact of elements of first and 
second line control programs on the dynamics of epidemics and resistance. 
In Chapter 9, a more detailed examination of the impact of elements of control 
on disease and resistance is presented. This chapter focuses on the priorities for control 
in representative settings which differ by disease burden, resistance prevalence, and 
level of control. 
Chapter 10 provides a final summary and discussion of the entire thesis, along 
with brief consideration of implications of this research and future studies. 
20 
1. Chapter 1 
Epidemiology of tuberculosis 
"But let me add a warning: do not get snobbish. 
I remember I used to sort of despise the untutored, 
ignorant folk who did not have or had not had TB. I 
looked down upon such unfortunates as an 
inexperienced, inferior lot, who after all, couldn't know 
much about life or anything else. They simply didn't 
belong, thought I with a superior sniff—until one day a 
friend, an eminent TB specialist, sensing my attitude, 
maliciously told me that truth—that autopsies reveal the 
democratic fact that nearly everyone has had it! Which 
leaves us only one point of superiority to brag about: 
We know it and the rest of them don't." 
— Eugene O'Neill, in a message to 
patients with tuberculosis 
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I. Goals 
I. A. To review the epidemiology of tuberculosis. 
I. B. To review the methods for measuring and surveillance of 
tuberculosis disease burden. 
1. C. To review trends in resistance to tuberculosis drugs. 
II. Abstract 
Tuberculosis, an infectious disease caused by Mycobacterium tuberculosis, is . 
a leading cause of death globally. One third of the world's population is infected with 
M. tuberculosis, although only about one in ten of infected individuals will experience 
active disease in their lifetime. The annual global incidence of tuberculosis is 
estimated at 8.5 million new cases, and of these 3.7 million smear positive cases. 3 
million deaths are attributed to tuberculosis annually, making tuberculosis the 
leading cause of death globally, and second to HlV/AlDS amongst infectious 
diseases. The burden of disease is disproportionately found in developing countries, 
with over 90% of cases located in 22 designated high burden countries (HBC). The 
common measures for surveillance of tuberculosis include incidence and prevalence 
rates, mortality rates, and prevalence of resistance. 
Resistance to antituberculosis drugs has been observed since the introduction 
of chemotherapeutic treatment in the 1960s. Improved regimens, including use of 
multiple drugs and the introduction of the more effective drug rifampicin, allowed for 
reduced rates of resistance amongst treated cases (for review of commonly used drugs 
see Appendix 4). With the resurgence in tuberculosis epidemic in the early 1990s, 
there were also noticeable increases in resistance prevalence in a number of locations. 
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Most notably, outbreaks of MDR in New York City and increases in overall resistance 
in Eastern Europe alerted concerns over treatment practices. In 1993, the World 
Health Organization (WHO) began surveillance for tuberculosis resistance amongst 
member countries. Surveillance showed the existence of hotspots of resistance, with 
six regions found to have over 30% prevalence of resistance to at least one drug and 
over 3% for MDR. 
III. Global burden 
Tuberculosis, an infectious disease caused by Mycobacterium tuberculosis, 
annually causes more deaths than any other single pathogen. An estimated 2 billion 
individuals, one third of the world's population, are infected with M. tuberculosis. 
While many are infected with the bacteria, only about 10% of infected individuals 
ever develop active TB disease, while the rest remain latently infected. In 2002, 
WHO estimated a global incidence of 8.5 million new cases of active TB, with 3.7 
million smear positive cases. (Dye, Scheele et at. 1999; WHO 2000; WHO 2003) 
III. A. Mortality 
An estimated 3 million deaths annually are attributable to TB, accounting for 
3% of all deaths worldwide. Tuberculosis is the 8''^  leading cause of death globally. 
(Table 1-1, (Mathers, Stein et al. 2002)) Amongst infectious diseases, TB is the 
second largest cause of deaths, after HIV/AIDS. (Table 1-2. (Mathers, Stein et al. 
2002)) Together, infectious and parasitic diseases accounted for 19.3% of all global 
deaths in 2001. Amongst communicable diseases (this classification includes 
infectious and parasitic diseases), diseases HIV/AIDS was the leading cause of death, 
accounting for 5.1% of global deaths. This is followed by diarrhoeal diseases, 
accounting for 3.5% of global deaths. Tuberculosis is the third leading cause of 
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deaths amongst communicable diseases, accounting for 2.9% of global deaths. With 
over 90% of TB cases found in developing countries, this affect is disproportionately 
seen in the developed world. In developing countries, tuberculosis is again the 8'^ 
leading cause of death, accounting for 5% of deaths. In comparison, in developed 
countries, tuberculosis is not found amongst the top ten causes of death. (Mathers, 
Stein et al. 2002) 
Ten leading causes of deaths, 
global estimates 2000 
% of total 
deaths 
1 Ischaemic heart disease 12.6% 
2 Lower respiratory infections 11.1% 
3 Cerebrovascular disease &6% 
4 Chronic obstructive pulmonary disease 4J% 
5 HIV/AIDS 4.6% 
6 Perinatal conditions 4.5% 
7 Diarrhoeal diseases 3.6% 
8 Tuberculosis 2.9% 
9 Road traffic accidents 2.2% 
10 Trachea, bronchus, lung cancers 2.19b 
Table 1-1. Ten leading causes of deaths, from 2000 global estimates. 
The top ten leading causes of deaths amongst all countries represented in the survey. 
Amongst infectious diseases, HIV/AIDS accounted for 4.6% of all deaths, and TB for 
2.9%. Source: Table reproduced from (Mathers, Stein et al. 2002). 
Number of deaths 
% of total global 
deaths 
All Infectious 
and parasitic 
diseases 10,937,452 19.3% 
HIV/AIDS 2,865,804 5.1% 
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DIarrhoeal 
diseases 2,001,193 3.5% 
Tuberculosis 1,644,381 2.9% 
Childhood-cluster 
diseases 1,318,151 2.3% 
Malaria 1,123,764 2.0% 
Table 1-2. Total global mortality rates for infectious and parasitic 
diseases. Together, infectious and parasitic diseases accounted for 19.3% of all global 
deaths in 2001. Amongst communicable diseases, HIV/AIDS was the leading cause o f death, 
accounting for 5.1% of global deaths. This is followed by diarrhoea! diseases, accounting for 
3 .5% of global deaths. Tuberculosis is the third leading cause of deaths amongst 
communicable diseases, accounting for 2 .9% of global deaths. Estimates for deaths 
attributable to communicable diseases as reported in the World Health Report 2002, which 
provides estimates for mortality, incidence, prevalence, YLL, YLD and DALYs by sex, age 
and cause in 6 W H O regions in 2001. Source: (WHO 2002). 
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Figure 1 -1. The number of deaths attributable to tuberculosis 
according to gender and age in 2001. Estimates for deaths attributable to 
communicable diseases as reported in the World Health Report 2002. The highest death rates 
due to TB were found in children aged 0-4, followed by those in the age group 30-44. The 
death rate was slightly higher in men than in women for ages 30-80. Source: ( W H O 2002). 
III. B. Incidence rates 
Over 80% of TB cases occur in 22 countries designated by the WHO as High 
Burden Countries (HBC). The average annual incidence rate in the HBCs is 80 cases 
per 100,000, ranging from 30 to 260 cases per 100,000. (Netto, Dye et al. 1999; 
WHO 2003) Regions with less than 10 cases per 100,000 are considered low 
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incidence, while areas with less than 1 case per 100,000 are entering the elimination 
phase, and below 0.1 cases per 100,000 TB are considered eliminated. (Clancy, 
Rieder et al. 1991; CDC 1998; Broekmans, Migliori et al. 2002) 
Studies have suggested that an annual risk of infection of 1% corresponds to 
an annual incidence rate of approximately 50-100 cases per 100,000. With this 
assumption, we consider high incidence rates, as found in the HBCs, ranging from 50 
- 250 cases per 100,000 may correspond to an ARl of approximately 0.5 - 2.5%. 
Other studies have used similar estimates, such as an ARl of ] .5-2.5% in Africa, 0.5-
1.5% in Americas, and 1-2.25% in Southeast Asia and Western Pacific. (Sudre, ten 
Dam et al. 1992) We consider low incidence rates, of below 10 cases per 100,000, to 
correspond to an epidemic with an ARl of less than 0.1%. We use these estimates as 
rough guidelines for considering the timescale of epidemics. 
III. C. Case notifications 
In 2003, 183 countries contributed reports of case notifications to the WHO 
survey. 3.8 million new cases of TB were notified, with an notification rate of 62 
cases per 100,000 population. Of these, 1.6 million (42%) were smear positive. In 
comparison, estimates suggest that there are 8.5 million new cases, with 3.7 million 
smear positive, annually. The reported case notifications in 2003 represents only 45% 
of the estimated new cases and 43% of the smear positive cases. (Dye, Watt et al. 
2002; WHC) 2003) 
The overall global notification rate of TB cases has remained nearly constant 
since WHO surveillance records began in 1980. Meanwhile, the number of cases 
enrolled in DOTS programs has increased much faster. The average global 
notification rate has remained nearly constant since 1980, fluctuating between 50 - 70 
sputum smear positive cases per 100,000. (Figure 1-2, (WHO 2003)) Recent 
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estimates show detection of about 30-40% of global incidence. The WHO has set a 
target for detection of 70% of incidence. (Dye, Watt et al. 2002; WHO 2003) 
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Figure 1-2. Global notification rate of smear positive cases. Source for 
case notification rates: (WHO 2003). 
IV. High burden countries 
Over 80% of new TB cases are found in 22 high burden countries (HBC). The 
regions with the highest incidence rates include Southeast Asia, sub-Saharan Africa, 
and eastern Europe. 37% of the global incidence is found in the South-East Asia 
region, 21% in the African region, and 22% in the Western Pacific region. Together, 
these three regions account for 80% of notified cases. (WHO 2003) 
The number of new cases found in the high burden countries in 2002, as 
reported by the WHO, is shown in Figure 1-3 A. The highest overall number of cases 
are found in India (815,000 cases), China (651,000 cases), Indonesia (261,000 cases), 
Bangladesh (147,000 cases), and Nigeria (119,000 cases). The standardized incidence 
rates per 100,000 population are shown in Figure 1-38. The standardized incidence 
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rates range from 28 cases per 100,000 in Brazil to 261 cases per 100,000 in 
Cambodia. The top five highest standardized incidence rates are found in Cambodia 
(261 cases per 100,000), Zimbabwe (252 cases per 100,000), South Africa (226 cases 
per 100,000), Kenya (213 cases per 100,000), and Tanzania (146 cases per 100,000). 
(Figure 1-3) 
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Figure 1-3. Incidence in the 22 high burden countries. The disease 
burden found in the 22 high burden countries is shown in (A) as the estimated 
thousands of cases in (B) as the estimated incidence rates per 100,000 
population. Countries are listed from left to right in order of highest number 
of new cases. Source for incidence and incidence rates: (WHO 2003). 
IV. A. Trends by region 
Recent trends in tuberculosis epidemics vary distinctly by region. In the 
developed market economies, over the past twenty five years, there has been a marked 
reduction in disease levels. In comparison, in many developing countries, slower 
implementation of control programs and limited resources have allowed for a 
continued increase. In regions with high prevalence of HIV, there has been a notable 
increase in incidence rates, fueled by the HIV epidemic. 
Shown in Figure 1-4 are the trends in case notifications by WHO regions. 
Case notifications have been recorded in these regions since 1980. Amongst these 
regions, notification rates have been increasingly notably only in Africa. In 
29 
particular, there have been significant increases in regions of Africa with a high 
prevalence of HIV. Within the other regions, the average notification rates have 
stayed fairly constant in recent years. The lowest notification rates are found in the 
regions of the Americas and Europe. Over the past five years, there has been a slight 
decrease in notification rates in the Americas, and a slight increase in Europe. (Figure 
1-4) 
In Figure 1-5, the smear positive notification rates, as recorded by WHO 
surveillance since 1993, are shown for each region. While the trends for each region 
are similar to that seen in Figure 1-4 with the total notification rates, several 
additional observations can be made here. First, the increase in case notifications in 
Africa in the past decade has come disproportionately from smear positive cases. 
While in 1993 smear positive cases accounted for about one fourth of total 
notifications, by 2001 smear positive cases accounted for nearly one half of total 
notifications. Secondly, there has been an increase in smear positive notifications in 
the Southeast Asia region, which was not discemable from trends in the total 
notifications. Again, the increase in case notifications appears to be 
disproportionately amongst smear positive cases. Similarly, there were slight 
increases in smear positive notification rates in both the Western Pacific and Eastern 
Mediterranean regions which were not discernable from total notification rates. 
Third, while there appears to be a slight increase in total notifications in Europe over 
the past five years, the smear positive notification rate has stayed nearly constant at 10 
cases per 100,000. The frequency of smear positive cases in the Europe region has 
declined from one in four (in 1993) to one five cases (in 2001). (Figure 1-5) 
As can be seen in Figure 1-5, the region with the lowest smear positive 
notification rates over the past decade is Europe, with a smear positive notification 
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rate that has stayed nearly constant at 10 cases per 100,000. The regions of the 
Western Pacific, the Eastern Mediterranean, and the Americas all have maintained 
smear positive notification rates near or below 20 cases per 100,000 since 1993. In 
the Southeast Asia region, smear positive notification rates have increased from 20 in 
1993 to nearly 40 in 2001. The greatest increase was seen in the Africa region, with 
an increase from 20 in 1993 to nearly 60 smear positive cases per 100,000 in 2001. 
(Figure 1-5) 
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Figure 1-4. Regional trends in the notification rates by region since 1980. 
The case notification rates are given as new cases per 100,000 population in each of 
these six regions: Africa, Southeast Asia. Western Pacific, Europe. Eastern 
Mediterranean, and Americas. Source for the case notification rates is from (WHO 
2003^ 
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The smear positive notification rates are given as new cases per 100,000 population in each of these six 
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Source for the case notification rates is from (WHO 2003). 
33 
AFRICA 
0-14 15-24 25-34 35-44 45-54 55-64 
Age 
65+ 
EUROPE 
0-14 15-24 25-34 35-44 45-54 55-64 65+ 
Age 
WESTERN PACIFIC 
0-14 15-24 25 -34 3 5 - 4 4 4 5 - 5 4 5 5 - 6 4 65+ 
Age 
EASTERN MEDITERANNEAN 
w o 
K M 
g 
'•j 
a 
0-14 15-24 25-34 35 -44 4 5 - 5 4 55 -64 
Age 
65+ 
II 
£ S 
OT O 
c 
25 
20 
15 
10 
5 
0 
SOUTHEAST ASIA 
0 
* = 3 0 
c 
0-14 15-24 25-34 35-44 45-54 55-64 
Age 
AMERICAS 
65+ 
g 
% "v; w — — - ^ 8 — 0 
a 
0-14 15-24 2 5 - 3 4 35 -44 4 5 - 5 4 55 -64 65+ 
Age 
Figure 1-6. Smear positive notification rates by region and age. The smear 
positive notification rates are given as new cases per 100,000 population in each of these six regions: 
Africa, Southeast Asia, Western Pacific, Europe, Eastern Mediterranean, and Americas. Note that 
different scales are used for the notification rates in each figure, to allow for comparison of the relative 
incidence by age within each region. Source for notification rates is (WHO 2003). 
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V. Measures of TB burden 
Tuberculosis burden can be measured in a number of different ways, including 
mortality rates, case numbers, infection prevalence, incidence rate, and annual risk of 
infection. The introduction of chemotherapy in the 1960s has altered the relative use 
of these measurements in surveillance. In the prechemotherapy era, a good measure 
of TB burden in a region was obtained through mortality rates. Under no treatment, 
the TB mortality rate was estimated at approximately 50% of the incidence rate. 
However, with improvements to treatment, the mortality rates have been significantly 
reduced, and this is no longer a reliable indicator of disease burden. (Enarson and 
Murray 1996; Davies 1998) 
Another measure for TB epidemics is simply case numbers in a population. In 
the prechemotherapy era, there was an estimated 2:1 ratio of prevalence to incidence. 
This translated into an average case duration of infectiousness of 2 years. However, 
treatment has reduced the average case duration of infectiousness and disrupted this 
ratio. Estimating case numbers now provides a good measure of the burden and 
density of disease at a particular moment in time. (Enarson and Murray 1996) 
V. A. Estimates of the proportion infected and ARI 
The prevalence of TB infection in a population can be estimated through 
surveys using the tuberculin skin test. However, use of the skin test to estimate 
prevalence of infection is complicated by test specificity. In particular, the test may 
show positive for detection of other mycobacteria, particularly in regions with high 
environmental mycobacteria, or due to BCG vaccination. Once the prevalence of 
infection has been estimated, from serial skin test surveys within a population, the 
annual risk of infection may be estimated. The annual risk of infection represents an 
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estimate of the probability of infection. Again, difficulties with this include those 
inherent to the skin test, including infection with non-tuberculosis mycobacteria. 
The annual risk of infection was first estimated with models developed by 
Styblo, using data from both developed and developing nations. In these models, a 
relationship between the incidence of smear positive cases and the risk of acquiring 
new infection is calculated. This study estimated that there is an annual risk of 
infection of 1% for each 49 smear positive cases (also referred to as the 1:50 rule). 
This has been held as the 1:50 rule for estimating incidence. However, the 
introduction of treatment has disrupted this ratio, which is expected to increase as 
incidence decreases under good treatment. (Styblo 1985) 
V. B. Current surveillance 
The most common measure today for TB burden has become incidence of 
disease. The incidence rate is typically measured as a rate of new cases per 
population of 100,000, in order to allow for standardized comparison. In addition, 
measures of disease prevalence provide a snapshot of the density of disease at a 
particular moment. The standardized case rate is reported in WHO surveillance 
studies as the number of cases present per 100,000 population. Understanding the 
trends in regional TB control programs is also important in understanding the state of 
a particular TB epidemic. Measures reflecting the level of TB control include the 
rates of detection and treatment success (including completion and cure). In addition, 
the proportion cases reporting under DOTS programs, reflects on the program, with 
estimated cure rates under both DOTS often much higher than those under non-DOTS 
programs. (WHO 2003) 
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V. C. Mortality 
In the prechemotherapy era, mortality rates were a good indicator of the TB 
epidemic. There was a nearly constant 1:2 relationship between incidence and 
mortality. However, the introduction of effective treatment significantly reduced the 
death rates amongst TB cases, and other measures provided better indicators of the 
disease levels. Even before the introduction of chemotherapy, the mortality rates 
showed significant declines in the early 1900s, correlated to improvements in overall 
health care and standards of living. In the early 1900s, there was a decline in 
mortality on average of 4% per year. From 1945 to 1960, there was continued 
decrease in mortality rates in industrialized countries, followed by a stabilization 
coinciding with the introduction of effective chemotherapy including use of 
streptomycin and isoniazid in treatment of cases. (Davies 1998) (Enarson and 
Roullin 1998) 
VI. DOTS 
The WHO strategy for TB control is known as DOTS (Directly Observed 
Treatment, Short Course). The DOTS strategy is defined by five central elements, 
which include, but reach far beyond recommendations for standardized treatment 
regimens. The five central elements defining DOTS programs are: government 
commitment, case detection, short course chemotherapy, regular supply of all 
essential anti-tuberculosis drugs, and a standard reporting system for notifications and 
treatment results. The treatment regimens are standardized, with regimens for new 
cases consisting of at least four drugs. The short course chemotherapy (SCC) 
regimens for new cases last from six to nine months, with direct observation for at 
least the first two months of treatment. Case detection is through self-reporting and 
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diagnosis through sputum smear microscopy. (Weis, Slocum et al. 1994; Wise 1998; 
WHO 1999; WHO 2003) 
Since 1995, over 10 million cases have been diagnosed and treated under 
DOTS. As of 2002, 155 countries implement DOTS programs to some extent, with 
61% of the world's population living in areas with access to these programs. In 2002, 
2.4 million new cases (1.2 million smear positive cases) were notified under DOTS 
program. About 29% of total estimated incidence and 32% of estimated smear 
positive incidence are notified under DOTS. (WHO 2003) 
DOTS programs have consistently maintained higher cure rates, achieving 
cure rates as high as 95%. The global average for treatment cure under DOTS is 78%, 
compared to 45% reported under non-DOTS programs. DOTS programs maintain 
higher standards of treatment, increasing cure rates and reducing mortality as well as 
resistance. (Wise 1998) (Raviglione, Dye et al. 1997; Dye, Watt et al. 2002) Under 
non-DOTS programs, in comparison, there are far more variable outcomes. Non-
DOTS programs show lower rates of treatment success, unreliable outcomes, higher 
rates of chronic cases, and higher rates of acquired resistance. However, comparing 
non-DOTS programs directly is difficult because most lack standardization of 
methods and variable reliability and recording of case outcomes. (Raviglione, Dye et 
al. 1997; WHO 1999; WHO 2003) 
DOTS has been ranked by the World Bank as one of the most cost effective 
health interventions. (Wise 1998) In many of the HBCs, DOTS offers a low cost 
alternative within health services with limited funding, political support, and technical 
expertise. (WHO 1999; Wilton, Smith et al. 2001; WHO 2003) Maintaining this low 
cost is important in order to allow viable implementation within the developing world, 
where most cases are found. 
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VII. Resistance 
The emergence of drug resistant strains has further complicated tuberculosis 
control. Epidemics of multiple drug resistant (MDR) tuberculosis have been reported, 
including widely publicized outbreaks in New York and the former Soviet Union. 
MDR tuberculosis poses a significant challenge for treatment programs, as this form 
of tuberculosis is significantly more difficult and expensive to treat. (Eltringham and 
Drobniewski 1998; Bleed, Dye et al. 2000; Dye, Fengzeng et al. 2000; Espinal, Kim 
et al. 2000; Espinal, Laszio et al. 2001; Raviglione, Gupta et al. 2001) 
Clinical resistance is defined as a case that emits resistant mycobacteria in 
their sputum. Mycobacterial confirmation of resistance, through culture or other drug 
susceptibility tests, is required to designate a case as resistant. (See Chapter 2 for 
more on resistance testing) However, resistance may be suspected amongst any cases 
which fail first line treatment. Under many programs, in particular in developing 
countries, resources for drug susceptibility testing of all cases are not available. 
Under these circumstances, cases which fail one or more courses of first line 
treatment, should be suspected of having resistance, and may be placed on retreatment 
regimens. 
Primary resistance is defined as a new case which has been infected with a 
resistant strain. By definition, cases with primary resistance have received no 
previous treatment. In contrast, cases with acquired resistance have developed 
resistance during a course of treatment, and have received at least four weeks of 
previous treatment. However, because it has proved difficult to correctly identify 
cases as having primary or acquired resistance, the WHO has changed classifications 
to differentiate between resistant cases based on previous treatment. Cases with 
"initial" resistance are defined simply as those which present with resistance, without 
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reference to treatment history. Resistant cases with previous treatment are defined as 
those that have received at least one month of previous treatment and do not respond 
to first line regimens. 
Cases continuing to excrete bacilli in sputum after 5 months of treatment are 
designated as treatment failures, and may be placed on retreatment regimens. DOTS 
retreatment regimens usually consist of five drugs, including use of isoniazid, 
rifampicin, and ethionamide throughout, and pyrazinamide and ethambutol in the 
initial phase. Under proper administration, most of the cases which remain infectious 
after 5 months of a retreatment regimen are resistant to at least one of the first line 
drugs. Cases which fail a retreatment regimen are designated as chronic cases, having 
received at least two courses of therapy. Chronic cases show high rates of acquired 
resistance and often MDR. (WHO 1997; Shimao 1998; WHO 1999; WHO 2003) 
Resistance has been observed since the introduction of chemotherapy for 
tuberculosis. In the early regimens, treatment with only one drug, isoniazid or related 
compounds, allowed for high rates of resistance. (Buck 1952; Hobby 1952; Steenken 
1952; Szybalski 1952; Barnett 1953) Studies also observed high rates of resistance 
when patients were treated with either streptomycin or PAS alone. (Mitchison 1950) 
Analysis of these early studies showed that these regimens could improve patient 
symptoms and prolong life, but cases remained infectious and developed resistance to 
the drugs used. (Mitchison 1969) Including a second drug in the treatment regimen 
was shown to reduce the observed rates of resistance to either drug, when compared 
to monotherapy. (Tripathy, Menon et al. 1969) With the introduction of rifampicin in 
the early 1970s, the treatment of TB improved, allowing regimens to be reduced to 6 
months while achieving higher cure rates. Use of rifampicin during the initial two 
months of treatment appeared to give needed bactericidal and sterilizing activity to 
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clear a large proportion of the mycobacteria during the early phases of treatment. 
(Dickinson and Mitchison 1970; Mitchison 1970; Dickinson and Mitchison 1981) 
With the use of short course chemotherapy regimens, containing four or five drugs 
including rifampicin, there was an improvement not only in treatment cure rates, but 
also in a reduction in resistance. Including rifampicin in the early phase of a 
treatment regimen significantly reduced the rates of resistance to any of the drugs 
used. (Fox and Mitchison 1975; Dickinson and Mitchison 1976; Fox and Mitchison 
1976) (See Appendix 4 for more details on drug action of rifampicin and other drugs 
commonly used within chemotherapy regimenss). 
Early studies also examined the treatment of resistant cases. Cases with initial 
resistance showed higher rates of treatment failure and relapse. Cases with resistance 
to a single drug, isoniazid or streptomycin, could be cured with extended regimens 
containing four drugs including rifampicin. However, treatment of cases with 
resistance to both isoniazid and rifampicin were far more difficult; over 70% of these 
cases failed treatment or relapsed. (Mitchison and Nunn 1986) 
With the resurgence o f T B epidemics in the early 1990s, the resistance 
problem has also grown. Epidemics of resistance were reported in a number of areas. 
The highest prevalences of MDR were found in Nepal (48.0%), Gujarat, India 
(33.8%), New York City, (30.1%), Bolivia (15.3%), and Korea (14.5%). (Cohn, 
Bustreo et al. 1997) 
The United States also showed considerable increases in overall TB incidence 
from 1985 to 1992. In areas of highest burden, the epidemic appears to have been 
fueled by poor control and treatment practices, and within high risk groups, including 
immigrants and HIV coinfected. (McCray E 1997) New York City was a prominent 
high burden area, in which the incidence o f T B nearly doubled during the early 1990s. 
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Resistance and MDR outbreaks contributed to the NYC epidemic, Amongst all cases 
tested by culture in NYC in 1991, over 30% showed resistance, and 19% were 
resistant to both isoniazid and rifampicin (MDR). Amongst cases which had received 
prior treatment, 44% had resistance to at least one drug, and 30% were resistant to 
both isoniazid and rifampicin. Cases coinfected with HIV and injection drug users 
were more likely to show resistance. (Frieden, Sterling et al. 1993) A high 
proportion of new resistant and MDR cases were attributable to ongoing transmission, 
representing primary resistance. The overall level of resistance to any drug amongst 
new cases increased from 10% in 1982 to 23% in 1991. RFLP analysis of strains 
showed clustering of a high proportion of MDR cases, providing additional support 
for high rates of recent MDR transmission. (Ailand, Kalkut et al. 1994; Friedman, 
Stoeckle et al. 1995; Bifani PJ 1996; Munsiff, Bassoff et al. 2002) 
Eastern Europe has also suffered significant increases in resistance levels over 
the past decade. In the Russian Federation, the rates of morbidity, mortality, and 
relapse for tuberculosis have increased along with incidence since 1991. These 
changes are correlated to increases in drug resistance. (Viljanen, Vyshnevskiy et al. 
1998; Davies 2001; Yerokhin, Punga et al. 2001) 
In order to quantify the extent of the resistance problem, the WHO and the 
International Union against Tuberculosis and Lung Disease (lUATLD) started the 
Global Project on Anti-tuberculosis Drug Resistance Surveillance in 1994. This 
project coordinated a global resistance surveillance effort within 58 regions from 
1994 to 2000, presented in two WHO reports. (WHO/IUATLD 1997; 
WHO/IUATLD 2000) Drug resistance was found in every region surveyed. There 
was a wide range in resistance reported; the resistance prevalence in new cases ranged 
from 1.7-37% (median 10.7%) in countries surveyed. The prevalence of resistance to 
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a single drug ranged from 2.9-40.8%. Prevalence of MDR, defined as resistance to at 
least isoniazid and rifampicin, ranged from 0 -18%. Six regions were found to be 
hotspots of MDR, with greater than 3% MDR prevalence. (Figure 1-7) 
(WHO/IUATLD 1997; WHO/IUATLD 2000) 
The resistance prevalence within a region was found correlated to a number of 
factors, in particular treatment patterns. Higher resistance rates were found in regions 
with poor program conditions. The resistance prevalence was negatively correlated to 
the proportion of cases notified under DOTS programs. Higher resistance prevalence 
was also correlated to a greater proportion of previously treated cases registered, 
another measure of treatment quality. In addition, higher resistance rates were 
correlated to the time since the introduction of rifampicin and since National 
Treatment Program (NTP) formation. (WHO/IUATLD 2000) 
Using data from several of the WHO studies, we examined the relationship 
between resistance prevalence and treatment. Shown in Figure 1-8 is the prevalence 
of single (DR) and multiple drug resistance (MDR) by the treatment and cure rates 
found in that region. The prevalence of both DR and MDR are seen to be inversely 
proportional to the cure rate. The prevalence of resistance also decreases with 
increasing notification rates; however the strength of this correlation is less. (Figure 
1-8) In order to further explore the nature of the relationship between resistance and 
treatment rates, the correlation between the resistance prevalence and notification was 
examined stratified by program cure rates. When the program cure rates were high, 
increasing the notification rates was correlated with reductions in the prevalence of 
both DR and MDR. However, at lower program cure rates, increasing the notification 
rates had more variable outcomes, and could increase the prevalence of DR and 
MDR. (Figure 1-9) 
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Figure 1-7. Prevalence of resistance within all regions surveyed in the WHO/IUATLD 2000 report. The prevalence of any 
resistance and MDR is given as a proportion of all TB cases found in each region. Regions are listed from left to right in order of 
resistance prevalence. Source: prevalence of resistance as reported by the WHO/IUATLD Global Project on Anti-tuberculosis drug 
resistance surveillance, from (WHO/IUATLD 1997; WHO/IUATLD 2000). 
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Figure 1-8. Treatment and prevalence of resistance: higher rales of treatment 
notification and success are correlated to lower prevalence of resistance. F o r each r eg ion 
which repor ted a r e s i s t ance p r e v a l e n c e wi th in ( W H O / I U A T L D 2000) , t he c o r r e s p o n d i n g t r e a t m e n t 
success and no t i f i ca t ion ra tes f o r each reg ion w e r e f o u n d f r o m ( W H O 2 0 0 3 ) . T h e p r e v a l e n c e o f 
any r e s i s t ance ( D R P r e v a l e n c e ) and M D R ( M D R Preva l ence ) is s h o w n re la t ive t o e i ther t h e 
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of resistance as reported by the WHO/IUATLD Global Project on Anti-tuberculosis drug resistance 
surveillance, from (WHO/IUATLD 1997; WHO/IUATLD 2000); treatment success and notification rates for 
these regions are from (WHO 2003). 
Revalues: (A) DR Prevalence and Treatment Success Rate, R^= 0.191. (B) MDR Prevalence and Treatment 
Success Rate, R^= 0.0901 (C) DR Prevalence and Notification Rate, R"= 0.0372. (D) DR Prevalence and 
Notification Rate, R-= 0.0028 
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Figure 1-9. Resistance prevalence from surveillance by cure and notification 
rates in program. The relationship between resistance prevalence and notification rate is explored. When 
the cure rates are high (above 80%) in the region, higher notification rates are correlated to a lower 
prevalence of any resistance (DR) and MDR. In comparison, when the cure rates are low (at a range of 45%-
70%) within the region, higher notification rates are correlated to higher prevalence of any resistance (DR) 
and MDR. Source: prevalence of resistance as reported by the WHO/IUATLD Global Project on Anti-
tuberculosis drug resistance surveillance, from (WHO/IUATLD 1997; WHO/IUATLD 2000); treatment 
success and notification rates for these regions are from (WHO 2003) 
VIII. Resistant strains transmission 
As reviewed in the previous section, recent surveillance programs have documented 
the emergence of resistance within TB epidemics. To begin to understand the spread of 
drug resistance, it will be helpful to review efforts to characterize the transmission rates of 
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drug resistant strains, and how this compares to the spread of other drug sensitive strains 
within the same population. 
The relative transmission rate of resistant, and in particular MDR, strains remains a 
source of significant uncertainty. Experiments have suggested significant variation in the 
transmission rates of resistant strains, ranging from reduced to greater than drug sensitive 
strains. In one study, the contacts of source cases with either sensitive or resistant TB were 
examined, and similar risks of infection and disease were found amongst contacts of either 
type. Higher risks of infection were found only amongst resistant cases which were 
previously treated. (Snider, Kelly et al. 1985) A recent study in Brazil also found similar 
risks of infection and disease for drug sensitive and resistant source cases, with about 40% 
of household contacts infected and 4% with active disease. (Teixeira, Perkins et al. 2001) 
Another study used contact tracing combined with RFLP analysis to show MDR 
transmitted to contacts at similar rates. In another study, 6% of contacts with MDR 
patients were found to convert to active disease. (Nitta, Knowles et al. 2002) This can be 
compared to another study in which 4% of national and 8% of foreign born contacts of 
drug sensitive cases converted. (Marks, Taylor et al. 2000) These studies together suggest 
similar rates of conversion amongst contacts of sensitive and resistant source cases. 
Studies have also investigated the proportion of resistant cases due to ongoing 
transmission, by two different methods. The first method involves estimating the 
prevalence of resistance amongst new and previously treated cases, assuming that new 
cases are caused by primary resistance, and previously treated strains by resistance 
acquired during treatment. This classification was used in initial studies of resistance. 
(WHO/IUATLD 1997) Later studies, using RFLP analysis and contact tracing, revealed 
that the proportion of acquired resistant cases were overestimated, as some of the 
previously treated cases appeared to have been initially infected with resistant cases. (Van 
Rie, Warren et al. 2000) In order to correct for this, later surveillance reports referred to 
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the proportion of resistant cases amongst new and previously treated cases, without 
inferring from this the cause of resistance. (WHO/IUATLD 2000) In general, contact 
tracing or strain typing are required to differentiate acquired and primary resistance. 
More recently, convention has led towards using clustering of strains as a surrogate 
for recent transmission, and such analysis has been used to estimate the relative proportion 
of resistant strains in a population due to ongoing transmission. In an area of high 
incidence (Capetown, South Africa), the proportion of resistance due to primary 
transmission, as detected by RFLP strain typing, was high; over 50% of MDR cases were 
clustered. (Van Rie, Warren et al. 2000) In Denmark, over 70% of resistant strains were 
found to be clustered. (Thomsen, Bauer et al. 2000) There have also been reports of ' super 
fit' resistant strains which have been found more frequently in clusters and are believed to 
have greater transmission. (Agerton, Valway et al. 1999) (Toungoussova, Sandven et al. 
2002) (Kruuner, Hoffner et al. 2001) 
Other strain typing studies have found resistant cases less likely to be found in 
clusters. (Samper, Iglesias et al. 1998; Garcia-Garcia, Jimenez-Corona et al. 2000) (Nitta, 
Knowles et al. 2002) Cases with a particular INH resistance mutation were found in 
clusters less frequently than drug sensitive strains. (Van Soolingen, Borgdorff et al. 1999) 
Further discussion of studies considering the relative fitness of resistant strains, as well as 
model simulations exploring the implications of varying fitness costs, are found in 
Appendix 5. 
IX. Summary 
In this chapter, 1 reviewed trends in epidemiology of TB, methods for measuring 
disease burden and surveillance of epidemics, and trends in drug resistance. This sets the 
scene for the questions posed in this thesis, highlighting the recent (and progressing) state 
of TB epidemics worldwide. Resistance emerges from treatment patterns, and has been 
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found worldwide in every region surveyed, with small number of regions showing 
hotspots, or highly elevated levels of, drug resistance. I also review studies characterizing 
the transmission rate of resistant strains, and comparison to drug sensitive strains, and 
discuss why this is of importance to understanding resistant epidemics. In Chapters 5-9,1 
develop models to understand the emergence of resistance within TB epidemics, comparing 
the trends in resistance available from initial local and gloabal resistance surveillance. The 
relative fitness of resistant strains is incorporated into the model developed in Chapter 5, 
and the sensitivity of model to these parameters assumptions are explored in Chapter 6. 
The effects of relative fitness are also considered in a within-host model for TB infection 
developed in Appendix 5. To complement these analyses, a full review of control 
programs, how they have developed over time, and current practices worldwide, is 
reviewed in Chapter 3. Together with a review of the molecular biology of M. tuberculosis 
in Chapter 2, this forms the basis for the models developed in later chapters. 
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2. Chapter 2 
Molecular biology of tuberculosis 
. . . strangely-visited people 
All swol'n and ulcerous, pitiful to the eye, 
The mere despair of surgery, he cures, 
Hanging a golden stamp about their necks. 
Put on with holy prayers; and 'tis spoken, 
To the succeeding royalty he leaves 
The healing benediction..." 
— Shakespeare, in Macbeth 
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I. Goals 
I. A. To review the molecular biology of tuberculosis. 
I. B. To examine the lifecycle, transmission, and virulence of 
Mycobacterium tuberculosis. 
II. Abstract 
Tuberculosis is an infectious disease caused by Mycobacterium tuberculosis. 
M. tuberculosis is an aerobic, non-motile, acid-fast bacillus, with a slow generation 
time (both in vitro and in vivo) of about 24 hours. M. tuberculosis is transmitted 
principally through direct contact with a source case that emits infectious droplet nuclei 
in their sputum. After entering a susceptible host, droplet nuclei lodge in alveolar 
regions of the lungs. From early after infection, mycobacteria encounter a host immune 
response. The balance set in this early challenge by the immune system may determine 
the outcome of infection. In the majority of cases, infection is successfully contained 
by the immune response, and the initial foci of disease are healed. However, 
mycobacteria may remain dormant in the body, and this latent infection reactivate years 
or decades later in reactivation or post-primary disease. In a small proportion of cases, 
infection leads directly to progression and primary disease. The ability of a strain to 
successfully infect a susceptible host and cause progressive primary disease is known 
as virulence. 
III.Lifecycle of tuberculosis disease 
III. A. Transmission 
Tuberculosis is an airborne transmissible disease caused by Mycobacterium 
tuberculosis. Tuberculosis is transmitted directly from patients with active pulmonary 
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or laryngeal TB to a susceptible individual by the inhalation of small aerosolised 
infectious droplets. These droplet nuclei are expelled from an infectious individual 
-when they cough or sneeze. (Johnston RF 1974) These droplet nuclei are 1 - 5 
microns in diameter, small enough to dry while airborne, contain several tubercle 
bacilli, and can remain suspended in the air for several hours. A single cough can 
produce on the order of 3000 infectious droplet nuclei. The air in a closed room can 
remain infectious even after an infected patient leaves the room. (Haas 2000; Mandell 
2000) 
More recently, the mode of transmission through airborne droplet nuclei has 
been characterized through experiments on sputum from infectious patients. Fennelly's 
cough box has been used to isolate viable airborne mycobacteria emitted in droplet 
nuclei from infectious cases. In these experiments, patients are asked to cough through 
into tubing which leads into Fennelly's cough box. The air in the box is then sampled 
and the size of the particles estimated. These experiments have found a wide range in 
the number of colony forming units (CFU) generated per patient sample. As expected, 
smear positive cases generated more CFUs than smear negative. The size of the 
particles in these experiments was also estimated, and found that 49% of particles 
which contained bacilli were in the range of 1.1-2.1 jiim. (Fennelly and Nardell 1998) 
III. B. Risk of transmission 
The probability of transmission when another person inhales droplet nuclei is 
related to several factors, including the duration of exposure, closeness of contact, 
infectiousness of the TB patient, and the environment of exposure. Brief contact with 
an infectious individual carries little risk for infection, and prolonged exposure is 
usually required. Large respiratory secretions do not factor into the transmission of TB, 
as they are removed by mucociliary action and coughing. 
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After inhalation, the droplet nuclei travel to the alveolar region. However, the 
majority of the droplet nuclei are trapped in the airways, and are removed or destroyed 
in the respiratory tract. Only the smallest of the droplet nuclei, containing about 1 to 2 
tubercle bacilli, reach the alveolar space. Successful human infection is estimated to 
require from 5 to 200 tubercle bacilli. This number is a function of virulence of the 
tubercle bacilli and the host microbactericidal activity of alveolar macrophages. 
Transmission occurs through prolonged intimate contact with an infectious case. 
(Grzybowski, Barnett et al. 1975) Most of transmission occurs from sputum positive 
cases with extensive pulmonary disease and cavitary lesions. (Iseman 2000) The 
studies first supporting transmission by airborne droplet nuclei, and quantifying the 
risks of transmission, were performed in the 1970s. (Rouillon, Perdrizet et al. 1976; 
Iseman 2000) Contact investigation studies have allowed the analysis of the risk of 
transmission of infection and disease to contacts of cases. Higher rates of both 
infection and disease have been associated with close contact to a smear positive index 
case. 
Contact investigation studies have shown that the risk of transmission is 
correlated to the smear status of the index case, with higher rates of transmission from 
smear positive cases. (Rouillon, Perdrizet et al. 1976; Rose, Zerbe et al. 1979) In one 
study in England in 1954, 65% of household children contacts of smear positive culture 
positive cases were infected, with 27% when the index case was smear negative culture 
positive. (Shaw and Wynn-Williams 1954) In another study in Canada, 45% of 
household contacts of smear and culture positive cases were infected, while 26% were 
infected when the index case was smear negative culture positive. (Grzybowski and 
Allen 1964) 
The risk of infection also depends upon the duration and intensity of contact. A 
common distinction is household and casual contacts; household contacts experience a 
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much higher risk of infection. In one such study, when the index case was smear 
positive, 46% of household contacts were infected, while 34% of non household 
contacts were found infected. When the index case was smear negative but culture 
positive, 28% of household contacts and 24% of non-household contacts were found 
infected. (Rose, Zerbe et al. 1979) Another study in the Netherlands gave similar 
results: when the index case was smear and culture positive, 20.2% of household 
contacts were infected, while 3.7% of casual contacts were infected. When the index 
case was smear negative but culture positive, 1.1 % of household contacts were 
infected, while 0.2% of casual contacts were infected. (Loudon and Romans 1969) 
Another study in Canada from 1966-1971 examined both the risks of infection 
and disease amongst household and casual contacts of smear positive or negative cases. 
This study found higher rates of infection amongst older contacts, amongst household 
contacts, and amongst contacts of smear positive index cases. The risk of infection due 
to close contact with an active smear positive case was 27%, compared to 12% from 
casual contact. However, amongst contacts of the older age groups, there was also less 
of a difference between the rates of infection amongst contacts of smear positive and 
negative index cases. This suggests that the higher infection rates in the older age 
groups are partially attributable to risks of lifelong exposure and reactivation of 
infection acquired previously from another source. This study also examined the rates 
of disease amongst contacts, and found higher rates of disease amongst younger 
contacts, amongst close contacts, and amongst contacts of smear positive index cases. 
(Grzybowski, Barnett et al. 1975) In a more recent study, contacts of index cases were 
examined according to grade of sputum smear positivity. 609 contacts of 134 index 
cases were traced over two years. This revealed four new cases of active disease, each 
a close contact of a highly smear positive index case. (Liippo, Kulmala et al. 1993) 
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III. C. Virulence 
Virulence describes the capacity of the bacterial strain to infect a host and 
produce active progressive disease. Infectivity describes the likelihood of the strain to 
cause an infection given exposure to a susceptible host. Given the difficulty in 
measuring and quantifying extent of exposure, it has not been possible to separate the 
strain infectivity from disease progression. Together, the ability of the strain to infect a 
susceptible host and to cause progressive disease is referred to as virulence. (Iseman 
2000) Mycobacterial strain virulence has been tested in animal models. Typical 
measurements of strain virulence in animal models include number of bacilli in organs, 
severity of tissue damage, and extent of dissemination. 
III. D. At risk for infection 
Close contacts of an infectious tuberculosis patient are at highest risk for TB 
infection. The risk of infection is greater when the contact is emitting a higher number 
of mycobacteria in their sputum: thus higher risks are found for active patients with 
positive acid fast smears, as opposed to only positive cultures. Rates of infection are 
about 27% for close (household) contacts of infectious TB patients. (Haas 2000) 
(American Thoracic Society 1992) 
III. E. Infection 
In the alveolus, the tubercle bacilli begin to compete against the host resistance. 
The bacilli are phagocytosed by non-activated alveolar macrophages. The intracellular 
bacilli either multiply or are destroyed, depending on the virulence of the bacilli and the 
innate microbacteriocidal activity of the macrophage. The tubercle bacilli appear to 
have evolved a mechanism to largely subvert the killing action of the macrophage. 
Infected macrophages also produce and release chemotactic factors that attract more 
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macrophages and monocytes, as well as inflammatory cytokines that activate 
complement. Infected macrophages may also die, releasing bacilli and attracting more 
monocytes. 
Secondary sites of infection begin to form about two weeks after the initial 
infection. A small number of the infected alveolar macrophages begin to spread 
through lymphatic channels to regional lymph nodes, and through the bloodstream to 
other tissues and organs. The areas where TB is most likely to develop are the lungs, 
kidneys, brain, and bone. 
III. F.Formation of the tubercle 
Over the course of a month after the initial infection, the immune system 
responds to the tubercle bacillus by the formation of small nodules called tubercle 
granulomas. The formation of these tubercle contributes to the halting of the 
logarithmic multiplication of the bacillus, the decrease in bacillary numbers, and the 
control of infection. The tubercle is formed by rapid and sustained recruitment of T 
cells and monocytes. The tubercle has central cavitation and liquefaction; cavity 
formation occurs with massive tissue necrosis stimulated by cell mediated cytotoxicity. 
Bacilli are found both extracellularly in liquefied areas and intracellularly in tissue 
macrophages. The end result of this process of tubercle formation, which is driven by 
antigen, is the control of bacillary multiplication. 
The primary and secondary sites of TB infection are rarely sterilized, even 
during the lifetime of the host. The persistence of viable bacilli in the sites of infection 
grants the host immunologic responsiveness as well as immunity to superinfection. 
Thus, hosts that retain viable bacteria will rapidly eliminate a new infection. If, 
however, one manages to completely sterilize an infection by use of heavy 
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chemotherapy, such that no viable bacilli remains in the host, then the hypersensitivity 
and immunity will be lost within a few months. 
III. G. Latency 
TB infection can progress to TB disease when the immune system fails to keep 
in check the growth of the tubercle bacilli. This progression to disease occurs in 
approximately 10% of individuals infected with the tubercle bacilli. Of this 10%, 
approximately half of the infected individuals will develop the disease within the first 
two years after infection {primary tuberculosis), and another half later in their lives 
{reactivation tuberculosis). 
The risks of progression to active disease are greatest soon after infection, 
declining exponentially with time since initial infection. About 1.5% of cases progress 
to active disease within the first year after infection. Within five years after infection, 
the cumulative risk for progression is 5 to 10%. The remaining lifetime risk for 
progression is about 5 to 10%. (Enarson and Roullin 1998) (American Thoracic 
Society 1990) 
III. H. Period of infectiousness 
A patient with pulmonary tuberculosis is infectious during the period when they 
are emitting infectious droplet nuclei. Thus, in order to be infectious, the bacterial load 
within a patient must reach a certain level and must be located within the cavities of the 
lung where there is access to the airways. A patient is considered to be infectious if 
(and only if) they test sputum smear-positive. A typical sputum test is sensitive to 
detect a minimum of 5,000 - 10,000 acid fast bacilli (AFB) / mL sputum. (Levi 1995) 
The degree of infectiousness declines rapidly as appropriate treatment therapy is 
started. Usually within two weeks of initiating chemotherapy, patients will become 
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non-infectious, as their cough and concentration of bacilli in sputum decreases. Thus, a 
patient is rendered non-infectious soon after the start of effective treatment. The time 
from initiation of treatment to culture conversion and presumed non-infectiousness may 
vary. Early studies suggested that within a month after the start of treatment organisms 
were non viable. While cases may remain smear positive up to 6 months after the start 
of treatment, the culture should turn negative after a month. Cases remaining culture 
positive after 3 months should be suspected of treatment failure and resistance. (Harris 
and Karakusis 1979) More recent studies have also shown that most cases convert to 
culture negative status within 4 to 8 weeks (75% of cases). (Cohn, Catlin et al. 1990) 
In terms of clinical treatment practices, the normal program practices consider that 
three consecutive negative smear positives are correlated to very low probability of 
transmission. (American Thoracic Society 1992) 
IV. Diagnosis 
Tuberculosis is clinically diagnosed by a sputum test. Sputum is taken from the 
patient and cultured to test for the presence of mycobacteria. The test is not specific to 
M. tuberculosis, and therefore will also detect other mycobacteria. The sputum test can 
give a false positive for tuberculosis if there is a large presence of other mycobacteria 
in the environment. The sputum smear test can detect only active cases of tuberculosis. 
When an infected patient becomes infectious (the mycobacterial load exceeds a 
threshold, and has access to the airways) mycobacteria will be emitted in the sputum 
and detectable in culture. The limitations of this common diagnostic are clear: infected 
patients cannot be diagnosed until they become infectious; lack of specificity gives 
false positives; there is no quantitative measure for the bacterial load of the infection. 
(Allen BW 1992; Levi 1995) 
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A TB skin test is used to test for infection with M. tuberculosis. This skin test 
detects reactivity to tuberculin, a mixture of mycobacterial antigens. (Bothamley 1991) 
To diagnose infection with tuberculosis, tuberculin is injected into the skin and the 
induration response is measured at 2 or 3 days. The test is read by observing the size of 
induration at the site of contact with the tuberculin. The extent of induration reflects 
the patient's immune reaction to the mycobacteria. (Bothamley 1999) A test is 
classified according to the patient's risk group, such that a larger induration is required 
of those individuals who have fewer known risk factors for tuberculosis. An induration 
o f > 5 mm is considered positive for individuals in contact with active cases of 
tuberculosis, or who are infected with HIV. An induration of > 10 mm is considered 
positive for those of middle-risk for tuberculosis, such as residents of an area with a 
high prevalence. An induration of > 15mm is required for individuals with no known 
risk factors for tuberculosis. (Bothamley 1999) 
The induration response to the application of tuberculin represents the 
development of delayed-type hypersensitivity (DTH). Macrophages and T cells that 
have been previously exposed to mycobacterial antigens will rapidly respond to the 
presence of these antigens on the skin. Memory T cells, responsive to M. tuberculosis, 
will gather at the site of the skin infection and will activate the release of cytokines and 
proliferation of immune cells. False-positive skin tests can be produced by exposure to 
other cross-reacting mycobacteria present in the environment. Infected patients may 
also test negative (a false-negative) for the skin test if complications, such as 
progression of AIDS, interfere with the THl immune response. (Bothamley 1991) 
V. Properties of M. tuberculosis 
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V. A. Morphology of the tubercle bacillus 
The M. tuberculosis bacillus is a member of the genus Mycobacterium. There 
are some 55 species of mycobacterium, but those most closely phyologenetically 
related to M. tuberculosis are known as the M. tuberculosis complex and include M. 
bovis,M. microti, and M africanum. (Fishman 1988; Gangardharam and Jenkins 1997; 
Iseman 2000) 
The most distinguishing characteristic of the microbes in the M. tuberculosis 
complex is their acid-fast property. These mycobacteria resist staining with traditional 
stains, including the Gram stain, but retain dyes which have penetrated the cell wall. 
This is due to the high lipid content of the mycobacterial cell wall. The mycobacterial 
cell wall is lipid rich, containing waxes and glycolipids that account for about 60% of 
the cell as dry weight. This cell wall gives mycobacteria a waxy coat that serves both 
as a defence and to retain fluid. This may contribute to ability of mcyobacteria to 
remain viable for long periods. The primary components of the cell wall include 
peptidoglycans, arabinogalactans, and mycolic acid. The long chain mycolic acids, 
which are unique to mycobacterial cell walls, contribute to the acid fastness of the cell. 
(Levi 1995; Davies 1998; Iseman 2000) 
M. tuberculosis is slow growing, with a generation time in vitro of about 24 
hours. This generation time depends on environment and culture technique. Visible 
colony growth on solid culture medium takes at least three to six weeks to appear. 
Cultured in vitro, M. tuberculosis appears rod shaped and slightly curved or straight. 
The mycobacterium also appears smaller than most bacterial pathogens, about 1 to 4 
mm in length and 0.3 to 0.6 mm in diameter. The mycobacteria are also observed to 
grow in dense clusters referred to as 'cords' because the bacteria are aligned in parallel. 
M. tuberculosis is an aerobic bacillus, whose growth and virulence appears to be related 
to the availability and use of oxygen. When deprived of oxygen, mycobacteria have 
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been shown to remain viable, but have slowed or ceased replication. (Levi 1995; 
Davies 1998; Iseman 2000; Mandell 2000) 
V. B. Virulence 
Bacterial virulence refers to the ability of a pathogenic organism to cause 
disease. For mycobacteria, virulence depends upon factors which influence the ability 
to infect a human host, to enter and survive within macrophages, and to overcome 
immune defences and cause active disease. (Grange 1998) 
The virulence of a tuberculosis strain depends on its ability to survive host 
defences. Virulence of M tuberculosis is thought to be multifactorial, with a complex 
interaction between component factors determining virulence. (Gordon 1996) A key 
determinant of mycobacterial virulence is the ability to enter host macrophages and 
persist in the typically acidic environment. Mechanisms of this persistence have been 
shown to include an avoidance of the endocytic pathway and localization within the 
macrophage to non-acidic vacuoles. (Barker, George et al. 1997) The ability to 
replicate within macrophages has also been shown necessary for mycobacterial 
virulence. Studies have examined the genes selectively expressed in mycobacteria 
growing within macrophages. The genes found to be upregulated in mycobateria found 
within macrophages include those functioning in protection from oxidative stress and 
nutrient utilization. (Triccas 1999) These findings suggest that mycobacteria 
upregulates genes to enhance its survival within the macrophage environment. 
V. C. Dormancy 
M. tuberculosis has the ability to remain dormant for extended periods of time. 
(Koch 1997) The biological nature of this dormancy is not well understood. However, 
this feature is central to allowing bacteria to remain in a host for years following the 
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initial infection, a state referred to as latent tuberculosis. (Colston 1999) This makes 
bacterial sterilization of a host very difficult, particularly since many of the 
antituberculosis drugs are active only on dividing cells. (Smith 1994) Drug treatment 
will usually kill most of the mycobacterial population within several weeks; however, 
mycobacterial persisters can evade the drug by entering into a dormant state and remain 
in the host. These remaining bacilli can later lead to reactivation of the infection and 
post-primary tuberculosis. (Colston 1999) 
VI. Host-Parasite Interaction 
Infection begins as a susceptible host inhales droplet nuclei containing 
mycobacterium. Successful droplet nuclei will lodge in alveoli and air passages of the 
lung, establishing the initial site of infection. This is referred to as the Ghon focus, or 
the local focus of disease. From this initial focus, mycobacteria are transported to 
lymph nodes in the long, where foci of disease develop. Together, the Ghon focus and 
the foci established in the lung are referred to as the primary complex. From this initial 
primary complex of disease, mycobacteria may continue to disseminate further in the 
body, when carried by the lymphatic and blood streams to other organs. In most cases, 
the primary infection is resolved by host defences, and individuals remain latently 
infected but do not directly progress to active disease. The early host immune response 
may resolve the initial infection but leave mycobacteria in the primary complex 
dormant; in about 10% of infections, cases reactivated to post-primary disease decades 
after the initial infection. (Dannenberg 1998; Davies 1998) 
The time table for development of tuberculosis disease was described by Koch 
as occurring in 4 stages. In the first stage of disease, lasting from 3 to 8 weeks after 
initial infection, and includes the development of a primary complex of disease. 
During this stage, there is phagocytosis into macrophages, and most of the 
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mycobacteria from the initial infection likely die. The remaining mycobacteria are able 
to proliferate within the macrophages. In this stage the early cellular immune response 
also begins, and there is a conversion to tuberculin positivity. In the second stage, 
lasting up to 2 months, there is continued dissemination of the bacteria from the 
primary focus, and the disease may spread to other locations and organs. During this 
stage, the remaining mycobacteria replicate within macrophages, and cause cell death. 
The immune response also continues: chemotactic factors and complement are 
activated, and monocytes are recruited. In the third stage, lasting 3 to 4 months, there is 
continued spread of disease from the primary focus. In the fourth stage, lasting up to 
3 years, there is resolution of the primary complex, and continued development of more 
slowly growing extrapulmonary lesions. (Dannenberg 1998; Davies 1998) 
Reactivation, or secondary tuberculosis infection, usually begins in the apical or 
posterior segments of the upper lobes. The infection is believed to originate in these 
locations because of the favourable environment for tubercle bacilli multiplication. As 
an obligate aerobe, the tubercle bacillus reproduces best in a high oxygen environment. 
The relatively high partial pressure of oxygen in the upper portions of the lungs is 
particularly suitable for the tubercle bacilli lifestyle. (Dannenberg 1998; Davies 1998; 
Grange 1998) 
VI. A. Host Resistance to Infection 
Numerous studies have suggested that individuals vary in susceptibility to 
tuberculosis disease, and that genetic variation is important in determining the outcome 
of infection. (Skamene 1991) (Hoal 2002; Malik and Schurr 2002) Whole-genome 
linkage analyses in families with multiple cases have also been useful in identifying 
factors associated with susceptibility. (Hoal 2002) Sibpair studies have found that host 
genetic factors can be important determinants of susceptibility to infectious diseases. 
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including tuberculosis. Mutations in interferon gamma receptor lead to increased 
susceptibility to mycobacteria and BCG infection in homozygous children. Variation 
in the vitamin D receptor has also been associated with susceptibility. (Hill 1998) In 
one study, families with two siblings affected by tuberculosis were examined with a 
genome-wide linkage study to identify genes that affect susceptibility. Two loci 
showed repeated coinheritance with susceptibility. (Bellamy, Beyers et al. 2000) In 
other family studies, mutations in genes for interferon-gamma receptor and the 
interleukin-12 receptor have been correlated to increased susceptibility. This suggests 
that IFN-gamma and IL-12 may be involved in the pathways for resistance to infection. 
In particular, cytokines in pathways for macrophage upregulation have been implicated. 
The absence of key cytokines in children has been associated with susceptibility to 
lethal mycobacterial infections. It is suggested that mutations in these cytokines may 
have more subtle affects on these pathways that could influence susceptibility in the 
adult population. (Levin and Newport 1999) 
Use of animal models of tuberculosis, in particular the mouse, has provided 
valuable contributions in identifying candidate genes involved in resistance to 
infection. Studies using mouse models of tuberculosis have found that susceptibility to 
infection and disease is a complex genetic trait. (Schurr, Malo et al. 1991) (Kramnik, 
Demant et al. 1998) Several genes have been correlated to susceptibility to disease in 
mice, including the N ram pi (natural-resistance-associated macrophage protein 1) gene 
and sstl (susceptibility to tuberculosis 1) gene. Variation at the sstl locus has been 
correlated to growth rates of virulent mycobacteria in the lungs. (Kramnik, Dietrich et 
al. 2000) 
Nramp I was first isolated by positional cloning of a locus found associated with 
host resistance. The Beg gene was known to segregate as a single dominant autosomal 
gene and to control susceptibility to mycobacteria. Expression of the Beg gene was 
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known to activate macrophages to destroy ingested intracellular parasites as part of the 
early nonspecific immune response shortly after infection. The Beg gene was mapped 
using positional cloning in mice, and overlapped a region that included the Nramp 
gene. (Skamene 1994) Mutations in Nramp 1 were sufficient to reduce mice resistance 
to infections with mycobacterium, as well as salmonella and leishmania. (Canonne-
Hergaux, Gruenheid et al. 1999) An Nramp 1 homologue, known as N R A M P l , has 
been identified in humans and found associated with susceptibility to tuberculosis. 
(Liu, Fujiwara et al. 1995; Bellamy, Ruwende et al. 1998) Nramp 1 has been 
characterized as an integral membrane protein expressed in the lysosomal compartment 
of macrophages. Nramp 1 is thought to be involved with regulating mycobacterial 
replication after phagocytosis into macrophages. (Canonne-Hergaux, Gruenheid et al. 
1999; Buu, Sanchez et al. 2000) 
VI. B. Immunology 
The tubercle bacteria first encounters host immune system in the form of 
alveolar macrophages, which phagocytose and carry the bacteria to lymph nodes. For 
the first several weeks after the initial infection, the bacteria grow exponentially. After 
several weeks, two components of the cell-mediated immunity develop: delayed type 
hypersensitivity (DTH) and protective cell mediated immunity (CMl). These two 
components are thought to be closely associated, and seem to occur at the same time 
after infection, coinciding with conversion to a positive tuberculin skin test. The 
development of protective immunity is a result of THl activation, while a TH2 or 
mixed TH1/TH2 response leads to DTH and progression of disease. The development 
of skin hypersensitivity occurs with the establishment of memory T cells that recognize 
the mycobacterial antigens. (Grange 1998) 
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VI. C. Macrophage Interaction 
The ability to survive in the macrophage is essential to the ability of M. 
tuberculosis to successfully infect a host. A strain that is unable to survive within the 
macrophage environment will be cleared by the host immune system. Upon 
encountering the macrophage, the bacilli is phagocytosed inside the cell and carried 
within a compartment known as a phagosome. The components of this compartment 
are destined for degradation, which is accomplished by fusion of the lysosome with the 
phagosome. The lysosomal enzymes are released into the phagosome, and degrade its 
components. The lysosome is maintained at a higher pH, required for the lysosomal 
enzymes to function. (Grange 1998) 
In order to survive, the bacilli must evade the macrophage defences. There are 
two primary mechanisms that M. tuberculosis uses to evade these defences. The first is 
by preventing the fusion of the phagosome to the lysosome. The second is preventing 
the acidification of the phagosome, so that the lysosomal enzymes will remain inactive. 
The cellular location of the bacilli within the macrophage determines the nature of the 
immune response. Bacterial antigens contained within the macrophage phagosomes are 
presented by MHC-II to CD4+ T cells, which activate the proliferation of the 
macrophage. In contrast, bacterial antigens present within the cytoplasm of the 
macrophage are presented by MHC-1 to CD8+ T cells, which in turn lyse the 
macrophage. (Grange 1998) 
VI. D. THl and TII2 responses 
One of the key immunologic features of the pathogenesis of tuberculosis is the 
interplay between two classes of CD4+ T helper cells, THl and TH2. Depending upon 
which prevails in a given infection, the mycobacterial population will either be cleared, 
form a latent infection, or form primary tuberculosis. Studies have examined the 
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factors that influence the dominance of either THl or TH2. Correlations between 
development of active disease and the balance between THl and TH2 response have 
been shown. Cases with active disease have excess expression of cytokines in the THl 
pathway. In comparison, individuals with latent infection show higher expression of 
cytokines in the TH2 pathway. 
Cytokines of either group were found to cross-regulate and inhibit the 
proliferation and activation of those in the other group. THl cells activated against M. 
tuberculosis produce the cytokines IL2 and IFNy, promoting protective immunity. 
Activated TH2 cells produce 1L4, 1L5, 1L6, and ILIO cytokines, promoting tissue 
destruction. When the THl response dominates the response to an infection, 
granuloma formation and protective immunity result. When either a TH2 or a mixed 
TH1/TH2 response exists, the immune response will lead to the development of 
hypersensitivity and the progression of disease. (Grange 1998) The cytokines 
produced by either pathway inhibit the maturation of cells from the other pathway, thus 
locking in a given THl or TH2 response. For example, the TH2 cytokine ILIO inhibits 
the THl maturation pathway. (Mossman 1991) 
VI. E. Vaccine 
The common vaccine against tuberculosis is BCG, which was first derived from 
an avirulent strain of bovine M tuberculosis. BCG provides protective immunity by 
activating macrophages to recognize the tubercle bacilli. When an immune individual 
is infected with tuberculosis, they will rapidly mount an immune response to clear the 
infection. 
However, the efficacy of BCG vaccination is found to vary greatly (from 80% 
to 0%) in different trials. (Fine 1995) This variation has been best explained by 
regional differences in environmental mycobacteria. Depending on the prevalence and 
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type of local mycobacteria in the environment, a population may be at higher risk for 
sensitization to mycobacteria and development of either a THl or a TH2 response. The 
BCG vaccine acts by promoting the existing T helper cell pattern, such that it will 
imprint either a THl (protective) or TH2 (tissue-damaging susceptibility) response. 
(Bretscher 1991) However, in those individuals not previously sensitized to 
mycobacteria, BCG vaccination will produce a THl response, affording protection to 
tuberculosis infection. (Ten Dam HG 1980) Thus, BCG is often given to the young, 
particularly in regions where the efficacy of vaccination is likely to decrease with age. 
VII. Fitness of M. tuberculosis strains 
The resistance to treatment with antibacterial drugs has often been found 
associated with a fitness cost to the resistant organism. The fitness of an organism has 
several important components, including: the growth rate (births and deaths) both 
within an infected host and within the environment, the transmission rate for infection 
of new hosts, and the clearance rate from an infected host. The fitness cost of 
resistance is measured by comparing these rates for sensitive and resistant strains. 
The experimental evidence to support a fitness cost of resistance comes from a 
number of organisms and suggests that this cost is widespread. Such experiments have 
measured the relative growth rates of sensitive and resistant strains in vitro (through 
competition experiments). (Andersson and Levin 1999) Other experiments have 
looked retrospectively at previously collected data from patients and examined the 
correlation between sensitive and resistant frequencies to the rate of antibiotic 
consumption. (Austin, Kakehashi et al. 1997) 
Fitness costs of plasmid-encoded resistance have been studied in E. coli. E. coli 
carrying plasmids with resistance genes have been found to have decreased growth rate 
compared to organisms free of this plasmid. Bacteria grown carrying a resistance 
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plasmid have been found to acquire chromosomal mutations that restored the growth 
rate. (Lenski, Simpson et al. 1994; Lenski 1998; Lenski, Mongold et al. 1998) 
A fitness cost has also been found associated with mutants resistant to 
streptomycin. The drug acts by interfering with protein synthesis, targeting the 
bacterial ribosome. (Goodman 1996) The most common mechanism of streptomycin 
resistance is the mutation of genes affecting the bacterial ribosome, which prevent the 
enzymatic inhibitory action of streptomycin. The primary mutation found in human 
tuberculosis cases resistant to streptomycin is a point mutation that alters the ribosomal 
binding site. (Goodman 1996) The ribosomal mutations (in the rpsL gene) causing 
streptomycin resistance reduce the efficiency of translation. The reduced translation 
rate is thought to result in the reduced fitness of the streptomycin resistant bacteria 
compared to wild type. (Bohman, Ruusala et al. 1984) 
However, there also is some evidence suggesting the existence o f ' n o cost' 
resistance mutations. For example, resistance to high concentrations of streptomycin, 
conferred by a substitution at the 42"^ codon of the rpsL gene in S. typhimurium, shows 
fitness similar (or even slightly higher than) wild type. Other mutations found to cause 
resistance to streptomycin have been shown to confer fitness disadvantages. Thus, the 
fitness cost of drug resistance appears to be allele-specific. (Andersson and Levin 1999) 
VII. A. Resistant MTb strains 
In M. tuberculosis strains, there is some, although limited, experimental 
evidence to suggest a fitness cost associated with developing antibacterial resistance. 
Tubercle bacilli resistant to isoniazid have shown reduced fitness in vitro. Whether this 
holds true in vivo is unclear. There is limited experimental evidence to suggest how 
resistance to other common tuberculosis antibiotics affects strain fitness. 
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There is also evidence that resistance to isoniazid may be correlated with 
decreased virulence. Although INH resistance does not seem to affect bacterial 
replication in monocytes in vitro, these mutations do confer increased sensitivity to 
reactive oxygen. As tubercle bacteria are exposed to high levels of oxygen during the 
course of an infection, the resistant mutants may be more compromised by the 
environmental conditions present in vivo. Resistance to isoniazid may be deleterious to 
the response of the pathogen to the immunological defence of the host cells. (Davies 
1998) 
There also appears to be an important role for compensatory mutations in the 
fitness of resistant strains, both in vitro and in vivo. M. tuberculosis strains resistant to 
isoniazid, which normally show reduced fitness in vitro, have been found to have 
increased fitness when associated with a second-site mutation in the katG gene. This 
intragenic suppressor mutation appears to serve as a compensatory mutation. 
A study has also examined deletions of the katG gene, which confers high 
resistance to isoniazid, and is associated with decreased strain fitness. The loss of the 
katG gene is believed to cause the loss of catalase activity as well as bacterial virulence. 
Such AkatG mutants were found to rapidly acquire second-site compensatory mutations 
that restored virulence while maintaining the high level of isoniazid resistance. The 
compensatory mutation was mapped to the promoter region of the aphC gene. The 
mutation increased transcription from this promoter, resulting in increased levels of the 
AphCp. The over-expression of this alkyl hydroxy peroxidase is believed to 
compensate for the effects of the decreased catalase activity. (Sherman, Mdluli et al. 
1996; Heym, Stavropoulos et al. 1997) However, more recent experimental evidence 
has suggested that the over expression of aphC (on a plasm id) will not restore the 
virulence of a katG mutant. The overexpression of aphC was not seen to affect the level 
of resistance of bacteria, in either a katG wild type or mutant background. (Heym, 
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Stavropoulos et al. 1997) The mechanism for the compensatory mutation in the aphC 
gene remains unclear; it is possible that the mutation must be chromosomal (as opposed 
to carried on a plasmid) to restore virulence. It is also possible that there is an 
additional factor that is regulated by this mutation, which is responsible for the restored 
virulence. 
VII. B. Compensatory mutations in tuberculosis treatment 
The fitness of the resistant strain, and the evolution of compensatory mutations 
that may increase competitive fitness, are important considerations in the design of 
treatment protocols. A common suggestion to the public-health problem of epidemics 
of antibiotic resistance is to reduce antibiotic consumption. Such an argument 
presupposes that in the absence of selective pressure of the antibiotic, the resistant 
organism will be less fit than the corresponding sensitive strain. Indeed, if this were 
always the case, such a solution would be tenable. When the sensitive strain maintains 
a fitness advantage in the absence of drug selection, under the appropriate conditions, 
removing the selection will allow for the re-establishment of a sensitive population. 
The timescale for the reversion of the population to sensitivity should be similar to the 
time taken for the emergence of resistance. 
However, when the resistant strain adapts to its environment through the 
acquisition of compensatory mutations that increase its fitness, this no longer holds 
true. Once the drug selection is removed, the compensated resistant strain retains its 
fitness advantage. And if the fitness of the resistant is greater than that of the sensitive, 
then simply removing the drug selection is unlikely to allow for reversion to a sensitive 
population. Even if the fitness of the resistant strain with the compensatory mutation is 
not greater than that of the sensitive strain, in the absence of drug, the increased fitness 
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of the resistant will mean that the timescale for the replacement of the resistant 
population with sensitive organisms will be longer than the converse. 
VIII. Summary 
In this chapter, 1 review the molecular biology of M tuberculosis. The key 
elements of MTb reviewed here include lifecycle, transmission and virulence. Also 
briefly discussed is the diagnosis of infection, but more details on diagnostic tests for 
active cases can be found in Chapter 3, which reviews TB treatment. Understanding 
these properties of MTb sets the stage for exploring the nature of TB epidemics, and of 
interest in this work, how to best model the transmission of TB amongst individuals 
within a population and the impact of chemotherapy and other elements of a control 
program. This also provides introduction to the basis for the models developed in 
Chapter 5 for transmission and treatment, as well as within-host models considered in 
Appendix 5. 
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3. Chapter 3 
Treatment of tuberculosis 
"It happens then as it does to physicians in the treatment of 
Consumption, which in the commencement is easy to cure and 
difficult to understand; but when it has neither been discovered 
in due time nor treated upon a proper principle, it becomes easy 
to understand and difficult to cure. The same thing happens in 
state affairs; by foreseeing them at a distance, which is only done 
by men of talents, the evils which might arise from them are 
soon cured; but when, from want of foresight, they are suffered 
to increase to such a height that they are perceptible to everyone, 
there is no longer any remedy." 
— Machiavelli 
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I. Goals 
I. A. To review the literature on the treatment of tuberculosis. 
II. Abstract 
The introduction of effective chemotherapy for tuberculosis in the 1960s 
allowed for the rapid cure of patients. The first effect of introducing TB programs 
which included chemotherapy was the rapid reduction in mortality, while allowing 
infectious cases to live longer. The early regimens often included only one or two 
drugs, allowing for rapid selection for drug resistance. The introduction of rifampicin 
in the late 1960s and the use of multi-drug regimens reduced the rate of emergence of 
resistance. The establishment of short course chemotherapy (SCC) and national 
treatment programs under the WHO guidelines for DOTS (Directly observed treatment, 
short course chemotherapy) standardized treatment practices. The DOTS guidelines 
proscribe treatment of a new case with at least four drugs for 6 to 9 months. DOTS 
programs have been shown to rapidly reduce the incidence and death rates. 
The detection of infectious cases is central to any treatment program, and 
accordingly is a cornerstone to improvements in TB control programs. Traditional 
methods for case detection include the smear and culture tests. Newer methods include 
the more rapid and automated radiometric culture systems such as BACTEC, the non-
radiometric system MB/BacT, and various serological or molecular methods including 
PCR-based analysis and DNA chips. 
The continued emergence of resistance under these programs, has led to a 
growing need for drug susceptibility testing (DST). Traditional methods for DST 
include culturing sputum samples and determining resistance by the absolute 
concentration, ratio, or proportion methods. Newer methods for DST include 
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automated radiometric systems such as BACTEC, which allow for faster culture with 
higher sensitivity. In addition, the development of molecular methods using PCR based 
systems has provided a fast and sensitive alternative test. These tests require 
knowledge of the genetic basis of resistance and rely on sequencing or hybridization to 
search for particular mutations associated with resistance. 
III.Progress in tuberculosis treatment: a historical 
perspective 
Prior to the use of chemotherapy to treat tuberculosis, cases were treated largely 
by in sanatoria. Confinement in sanatoria served to reduce the spread and transmission 
of disease, as well as to offer patients the best opportunity available for cure. This 
included bed rest, a nutritious diet and fresh air. In addition, some surgical methods 
and collapse therapy were used for treatment. Treatment of tuberculosis with 
chemotherapeutic regimens began with the discovery of streptomycin in the 1940s. 
Treatment with either streptomycin or PAS resulted in a more rapid cure than achieved 
in sanatorium. Chemotherapy led to sputum conversion as well as clinical 
improvement after 2 to 3 months of treatment with either streptomycin or PAS. 
However, the effects of treatment did not appear to be long-lived. There were high 
rates of relapse to disease shortly after treatment was stopped. (Medical Research 
Council 1948) Use of combined chemotherapy with both streptomycin and PAS 
prevented the emergence resistance to either drug, and the cure rates were better than 
for use of either drug alone. (Medical Research Council 1950) 
Isoniazid was introduced for use in the treatment of tuberculosis in 1952. 
Treatment regimens used in clinical trials by the MRC in 1955 included either isoniazid 
alone, or in combination with streptomycin or PAS. These trials also confirmed that 
treatment with a single drug resulted in high rates of drug resistance. (Medical 
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Research Council 1955) Standard regimens for treatment were developed over the 
following decade. The standard regimen included streptomycin, isoniazid, and PAS 
given for from 18 months to 2 years. There were difficulties with these early regimens, 
including high rates of adverse reactions, patient default, poor adherence, failure, and 
resistance. (Crofton 1960; BMRC 1973) In the early 1960s, studies showed that home 
treatment was effective. With the successes of these chemotherapy regimens, treatment 
in sanatorium became less important. (Tuberculosis Chemotherapy Centre 1959) The 
introduction of rifampicin in the 1970s provided great improvements to treatment. 
Including rifampicin allowed regimens to be shortened to 6 to 9 months, referred to as 
short course chemotherapy (SCC). (Fox and Mitchison 1975; Fox and Mitchison 1976) 
The emergence of cases resistant to tuberculosis drugs was seen shortly after the 
chemotherapy was first used in treatment. When regimens of monotherapy were 
common in treatment, resistance was seen to rapidly emerge. The introduction of 
treatment into a population often led to an increase in case duration of infectiousness, 
creating chronic infectious cases which were unresponsive to treatment. Many of these 
cases turned out have drug resistance. With the introduction of rifampicin to traditional 
treatment, there were significant improvements in treatment cure and a reduction in the 
amount of chronic cases produced. (Lutwick 1995) 
IV. Treatment standards 
IV. A. Aims 
The aims of treatment regimens are to reduce case mortality and infectiousness, 
stop cycles of transmission, and decrease incidence and burden of disease. 
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IV. B. Treatment of smear positive cases 
A number of different effective regimens for treatment of smear positive 
pulmonary tuberculosis are found in clinical trials in both developed and developing 
countries. The typical regimen is given for at least 6 months, the shortest required 
duration, with a continuation phase of 2 or 3 months. However, longer duration of 
treatment is required if no pyrazinamide is used in the initial phase or no rifampicin in 
the continuation phase. Regimens vary by daily or intermittent dosing, self-
administered or DOT, regimen and supervision can vary from initial to continuation 
phase. The relapse rates on these regimens are generally low, below 5%. (Davies 
1998; Iseman 2000) These regimens all consist of an initial intensive phase of 2 
months and a continuation phase of 4 to 6 months. Fewer drugs are needed for the 
continuation phase; however, it is critical to include those drugs, including rifampicin, 
which have strong sterilizing activity. The continuation phase is necessary in order 
remove remaining bacteria and prevent relapse. 
The regimen recommended for use within DOTS programs for treatment of 
smear positive cases depends upon treatment history. New cases are defined as those 
which have not received any prior tuberculosis treatment; initial cases are defined as 
those in which prior treatment may be suspected but not confirmed. (WHO 1999; 
WHO 2003) The recommended regimen for new smear positive cases includes an 
initial phase with at least four of the first line drugs, including isoniazid, rifampicin, 
pyrazinamide, ethambutol, and streptomycin. Proper administration of this regimen to 
a drug sensitive smear positive patient results in a rapid reduction in bacterial load, 
reduction in symptoms, and conversion to smear negative within several weeks. 
During the continuation phase at least two drugs, including rifampicin, are given. 
(WHO 2003) 
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Retreatment cases are defined as those that have received at least one month of 
previous antituberculosis treatment, which remain smear or culture positive. This class 
includes cases which have failed treatment, relapsed, or defaulted. The recommended 
standardized retreatment regimen includes five drugs in the initial phase, followed by 
three drugs in the continuation phase. This regimen can offer high cure rates for drug 
sensitive cases as well as those with single resistance to isoniazid or streptomycin. 
However, cases which have developed MDR are most at risk of failure on these 
retreatment regimens. (WHO 1997; WHO 2003) 
IV. C. Treatment of smear negative cases 
Many TB programs have questioned whether to treat cases diagnosed with 
active disease without bacteriological confirmation. A high proportion of cases which 
are either smear negative or have no mycobacteriological confirmation of disease do 
receive s e e treatment. (Sbarbaro 1989) When smear samples are unavailable or the 
smear test inconclusive, treatment may continue as if the test were positive until further 
results are available. Such presumptive treatment provides caution in treating cases 
which may be infectious, reducing transmission. However, the treatment of smear 
negative cases is a secondary priority for a TB program in a high burden country. The 
first priority is the detection and effective treatment of smear positive cases. Most of 
transmission occurs from smear positive cases, while the relative contribution of smear 
negative cases to transmission remains unclear. Further, smear negative cases have 
fewer symptoms and are harder to diagnose. However, when resources allow, 
treatment of smear negative cases is important both for curing the patient and for 
stopping transmission if the case is infectious. (Davies 1998; Colebunders and Bastian 
2000; Iseman 2000) 
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Smear negative cases can be treated effectively with a four month regimen. 
(Dutt, Moers et al. 1989) Several clinical trials have shown the effectiveness of 
regimens for treatment of smear negative cases. In one Hong Kong study, 1019 smear 
negative pulmonary TB cases were followed. 36% of these cases had one or more 
initial sputum sample culture positive. This study showed that 2-3 months treatment 
with the basic four drug regimen (isoniazid, rifampicin, streptomycin, pyrazinamide) 
was not adequate. Relapse rates at 60 months were high; for cases with one culture 
positive specimen there was a 32% relapse rate, compared to 11% for those culture 
negative. (Hong Kong Chest Service/Tuberculosis Research Centre/Madras/British 
Medical Research Council 1984; Hong Kong Chest Service/Tuberculosis Research 
Centre/Madras/British Medical Research Council 1989) In the second Hong Kong 
study for treatment of smear negative cases, of 1710 smear negative pulmonary cases, 
35% had one or more initial sputum culture positive samples. The cases were given 
either 3 or 4 month regimens. Amongst cases receiving 3 months regimens of HRZS 
either daily or three times a week, there was a 7% relapse rate. There was a 4% relapse 
rate for the same regimen given for 4 months. Amongst cases receiving the 4 month 
regimen, there was a 2% relapse rate for drug sensitive cases and 8% for cases resistant 
to H/S but susceptible to R. (Hong Kong Chest Service/Tuberculosis Research 
Centre/Madras/British Medical Research Council 1989) 
In areas with a high prevalence of HIV, coinfection may complicate the 
detection and treatment of smear negative cases. In such circumstances, it may be 
advisable to treat HIV coinfected cases with a full course of SCC even when smear 
negative. (Colebunders and Bastian 2000) 
V. Effect of treatment on disease 
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Effective treatment rapidly reduces the infectiousness of patients. Within two 
weeks, treatment reduces the frequency of coughing in active cases, reducing the 
production of droplet nuclei in sputum. (Loudon and Spohn 1969) Under modem 
treatment regimens, effective treatment is seen to result in smear conversion within 
several weeks. (Lutwick 1995) The first effect of introducing treatment is to reduce 
the case mortality. As new programs are introduced, the death rate is reduced, allowing 
cases to live longer. When this treatment does not result in high cure rates, this may 
allow for an increase in case duration of infectiousness. 
V. A. Deaths under treatment program 
Several studies have examined the mortality rates under TB treatment programs 
in developed countries. In one study in England in 1978-9, amongst 1312 adults with 
pulmonary TB receiving treatment, 163 (12%) died before completing treatment. 
Factors correlated to death included smear positive status, extent of cavitation, and age. 
(Humphries, Byfield et al. 1984) An analysis of another UK study from 1983-1985 
found a case fatality rate of 12.9% for adult smear positive cases under treatment. This 
was ten fold greater than the death rate for age-matched controls. Again, age and 
extent of disease was correlated to death during treatment. (Cullinan and Meredith 
In program conditions, introducing DOTS SCC has been shown to rapidly 
reduce the number of deaths due to TB. The implementation of DOTS SCC in high 
burden countries has reduced the incidence of disease and has prevented a high 
proportion of deaths. In China, dramatic improvements to control over the past decade, 
including the implementation of standardized DOTS programs and increased case 
detection, has significantly reduced incidence. Over 50% of deaths were prevented in 
this region from 1991-1997, according to a study which estimated the predicted number 
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of cases and deaths that would have occurred, if such improvements were not 
implemented. (Dye, Fengzeng et al. 2000) Similarly, in Peru, the introduction and 
improvements to DOTS programs significantly reduced the incidence of disease. These 
improvements to control, including increased case detection and standardized treatment 
with higher cure rates also resulted in reduced mortality. It was estimated that from 
1991-2000 nearly 70% of deaths were prevented by implementing these improvements. 
(Suarez, Watt et al. 2001) 
VI. Case Detection 
Cases are detected by either passive or active means. Passive case detection 
refers to symptomatic individuals who report to health authorities seeking treatment. 
Active case detection entails screening programs to detect either latent infection or 
active disease amongst a wider population. Such screening may be implemented within 
select at-risk populations, such as new immigrants, high prevalence communities, and 
contacts of current cases. 
VII. Global Case Detection and DOTS 
The majority of global case detection currently occurs through passive means. 
An estimated 40% of new smear positive cases are detected each year, with about 27 % 
(1.02 million cases) of these occurring under DOTS programs. DOTS programs have 
been implemented in 148 countries, and 55% of the world's population lives within 
regions providing DOTS. The average treatment success under DOTS has been 
estimated at 80%. (WHO 2002; WHO 2003) 
The WHO has set a global target for 2005 of 70% case detection and 85% 
treatment success. The rate of increase in case finding has stayed similar since 1994; in 
order to reach detection goals this needs to be increased. The expansion of DOTS 
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programs has been commonly constrained by factors including resources for staff, 
laboratories and technical equipment, unregulated private sector, decentralization and 
poor access to health services. In addition, the expansion of DOTS coverage usually 
involves notification of cases which would otherwise have been detected under non-
DOTS programs. This has meant that the 60% of global cases remaining undetected 
has not been reduced. National programs have not notified more than 40% of smear 
positive cases, raising questions about whether some limit of current detection 
programs has been reached. (WHO 2002; WHO 2003) 
VII. A. Active Case Detection 
In regions of low incidence, a high proportion of new cases are found amongst 
high risk groups, including contacts of smear positive cases. Screening contacts of 
known cases for infection and disease can be an important method for active case 
detection. Such screening can uncover an emerging epidemic and allow for early 
prevention. The recommended methods for screening are by concentric circles, such 
that those with the greatest contact with the source case are screened first. (Narain, 
Nairet al. 1966) (Grzybowski, Barnett et al. 1975) (Egsmose, Ang'awa et al. 1965; van 
Geuns, Meijeret al. 1975) (Veen 1992) (Sebek 2000) Close contacts include 
individuals sharing a household, but may also be found amongst individuals sharing 
equivalent amounts of time in close proximity in work settings, hospitals, homeless 
shelters, or even social settings as nightclubs. Casual contacts include most 
occupational and social contacts. (Chapman and Dyerly 1964) (Grzybowski, Barnett et 
al. 1975) (Narain, Nair et al. 1966) (Chin, DeRiemer et al. 1998) (Barnes, el-Hajj et al. 
1996) (Reichler, Taylor et al. 2002) 
While the basis of global TB control is passive case finding, there are also select 
examples of programs that incorporate active case finding. For example, contact 
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tracing is commonly employed in the US and UK as a means of identifying infected 
individuals and new cases. These have been shown to be useful in increasing levels of 
detection, often reaching cases which otherwise would not have been identified or had 
access to medical resources. (Menzies 1997; CDC 1998; Murray and Salomon 1998; 
Broekmans, Migliori et al. 2002) 
Recent studies have suggested that contact tracing is an effective means to 
identify new cases. Retrospective studies have shown that about 10% of new cases 
were detected through contact tracing, and about 1% of close contacts of a smear 
positive source case developed active disease. The screening of casual contacts, such 
as occupational or social contacts spending only short periods in shared spaces, is 
suggested to be of only limited importance in finding new cases. (Marks, Taylor et al. 
2000) A study in San Francisco found that 5% of cases were identified through contact 
tracing. Of contacts of smear positive cases examined, 1% were found to develop 
disease. (Behr, Hopewell et al. 1998) 
However there are difficulties in contact tracing. First, it is not straightforward 
to assume that contacts were infected by the identified source case and carry the same 
strain. In a San Francisco study, 30% of those contacts with disease were found to 
carry a distinct strain. (Behr, Hopewell et al. 1998) Contacts of smear positive cases 
may have other risk factors for disease. In particular, both the source case and contact 
may be within a high risk group. In addition, contact tracing has limitations in 
detection. In another San Francisco study, in 70% of clusters contact tracing failed to 
identify secondary cases. Although this was within the context of well functioning 
control program, it was considered that delays in diagnosis of the source case and 
evaluation of contacts contributed to missing cases. (Chin, DeRiemer et al. 1998) 
Other studies have also found that even very good control programs which include 
contact tracing for active detection often miss cases. Even under the best programs, 
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there are often not enough resources to thoroughly investigate contacts. (Reichler, 
Taylor et al. 2002; Reichler, Reves et al. 2002) 
In order to optimize available resources for contact investigation, resources may 
be focused on those at highest risk. Several studies have developed models to examine 
the usefulness of contact investigations. (Weis 2002) (Gerald, Tang et al. 2002) 
Depending upon local control priorities, contact tracing can be used to the 
appropriate extent and for either detection of new cases or infections. In high burden 
developing countries, the priorities may need to focus on identifying new cases that 
may otherwise not have received treatment. In low incidence regions, contact 
investigation is unlikely to detect many new cases, and the focus can turn to screening 
contacts for TB infection and treatment to prevent progression to disease. (Wares, 
Akhtar et al. 2000; Pronyk, Joshi et al. 2001) 
VII. B. Screening amongst high risk groups 
In low incidence regions, there emerge sub-populations that are at higher risk 
for disease. These often include immigrants from high-incidence countries, close 
contacts of infectious cases, homeless, drug users, and those co-infected with HIV. 
Active screening amongst targeted high-risk groups may be beneficial. A high 
proportion of cases occur amongst the poor, who may have less access to health 
services. Screening programs connected with homeless shelters and drug clinics may 
identify cases which otherwise would remain untreated, and reduce cycles of 
transmission amongst groups sharing confined spaces. Active screening within high-
risk groups should include skin testing for diagnosis of latent tuberculosis infection, 
followed by preventive treatment of LTBI. Chest x-rays for diagnosis of active disease 
is not recommended as a screening tool amongst non-symptomatic individuals in high-
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risk groups. Rather, chest x-rays are reserved as a diagnostic tool. (CDC 1998; 
American Thoracic Society 2000; Society 2000) 
Screening of new immigrants has become increasingly important in TB control 
in low incidence countries. As the incidence amongst the native population declines in 
developing countries, an increasing number and proportion of cases are found amongst 
immigrant populations. Immigrants from regions of high incidence have a high 
probability of latent infection and risk of progressing to disease soon after arrival. 
(Nelson and Fingar 1995; CDC 1998; Lobato and Hopewell 1998; Dasgupta, 
Schwartzman et al. 2000) 
Estimates from the CDC suggest that there are at least 7 million foreign-bom 
persons in the United States infected with TB, and that 2-3% of these will develop 
disease unless given preventative treatment. An estimated 30% of cases occur in 
foreign-born. (McKenna, McCray et al. 1995) Difficulties in screening and providing 
treatment to foreign-born individuals include the size of the immigrant populations, 
access, cultural barriers, and previous BCG vaccination or exposure to environmental 
mycobacteria. (CDC 1998; Lobato and Hopewell 1998; American Thoracic Society 
2000) 
VII. C. Active case detection in low incidence regions, 
amongst high-risk groups 
Active case detection can play an important role in TB control in low incidence 
settings of developed countries. An important component of active detection programs 
is contact tracing. Effective programs include the identification of contacts of 
infectious cases, followed by skin testing and preventive therapy, and diagnostic 
(smear, culture, or chest x-ray) testing of contacts at high risk for or showing symptoms 
of disease. (Society 2000) 
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Studies have also considered the relative effectiveness of screening all contacts 
of an index case versus targeted screening of those at high risk. Much discussion has 
focused on attempting to define factors that put contacts at high risk for infection. The 
first obvious risk factor is close contact, but again there is difficulty in defining what 
constitutes close contact, and how much exposure to an infectious case puts an 
individual at significant risk of infection. (Marks, Taylor et al. 2000; Bailey, Gerald et 
al. 2002; Broekmans, Migliori et al. 2002) 
In the context of a low incidence environment, studies have suggested that 
screening of casual or social contacts has limited benefits. Studies have suggested that 
focusing on screening of close contacts is more cost-effective than expanding 
investigations to include casual contacts, which identify few addifional infections or 
cases. (Ansari, Thomas et al. 1998; Marks, Taylor et al. 2000) 
A second important component of active detection is screening within high-risk 
groups. In a low incidence setting, TB cases will increasingly be found clustered 
within groups at greater risk for infection or disease than the rest of the population. 
High-risk groups include new immigrants from countries with high incidence, poor or 
homeless, drug users, and AIDS patients. 
Screening programs have been implemented in a variety of settings in which 
there is a high risk of transmission amongst effectively close contacts outside the 
household setting. For example, case finding in prisons may be an effective means of 
detection and controlling of an outbreak. (Brock, Reeves et al. 1998; Saunders, Olive 
et al. 2001) Screening within hospital or emergency rooms can also be important in 
stopping nosociomal transmission cycles. (Asch, Leake et al. 1998) 
One of high-risk factors for TB disease is poverty or homelessness. Screening 
amongst these populations, which have less medical access, can be important in 
identification of new cases which would be unlikely to be found through traditional 
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passive detection. (Southern, Premaratne et al. 1999; Moss, Hahn et al. 2000; Solsona, 
Cayla et al. 2001) In some settings, screening within emergency departments has been 
more effective than screening in homeless shelters, for identifying new cases amongst 
homeless. (Nelson and Fingar 1995; Asch, Leake et al. 1998) 
In addition, preliminary models have considered cost-effective means for 
screening contacts. A model for targeted contact investigation suggests the importance 
of identifying risk-factors in contacts, and recommends testing only those contacts at 
highest risk of infection. (Bailey, Gerald et al. 2002) Other cost effectiveness studies of 
active screening programs have suggested that these are not always cost effective. In 
order to remain cost-effective, active screening programs need to rigorously keep to 
guidelines, identify a high proportion of contacts, provide skin testing to close contacts, 
and maintain high levels of preventive therapy amongst those identified with latent 
infections. Programs tend to be more cost-effective when there is higher risks of 
disease and rate of screening. (Macintyre, Plant et al. 2000) While screening of close 
contacts is often shown to be beneficial in identifying new infections and preventing 
new cases, screening new of new immigrants is not always cost-effective. (Dasgupta, 
Schwartzman et al. 2000) (Dasgupta, Schwartzman et al. 2000) 
VIII. Treatment Delays in detection and diagnosis 
Delays in treatment of tuberculosis may occur because of either patient or 
medical factors. Patient delays in reporting to health authorities may occur because of 
lack of access, cultural or social barriers, or stigma attached to infection with 
tuberculosis or other diseases. Once a patient has reported to a health authority with 
symptoms, further delays may occur before the case is accurately diagnosed. Delays 
relating to case diagnosis can be caused by failure to recognize symptoms or 
misdiagnosis. 
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These may all be complicated further when patients suffer multiple ailments. In 
addition, once symptoms of active TB disease are suspected, most programs 
recommend confinnation of disease by one or more laboratory methods. Typically this 
includes smear and culture tests and, when needed, chest x-ray for final confirmation of 
active pulmonary disease. Delays may occur in scheduling time to collect needed 
sputum samples from the patient, sometimes requiring repeat visits or multiple samples. 
Repeat tests may also be needed to confirm results of uncertain tests. Individuals who 
find it difficult to visit a clinic may not be willing or able to return for multiple visits, 
even to hear the results of their tests and begin appropriate treatment. This may 
become particularly important in amongst the poor or homeless, and when stigma is 
associated with visiting clinics. 
Delays may also occur in returning the results of these tests. A well-functioning 
laboratory service can typically return the results of a smear test within several days, 
and a liquid-based radiometric culture test within two weeks, and a solid-based culture 
test within 3 - 6 weeks. In addition, the local health authority may not have the 
required mycobacterial laboratory and need to send the sample to a remote laboratory, 
taking addifional fime and possible delays. Poor organization, shortages in staff or 
equipment, and poor technical training may all contribute to further delays as well as 
misdiagnosis. 
The time taken from onset of case symptoms to reporting and the start of 
treatment vary distinctively by region. Several studies have examined factors 
influencing patient reporting, as well as delays in case diagnosis. Many of these factors 
are cultural, such as associated stigma with visiting clinics, or economical, influencing 
access to health services. (Needham, Foster et al. 2001) Studies have also found that 
delays in patient reporting were related to poor health information, and lack of 
information regarding the symptoms and treatment of tuberculosis. These patient 
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delays were found to be longer in rural areas, in patients with lower education levels, 
and for patients who did not have prior information regarding tuberculosis. 
(Salaniponi, Harries et al. 2000; Wandwalo and Morkve 2000; Lienhardt, Rowley et al. 
2001; Needham, Foster et al. 2001) Improving general awareness on the symptoms of 
tuberculosis, available treatment, and how to access health care services are important 
measures to both increase case detection rates and reduce the delay in patient reporting. 
Even under strong control programs in developed countries, there may be 
significant patient delays in seeking care. Studies examining the reasons patients delay 
in reporting include concern over cost of treatment, difficulties in access to health 
services, misunderstanding of tuberculosis, and fearing immigration authorities. Patient 
delay was correlated to unemployment, uncertainty about where to seek care, and a 
belief that they could treat themselves. Conversely, the severity of the illness and 
symptoms were not seen to significantly affect patient delay. (Asch, Leake et al. 1998) 
These findings suggest a lack of equity in treatment, such that groups with lower 
education and knowledge about seeking health care and tuberculosis disease itself are 
less likely to receive treatment. 
Patients may experience delays once in hospital, waiting either for diagnosis or 
to start treatment. These delays may include intervals for referral, diagnosis, and 
initiation of treatment. Both doctor and clinic delays have been shown to contribute to 
overall institutional delays. (Salaniponi, Harries et al. 2000; Yilmaz. Boga et al. 2001) 
Clinical delays in treatment are often associated with atypical presentation, lack of 
symptoms, and waiting for culture results. Older patients and those without respiratory 
symptoms are more often initially misdiagnosed. (Mathur, Sacks et al. 1994) 
Delays in treatment are associated with admittance to a hospital with a low 
incidence of tuberculosis, and atypical clinical presentation. In hospitals with low TB 
admission rates, cases were more likely to be initially misdiagnosed. Further, the rate 
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of TB admissions was inversely proportional to the successful treatment outcome. At 
lower rates of TB admissions, cases were more likely to fail treatment, die, and transmit 
infection. Treatment delays amongst patients in a hospital may lead to nosociomal 
transmission. (Greenaway, Menzies et al. 2002) Within emergency room departments 
there have been more specific analysis regarding treatment delays. The time to 
diagnosis and initiation of treatment are lower in emergency rooms and hospitals which 
have a higher incidence of tuberculosis cases, and are more familiar with methods for 
diagnosis and treatment of tuberculosis. In addition, the time from admission of an 
infectious case to isolation is important in preventing nosociomal transmission, and is 
an additional measure important in these studies. (Mathur, Sacks et al. 1994; Moran, 
Fuchs et al. 1995; Moran, McCabe et al. 1995) 
The waiting times between onset of patient symptoms and reporting (patient 
delay) as well as between patient reporting and the initiation of treatment (medical 
delay) vary considerably by region and medical service. Examples of patient and 
medical delays have been estimated a wide range of settings. Studies on waiting times 
found in the literature are summarized in the Table 3-1. In general, longer delays were 
observed in rural as opposed to urban settings. This is likely attributable to difficulty in 
accessing and fewer medical resources. Longer delays were also associated with poor 
education, low income, and lack of knowledge about TB disease and care. 
Setting 
Total 
mean 
delay 
Mean 
patient 
delay 
Mean 
medical 
delay 
Notes Reference 
Canada 1 week or 
more in 
30% 
(Greenaway, 
Menzies et al. 
2002) 
Ethiopia 60 days 
(median), 
782 
(mean) 
6 days 
(median), 
9.5 days 
(mean) 
Longer delays associated 
with far distance to health 
service and poor knowledge 
about TB treatment. 
(Demissie, 
Lindtjorn et al. 
2002) 
Zambia 9 weeks Delay associated with female sex, outpatient diagnosis, 
lower education, visiting private doctor or traditional 
(Needham, 
Foster et al. 
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healer. 2001) 
The Gambia, 
West Africa 
Median delay from onset of symptoms 
to commencement of treatment of 8.6 
weeks (range 5-17). 
Delay longer in rural (12 
weeks) vs. urban (8 weeks). 
Delay not related to cure rate, 
but increased death rate. 
(Lienhardt, 
Rowley et al. 
2001) 
Botswana (Greek, 
Lockman et al. 
2000) 
Malawi 8 weeks 7 weeks 1 week 
(smear test 
in 4 days) 
(Salaniponi, 
Harries et al. 
2000) 
Tanzania 185 days 162 days 23 days 
(10%) 
Longer delay in rural, 
amongst low education, those 
visiting traditional healers. 
(Wandwalo and 
Morkve 2000) 
LA, California, 
USA 
60 days 
(mean 74 
days, SD 
216 days) 
Self-reported access barriers. 
1/5 patients delayed reporting 
for longer than 60 days. 
Delays more common in 
unemployed, those 
concerned with cost, 
difficulties seeking treatment, 
unsure where to get care, 
belief in efficacy of self-
treatment, and those fearing 
immigration authorities. 
(Asch, Leake et 
al. 1998) 
Gliana. West 
Africa 
4 months 
(median), 
7.7 
months 
(mean) 
4 weeks 
(median) 
8 weeks 
(median) 
In 44%, delay longer than 6 
months, strongly associated 
with rural residence. Long 
doctor delays associated with 
no sputum test, low diagnosis 
rates, rural setting, female 
patients, and those needing 
hospital admissions. 
(Lawn, Afful et 
al. 1998) . 
Kuala 
Lumpur, 
Malaysia 
12.5 
weeks 
7 weeks 2 weeks Sputum tests and chest x-
rays underutilized; private 
practitioners should be more 
alert to symptoms and 
diagnosis. 
(Liam and Tang 
1997) 
Victoria, 
Australia 
31% of patients started treatment within 31 days of symptoms onset. 
86% of smear positive cases started treatment within 3 days after 
positive smear test; longer medical delays were only found in private 
treatment. 
(Pirkis, Speed 
et al. 1996) 
Table 3-1 Treatment waiting times and delays. The delays in case t rea tment reported 
in studies listed b e l o w are s u m m a r i z e d accord ing to region. T h e t rea tment de lays are 
reported as the total mean de lay f rom suspected t ime of s y m p t o m s onset to init iation o f 
treatment. S o m e studies d i f fe ren t ia ted fur ther as the patient and medical de lays . T h e 
patient delay represents the t i m e f r o m onset to pat ient report ing to health services . The 
medical delay re fe rs to the t ime f rom patient repor t ing to initiation of t rea tment 
IX. Case Diagnosis -methods 
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Cases of active TB disease are diagnosed by a variety of means, including 
traditional smear and culture methods, as well as newer protocols such as radiometric 
and molecular methods. All of these tests are based upon obtaining and processing 
sputum samples. Sputum samples are collected from patients with persistent cough that 
produces secretions from the lower respiratory tract. Sputum specimens should be 
refrigerated and rapidly conveyed to the laboratory for tests. Sputum samples are first 
processed for homogenization and decontamination to remove respiratory secretions 
and treated with basic solutions to retard the growth of other bacteria. These solutions 
are then removed spinning the sample in a refrigerated centrifuge, and the mycobacteria 
concentrated in the pellet. The pellet can then be sampled directly for presence of 
mycobacteria by a smear test. In order to culture, the pellet should be resuspended in 
appropriate media to redistribute the mycobacteria. (Lutwick 1995; Davies 1998; 
Iseman 2000) 
In a smear test, a sample taken from the patient's sputum is smeared on a slide, 
stained, and examined by microscopy to determine the presence of acid fast bacilli 
(AFB). When performing smear microscopy, these samples isolated from a patient are 
treated with a dye that stains the waxy Hpid-rich mycobacterial cell wall. The dye is 
taken up through the lipid-rich mycobacterial cell walls through heating and alkaline 
treatment. Once the dye is absorbed into the mycobacterial cell walls, the cells retain 
this stain even when treated with an acid solution. The sample is then counterstained 
with a dye of another colour in order to reveal the mycobacteria present on the 
background of other cells. (Lutwick 1995; Davies 1998; Iseman 2000) 
Smear microscopy is the most commonly used method for diagnosis of active 
disease. The benefits of this method include a faster return of results, but this is 
balanced by the difficulties in diagnosing tuberculosis when the patient is infected with 
nontuberculosis mycobacteria. While the smear test has lower specificity and 
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sensitivity than culture techniques, the low cost, the ease of administration and 
interpretation have allowed the smear test to remain the most widespread method for 
diagnosis. In particular, in many resource poor settings this remains the only available 
means of microbiological confirmation of active TB disease. Most cases with cavitary 
lung disease are strongly smear positive, while patients with non-cavitary disease are 
likely to be smear negative. The sensitivity of the test appears to be able to detect at a 
level of above 7,800-9,500 bacilli per mL of sputum. (Yeager, Lacy et al. 1967; 
Hobby, Holman et al. 1973) The test is also limited by specificity; other non-
tuberculosis mycobacteria also have the same acid-fast properties that allow for the 
stain to be retained and show a positive smear result. The usefulness of smear in 
diagnosis is therefore also related to the prevalence of non-tuberculosis mycobacteria in 
the environment, and the proportion this contributes to mycobacterial disease. 
(Lutwick 1995; Davies 1998; Iseman 2000) (Perkins and Kritski 2002) (American 
Thoracic Society 1990) 
In culture-based diagnosis, a sputum sample isolated from the patient, as 
described above, is grown either in liquid or on solid medium. The choice of medium 
will affect the growth time required to detect the presence of mycobacterium. When 
grown on solid medium, the positive detection of mycobacterium takes from 3 to 8 
weeks. Culture-based tests have high sensitivity and specificity. Further, these tests 
are relatively both affordable and are easily performed, making them well suited for the 
developing world. (Lutwick 1995; Davies 1998; Iseman 2000) (Hale, Pfyffer et al. 
2001; Perkins and Kritski 2002) 
Use of liquid based media and radiometric techniques, such as the automated 
BACTEC system, can reduce the detection time to about two weeks. (Middlebrook, 
Reggiardo et al. 1977) In repeated trials, the BACTEC system has been shown to 
recover over 90% of M. tuberculosis specimens. (Roggenkamp, Hornef et al. 1999; 
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Harris, Rayner et al. 2000) Systems similar to BACTEC have been developed that 
allow for rapid and accurate detection of mycobacterium without the need for 
radioactivity. The most commonly used alternative is the automated non-radiometric 
MB/BacT system. (Yew, Tong et al. 2001) The MB/BacT system has been shown to 
be reliable for detection of mycobacterium in culture. In some trials, the MB/BacT 
system has shown slightly lower sensitivity in detection of mycobacterium than the 
more traditional BACTEC system, in particular for detection of smear negative cases. 
(Roggenkamp, Hornef et al. 1999; Harris, Rayner et al. 2000; Watterson and 
Drobniewski 2000) 
There have also been efforts to develop routine serological tests for 
tuberculosis, particularly for diagnosis of smear negative pulmonary disease. Such 
tests have been developed to detected antigens on the surface of the tubercle complex. 
However, these methods have largely lacked sensitivity in detection, as well as 
specificity due to cross reaction with other mycobacterial species. The use of ELISA 
tests for direct detection of antigens on M. tuberculosis have been developed from 
murine monoclonal antibodies. (Watterson and Drobniewski 2000) (Lutwick 1995; 
Davies 1998; Iseman 2000) 
In addition, tests have recently been developed for direct detection of disease 
through PCR. Such tests can reduce the diagnostic time from several weeks to several 
days. In addition, molecular amplification tests offer high specificity and sensitivity. 
In these tests, sputum samples from patients are treated to isolate DNA, which is then 
amplified by PCR for either sequencing or hybridization and RFLP analysis. PCR-
based tests have become commonly used for determination of mycobacterial species in 
some regions, with two direct M. tuberculosis nucleic acid amplification tests approved 
by the Food and Drug Administration in the USA. DNA microarrays have also been 
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used to rapidly screen for multiple mycobacterial species. (Soini and Musser 2001) 
(Watterson and Drobniewski 2000) (Hale, Pfyffer et al. 2001) 
X. Drug testing—methods 
X. A. Need for standardized protocols in network of centralized 
laboratories 
Drug testing is needed both for regional surveillance and for individual patient 
treatment. Drug resistance has existed since chemotherapy of tuberculosis began. Over 
the past decade, resistance has been found in every region surveyed and epidemics of 
MDR have placed an increasing burden on TB programs. (WHO/IUATLD 1997; 
WHO/IUATLD 2000) In order to prepare for the surveillance presented by the WHO 
working group on drug resistance surveillance, a network of laboratories was created in 
participating countries that coordinated case detection and drug testing methods. High 
standards of drug testing were maintained in these laboratories, although the methods 
varied slightly according to available resources in particular laboratories. The 
coordination of efforts allowed for the comparison of these methods across the 
laboratories in the network. Overall, these drug susceptibility testing methods showed 
a high degree of specificity and sensitivity, although the sensitivity tended to be a bit 
lower. Across the laboratories in the network, there was a high degree of concordance 
in the sensitivity of drug testing for isoniazid and rifampicin, but disagreement for 
susceptibility testing of other first line drugs. (Laszlo, Rahman et al. 1997) 
Recommendations for surveillance of resistance in Europe recommends 
establishing a network of laboratories that coordinate methods in order to ensure high 
proficiency and quality of testing, as well as the ability to compare results for regional 
surveillance. The working group further recommended that when resources are 
available, there should be drug susceptibility testing of all isolates. Drug testing for 
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resistance to at least isoniazid and rifampicin should be recorded, and for surveillance 
purposes, linked to records of case notification, diagnostic tests, and critical case 
information. (Schwoebel, Lambregts-van Weezenbeek et al. 2000) 
Drug susceptibility testing is also needed to guide patient treatment, allowing 
for prescription of optimal regimens by case. In order to ensure proficiency in and 
optimization of drug susceptibility testing methods, it is important to maintain high 
proficiency in laboratories performing these tests. Because maintaining such technical 
expertise, as well as obtaining all necessary resources, may be difficult within local 
laboratories, it is important that samples can be sent to regional laboratories. Such 
central laboratories can maintain the expertise needed. In addition, localization of 
needed resources within central laboratories can provide the needed drug testing at 
lower costs. (Heifets and Cangelosi 1999) 
X. B. Culture based methods 
The traditional method for diagnosing patient resistance to particular 
tuberculosis drugs is based on culture. A case sputum sample, containing active 
mycobacterium, is cultured on either solid or liquid medium containing that particular 
drug. Growth in the presence of drug is considered to show resistance. Typically, the 
sample is cultured on a number of different dilutions of drug, to allow the relative 
comparison of growth, and estimation of the minimum inhibitory concentration (MIC). 
The choice of medium will affect the time taken to culture the sample to detectable 
levels, but on average this takes 3 to 5 weeks. Sensitivity and contamination are also 
issues with culture based drug testing. Contamination of cultures may lead to false 
positives for resistance. 
There are three basic methods for measuring resistance in culture. In addition, 
for any of these three methods, resistance can be tested for either directly, taken from 
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the smear positive sputum, or indirectly, taken from colonies cultured in laboratory. 
While direct testing may allow for more accurate representation of the proportion of 
resistant organisms present in the sputum sample, indirect testing allows for selection 
of viable mycobacterium. The absolute concentration method involves inoculating a 
sample on plates containing varying concentrations of drug, as well as a control plate 
with no drug. If more than 1% of the inoculum grows on media containing critical 
concentrations of the drug, the sample is considered to be resistant. The resistance ratio 
method compares the growth of a patient sample to a standard laboratory strain. The 
results are reported as the ratio of the MIC of the patient to laboratory strain. The 
proportion method compares the growth of a strain in the presence and absence of drug. 
The sample is considered resistant if more than 1% of the colonies present on the 
control grow on media containing drug at a critical concentration. 
X. C. Automated radiometric methods 
With the increasing use of automated methods for detection of mycobacterium, 
such as the radiometric BACTEC system, methods have also been adapted to allow use 
of these automated systems for detection of resistance. The BACTEC system has been 
used allow for faster detection of resistance by the proportion method. The growth of 
patients sample is compared in the presence of drug and a 1:100 dilution of the sample 
in the absence of drug. The growth index values from two consecutive days are 
compared; the sample is considered to be resistant if there is slower growth in the 
sample with drug compared to the control. (Roberts, Goodman et al. 1983; Lee and 
Heifets 1987) (Rastogi, Labrousse et al. 1996; Davies 1998; Iseman 2000) 
The radiometric BACTEC method has been used to detemiine resistance is 
patient samples. The initial method took several weeks for detection of growth of 
resistant organisms. (Roberts, Goodman et al. 1983) (Siddiqi, Hawkins et al. 1985) 
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The MIC of strains has also been determined using the BACTEC method. The MIC as 
determined by BACTEC is considered to be closer to the true MIC of the strain present 
in the patient than as cultured on agar plates, as this method is faster, allows for more 
absorption and is more quantitative. (Lee and Heifets 1987) (Rastogi, Labrousse et al. 
1996) A multicenter trail using Bactec reported susceptibility results completed in 11-
23 days, compared with 33-42 days for conventional tests. (Middlebrook, Reggiardo 
et al. 1977) In more recent studies, use of the BACTEC method for susceptibility 
testing has been completed in an average of 8 days. (Pfyffer, Bonato et al. 1999) 
A more recent comparison of resistance tests by the automated, nonradiomateric 
MB/BacT system and the agar proportion method found the MB/BacT system to be as 
reliable as culturing on agar. The MB/BacT system was also considerably faster; the 
mean time to using the MB/BacT system was 4.7 days for resistant isolates and 10.8 
days for drug sensitive isolates, compared to 14.8 days for resistant and 21 days for 
sensitive isolates on agar plates. (Yew, Tong et al. 2001) 
X. D. Sensitivity and reliability of DST 
While this test does take the longest time to return results, it is affordable even 
in the developing world, and requires only relatively simple technical skills. However, 
the reliability of these tests is still dependent upon lab techniques and in particular 
attempts to avoid contamination. A further difficulty with culture-based resistance tests 
is that they can signal the presence of resistant mycobacteria in the sample, but not the 
relative amounts of sensitive and resistant organisms. 
X. E. Molecular tests for resistance 
Diagnostic tests relying on molecular methods use knowledge about the genetic 
basis of resistance to a particular drug. About 40 identified mutations or deletions to 
date have been shown associated with a resistance phenotype. The genetic tests are 
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most developed for the identification of rifampicin resistance, for which greater than 
95% of mutations can be found in the rpoB gene. (Kim, Lee et al. 2001) PCR based 
techniques involve amplification of a region of a gene, followed by either RFLP 
analysis or sequencing to differentiate wild type from mutant sequences. (Soini and 
Musser 2001) (Caws and Drobniewski 2001; Flu it, Visseretal . 2001) Direct 
sequencing of the resistance gene allows for the highest detection rate of the presence 
of genetic resistance in a sample, followed by RFLP analysis. The usefulness of either 
method varies by locus and test for each drug. (Nachamkin, Kang et al. 1997) 
A significant limitation of these molecular methods for resistance testing is that 
they do not reflect on level of resistance to a drug, and thus MICs cannot be determined 
from these tests. In addition, these tests only show genetic resistance, but this does not 
always translate into phenotypic resistance. PCR tests can typically be completed in 2-
3 days time under good laboratory condition ns. It may take several weeks, however, to 
take a sample, send to the laboratory, and to return results. In addition, there may be 
need for repeated drug tests requiring further patient samples. (Fluit, Visser et al. 2001; 
Soini and Musser 2001; Victor, van Helden et al. 2002) 
X. F. Other susceptibility tests for developing world use 
There has been an emphasis recently on the use and development of molecular 
based susceptibility testing methods, which will allow for faster and more accurate 
detection of the genetic resistance. However, the use of such molecular methods is 
only realistic within the context of the high market economies, and the small proportion 
of cases which fall under well funded TB programs which can afford to allocate 
resources for drug testing of all cases. (Fisher 2002) The vast majority of cases are 
found under the coverage of under funded programs which cannot afford any resources 
for general case drug testing, much less the building of standardized laboratories and 
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technical expertise required for the newer molecular based methods. There remains a 
great need, as resistance rates grow within these resource-limited programs, to diagnose 
case resistance profiles in a timely fashion before or shortly after beginning treatment. 
In order to meet this need, drug susceptibility testing methods which are applicable for 
wide scale application in developing world settings need to be considered; such tests 
need to be affordable, require few additional resources and low technical skill. 
A number of other tests for diagnosing resistance have been developed, and 
considered for their applicability to wide scale use in developing country and resource 
poor settings. For example, a swab test was used, and found to be as effective, cheaper, 
and easier to implement than indirect inoculation and culture to test media. However, 
this requires an average of eight weeks, the same as for traditional culture methods, to 
diagnose resistance. (Mathew, Nair et al. 2000) Another example is the microscopic 
observation broth-drug susceptibility assay (MODS), which allows for early detection 
of mycobacterium growth in liquid medium. MODS can be used for more rapid 
diagnosis of disease as well as detection of resistance. MODS offers a rapid, relatively 
inexpensive, sensitive and specific method for susceptibility testing. (Caviedes, Lee et 
al. 2000) 
X. G. Global drug testing 
The global use of drug testing and second line regimens are difficult to quantify. 
The best current estimates of prevalence of resistant cases come from WHO drug 
resistance surveillance project, which has been ongoing for the past eight years. This 
study has followed the prevalence of resistance to the major TB drugs in 54 
countries/regions, by sampling a proportion of active TB cases. Case samples are sent 
for drug sensitivity testing, with methods standardized through a system of shared 
protocols within a network of coordinated laboratories. (WHO/IUATLD 2000) 
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In some regions, drug testing has become an integral component of the TB 
control program. In the low incidence regions where TB has nearly entered the 
elimination phase and resources are available for individualized testing and treatment, 
programs have recommended drug testing of all new cases. In particular, this is 
important in regions with a high prevalence of primary resistance, or amongst 
immigrants from such regions. (Clancy, Rieder et al. 1991; CDC 1998; CDC 1998; 
Schwoebel, Lambregts-van Weezenbeek et al. 2000; Broekmans, Migliori et al. 2002) 
In the UK, the PHLS gathers samples of all new cases and tests for drug resistance. 
(Kumar, Watson et al. 1997; Eltringham and Drobniewski 1998) Similarly in the USA, 
regulations recommend the drug testing of new and previously treated cases. (CDC 
1998) 
Outside of these programs, drug testing of TB cases is more difficuh to 
quantify. Much of this happens in the private sector and is not officially monitored by 
surveillance or control programs. Some occurs within the structure of national and 
inter-national control programs, including DOTS-plus program. Some programs 
explicitly state the need for drug testing of all new cases in regions of high resistance 
prevalence. Other guidelines suggest that only chronic infectious cases not responding 
to treatment and cases with contacts of resistant patients should receive drug testing. 
Still, much of drug testing and treatment of resistant cases occurs in the private sector, 
outside of organized health authorities, and without coordinated patient records. 
X. H. Treatment of drug resistant cases 
Since the establishment of short course chemotherapy regimens consisting of 
four or five common first line drugs, acquired resistance emerges at lower rates per 
treated case. However, resistance to multiple drugs, particularly to INH and RIF, two 
of the most potent and effective first line drugs, has begun to be commonly observed. 
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(WHO/IUATLD 1997; WHO/IUATLD 2000) Primary resistance is a leading cause of 
treatment failure on first line SCC. As MDR emerged and caused noticeable strain on 
some health systems, due to the cost and difficulty associated with treating these cases, 
more studies began to focus on epidemiology and treatment of resistance. In order to 
treat cases resistant to one or more of the first line drugs, specialized regimens were 
developed. Some TB control programs developed clinical guidelines for treatment of 
resistant, and in particular, MDR cases. These guidelines include drug testing of new 
cases in order to identify resistance patterns and to modify treatment regimens 
accordingly. A central recommendation for treatment of resistant cases is to identity 
resistance early and ensure that the regimen used does not allow for monotherapy. 
Second-line regimens used to treat resistance provide a more effective cure than 
continued treatment with first-line regimens. This shift also ideally removes a high 
selective pressure for acquired resistance, which may occur under continued treatment 
with drugs to which the patient has already developed resistance. (WHO 1997; 
Espinal, Dye et al. 1999; WHO 1999; Bastian, Rigouts et al. 2000; Farmer 2001) 
Early clinical trials examined the impact of initial resistance on treatment 
outcome. The results of pretreatment drug susceptibility results were correlated to 
outcome. Initial resistance to a single drug was correlated with slightly reduced cure 
rates. (Hong Kong Tuberculosis Treatment Service/ British Medical Research Council 
1972) All the regimens appeared to be effective at treating cases with initial resistance 
to either isoniazid or streptomycin. However, the treatment was less effective with 
there was initial resistance to rifampicin. In addition, when neither rifampicin nor 
pyrazinamide were included in the continuation phase of treatment, the relapse rate for 
cases with initial isoniazid resistance was increased. (Hong Kong Tuberculosis 
Treatment Service/ British Medical Research Council 1972) (Davies 1998; Iseman 
2000) In another trial, the role of primary resistance on response to SCC was examined 
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again within 12 control trials in Africa, Hong Kong and Singapore. Amongst cases 
with initial resistance to isoniazid or streptomycin, 17% of those given a 6 month 
regimen of isoniazid and rifampicin, and 12% of those given rifampicin in the initial 2 
month phase failed treatment. The proportion of treatment failures decreased with 
increasing number of drugs used in the regimen, and a longer duration of treatment 
with rifampicin. The treatment failure rate was only 2% for cases which received a 4 or 
5 drug regimen that included rifampicin throughout the 6 months of treatment. 
(Mitchison and Nunn 1986) 
More recently, clinical trials have shown that MDR cases have poor response on 
s e e . MDR is the major cause of treatment failure on the DOTS retreatment regimens. 
(WHO 1997) Patients with patterns of MDR resistance showed low cure rates on the 
first line regimen. In addition, treating patients initially resistant to one or more drugs 
with these first-line drugs could allow for some periods of effective monotherapy, 
during which there could be rapid selection for resistance to the remaining drugs. 
Many patients developed resistance to all of the traditional drugs, and again, some 
turned to alternative treatments such as surgery. More recently, the development of 
new drugs, including various second-line drugs have been introduced in treatment of 
these multi-resistant cases. While many of these drugs remain early in use and are not 
as well characterized as the first line drugs, they have shown effectiveness in treatment 
of resistant cases. (WHO 1997) (WHO 1997; Espinal, Dye et al. 1999; WHO 1999; 
Bastian, Rigouts et al. 2000; Farmer 2001; Sterling. Lehmann etal . 2003) 
In response to the poor response of MDR cases to SCC, specialized regimens 
were developed to treat cases with initial resistance. The recommended regimens for 
treatment of MDR cases includes an initial intensive phase lasting at least 6 months, 
followed by a continuation phase of 12 to 18 months. During the initial phase, 4 or 
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more drugs should be used, and 3 or more of the most active drugs should be used in 
the continuation phase. (WHO 1997; WHO 2003) 
Resistance can either be treated using standardized or individualized regimens. 
Where resources for drug testing are available, all cases failing treatment should 
receive drug testing. Cases diagnosed with resistance should then be placed on 
specialized regimens. When resources for drug testing are not available, standardized 
regimens should be used for retreatment. However, cases failing retreatment regimens 
should be referred to either specialized centers for resistance treatment or receive 
retreatment regimens that are based on knowledge of the likely resistance patterns. 
There are several benefits to using regimens standardized within the region for 
treatment of MDR cases. First, this allows for a lower cost (WHO 1997; WHO 1999; 
Bastian, Rigouts et al. 2000; Farmer 2001) 
Programs can also offer individualized treatment for MDR cases through 
centers of excellence. Referring MDR cases to specialized centres allow individualized 
treatment with less effort and changes to local care practices. Such centres can achieve 
high cure rates for MDR cases with lower cost, by offering individualized treatment 
regimens tailored to drug susceptibility patterns of the patient, can give fully observed 
therapy and ensure adherence through a long and difficult treatment. However, such 
care is costly, including expensive second line drugs, testing facilities, laboratories, and 
a high level of care. (Farmer 2001; Mitnick, Bayonaeta l . 2003; WHO 2003). 
XI. Summary 
In this chapter, I review literature on the treatment of TB. I begin with a 
historical perspective, starting with the introduction of the early chemotherapy 
regiments in the 1960s. While these were typically based on monotherapy, they did 
offer a rapid cure in a high proportion of cases. As was soon realized, however. 
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monotherapy led to high levels of drug resistant cases. Introduction of rifampicin, 
which had effective sterilizing activity, in the regimens in the later 1960s vastly 
improved cure rates. Today, the standard chemotherapy regimens are based on the 
World Health Organization's DOTS-SCC program. The basic requirements of DOTS 
programs are briefly reviewed here. I also provide an overview of what constitute the 
basic elements of a control program, including the case detection and cure rates, and 
survey these for TB programs. I also review the current standards and methods for case 
diagnosis and drug susceptibility testing. This review provides basis to understand the 
context of current treatment practices for TB and control programs, and to understand 
the development of the model in Chapter 5 for TB transmission, which includes 
treatment, as well as the model developed in Chapter 8 that includes many of the 
elements of control programs discussed here. 
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Chapter 4 
Review of mathematical models of tuberculosis 
epidemiology 
"It was the fashion to suffer from the lungs; everybody was 
consumptive, poets especially; it was good form to spit blood after each 
emotion that was at all sensational and to die before reaching the age of 
thirty" 
— Alexander Dumas 
CHAPTER 4 
REVIEW OF MATHEMATICAL MODELS OF TUBERCULOSIS EPIDEMIOLOGY 
I. GOALS 
II. ABSTRACT 
HI. INTRODUCTION 
IV. INTRINSIC DYNAMICS OF EPIDEMICS 
IV. A . DISEASE RISKS 
IV. B . LONG TERM DYNAMICS OF EPIDEMICS 
IV. C . T B IN ENGLAND AND W A L E S 
V. CONTROL STRATEGIES 
VI. DRUG RESISTANCE 
VI . A . EMERGENCE OF ACQUIRED D R U G RESISTANCE 
VI . B . M D R TRANSMISSION (AND EVALUATING EFFECTIVENESS OF CONTROL STRATEGIES) 
VH. CONCLUSION 
I. Goals 
I. A. To review the literature on mathematical models of 
tuberculosis epidemics. 
II. Abstract 
In this section, previous mathematical models of tuberculosis are reviewed. 
The models and studies included have made critical contributions to understanding 
historical tuberculosis epidemics and their intrinsic dynamics. Models which focus 
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specifically on understanding the dynamics of drug resistant tuberculosis are also 
examined. The critical components of these models are compared in Table 4-1. 
III. Introduction 
Mathematical models for infectious diseases are used for many purposes 
within the study of infectious disease epidemiology. Epidemiological models may 
focus on the transmission and dynamics of an epidemic within a population. These 
models may also include control strategies, and be used to weigh the benefits of 
possible interventions. Other models may consider the dynamics of a bacterial or viral 
infection within an individual. Such within-host models may be used to consider the 
impact of drug treatment on the infection, the interaction with the host immune system, 
and the emergence of drug resistant organisms. In addition to the range of possible 
uses of mathematical models in the study of infectious diseases, the methods used in 
developing the model are also important. The types of models typically used are 
deterministic, defined by a set of ordinary or partial differential equations, or stochastic. 
Models may consider only the disease state in subdividing a population, or may further 
subdivide according to categories such as age. The inclusion of additional categories 
should be appropriate and justified by the disease and situation. Ideally, both the 
methods and type of models will be selected as those best suited to the question at 
hand. 
In this chapter, the literature on mathematical models of TB is surveyed, 
highlighting those mainstream and influential studies most relevant to this thesis. First, 
models used to understand the natural history and epidemiology of TB are reviewed. 
Second, models used to consider various treatment strategies for the control of TB are 
presented, followed by a final section on models that include drug resistance. The most 
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relevant elements of each of these models, including parameters for basic disease as 
well as control, and for model formulation and design, are compared in Table 4-1. 
Many of these elements (shown as 'Bahcall ' in Table 4-1) are considered in the 
models developed in later chapters of this thesis. As shown in Chapter 6, when the 
sensitivity of the model parameters is examined, the parameters that are most central to 
modeling resistance are the inclusion of both acquired resistance and primary 
transmission. The inclusion of multiple strains within one population, is required in 
order to examine the dynamics for emergence of resistance from within an entirely drug 
sensitive epidemic (as all were pre-chemotherapy). In addition, this is needed to model 
the dynamics between sensitive and resistant strains that may continue after their 
emergence, and is likely to be central to understanding current epidemics, in which 
resistance has remained at relatively low prevalence. 
In the chapters to follow, we develop a model to address the emergence, 
transmission, and control of resistant TB. This model includes many of the aspects of 
previous models reviewed here and considered essential to TB models. In addition, the 
model adds new components suited to address the questions posed in this thesis. In 
Table 4-1, the components of the model developed in later chapters of this thesis 
C'Bahcall") are compared to the models reviewed in this chapter. 
Some of these studies, as noted in Table 4-1, have included age structure. Since 
age structure can be an important component of TB epidemiological models, 1 also 
considered the use of age structure in developing models within this thesis. However, 
based on in initial simulations of a model incorporating age structure, presented in 
Chapter 5, it is suggested that age structure has limited impact on the overall model 
conclusions, and is therefore not used for the subsequent model simulations throughout 
the thesis. Within these limited studies presented in Chapter 5, examining the 
prevalence of resistance by age in England and comparing these to simulations with 
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model that incorporates age structure, we conclude that that this does not significantly 
impact on model predictions for overall prevalence of resistance, dynamics between 
strains, or on the impact of control. However, if in considering a particular scenario, 
there appeared to be strong relationship between age and a particular parameter key to 
the models as developed here, it may prove helpful to incorporate age structure into a 
model. For example, if studies revealed significant variation in suscepfibility to a 
particular resistant strain by age, this could affect resistance prevalence and the relative 
transmission and success of the resistant strain. Similarly, if treatment efficacy for 
resistant cases varied significantly by age, this could impact model predictions. 
However, from current studies, there has not been reason to suggest that the resistance 
prevalence by age will vary, or reflect more than the relative disease risks by age, 
combined with the relative proportion of resistant strains circulating in the populafion. 
IV. Intrinsic dynamics of epidemics 
Early models of TB spread and persistence have largely focused on an historical 
dynamics perspective of defined epidemics. These models have shown that the long 
latency period of tuberculosis results in epidemics with slow dynamics. 
IV. A. Disease risks 
Early models from Sutherland were used to estimate the risk of developing 
disease from surveys on military recruits in the Netherlands. The relative contribution 
of primary, endogenous, and exogenous disease to annual incidence was estimated. 
The highest disease risk was found to occur shortly after primary infection, followed by 
reinfection, and finally latent infection with no reinfection. (Sutherland, Svandova et 
al. 1976) The risk of developing disease within five years after primary infection was 
estimated at 5.06% per anum. For five years after a reinfection event, the annual risk of 
developing disease was slightly lower at 1.91%. In the absence of reinfection, latently 
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infected individuals experienced a 0.0253% annual risk of endogenous reactivation. 
Latent infection was also shown to confer protection from reinfection disease, 
estimated at 63% (for men) and 81% (for women) protection. (Sutherland, Svandova et 
al. 1982) 
IV. B.Long term dynamics of epidemics 
More recently. Blower has examined the intrinsic dynamics of long term TB 
epidemics. The model presented by Blower et al. consists of three states: susceptible, 
latent, TB disease (S, L, T), in which infected individuals can progress to an infectious 
case either directly (primary) or after a period of latency (reactivation). In an expanded 
five state model, active TB cases are either infectious (Tj) or non-infectious (Tn), move 
to the recovered class through natural cure, and return to disease through relapse. 
(Blower, McLean et al. 1995) 
Using these two models, Blower demonstrates that tuberculosis epidemics can 
be modeled as the combination of a series of time-lagged epidemics, representing the 
fast dynamics of primary progression to disease and the slow dynamics of endogenous 
reactivation. The time lag between the rise of these sub-epidemics occurs because the 
dynamics of each are age-dependent with reactivation TB occurring more often in older 
individuals. During the course of an epidemic, the relative proportions of each sub-
epidemic will shift. Fast cases (primary disease) predominate early in an epidemic, 
while slow cases (reactivation disease) predominate in a mature epidemic. Similarly, 
the age-distribution in an epidemic will shift toward older individuals as the 
contribution of reactivation disease increases with progression of an epidemic. Using 
this model. Blower et al. demonstrated the slow intrinsic dynamics of tuberculosis 
epidemics, with an estimated mean epidemic length of 100 years. The authors also 
define the basic reproductive number of each sub-epidemic, and the threshold 
susceptible population size required for a TB epidemic to emerge. (Blower, McLean et 
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al. 1995) Sensitivity analysis reveals that the parameters most significantly affecting 
the epidemic are equilibration time, the effective case contact rate, the fraction of new 
infections that develop primary disease, and the TB mortality rate. (Porco and Blower 
1998) 
The central conclusions of these papers by Blower et ai. are that TB epidemics 
occur on long timescales, and can be understood in terms of the combination of fast and 
slow progression to disease. These are conclusions central and common to the 
understanding of TB epidemics, repeated and verified by a number of models. 
IV. C. TB in England and Wales 
Vynnycky and Fine have rigorously characterized the dynamics of the 
tuberculosis epidemic in England and Wales over the past century. (Vynnycky and Fine 
1997) The authors described the dynamics of TB infection and disease since 1900 
using an age-structured deterministic model which includes classes for susceptible, 
immune, infected, latent, reinfected, endogenous and exogenous disease. Infected 
individuals are at risk for primary disease for five years, after which time infecteds who 
have not developed disease move into a latent class (with a lower rate of progression to 
disease). 
The effective contact rate is defined as contact sufficient to lead to infection, 
and is derived each year as the annual rate of infection divided by the prevalence of 
infectious cases. As this information was not available prior to 1950, trends in age-
specific mortality rates were used to estimate tuberculosis prevalence during these 
years. They estimate that with a case fatality rate of 50% in the prechemotherapy era, 
the average duration of infection was 2 years. The introduction of chemotherapy in the 
1950s gradually reduced case fatality to 25% and duration of infection to 1 year. 
(Vynnycky and Fine 1997) 
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Vynnycky finds that a model allowing for reinfection provides a better fit to the 
data. The best fit came from the assumption that reinfection occurs at the same rate as 
first infection, but is less likely to result in primary disease progression. This suggests 
that prior infection confers partial (but not complete) immunity to exogenous disease, 
and that reinfection contributes significantly to the long term trends in tuberculosis 
prevalence. (Vynnycky and Fine 1997) 
V. Control strategies 
Mathematical models of TB transmission dynamics have also been used to 
analyze the effectiveness of different interventions on the prevalence and incidence of 
infection and disease. The current predominant strategy is the World Health 
Organization (WHO) sponsored national treatment program, DOTS. Dye provides a 
model for DOTS control of TB, based upon an age-structured model of (drug-sensitive) 
TB transmission. (Dye, Garnett et al. 1998) In this model, latently infected individuals 
can progress to disease either by endogenous reactivation or exogenous infection. 
Active TB cases are either infectious (I) or non-infectious (N). Cases receive either 
good treatment, and return to the infected latent class, or bad treatment, leading to 
treatment failure. The model also provides for self-cure, smear conversion, and the 
immunization of susceptibles. The DOTS strategy is incorporated into the model with 
estimates for case detection and cure rates. This model is used to consider the impact of 
current and higher levels of case detection and DOTS treatment on the course of TB 
epidemics in global settings. Increasing case detection and DOTS cure rates are shown 
to reduce incidence of disease and deaths due to TB. (Dye, Garnett et al. 1998) 
Murray has also produced a model considering the effectiveness of different 
interventions. Murray presents a more detailed model of the transmission and treatment 
of drug-susceptible TB, including INH chemoprophylaxis, superinfection of latently 
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infected individuals, and three clinical types of active TB disease (smear-positive 
pulmonary, smear-negative pulmonary, and extra-pulmonary). In this model, infected 
individuals progress to active disease at either a fast (1-5 years) or slow (5+ years) rate, 
and can receive INH preventive therapy, which slows the rate of progression. Infected 
individuals with slow latent TB experience protection from reinfection v, and are 
reinfected at a rate (1 -v), leading to fast progressive TB. Untreated cases have either a 
fast or slow rate of case detection and diagnosis. Treatment of infectious cases is either 
good (complete regimen) or bad (incomplete), with distinct cure and death rates. 
Recovered cases relapse to active TB at either a fast or slow rate. (Murray and Salomon 
1998) 
This TB transmission model is considered both in the presence and absence of 
HIV co-infection, making this model useful for evaluating the impact of control 
strategies in levels with high HIV prevalence. The authors consider the impact on 
incidence and mortality of supplementing current DOTS with additional strategies. 
Their analyses incorporate projections for the level of DOTS implementation, the 
extent of BCG coverage (including assumptions on duration of efficacy), and the level 
of HIV infection. (Murray and Salomon 1998) 
VI. Drug resistance 
With the increase in drug resistant tuberculosis over the past decade, models 
have also considered the development of drug resistance. Blower built upon her 
previous three compartmental model (S,L,T) to include the development of drug 
resistance. She presents both a model with one TB strain (DS) and with two strains 
(DS and DR). In the two-strain model, susceptible individuals can be infected with 
either a DS (S) or DR (R) strain, and either remain latently infected (Ls or LR) or 
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progress directly to an infectious case (TG or TR). Individuals with a latent drug-
sensitive infection (LG) can also receive chemoprophylaxis and be cured. Infectious 
cases of both DS and DR receive treatment, but the latter is treated less effectively. 
Treated DS cases develop drug resistance and move into the TR class at a constant rate. 
This allows for easier mathematical manipulation of the model, but does not seem an 
appropriate definition of acquired resistance, which should be a set proportion of 
treatment failures that develop resistance. New cases of acquired drug resistance are 
perpetuated through transmission of primary drug resistance. The possibility of a 
fitness cost of resistance is considered in terms of a reduced rate of transmission (PR < 
Ps). (Blower, Small et al. 1996) 
The equilibrium conditions of this model provide for three outcomes: the 
persistence of DR, the persistence of both DS and DR, or the eradication of both DS 
and DR TB. Which outcome occurs is determined by comparing the effective 
reproductive number for DS and DR. Also proposed is an evaluation criteria r^AX, 
defined as the maximum acceptable probability of treatment failure, given the number 
of DR cases produced for each DS case. A control strategy, as specified by parameters 
for the effective treatment rate, the emergence of acquired resistance, and the relative 
treatment efficacy of DR TB, can be evaluated in terms of the effective reproductive 
number and r^Ax- (Blower, Small et al. 1996) 
This analysis does contribute an understanding of the application of theoretical 
thresholds for model outcomes to inform on the impact of treatment. However, the 
application of these thresholds is limited by model structure. The idea of using the 
defined value r^Ax is both interesting and important in providing some measure for 
control programs to use in assessing the resistance problem. It is also nice to see a 
quantitative measure for the relative production of acquired resistance, as this does 
reflect on the state of treatment and effectiveness of the control program. The relative 
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production of acquired resistance will also reflect on the likely future course of the 
epidemic, and signal need for improved case management. However, the quantity 
defined in this model, rwAX, may not be the most useful measurement for such 
considerations. First, the rate of acquired resistance is defined as a steady proportion of 
the treatment rate, when this should be only amongst cases failing treatment. Second, 
the treatment cure rates for both sensitive and resistant cases need to be incorporated. 
Third, the number of resistant cases produced for each sensitive case is in practice 
difficult to measure. A more practical alternative might include consideration of the 
rate of resistance amongst new and previously treated cases. Such measures can be 
compared to surveillance data, with the limitations as described in chapter 1 for the 
measurement of resistance prevalence. 
VI. A. Emergence of Acquired Drug Resistance 
Dye presents another model for the emergence and transmission of drug 
resistant TB, expanding on Blower's model by including classes for previously treated 
individuals. The model is used to estimate rates of acquired resistance to each drug, 
and to predict trends in prevalence of resistance over time. 
This model includes latent classes for slow and fast progression to disease for 
sensitive (Ls and Lp) and resistant (L's and LV) strains, representing reactivation and 
primary disease, respectively. Again, there are both infectious (1) and non-infectious 
(N) TB disease, but only the former receives treatment. Infectious drug sensitive cases 
self-cure at a rate n and relapse from self-cure at a rate r,,. Infectious cases are detected 
and treated at a rate 5 and a proportion K of DS cases are cured. (1-K) of treated DS 
cases fail, and move into a previously treated class. Of the DS patients who fail 
treatment, a proportion p develop acquired drug resistance and move into previously 
treated resistant class (F), while (1-p) fail treatment and remain drug sensitive (P). 
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Infectious drug resistant cases (I) are cured at a rate K'. The relative fitness of resistant 
(DR or MDR) strains in tenns of the strain transmission is estimated as the relative 
transmission coefficient (cV c). (Dye and Espinal 2001) 
The authors use this model to predict typical rates of acquired resistance, 
defined here as the probability that a patient who fails treatment will gain drug 
resistance. The rate of acquired resistance (p) is estimated for each of the four first 
line TB drugs. Sensitivity analysis showed that the final drug resistance prevalence is 
most significantly affected by the relative transmission rate of resistant strains. If a 
drug resistant strain is assumed to have equal transmissibility as its sensitive 
counterpart, then the resistant strain (with a greater R value) will in time replace all 
sensitive strains. However, if the resistant transmission is reduced enough so that RR < 
Rs, then both sensitive and resistant strains will coexist. Using assumptions for the 
transmission rates of resistant strains, the authors predict the equilibrium prevalence of 
resistance, finding that resistance should saturate at 1-5% (low value for INH, high 
value for MDR) of all TB cases in a population. The authors note that this is 
approximately the cun ent observed levels of resistance in many countries, suggesting 
resistance is approaching its saturation limit. The authors add a word of caution that 
these conclusions depend strongly on the estimates for the transmissibility of resistant 
strains. (Dye and Espinal 2001) 
This analysis makes several important contributions. First, the rate of acquired 
resistance to each drug is estimated in a novel method from surveillance data. Here, the 
acquired resistance rate is assumed to be equal to the relative proportion of previously 
treated cases which are resistant. This is a useful measure for estimating the 
approximate rates of acquired resistance amongst treatment failures. These estimates, 
for other measurements of acquired resistance, are limited by estimation of rates of 
acquired resistance from surveillance and defining cases as new or previously treated. 
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Second, it is a good idea to examine the relative fitness and identify important factors in 
understanding the competition and transmission of resistance. These studies are also 
limited, as previous, by the estimation of transmission rates for resistance cases. Later 
studies looked at the range of resistance from estimates, using these range estimated 
ranges for predicted resistance prevalence. (Dye, Watt et al. 2002; Dye, Williams et al. 
2002) 
VI. B.MDR transmission (and evaluating effectiveness of control 
strategies) 
Another model focuses on MDR strains and addresses the control of MDR 
epidemics. This model considers the dynamics of an MDR epidemic separated from 
other TB cases (drug sensitive or singly drug resistant) that may exist in a population. 
The model includes transmission of primary MDR, but not the emergence of acquired 
resistance. In the model scenarios, MDR cases are introduced either into a totally 
susceptible population (in which there are no TB infections), or a population with a 
proportion (z) previously infected with either drug sensitive or singly drug resistant TB. 
Previous infection is assumed to afford some immunity against reinfection with MDR, 
thus increasing the proportion of non-MDR TB in the initial population slows the 
spread of MDR cases once introduced. Again, MDR strains are considered to have a 
lower fitness relative to DS strains, incorporated into the model with a lower contact 
rate for MDR (c^) than for DS (c). 
This model is used by the authors to consider how to target control strategies for 
MDR-TB. The reproductive number for MDR is defined in the absence (ROM) and 
presence (RGM) of chemotherapy, and based on treatment data from six countries 
(Espinal, Kim et al. 2000), they define combinations of case detection, treatment, and 
cure required to eradicate a MDR epidemic (in terms of keeping RQM < !)• (Dye and 
Williams 2000) 
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This analysis contributes the idea of using defined R values to assess control of 
MDR epidemics. Defining such thresholds based on model parameters allows for 
consideration of the conditions required to prevent or control an epidemic. However, 
the applications of this model to real program settings are severely limited by 
considering only MDR epidemics in isolation. MDR emerges through the treatment of 
sensitive cases, and continuing MDR transmission depends upon the dynamics and 
interaction with the overall TB epidemic. Because epidemics of MDR cases are 
considered in the absence of interaction with drug sensitive cases, the R values defined 
are applicable only for MDR epidemics in isolation. These R values are the same as for 
drug sensitive epidemics, differing only by transmission and cure rates. Thus, while it 
is useful to define R values for MDR epidemics and use this to consider threshold 
criteria for eradication, the model should incorporate the emergence as well as 
transmission of resistance. 
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Table 4-1. Summary of the seven models reviewed in this section and the 
model presented in this thesis, comparing critical model components. 
VII. Conclusion 
We have surveyed the literature on mathematical modelling of tuberculosis 
epidemics in this section in order to provide background into the basis of the model 
developed in the following sections. We have highlighted in Table 4-1 the key 
elements of models considering resistance within TB epidemics, and these elements 
will be explored further through the model development in Chapter 5 and sensitivity 
analysis in Chapter 6. 
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I. Goals 
I. A. To formulate a deterministic compartmental 
mathematical model for the acquisition of resistance and 
transmission of both sensitive and resistant TB strains. 
I. B. To examine the dynamics of resistance within TB 
epidemics. 
II. Abstract 
A mathematical model for the emergence and transmission of resistant 
tuberculosis is developed in order to explore the dynamics of resistance within 
epidemics of TB. The compartmental deterministic model includes the emergence of 
acquired drug resistance during treatment as well as the transmission of primary 
resistance, within the context of a drug sensitive epidemic. The model includes three 
strains (one drug sensitive, one with single drug resistance, and one MDR), and allows 
for infection as well as reinfection. The basic and effective reproductive number for 
each strain in the absence (RQ) and presence of treatment (R), respectively, are defined. 
The critical treatment rates for strain eradication are derived, showing the balance 
between notification and cure rates. 
Resistance is seen to emerge, in the model simulations, as series of linked sub-
epidemics. The MDR epidemic emerges from a drug sensitive epidemic through 
acquired resistance, and these remain linked through treatment. After the initial 
emergence of acquired resistance during the early stages of a resistant epidemic, most 
of new resistant cases are due to primary transmission. 
III.Methods 
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III. A. Simulations 
Model simulations were run in Berkeley Madonna and C++. The set of 
ordinary differential equations for the model were resolved with Runge Kutta (RK4) 
method with a time step of 0.05 year. The size of the time steps was examined but did 
not significantly affect the numerical output. These differential equations, a flow chart 
of the model, and the parameter names and values are shown in Appendix 1. 
III. B. Formulating the model: Epidemiological model for 
the spread of TB 
Susceptible individuals are infected at rate equal to the force of infection (A.). 
The force of infection, X, is equal to the proportion of infectious cases i ~ ) multiplied 
by the effective contact rate (c). The effective contact rate is equal to the probability of 
contact multiplied by the probability of transmission. 
Equation 5-1 X = c — 
N 
A proportion p of infected individuals develops primary TB, defined as 
progression to active disease within five years of infection. The remaining infected 
individuals {1-p) move into a latent class (L) and then progress to disease at rate v. 
A fraction i of disease progressions lead to an infectious case, with the 
remaining (1-;) resulting in non-infectious (Nl) TB. Non-infectious TB cases have 
fewer symptoms, do not experience an increased mortality, and do not receive 
treatment. Nl cases self-cure at a rate K, the same as for infectious cases. 
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Infectious cases of TB (I) are detected at a notification rate («) and are treated 
with a success rate of 0 . Infectious cases also self-cure at a rate K, while treated and 
cured cases relapse to disease at a rate w. 
X L 
Susceptible U . e n . 
Non-Ill feet 
Cured 
I 
Infectious 
Figure 5-1. Model for the transmission of a single strain of tuberculosis. 
Infectious cases (I) transmit infection to susceptible individuals (X) in the population. Newly 
infected cases either progress directly to active disease or remain latently infected (L) and 
experience a slow rate of reactivation to disease. New cases of active disease are either 
infectious (I) or non-infectious (NI), and both may self-cure and become 'cured' (C). Infectious 
cases also receive treatment which results in faster cure. Recovered individuals (C) may 
relapse to disease. 
III. C. Model for primary transmission of resistance 
The model is expanded to include three strains, accounting for drug sensitivity 
(S), resistance to one drug (R), and resistance to two or more drugs (MDR). 
Susceptible individuals can be infected with a sensitive (S), singly resistant (R), or 
multiply resistant (M) TB strain at a rate o f ^ s , or Xm accordingly. The strain-
specific force of infection is defined as given for drug sensitive strains (Xg) in Equation 
5-2. The force of infection varies by strain depending on both the strain-specific 
contact rate and the prevalence of infectious cases. 
Equation 5-2 
Infectious cases of TB (I) are sensitive (Is), singly resistant (1R), or multiply 
resistant (1^), and are detected at a notification rate (n). Sensitive cases are treated with 
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a success rate of 0s- Singly resistant cases are treated with a lower efficacy of OR, and 
multiply resistant cases at an even lower efficacy of OM. Infectious cases also self-cure 
at a rate K, while treated and cured cases relapse to disease at a rate w. Non-infectious 
cases are considered to be strain-independent, as these cases do not receive treatment or 
transmit disease. 
Ls Is Cs 
X LR IR CR 
L M I m 
Figure 5-2. Model expanded to include the transmission of three strains, including a drug 
sensitive (S), a singly resistant (R), and a multiply resistant (M) strain. Each strain f o l l o w s the 
transmission dynamics as outlined in Figure 5-1. Susceptible individuals (X) are subject to 
infection by an S, R, or M strain. Infected individuals either progress directly to active disease 
or remain latently infected (L) and are subject to a slow rate of reactivation disease. Active 
cases may be either infectious (I) or non-infectious (Nl). Note this diagram does not reflect the 
reinfection included in the model. 
III. D. Acquired resistance: treatment and emergence of 
resistance 
There are three outcomes for the treatment of a drug-sensitive case (Is): cure, 
failure with drug sensitivity, and failure with drug resistance. Treated 1$ cases are 
successfully cured at a rate Og. A proportion r of the (1 -0s ) cases that fail treatment 
acquire single resistance. The remaining (1-r) (1-Os) fail treatment and remain drug 
sensitive. This last class includes individuals with chronic drug sensitive TB, who 
remain sputum smear positive after repeated treatments. 
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Similarly, treated singly drug resistant cases (IR) are cured at a rate A 
proportion r? of treatment failures gain a second resistance mutation and move into the 
class, while the remaining treatment failures remain in IR. 
A treated MDR case has only two of these outcomes—cure (at rate <I)M) or 
treatment failure, remaining in the IM class. The probability of resistance emerging 
given treatment failure (r) depends upon the type of treatment and control program in 
place. 
Ls Is Cs 
X LR IR CR 
LM Im CM 
Figure 5-3. Model expanded to include the emergence of acquired resistance 
during treatment. Treated infectious drug sensitive cases (Is) are either cured (Cs), fail 
treatment and remain drug sensitive (Is), or fail treatment and acquire resistance (IR). Similarly, 
treated singly resistant cases (IR) are either cured, fail treatment and remain singly resistant (IR), 
or fail treatment and acquire higher levels of resistance (IM). 
III. E. Model for reinfection 
In the model, latently infected or previously treated individuals are subject to 
reinfection. Previously infected individuals are subject to the same force of infection 
as are non-infecteds, but may gain partial protection (1-y) from developing exogenous 
disease. This protection is considered to be independent of strain type, such that 
latently infected individuals are equally susceptible to reinfection with any strain. For 
simplicity, only those reinfection events which successfully lead to primary progression 
and exogenous disease are considered. Thus, previously infected individuals 
experience exogenous disease at a rate o f y ^ (As +Ar +Am). 
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L R IR C R 
Figure 5-4. Model including reinfection. The model is shown to include 
reinfection for (A) a single strain model and (B) a two strain model. The dashed lines 
reflect routes of reinfection. 
IV. Model Parameters 
This section reviews the basis for the key model parameter estimates. As noted, 
these are based on reviews of literature and of previous models, noting their parameter 
estimates, as some new analyses. These parameter estimates are summarized in Table 
5-5, which also notes the sources. 
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IV. A. Basic disease parameters 
(1) Progression to disease 
Only a small percentage of individuals infected with TB ever develop disease. 
A proportion of these progress rapidly to primary disease, defined as disease occurring 
within five years after initial infection. Estimates for the proportion developing 
primary disease range from 5-15%, and this is the basis for the parameter range used in 
the current model estimates (Table 5-5). The rates of progression to primary disease 
are higher in immune compromised individuals, in particular due to HIV coinfection, as 
well as in the elderly. (Davies 1998)(Bass 1990 ARRD)(Enarson and Roullin 1998) 
Estimates for the risk of progression to disease can be found from 
epidemiological studies. The annual risk of infection was estimated from records of 
tuberculin sensitivity of adult male military recruits in the Netherlands between the 
1930s and 1969. Using these estimates of the annual risk of infection, and notification 
data for the Netherlands, the risks of developing primary, reactivation, and exogenous 
disease were then estimated. These studies showed the highest risk of developing 
primary disease in the first year after infection, declining slightly over five years after 
infection, and then stabilizing at a low rate. It was assumed that there was a 
characteristic risk of progression to primary disease within the first five years after 
initial infection, distinct from progression to endogenous reactivation disease after five 
years. The annual risk of developing primary disease for the first five years after initial 
infection was estimated at 5.06% for adult males. After the first five years after 
primary infection, the risk of developing disease decreased significantly. The average 
annual rate of progression to endogenous reactivation disease was estimated at 
0.0253%. (Sutherland, Svandova et al. 1982; Sutherland, Bleiker et al. 1983) 
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Subsequent studies estimated the risks of disease progression by fitting this data 
set to their own models. One study estimated the proportion of incident cases 
progressing to primary disease at 14% (range 8-15%), slightly higher than original 
estimates. (Dye, Garnett et al. 1998) In another study, the risks of progression to 
disease were estimated from data in England and Wales. The risk of primary 
progression after first infection was estimated at 8.6% in the first year, with a 13.8% 
cumulative risk in the first five years. The annual risk of reactivation to endogenous 
disease was estimated at 0.03%. (Vynnycky and Fine 1997) 
In the model develop here, I use estimate for the proportion progressing to 
active disease of 5-15%, based on the previous model estimates reviewed above. For 
the rate of endogenous reactivation use 0.03%, similar to the Sutherland et at. 
estimates. 
(2) Effective contact rate (ECR) 
The effective contact rate (c), as defined in the model, is the number of people 
effectively contacted by each case. The commonly used estimate is such that each case 
infects on average 10 individuals per year. This estimate comes from studies by Styblo 
on TB incidence in the Netherlands. The annual risk of infection was correlated to the 
incidence of smear positive cases. Assuming an average case duration of 
infectiousness of two years, each smear positive case would contact and infect on 
average 10 individuals per year. (Styblo, 1991) More recent models have used this 
estimate for the ECR, with values ranging from 5 - 1 5 contacts per year. (Blower, 
McLean et al. 1995), (Porco and Blower 1998), (Dye and Williams 2000; Dye and 
Espinal 2001) Similarly to these previous model estimates, 1 use parameter range for 
the effective contact rate of 5-15 cases / year (average of 10). 
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(3) Case fatality and self-cure rates 
The case fatality rate for active TB cases has been significantly reduced over the 
past century. This is related both to improvements in general health care and to the 
advent of chemotherapeutic treatment. In the prechemotherapy era, the average case 
duration of infectiousness was estimated at two years. Estimates of the mortality and 
cure rates, in the absence of treatment, are found in several sources. One source reports 
that in the absence of treatment, 50% of cases die within five years, 30% are cured, and 
20% remain chronically infectious. (Grzybowski 1991) From another source, in the 
absence of treatment 50% of cases die within five years, 25% are cured, and 25% 
remain infectious. (Davies 1998) The results of early studies reporting the clinical 
course of patients in sanatorium, in the pre-chemotherapy era, can be found 
summarized in Table 5-1, reproduced from (Enarson and Hopewell 1998). This was 
the most useful source for estimating mortality and cure rates, as it reports the 
proportion of cases dead or recovered at 18, 36, and 60 months since diagnosis of 
disease. The model was fit to the data set shown in Table 5-1 for the proportion of 
cases which self-cure, die, or remain infectious over the course of five years after onset. 
The model fit is given in Equation 5-3, where 1 represents smear positive cases, and the 
parameters for the mortality rate (p.), the TB mortality rate (pi) and the self-cure rate 
(K). AS only a proportion of cases were shown in this data set, it was assumed a 
population of size 100 in order to fit model to data. This allowed fitting of the 
maximum likelihood estimate (MLE) and calculation of confidence intervals, although 
it should be noted that the confidence interval depends upon the actual population size 
of the data set. The parameters for the TB mortality rate (P-Y) and the self-cure rate (K) 
were fit, with maximum likelihood estimates (MLE) of )j,T == 20% and K = 17%. 
(Figure 5-5) 
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Equation 5-3 
d ( / ) 
dt 
= - ( / / + /^ + K)I 
Time since 
diagnosis 
(months) 
Remain 
smear 
positive 
Dead Recovered 
18 42% 30% 28% 
36 25% 40% 35% 
60 18% 49% 33% 
Table 5-1. The clinical course of untreated tuberculosis. With increasing time 
since diagnosis, the proportion of cases remaining smear positive declined, while the proportion 
dead or recovered increased. At five years since diagnosis, 49% of cases have died, and 33% 
have recovered. Source: (Enarson and Hopewell 1998) 
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Figure 5-5. Parameter estimates for the TB mortality and selj-cure parameters. 
The model was fit to the data set shown in Table 5-1 for the proportion of cases which self-cure, die, or 
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remain infectious over the course o f five years after onset . The M L E estimates for the T B mortality rate 
(I^ T) and the self-cure rate (K) we re PY = 2 0 % and K = 17%. 
A. Est imate for the T B mortal ity rate (HT). The maximum likelihood estimate (MLE) for the 
TB mortality rate from fitting the model to the data set in Table 5-1, is | iT=20%. The 9 5 % 
confidence interval for the M L E fit for the T B mortali ty rate is = 16-23% (solid line). 
B. Estimate for the se l f -cure rate (K). T h e maximum likelihood estimate (MLE) for the TB 
self-cure rate (K), from fitting the model to the data set in Table 5-1, is K = 17%. The 9 5 % confidence 
interval for the M L E fit for the self-cure rate is K = 13 -20% (solid line). 
(4) Infectious disease 
Infected individuals who progress to active disease may develop either 
infectious or non-infectious disease. Infectious disease occurs in the lungs in aerated 
caseous foci such that causes cases emit infectious particles in sputum. Non-infectious 
cases do not emit infectious particles in sputum and are therefore unable to transmit 
infection. The treatment regimens recommended for smear negative patients tend to be 
of shorter duration and require fewer drugs. Smear negative cases also experience 
reduced mortality. The proportion developing infectious disease has been difficult to 
estimate because of limitations both in case reporting and diagnosis. First, there may 
be differential reporting of infectious and non-infectious cases. Non-infectious cases 
tend to have fewer symptoms and cases may not seek medical treatment. In addition, 
non-infectious cases are more difficult to diagnose. Secondly, infectiousness is 
clinically classified based on a positive sputum smear or culture test. Due to limitations 
of these tests in detecting infectious particles in the sputum, the reverse does not hold, 
and a proportion of smear negative patients have been shown to transmit infection. 
(Davies 1998; Fishman and Elias 1998) 
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IV. B. Primary Resistance 
IV. B. 1. Estimates of resistant strain transmission 
The relative transmission rate of resistant, and in particular MDR, strains 
remains a source of significant uncertainty. Experiments have suggested significant 
variation in the transmission rates of resistant strains, ranging from reduced to greater 
than drug sensitive strains. In one study, the contacts of source cases with either 
sensitive or resistant TB were examined, and similar risks of infection and disease were 
found amongst contacts of either type. Higher risks of infection were found only 
amongst resistant cases which were previously treated. (Snider, Kelly et al. 1985) A 
recent study in Brazil also found similar risks of infection and disease for drug sensitive 
and resistant source cases, with about 40% of household contacts infected and 4% with 
active disease. (Teixeira, Perkins et al. 2001) Another study used contact tracing 
combined with RFLP analysis to show MDR transmitted to contacts at similar rates. In 
another study, 6% of contacts with MDR patients were found to convert to active 
disease. (Nitta, Knowles et al. 2002) This can be compared to another study in which 
4% of national and 8% of foreign born contacts of drug sensitive cases converted. 
(Marks, Taylor et al. 2000) These studies together suggest similar rates of conversion 
amongst contacts of sensitive and resistant source cases. 
Studies have also investigated the proportion of resistant cases due to ongoing 
transmission, by two different methods. The first method involves estimating the 
prevalence of resistance amongst new and previously treated cases, assuming that new 
cases are caused by primary resistance, and previously treated strains by resistance 
acquired during treatment. This classification was used in initial studies of resistance. 
(WHO/IUATLD 1997) Later studies, using RFLP analysis and contact tracing, 
revealed complications in making this distinction. The proportion of acquired resistant 
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cases were being overestimated, as some of the previously treated cases appeared to 
have been initially infected with resistant cases. (Van Rie, Warren et al. 2000) In order 
to correct for this, later surveillance reports referred to the proportion of resistant cases 
amongst new and previously treated cases, without inferring from this the cause of 
resistance. (WHO/IUATLD 2000) In general, contact tracing or strain typing are 
required to differentiate acquired and primary resistance. 
More recently, convention has led towards using clustering of strains as a 
surrogate for recent transmission, and such analysis has been used to estimate the 
relative proportion of resistant strains in a population due to ongoing transmission. In 
an area of high incidence (Capetown, South Africa), the proportion of resistance due to 
primary transmission, as detected by RFLP strain typing, was high; over 50% of MDR 
cases were clustered. (Van Rie, Warren et al. 2000) In Denmark, over 70% of resistant 
strains were found to be clustered. (Thomsen, Bauer et al. 2000) There have also been 
reports of'super fit' resistant strains which have been found more frequently in clusters 
and are believed to have greater transmission. (Agerton, Valway et al. 1999) 
(Toungoussova, Sandven et al. 2002) (Kruuner, Hoffner et al. 2001) 
Other strain typing studies have found resistant cases less likely to be found in 
clusters. (Samper, Iglesias et al. 1998; Garcia-Garcia, Jimenez-Corona et al. 2000) 
(Nitta, Knowles et at. 2002) Cases with a particular INH resistance mutation were 
found in clusters less frequently than drug sensitive strains. (Van Soolingen, Borgdorff 
et al. 1999) 
IV. B. 2. Relative fitness resistant strain 
In order to account for possibly different transmission rates, each strain in the 
model is given a distinct transmission parameter. It is assumed that single drug 
resistance does not confer a significant fitness cost, but that MDR may have reduced 
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transmissibility (cs = CR > CM). Further consideration of the fitness of resistant strains 
and the implications of relative fitness on within host dynamics under chemotherapy 
treatment is explored within a model and simulations found in Appendix 5. 
IV. C. Acquired resistance rates 
In the model, cases failing treatment may either remain chronically infectious or 
gain resistance. The probability of acquiring resistance, given treatment failure, is 
equal to the parameter r (the acquired resistance rate). 
(1) Clinical evidence for resistance amongst treatment failures 
Previous treatment has been shown repeatedly to be a primary risk factor for 
resistance. (Borchardt, Kirsten et al. 1996; Janmeja and Raj 1998) (Iseman 1999) As 
shown in Table 5-2 the proportion of cases with acquired resistance increases with the 
number of previous courses of treatment. In this trial, of cases having received one 
course of treatment, 33% had resistance to one drug and 22% MDR. Amongst cases 
which received two courses of treatment, 64% had developed resistance to one drug 
and 55% MDR. Amongst cases which received three courses, 100% had single 
resistance and 97% MDR. (Chaulet and Zidouni 1998) 
Courses of 
treatment 
Patients 
assessed 
Resistant to at least 
one drug 
Resistant to INH and 
RIF at least (MDR) 
One 27 9 33% 6 22% 
Two 22 14 64% 12 55% 
Three 32 32 100% 31 97% 
Total 81 55 68% 49 60% 
Table 5-2. Acquired bacterial resistance in 81 patients previously treated by one or 
more courses of chemotherapy containing isoniazid and rifampicin for 6 months; 
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Algeria 1992. Source: (Mazouni, Zidouni et al. 1992) cited in (Chaulet andZidouni 
(2) Estimates from surveillance and model 
Estimates found in the literature suggest that acquired resistance accounts for 
only a small proportion of treatment failures, and that cases are more likely to fail 
treatment for other reasons. For example, in one study, the proportion of treatment 
failures acquiring resistance was estimated from surveys on the resistance prevalence 
amongst new and previously treated cases. The regression line for the incidence of 
resistant to sensitive cases amongst previously treated cases was taken, with the slope 
assumed to equal the relative treatment cure rate for resistant cases, and the intercept 
the proportion which acquired resistance. This estimated resistance amongst treatment 
failures at a rate of 13% for isoniazid, 8% for rifampicin, and 7% for MDR. This study 
suggests that rates of acquiring single resistance may be low because many singly 
resistant cases are cured by SCC, and are more likely to fail treatment for reasons other 
than resistance. (Dye and Espinal 2001) 
In order to estimate the appropriate rates of acquired resistance to use in our 
model, simulations were run to compare predicted and observed resistance prevalence. 
The notification, treatment, and cure rates in several different locations were used to 
simulate a model epidemic. The rate of acquired resistance (/-) was varied such that the 
observed prevalence of resistance was matched by the model. All other intrinsic model 
parameters (those not determining part of the control strategy) were held constant. The 
effect of jointly varying other parameters is examined in Chapter 6. Model simulations 
were performed to simulate the scenarios represented in Table 5-3. Within each 
location scenario, the model parameters for control program were also held constant. 
In each example, the cure rates for sensitive and resistant cases were used as shown. 
The notification and treatment rates were used as given in recent surveillance reports 
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for that region. (WHO 2003) In order to reproduce close to the given prevalence of 
single resistance and MDR, an acquired resistance rate (r) of 5-15% was used in the 
model. 
In Peru and Hong Kong, there was 100% reporting under DOTS and strong first 
line control including high treatment and cure rates. In both of these scenarios, it was 
difficult to fit the resistance prevalence observed to the given treatment and cure rates. 
This most likely reflects the recent improvements in program control in these regions, 
which followed years of much poorer treatment practices, that had resulted in the 
buildup of resistance levels. Under the strikingly poor cure rates found in Ivano Oblast, 
a higher rate of acquired resistance was used in order to match the higher resistance 
prevalence found. This is likely to reflect higher probability of acquiring resistance 
under poor control practices. 
A noted limitation of these simulations is the assumption that the control 
program parameters are constant over time. While this will matter less in high 
incidence regions where most of incidence due to recent transmission, this can have a 
stronger effect in those low incidence regions in which control program improvements 
have sharply reduced incidence. In such cases, much of new incidence may be due to 
reactivation of latent infection acquired years to decades earlier, under poorer control 
programs/ conditions. As the regions noted in Table 5-3 do not fit such criteria (they 
remain largely high incidence regions) this may hold for these regions. However, in 
Peru and Hong Kong, this may account for different estimates of R. 
DS 
cure 
rate 
DR 
cure 
rate 
MDR 
cure 
rate 
Prevalence 
single 
resistance 
Prevalence MDR 
Location Source: ^ Source: ^ 
Korea 85% 75% 10.6% 2.2% 
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Peru 85% 79% 58% 18% 3% 
Hong 
Kong 89% 80% 60% 12.2% 1.4% 
Ivano 
Oblast 37% 24% 32.4% 9% 
Dominica 
n 
Republic 
28% 23% 
Italy 63% 43% 12.3% 1.2% 
Table 5-3. The cure rates and prevalence of resistance from surveillance in 6 
locations. 
' Shown is the cure rate for drug sensitive, singly resistant, and MDR cases amongst all (new 
and previously treated) smear positive cases. Source for the cure rates in these 6 countries. (Espinal, 
Kim et al. 2000) 
^ Shown is the prevalence of single resistance and MDR amongst all cases. No data was 
available for the Dominican Republic, as this country was not reporting to the WHO under DOTS. 
Source for the prevalence of resistance in these 6 countries: (WHO/I UATLD 2000). 
(3) Control program and quality of treatment 
These estimates of the proportion of acquired resistance have been made 
assuming that there is an inherent risk of acquiring resistance during treatment. 
However, there is also evidence that this statistic depends upon the quality of treatment. 
Under good control measures, there is a low rate of acquired resistance. When the 
control is poor, higher levels of resistance are found, particularly when there are lower 
rates of DOTS implementation. (WHO/IUATLD 2000) 
The rates of acquired resistance are correlated to the quality of treatment, 
including regular drug supply and supervision of therapy. Higher rates of resistance 
have been associated with errors in treatment and case management. (Mahmoudi and 
Iseman 1993) Poor treatment practices correlated to increased resistance rates include 
adding one drug to a failing regimen, using an inadequate regimen, not diagnosing 
initial resistance, and poor patient adherence. (Iseman 1999) Use of supervised DOT 
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treatment combined with regulated drug supply has been shown to reduce the 
proportion of cases developing resistance. (Weis, Slocum et al. 1994) 
IV. D. Reinfection 
Individuals previously infected with tuberculosis are subject to reinfection. The 
possibility of reinfection has been long recognized. (Romeyn 1970; Canetti, Sutherland 
et al. 1972). Patients have been observed to relapse with disease of a different drug 
resistance pattern. Most notably, patients treated for drug resistant TB have been seen 
to relapse with a drug sensitive case. Before molecular typing experiments were 
common, it was difficult to distinguish whether these cases were due to reversion of the 
drug resistance mutation or reinfection with a drug sensitive strain. (Stewart 1966) 
There have also been examples of patients with drug sensitive disease developing drug 
resistance as the result of exogenous reinfection with a resistant strain. (Small, Shafer 
et al. 1993) 
More recent experiments have provided further evidence for reinfection of 
tuberculosis patients. Molecular typing techniques have been used to compare strains 
collected from the same patient during initial and subsequent occurrences of disease. 
(Fine and Small 1999; Van Rie, Warren et al. 1999; de Boer AS 2000) When the RFLP 
pattern has significantly changed between collections, it is assumed that disease has 
been caused by a new strain. This is a reasonable assumption because the timescale for 
RFLP change is very long, with the pattern remaining constant between cycles of 
transmission. In particular, there seems to be a high degree of stability of 1S6610 
typing. (Niemann, Richter et al. 1999; Van Soolingen 2001) Using such methods, 
numerous studies have found examples of reinfection occurring in a wide range of both 
low and high incidence regions. 
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In high incidence regions, individuals are subject to a high annual risk of 
infection, and may be reinfected multiple times. However, current detection methods 
cannot differentiate the number of times an individual has been infected, or reveal 
which infection (or combination of infections) may have triggered disease progression. 
While reinfection may not greatly impact the overall prevalence of disease in 
low incidence countries, there may be a significant effect in localized areas with 
individuals at higher risk for reinfection. In particular, immigrants have been found to 
have a greater risk of reinfection, as do patients with HIV coinfection. For example, 
immigrants from high incidence countries may live in the same community, effectively 
creating a high incidence region. (Bandera, Gori et al. 2001) (Murray and Nardell 
2002) 
Previous models have also suggested the importance of reinfection in 
understanding the transmission dynamics of tuberculosis. Sutherland estimated the risk 
for exogenous disease at 1.91% annually for five years following reinfection. 
(Sutherland, Svandova et al. 1982) Vynnycky has shown that models which include 
partial susceptibility to reinfection provide a significantly better fit to observed trends 
in the decline of tuberculosis cases (within the older age classes) over the past century 
in the low incidence areas of England and Wales. Previous infection was estimated to 
confer approximately 40% protection from developing exogenous disease. (Vynnycky 
and Fine 1997; Vynnycky and Fine 2000). 
V. Mathematical definitions for model epidemic 
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V. A. Defining the basic and effective reproductive number 
The basic reproductive number, RQ, is defined as the average number of new 
cases caused by introducing one infectious case into an entirely susceptible population. 
This is a measure of reproductive potential as well as fitness. However, this measure 
does not hold in the later stages of an epidemic, when the population contains infected, 
infectious and cured individuals, each with differing levels of susceptibility to infection 
and disease. In such situations where the initial population is not entirely susceptible, a 
related measure, termed the effective reproductive number (R), is used to describe 
reproductive potential. R can also be defined within populations where the susceptible 
class is reduced through vaccination. .(Anderson 1991) Similarly, treatment can 
reduce the spread of infection and disease within the population. We therefore use the 
effective reproductive number (R) to describe the average number of new cases caused 
by one infectious case introduced into a susceptible population, in the presence of a 
control strategy. In this section, both the basic (under no treatment) and effective 
reproductive (under treatment) numbers are defined for the model described in the 
previous section. 
For tuberculosis epidemics, the basic reproductive number (Ro) is equal to the 
product of the probability of an infection progressing to active disease (b), the effective 
contact rate (C) and the duration of infectiousness (T). The effective reproductive 
number (R) has the same components; however, treatment may reduce the case 
duration of infectiousness (x). 
Equation 5-4 
Rn = b C T 
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For individuals infected with tuberculosis, there are two routes of progression to 
active disease: primary progression soon after infection, or latent infection followed by 
reactivation disease. The probability of a given infection leading to active disease (b) 
incorporates both possibilities. 
The effective contact rate (c) provides a measure for the per capita rate of new 
infections caused per infectious case. The ECR is equal to the probability of a contact 
between an infectious and susceptible times the probability of transmission per contact. 
While the contact rate depends on host and community factors, the transmission rate is 
considered to be strain dependent. Thus, a distinct ECR is defined for each strain, 
assuming an equal contact rate but varying transmissibility. 
The duration of infectiousness (T) is a measure of the average time cases spend 
in the infectious state. The case duration of infectiousness incorporates all routes for a 
case to become non-infectious, including cure by either natural self-cure or through 
treatment, and death from tuberculosis or other causes. Prior to use of chemotherapy 
for treatment of tuberculosis, the average case remained infectious for two years. The 
use of effective drug regimens results in faster cure and thus reduces the case duration 
of infectiousness. 
Solving the system of model equations at equilibrium allows for a measure of 
system dynamics. In addition, this allows a derivation of the basic reproductive 
number, which is inversely proportional to the proportion susceptible at equilibrium. In 
the examples given below, the model is solved for the proportion susceptible at 
equilibrium {X ). This is then used to derive the basic reproductive number (Ro) in the 
absence of treatment or the effective reproductive number (R) in the presence of 
treatment. These formulas are derived in scenarios with increasing levels of 
complexity. First, RQ is derived for a model for the transmission of one or three strains 
of TB in the absence of treatment. Second, R is derived for a model for transmission of 
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one or three strains in the presence of treatment. Third, R is derived for a model which 
includes reinfection in the presence of treatment. Fourth, R is derived for a model 
which includes both reinfection and interacting strains. 
Equation 5-5 
J = -1 
R. 
V. B. Ro defined: in absence of treatment 
In this first example, a model which includes the transmission of a single strain 
of TB, in the absence of treatment, was examined. The system of equations describing 
this model was solved at equilibrium for the proportion susceptible, and from this Ro 
was derived. 
Equation 5-6 
= C 
1 I f . 
I / / + u f j . + f i j . + K 
The components of the reproductive number, as delineated above, are easily 
discernable in this equation. The probability of contact and transmission is given by 
the effective contact rate (c). The case duration of infectiousness is given by the 
inverse of the rate of mortality from natural causes (|I) or TB (|J.T) and the self-cure rate 
(xX 
Equation 5-7 
1 
r = 
/ / + / / ^ + /r 
The proportion of infected individuals progressing to active disease is given by 
the sum of the proportion progressing to primary disease (immediately) and the 
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proportion progressing from latent to reactivation disease (at a rate v), all multiplied by 
the probability of developing infectious disease (/). 
Equation 5-8 b = i p + 
i ( l - p ) V 
jU + V 
Next, a three-strain model is examined, and the Ro values for each strain 
defined. In the absence of treatment, the three strains (sensitive, resistant, and MDR) 
remain unlinked, as treatment is required for acquired resistance. Thus, each strain is 
transmitted within separate epidemics in the population. The RQ of each strain differs 
only by the effective contact rate (c). The average case duration of infectiousness, in 
the absence of treatment, is the same for all strains. The proportion progressing to 
active disease is also strain-independent. 
Competition between the strains is determined by the relative transmissibility. 
The strain with the greatest ECR will dominate the epidemic at equilibrium. The time 
taken to reach this equilibrium state will depend upon the relative prevalence of each 
strain at the start of the simulation. For example, if the model simulation is begun with 
only drug sensitive cases, no resistance will ever emerge. Only if the simulation is 
begun with resistant strains will transmission cycles of resistance continue. 
Equation 5-9 
A. ^ O S 
B. ^OR 
C. 
1 
f j , + -t- K 
i p + 
i { \ - p ) V 
= c , 
1 
IU + jdj + K 
i p + 
i j l - p ) 
JU + u 
= c M 
1 
/ / + jUj- + fC / y + U y 
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V. C. R for one strain model 
The effective reproductive number (R) in the case of a one strain model, 
assuming no reinfection, is defined here. The system of equations was solved at 
equilibrium for the proportion susceptible, and from this the R value was derived as 
below. 
Equation 5-10 
1 
R = c 
/^ + jUj+K + n ( / ) - (xr + M, w 
\A1 J / / + W 
p + 
IJ. + V 
The components of the reproductive number are easily recognized in this 
definition, and similar to those for RQ defined above. The contact rate c and the 
probability of progression to active disease {b) have not been altered by including 
treatment in the model, and remain the same as for the definitions of Ro above. The 
duration of infectiousness (x) has been changed by including treatment. The case 
duration of infectiousness is equal to the probability of mortality, self-cure, treatment 
cure, or cure followed by relapse. In model parameters, the duration of infectiousness 
is given as below. In this description, it is easy to see how improvements to control 
through increased treatment {n) and cure rates ( 0 ) reduce the duration of 
infectiousness. 
Equation 5-11 
1 r /d + /u.,. + K + n ^+{K + n(p) / / + w 
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V. D. R for one strain model with reinfection 
The reproductive number is defined here for a one strain model which includes 
reinfection. As in the previous example, the system of equations was solved at 
equilibrium for the proportion susceptible, and from this the R value was derived. The 
model assumes that previous infection confers some given protection (at a rate of l-y) 
from reinfection, but that reinfected individuals have the same probability of 
progression given infection or reinfection. This is reflected in the derived R value; 
introducing reinfection affects the duration of infectiousness (T), but leaves unchanged 
the contact rate (c) and probability of progressing to disease (b). In particular, the case 
duration of infectiousness now incorporates the possibility for cured individuals to be 
reinfected and develop exogenous disease. By this definition, reinfection would extend 
the duration of infectiousness of the individual, through subsequent cases of infection 
and disease. While this may not apply to a strict definition of the duration of 
infectiousness of a single case, this does appear in the R value as reinfected individuals 
will stay in the infectious class of the model for a longer period. As shown, this 
depends upon the probability of a previously infected individual becoming reinfected 
and developing exogenous disease, given a s y z p X. 
As explored in Figure 5-6, varying the reinfection parameter has a very small 
impact on the duration of infectiousness. Higher rates of reinfection increase the 
duration of infectiousness, but this is not significant when compared to the affect of 
treatment. The impact of reinfection on duration of infectiousness also depends on the 
prevalence of infectious disease in the population; the greater the prevalence of disease, 
the more significant the increase in DOl with the reinfection parameter. (Figure 5-6C) 
From this examination, it appears that varying the reinfection parameter may affect the 
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model epidemic when there is a high prevalence of disease and treatment rates, but has 
little effect under low prevalence. (Figure 5-6) 
Equation 5-12 
/ 
7? = c 
1 
ju + ju-j^+K + n ^ - {K + n(l)) {w + y i p A ) 
u + w + Y i p 1 
T = 
// + [ij + K + n (p + {k + n (p) {w + yipX) 
u + w + yi pA. 
i p -t-
i i ^ - p ) V 
/ / + f 
w- (0 
o 0) 
.2 = 
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Figure 5-6. Reinfection parameter has small impact on duration of 
infectiousness, and depends upon the prevalence of infectious disease and the 
treatment rate. 
A. No treatment. The notification rate was set at 0% and the prevalence of infectious cases at 
1,000 cases per 100,000. Increasing the reinfection parameter results in a slight increase in the average 
case duration of infectiousness, f rom 3.305 years (at 0% reinfection) to 3.34 years (at 100% reinfection). 
B. Treatment rate =100%. The notification rate was set at 100% and the prevalence of 
infectious cases at 1,000 cases per 100,000. Increasing the reinfection parameter results in a slight 
increase in the average case duration of infectiousness, from 0.915 years (at 0% reinfection) to 0.945 
years (at 100% reinfection). 
C. Prevalence of disease. When there is a higher prevalence of disease, there is an increased 
opportunity for reinfection, and increasing the reinfection parameter has a slightly greater influence on 
the duration of infectiousness. The prevalence of disease was varied from 10"^  to lO' cases per 100,000. 
The notification rate was set at 100%. The susceptibility to reinfection was set at y= 0%, 50%, or 100%, 
as shown in the legend. 
D. Treatment rate has greater impact than reinfection on duration of infectiousness. The 
prevalence of infectious cases was set at 1,000 cases per 100,000. The notification rate was set at either 
NR = 0%, 50%, or 100%. The reinfection parameter was varied from 0% to 100%. Increasing the 
reinfection parameter had a small impact on the duration of infectiousness compared to increasing the 
notification rate. 
V. E. R for three strain model, non-interacting strains, no 
reinfection 
In this three-strain model, there are three unlinked sub-epidemics of TB, 
corresponding to the S, DR, and MDR strains. As each strain has distinct dynamics, a 
strain-specific reproductive number is defined. 
Equation 5-13 
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A. 
' '^s 
B. 
fl-V fdJ + AT + M - (AT + M ) W 
jU + W 
jU + u 
1 
JU + fJ.j + K + n (f)— (at + 77 ) - w 
jU + W 
' i p + i i t i P l i 
jU + V 
1 
14^  
; z + / z ^ + Rr + M(;)^ + 
\ / / + ! * / 
jU + u 
The duration of infectiousness, shown here for drug sensitive cases, is inversely 
proportional to the death, self-cure, and treatment rates, as well as the proportion of 
cured cases which relapse to disease. 
Equation 5-14 
T s 
/y + //.,. + /r + n {k + n (f)^.) 11' 
H +11' 
Treatment reduces the case duration of infectiousness. Increasing the treatment 
rate reduces the duration of infectiousness for each strain depending upon the strain-
specific cure rate. Treatment reduces the duration of infectiousness for sensitive cases, 
which experience higher cure rates, more than resistant cases. (Figure 5-7) 
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Figure 5-7. Treatment reduces the average case duration of infectiousness. 
Increasing the treatment rate (treatment rate, n) reduces the average case duration of infectiousness 
(DOl). When there is no treatment (n=0%), the average case duration of infectiousness is 2.2 years. As 
the treatment rate is increased, the DOl is reduced, depending upon the strain and treatment efficacy. 
The DOl of drug sensitive strains (DS) is reduced the most, followed by singly resistant (DR) and then 
MDR (MDR) strains, corresponding to the relative treatment efficacy. The treatment cure rate for DS 
cases is set at 90%, for DR cases at 70%, and for MDR cases at 40%. 
The probability of an infection leading to a case of active, infectious disease is 
common for all strains. As defined above, the probability of progression {h) is equal to 
the probability of primary progression (/;) and the probability of reactivation. 
Equation 5-15 b = i p + 
/ (1 - p) V 
/.I + V 
This presentation makes it clear that the fitness difference between the strains is 
due to treatment (each strain has a different treatment efficacy $ ) and transmission 
(strain-dependent effective contact rate, c). Thus, in this model, the two variables 
which determine the relative fitness of the three strains include one inherent to the 
strain (c) and one to the control strategy (O). As discussed above, resistant strains may 
have a fitness cost manifest in a lower rate of transmission. This representation 
illustrates how changes in the transmission rate (c) directly affect the reproductive 
number and strain fitness. 
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V. F. Rfor three strain model, non-interacting strains, with 
reinfection 
In this scenario, the model includes three unlinked strains, treatment, and the 
reinfection of previously infected individuals. This model does not include the 
emergence of acquired resistance during treatment. The solutions for the R values for 
each strain are shown below. As before, the difference in the R values between strains 
depends upon the contact rate and the duration of infectiousness. Also as in the 
previous example, increasing the notification rate and/or the strain-specific cure rate 
reduces the strain-specific duration of infectiousness. In addition, in this example, 
including reinfection will slightly affect the duration of infectiousness of each strain, as 
explored in the earlier example shown in Figure 5-6. 
Equation 5-16 
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V. G. R for three strain model, interacting strains 
In this scenario, the interaction between the strains resulting from acquired 
resistance during treatment complicates the equilibrium solution. In place of a 
complete solution of R for each strain, approximations were made based upon the 
previous examples. While the complete model follows the trends as given in the 
previous example for unlinked strains, the emergence of acquired resistance affects the 
equilibrium dynamics. 
Selection for resistance during treatment provides a link between the otherwise 
separate epidemics of each strain, shifting the equilibrium balance between the strains. 
When there are sensitive strains in the population which receive treatment, acquired 
resistance will increase the R value for the resistant strains. While the emergence of 
acquired resistance does not affect the transmission or duration of infectiousness of 
resistant strains, it does increase the base prevalence of resistance. Thus, at 
equilibrium, the same quantitative outcome, in terms of which strain will dominate the 
epidemic, will occur as given in the previous example. However, if at equilibrium 
sensitive strains remain and receive treatment, there will be a continuing low 
prevalence of resistance. New cases of acquired resistance will continue to emerge, 
and thus resistance cannot be eradicated unless either treatment is stopped or all 
infection is cleared from the population. 
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The inclusion of acquired resistance in this model also affects the point at which 
coexistence between the strains occurs. Coexistence is possible when the R values are 
equal and each greater than one. However, when acquired resistance increases the 
prevalence of resistance beyond its intrinsic fitness at equilibrium, then coexistence 
occurs when RR is this small (and not defined here) quantity less than Rg. 
VI. Treatment Outcomes: Critical Values 
The effective reproductive number (R) can be used to predict the outcome of a 
control strategy in terms of the survival of each strain. There are three basic model 
outcomes: the eradication of all strains, the survival only of resistance, or the 
coexistence of both sensitive and resistant strains. It is impossible to remove resistance 
from the population as long as sensitive cases remain, because of the possibility of 
acquiring resistance during treatment. 
The model outcomes are shown here in terms of strain R values. This is shown 
first for a model with one resistant strain (R, Table 5-4A and Figure 5-8), as a simpler 
example of the three possible outcomes. Next, the model outcomes are shown for a 
model with two resistant strains (R and M, Table 5-4B). In either scenario, the same 
three possible outcomes exist, as it is impossible to remove either single or multiple 
drug resistance from the population while drug sensitive cases remain. All TB in a 
population will be eradicated only if R of each strain is less than one. If R of any of the 
strains is greater than one, and the population receives treatment, resistance will 
continue. 
Table 5-4 
A. 
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<1 <1 Eradicate all TB 
strains 
<1 >1 Only RR persists 
>1 Rs < R R Coexistence 
B. 
Rs RR RM Outcome 
<1 
<1 <1 Eradicate all 
TB strains 
<1 
>1 >1 Only resistance persists 
R R < R M MDR dominates 
R M < R R DR dominates 
>1 
Rs < R R Rs < R M Coexistence sensitive 
and resistant 
RR < RM MDR dominates 
R M < R R DR dominates 
Table 5-4. The model equilibrium outcome based on the absolute and relative 
values of the effective reproductive number (R) for each strain. Three outcomes are possible 
under any given treatment strategy; the eradication of all strains, persistence of only drug resistance, or 
coexistence of drug sensitive and resistant strains. These three qualitative outcomes are the same 
whether a two (A) or three (B) strain model is used. 
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Figure 5-8. The model outcomes depending upon R values. The model outcomes 
for the two strain model, as described in Table 5-4 are illustrated. Three outcomes are possible under any 
given treatment strategy: eradication of all strains, persistence of only drug resistance, or coexistence of 
drug sensitive and resistant strains. When there is coexistence, drug sensitive strains will dominate the 
infectious pool when R S > R R , and resistant strains will dominate when R R > R S -
VI. A. 
strains 
Critical treatment rates for eradication all TB 
Using the criteria defined above, the control parameters required to eradicate all 
strains in a TB epidemic can be determined. The threshold level of treatment (n) and 
treatment efficacy ((D^) required to eradicate all three TB strains is calculated. 
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The relationship between notification rate and R value for each strain is 
illustrated in Figure 5-9. There exists a critical treatment rate at which the R value for 
each strain, assuming a given cure rate, equals 1. Increasing the treatment rate beyond 
this value brings R<] and results in removal of this strain at equilibrium conditions. As 
the strains are assumed to be unlinked in this scenario, with no emergence of acquired 
resistance during treatment, this allows for the removal of a single strain from the 
population while other strains persist. In this scenario, the treatment cure rate for DS 
cases is set at 90%, for DR cases at 70%, and for MDR cases at 40%. At low treatment 
rates, the combination of treatment and cure rates is not sufficient to reach the threshold 
for R<1 for any of the strains, and all strains persist. As the treatment rate is increased, 
there is a range at which the combination of treatment and cure rates result in the 
removal of the sensitive strain, but allow for persistence of resistance. At yet higher 
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treatment rates, as shown in this example for above 96% of cases treated, both sensitive 
and resistant strains are removed. (Figure 5-9) At moderate treatment values, the 
outcome is likely to tend to coexistence of sensitive and resistant strains. In order to 
select for persistence of only resistance, there must be high enough treatment and cure 
rates in order to clear all sensitive strains, while low enough to allow for a continuing 
epidemic of resistance. Finally, in order to eradicate all strains, the highest levels of 
treatment and cure for all strains is required. 
There exists a balance between the treatment and cure rates. Increasing either 
the treatment or cure rates reduces strain fitness. In terms of eradication criteria, a 
lower rate of treatment can be somewhat compensated for by a greater treatment 
efficacy. Shown in Figure 5-10 is the combination of treatment and cure rates such that 
Rs=]. (Figure 5-10) 
Effective reproductive number and model outcome 
10 0% 
T r e a t m e n t R a t e 
ALL 
persist 
SENS 
cleared 
SENS and DR 
cleared 
ALL 
cleaied 
Figure 5-9. Treatment rate and R value. The proportion of cases receiving treatment 
(the treatment rate) is varied from 0% to 100% in simulations, and the resulting R value for each strain is 
shown. When there is no treatment (treatment rate = 0%), all strains have the same R value. Increasing 
the treatment rate reduces the R value of each strain, but less so for resistant strains, which have lower 
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treatment cure rates. The threshold R values required to eradicate S, R, and MDR strains are shown in 
terms of the treatment rate. In this simulation, for treatment rates from 0-40%, all strains persist; from 
40-60% only sensitive is cleared; from 60-96% sensitive and singly resistant strains are cleared; and 
above 96% all strains are cleared. 
100% 1 
80% -
™ 60% 
40% 
2 0 % -
0 % 2 0 % 4 0 % 6 0 % 80% 100% 
Treatment Rate 
Figure 5-10. Balance between treatment and cure rate for eradication criteria. Increasing 
either the treatment or cure rate results in reduced R values for the strain. Shown is the combination of 
treatment and cu re rates such that Rs =1. For treatment and cure rates above this threshold, Rs<l and 
the strain will be removed. Below this threshold, Rs>l and the strain will persist. 
VI. B. Relative treatment efficacy for resistance 
The relative treatment efficacy for drug resistance required to eradicate all TB 
strains can also be calculated. This measure can be useful in comparing the control 
strategies for treating drug sensitive and resistant cases. The formula below gives 
threshold values for the relative treatment efficacy of single (R) and multiple resistant 
(MDR) cases, compared to drug sensitive, required to eradicate the epidemic. 
(Equation 5-18) This is determined from the threshold RS = RR = RM = L below which 
all strains in the population will be cleared. 
Equation 5-18 
N 
I p + I 
A \ - p) V 
' ft 
Jil + V ju + w + y I p 
I p + I 
. 0 - p) V 
jLI + V 
ju + w + y i p 
K (w + y i p k^) _ (w + J 
// + w + y / p A p w + y i p 
These expressions for the threshold values of treatment required to eradicate a 
TB epidemic can be useful in designing and evaluating control programs. If control 
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programs can achieve cure rates for resistant cases which are greater than those 
estimated here, than it is possible to prevent the scenarios depicted in the model in 
which resistance dominates at equilibrium. In this scenario, estimated critical relative 
treatment cure rate for MDR cases must be above 74% in order for MDR to have lower 
fitness than sensitive cases. This holds over all range notification rates. (Figure 5-11 A) 
The critical values for the relative cure rates also depend upon the relative contact rate 
assumed, assumed in Figure 5-11A to be reduced by 10% for MDR cases. The relative 
cure rate for MDR cases required to keep RM<RS is reduced with the MDR 
transmission rate, as shown in Figure 5-1 IB. Similarly, increasing the MDR fitness 
cost in transmission lowers the relative cure rate for MDR cases required such that 
MDR has lower overall fitness. (Figure 5-11) 
These results can be compared with estimates for the relative cure rates of MDR 
cases on first line regimens. Resistant cases have been observed to have low cure rates 
on first line short course chemotherapy (SCC). Under effective DOTS SCC, cure rates 
for drug sensitive cases are near 90%. Cases with isoniazid resistance have cure rates 
reduced to 70-80%, while for MDR cases cure rates are at highest 60%. (Raviglione, 
Gupta et al. 2001) One study estimated the relative cure rates for resistant cases under 
DOTS SCC treatment in program conditions, and found that the cure rate was reduced 
in proportion to the number of drugs the case was resistant to. MDR cases had cure 
rates ranging from 6% to 59%. Even in regions with 100% DOTS implemented, and 
high cure rates for drug sensitive cases maintained, the cure rates for MDR cases was 
only 58% in Peru and 60% in Hong Kong. (Table 5-3) (Espinal, Kim et al. 2000) 
As illustrated in Figure 5-1IC, if MDR has equal transmissibility as sensitive 
strains but reduced cure rates, then RM > Rs- As the MDR transmission rate is reduced, 
it is possible for the MDR strain to have lower fitness than the sensitive strain, even 
with reduced cure rates. The greater the fitness cost in MDR transmission, the lower 
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the MDR cure rate required to keep the fitness of the MDR strain below that of the 
sensitive. (Figure 5-1IC) Even with relative cure rates as high as 60%, MDR strains 
would need to have at least 15% reduced transmissibility to have RM<RS. This suggests 
that in most program conditions, MDR strains will have greater fitness unless they 
experience significantly reduced transmission. 
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Figure 5-11. Critical treatment and cure rates for eradication of sensitive and 
MDR strains. 
A. Critical treatment and cure rates for eradication of drug sensitive (S) and MDR (IVl) 
strains are shown such that Rs or RM, respectively, are equal to one. At treatment and/or cure rates 
above this line, Rs > 1 and RM>1, and both strains will persist. In between the two lines, Rs<l while 
RM>1, and the MDR strain will out compete the sensitive strain and dominate the population. For 
treatment and cure rates below both lines, both Rs and RM <1 and both strains will be removed at 
equilibrium. MDR cases are assumed to have a 20% reduced transmission rate compared to DS cases 
(p20%) 
B. The cure rate for MDR cases such that RM<RS. AS the fitness cost of the MDR strain ( / ) 
is increased (by reducing the relative MDR transmission rate), a lower MDR cure rate is needed to 
maintain RM<RS. The cure rate for sensitive strains is set at 90%, and the treatment notification rate at 
5096. 
C. The relative cure rate for MDR cases compared to sensitive cases such that RM<RS. 
As the fitness cost of MDR cases (/', in transmission) is increased, a lower relative MDR cure rate is 
required in order to keep RM < Rs. This relationship holds true over all treatment notification rates. 
VII. Age Structure 
As reviewed in Chapter 4, some previous models of TB have incorporated age 
structure. In terms of parameters, previous studies have suggested that the probability 
of progressing to primary disease, reactivation rate, proportion developing infectious 
disease, and the susceptibility to exogenous reinfection, self-cure rate, and the TB 
specific mortality rate can be considered to vary amongst age groups within a 
population. Studies modeling the natural history of TB epidemics have suggested the 
importance of including age structure and differentiating the relative disease risks by 
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age, in terms of understanding the progression of an epidemic within a population. 
These earlier modeling studies have not examined drug resistance, or considered the 
importance of including age structure on modeling and predictions of drug resistance. 
In this section, I briefly examine the importance of incorporating age structure into the 
model developed here. 
VII. A. Age structured model 
In order to consider the importance of age within our model, I incorporated age 
structure into the basic model, which includes one drug sensitive and one drug resistant 
strain. The assumptions regarding the basic model structure and parameter estimates 
are the same as developed within this chapter. The model is further defined with 5 year 
age classes, updated at the end of each year, with a constant birth rate into new 
susceptibles of age 0. Individual lifespan is set at 80 years, allowing only for TB-
specific disease mortality to shorten an individual's lifespan. 
As the clinical manifestations of tuberculosis disease depend on age, 1 assume 
some of the model parameters vary with age, based on survey of the literature (as 
reviewed in Chapters 2 and 3) as well as parameters used in other TB models (reviewed 
in Chapter 4). I review here the model parameters considered to vary by age within this 
section; the remaining parameters are assumed to be constant over the age classes. 
The probability of progressing to primary disease (p) is considered to be higher 
in the young (age 15-24) and oldest age groups, perhaps as each may have reduced 
immunity or protection from infection. There tends to be a lower case rate between the 
ages of 0 - 14, as individuals infected during these ages have reduced progression to 
disease. In adolescents (age 15-24) there is a high rate of progression to disease, and 
clinical forms include either childhood or progressive primary tuberculosis. (Starke JR 
1995; Donald PR 2000) 
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The proportion developing active pulmonary, infectious disease (/) is assumed 
to 50% in the age classes of 25 years and above. A lower proportion of infectious 
disease is assumed for the age classes of 0-25 years. Tuberculosis disease in the young 
is more likely than adult TB to be extrapulmonary (EPTB), or other forms, such as 
military TB. Those cases which are pulmonary (PTB) manifest fewer symptoms than 
adult cases, rarely producing sputum and usually culture and smear negative. (Wong, 
1994; Donald PR 2000) 
The reactivation rate (v) is considered to be higher in the oldest age class, which 
may overall experience lower immunity. The TB-associated mortality rate (wr) as well 
overall mortality rates vary by age. Both the youngest and oldest age classes were 
assumed to have higher risk of disease-associated mortality, as suggested by references. 
The notification rate is assumed to vary slightly with age, with the youngest age classes 
assumed to have slightly lower notification rates. This is based on references 
suggesting difficulty of case notifications in children. (Wong, 1994; Donald PR 2000) 
VII. B. Simulations 
Simulations were started with equal numbers of all susceptibles in each age 
class, into which one infectious drug sensitive case in the age class of 35-39 years was 
added. The simulations were followed for 100 years. Following the change in age 
distribution of individuals and cases over time, showed that for the first 10-20 years, the 
population size remained near constant, and then began to decrease, as the disease 
prevalence increased. After approximately 40 years, the disease prevalence approached 
equilibrium. At this time, there was a decrease in the size of the older age classes, a 
moderate decrease in the middle age classes, and no decrease in the young age classes. 
This corresponds to the prevalence of disease in each class. 
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1. Low and high incidence scenarios 
Next, I compared the age distribution of cases in scenarios of low and high 
disease incidence. In young age groups, the highest proportion of disease is caused by 
primary disease, under both scenarios. In comparison, the older age groups 
(approximately 50-80 years), contributed more of new incident cases in the low 
incidence (Figure 5-12A) than the high incidence scenario (Figure 5-12B). The highest 
proportion of disease was caused by reactivation disease in a low incidence scenario 
(Figure 5-12A), and primary disease in a high incidence scenario (Figure 5-12B). Each 
of these scenarios was run for the 100 years and the final incidence rates are shown. 
The higher proportion of primary disease in scenario B reflects the higher levels of 
disease and primary transmission. In comparison, in scenario A, there is a higher 
proportion of reactivation disease in the older age classes, reflecting the relatively 
lower levels of disease and primary transmission. 
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Figure 5-12. Incidence of disease across age groups, predicted by model. The 
incidence of disease by age was examined under a (A) low incidence and a (B) high incidence 
scenario. The incidence of primary disease (PRIM), reactivation disease (REACT), and disease 
due to exogenous reinfection (REINF) are shown under line which includes all disease (ALL). 
Incidence is given as new cases per 100,000. 
VII. C. Drug resistance by age 
When comparing the rates of resistance across age groups, shows that these are 
similar to drug sensitive cases. I next examined the incidence of drug resistance across 
the age groups. Again, 1 compared scenarios with either low or high incidence of 
disease. (Figure 5-13 A, B) In both scenarios, the trends in incidences of both DR and 
MDR cases appear similar to those of drug sensitive cases, across the age groups. 
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This brief consideration of age structure, suggests that, at least within the 
current model formulation and limited simulations, that inclusion of age structure does 
not significantly affect overall model considerations or predictions for resistance levels. 
Incidence DR and MUR Incidence DRand MDR 
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Figure 5-13. Incidence of drug resistance across age groups, predicted by 
model. The incidence of resistance by age was examined under a (A) low incidence and a (B) 
high incidence scenario. The incidence of drug sensitive, single (DR) and multiple drug resistant 
(MDR) cases, within model simulations. Incidence is given as new cases per 100,000. 
1. Mycobnet surveillance on resistance 
Next, 1 examined publicly available reports on the incidence of drug sensitive 
and resistant cases by broad age classes from a Mycobnet UK study, that includes 
reports of cases of active disease from centers across the UK from 1995-1999. Shown 
in Figure 5-14A are the notification rates of new active cases by year and age class. In 
Figure 5-14B are the numbers of these cases known to be INH resistant or MDR, again 
by age class. Comparing these two figures, it appears that the trends in resistance 
levels at the middle age classes are roughly comparable to the overall disease levels by 
age classes, with a peak in both the overall notification rates and the resistant cases in 
the 25-34 year age class. However, there appear to be fewer relative resistant cases 
found in the youngest (0-14) and oldest (65+) age classes. Comparing this to the above 
model simulations, we may expect that if there were no differences in the likelihood to 
develop resistance, that since there is a peak in the notification rates in the 65+ age 
class, there may also be a peak in resistance. These differences may be due number of 
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variables, including lower notification or detection of resistant case in these age classes, 
not accounting for other types of single (non-INH) drug resistance, and possibly limited 
or otherwise biased sampling. 
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Figure 5-14. Notification rates of TB cases (A) and resistant cases (B) 
across age groups from PHLS Mycobnet survey in England and Wales 
f r o m 1 9 9 5 - 1 9 9 9 . (A) initial M. tuberculosis isolates by age group, 1995-1999. (B) 
Isoniazid Resistance and Multi-Drug Resistance in Initial Isolates of M. tuberculosis, England 
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and Wales 1995 - 1999, by age group. (C) For comparison, from the WHO 2000 report, the 
Tuberculosis Notification Rates per 100,000 population, England and Wales, by age, 1993-
2000. 
VIII. Model parameter values 
Parameter Explanation Estimated values Source 
N Population size Held constant 
I Per capita rate of 
infection 
c Effective contact rate 5-15 (average 10) 
infections/ 
infectious case -
year 
(Styblo, 1991), 
(Blower, McLean et al. 1995), 
(Porco and Blower 1998), 
(Dye and Williams 2000; Dye 
and Espinal 2001) 
i Proportion infectious 0 . 4 - 0 . 6 (Fishman and Elias 1998) 
(Davies 1998) 
P Proportion infected 
progress to primary 
disease 
(Sutherland, Svandova et al. 
1982; Sutherland, Bleiker et al. 
1983) (Vynnycky and Fine 
1997) 
V Rate latent infected 
progress to infectious 
disease 
0.03% (Sutherland, Svandova et al. 
1982; Sutherland, Bleiker et al. 
1983), (Vynnycky and Fine 
1997) 
7 Reinfection parameter Varied 
K Self-cure rate for DS 10% (Chaulet and Zidouni 1998) 
(Enarson and Hopewell 1998), 
Estimates in this chapter. 
n Notification rate for 
sputum smear positive 
cases 
<|)s treatment cure rate of 
DS cases 
Developed: 70-
95%, developing: 
(WHO/IUATLD 2000; WHO 
2003), (Chaulet and Zidouni 
1998) 
<t>R Treatment cure rate of 
single DR cases 
Developed: 70-
95%, developing: 
(similar to DS cure 
rates) 
(Espinal, Kim et al. 2000) 
<t>M Treatment cure rate of 
multiple DR cases 
developed: 50-80% 
developing: 4-60%) 
(reduced cure 
rates) 
(Espinal, Kim et al. 2000) 
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r 
Prob. of acquiring 
resistance mutation 
during drug treatment 
of DS case 
Developed: 
low(5%) -
high(10%) 
Developing: high 
(Chaulet and Zidouni 1998), 
(Dye and Espinal 2001) 
V-
Mortality rate (not TB) 0.015 Average life expectancy 80 
years 
|IT Mortality rate due to TB 15-30 (mean 20)% (Grzybowski 1991; Chaulet 
and Zidouni 1998; Davies 
1998; Enarson and Hopewell 
1998), Estimates in this 
chapter. 
W relapse rate 2-5% (Chaulet and Zidouni 1998) 
Table 5-5. Estimates of values for model parameters. Unless otherwise indicated, 
parameter values are given as rate per year. For control parameters (including the 
notification, cure, and acquired resistance rates) ranges of values found in developed 
and developing countries are given. 
IX. Summary of Findings 
IX. A. Model formulation 
This model expands on previous in several respects. First, the interacting 
dynamics of sensitive and resistant cases within a tuberculosis epidemic are examined. 
Second, the emergence of acquired and transmission of primary drug resistance are 
incorporated, and the relative contribution of each to resistant sub epidemics examined. 
Third, the emergence of MDR is modeled in a two step process of the acquisition of 
resistance mutations. 
Resistance is seen to emerge in a series of linked sub epidemics, from one 
founding drug sensitive case. This models the establishment of drug sensitive 
epidemics in the prechemotherapy era. The simulation begins with the introduction of 
drug treatment and follows the emergence of resistance, from the acquisition of 
mutation during treatment, and transmission as primary resistance. 
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IX. B. Mathematical definitions 
Defining the basic (Ro) and effective (R) reproductive number in terms of model 
parameters provides insight into the model dynamics as well as the conditions under 
which resistance emerges and persists. The basic reproductive number (RQ) was 
derived by solving the system of equations at equilibrium for a model in which disease 
remained untreated. The effective reproductive number (R) was derived by finding the 
equilibrium solutions for a model which included the treatment of disease. The basic 
and effective reproductive numbers were derived for various versions of the model, 
including a model with one (drug sensitive), two (drug sensitive and resistant) and three 
(drug sensitive, singly resistant, MDR) strains, reinfection, and interacting strains. 
Both Ro and R depend upon the effective contact rate, duration of infectiousness, and 
probability of progressing to active disease. Effective reproductive numbers were also 
derived for each strain, in which the contact rate and duration of infectiousness were 
strain-dependent, while the probability of progressing to disease was strain-
independent. Treatment was seen to reduce the case duration of infectiousness, thus 
reducing the value of R. 
Defining the effective reproductive number allowed for further examination of 
model dynamics. The relationship between model outcome at equilibrium and R values 
was examined. In terms of the balance between sensitive and resistance, three possible 
model outcomes exist: eradication of all strains, eradication of only the sensitive strain, 
or coexistence of sensitive and resistance. Resistance emerges when Rs and/or RR are 
greater than one. If Rs >1 but RR < 1, then resistance will stay at a low level which is 
proportional to treated drug sensitive cases. The resistance prevalence will depend 
upon the proportion treated, as well as the cure and acquired resistance rates. When RR 
> 1, an emerging resistance epidemic has the potential to continue in a self-sustaining 
cycle. 
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Critical treatment rates were defined for the eradication of one or more strains at 
equilibrium. Sensitive strains were removed at lower treatment rates than resistant 
strains. Higher treatment rates were required to reach threshold values such that both 
sensitive and resistant strains were cleared. There is also a balance between 
notification and cure rates in terms of eradication criteria: Increasing either reduces the 
strain fitness, increasing both simultaneously results in synergistic reductions in strain 
fitness, and reductions in one can also be compensated for by increasing the other. 
These analyses apply to model equilibrium conditions, and thus not directly to 
predicting short-term changes in resistance prevalence as monitored in current global 
epidemics. However, several concepts are important in understanding TB resistance. 
These include the conditions for emergence of resistance, for competition between 
strains, and for sustaining an epidemic. First, competition between sensitive and 
resistant strains depends upon relative fitness. Second, resistance cannot be eradicated 
unless all sensitive strains are as well, as resistance will continue to emerge from the 
treatment of sensitive cases. Third, treatment has a differential impact on the fitness of 
each strain, with the implication that the conditions for eradication of each strain will 
differ, making it possible for one strain to succeed while another is removed under the 
same program. Lower treatment rates may allow for the clearance of sensitive strains, 
while allowing resistance to increase. Higher treatment rates are required to reduce 
prevalence of both sensitive and resistant strains. 
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I. Goals 
I. A. To examine the dynamics of the emergence, transmission, 
and persistence of TB epidemics and resistance in model 
simulations. 
I. B. To identify the conditions which most influence the 
emergence and spread of resistance within a population. 
I. C. To explore the sensitivity of model predictions for disease 
and resistance levels to parameter estimates. 
II. Abstract 
The model for the emergence and transmission of resistant epidemics 
developed in the previous chapter is used here to consider the dynamics of resistance 
emergence, transmission, and persistence. In the absence of treatment, an epidemic 
emerges and reaches equilibrium levels of disease on a timescale of approximately 
100 years. Introducing treatment reduces disease levels while selecting for resistance. 
Under poor control, with low cure rates, treating a greater proportion of cases 
increases the incidence of resistance. Under good control, with high cure rates for 
sensitive and resistant cases, increasing the treatment rates can contain and reduce the 
incidence of resistance. These results are most sensitive to the transmission rate of 
resistant strains. The greatest selection for the emergence and spread of resistance 
occurs under high treatment rates combined with low cure rates, when there is no 
fitness cost in resistance transmission. Under these conditions, increasing treatment 
coverage can increase the incidence of resistance as well as overall disease. 
The sensitivity of the model predictions to parameter estimates is explored 
through Monte Carlo based simulations. In the absence of treatment, the model 
predictions for the disease incidence are most sensitive to parameter estimates for the 
contact rate, the proportion progressing to primary disease, and the reactivation rate. 
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When treatment is introduced, the disease incidence is most influenced by fixing the 
notification and cure rates. Similarly, the resistance prevalence is principally 
determined by the notification and cure rates. When the notification and cure rates 
are fixed, the resistance prevalence is most strongly influenced by the uncertainty in 
estimating the rate of acquired resistance, the fitness of the resistance strain, and the 
contact rate. Under good control, high treatment and cure rates limit the incidence of 
disease as well as prevalence of resistance. In comparison, under poor control, low 
treatment efficacy allows for higher levels of both disease and resistance to develop. 
These model predictions are most strongly determined by fixing the treatment 
parameters for the rate and efficacy of treatment. 
III. Introduction 
The burden of TB in a population is measured in several ways, including the 
incidence and prevalence of disease, mortality rates, and the force of infection. The 
commonly used statistics for reporting are the annual incidence or prevalence rate of 
cases per 100,000 population. Since 1993, global surveillance by the WHO has 
subdivided incidence rates into cases which are sputum smear positive or negative. 
(Raviglione, Dye et al. 1997; Dye, Watt et al. 2002) While the prevalence and 
incidence rates are routinely estimated in surveillance programs, there are only a few 
examples of estimates of the prevalence of infection and the annual risk of infection 
(ARl). The latter two require longitudinal estimates of the prevalence of infection 
within groups of a population over the course of a number of years. Such studies 
were done by Sutherland in the Netherlands; these landmark studies have provided the 
basis for current understanding of TB transmission rates. (Sutherland, Svandova et al. 
1982) (Sutherland, Bleiker et al. 1983) 
173 
In this chapter, the burden of disease is measured as the incidence rate of new 
infectious cases per 100,000. For comparison, the prevalence of infection and 
prevalence rate of disease (as infectious cases per 100,000), are also shown in the first 
section. The resistance prevalence is given as the proportion of infectious cases with 
resistance. All case rates - for incidence, prevalence, and prevalence of resistance-
refer to infectious cases. 
Other mathematical models of tuberculosis epidemics have been formulated to 
consider the long term dynamics of tuberculosis epidemics. One has examined the 
natural history of tuberculosis over the course of the past century in England and 
Wales. (Vynnycky and Fine 1997) From this model, critical estimates of the 
dynamics of tuberculosis epidemics in low incidence regions have been made, 
including the importance of improvements in treatment, changing contact patterns, 
and the role of reinfection. (Vynnycky and Fine 1998; Vynnycky and Fine 1999; 
Vynnycky and Fine 2000; Vynnycky, Nagelkerke et al. 2001) 
Other models have also examined the role of resistance in tuberculosis 
epidemics. One study simulated the transmission of resistant strains and used the 
model to estimate predicted levels of resistance. (Dye and Williams 2000) This 
model was also used to consider the impact of treatment with DOTS SCC on an 
epidemic of MDR, calculating critical rates for control of resistance. (Dye and Espinal 
2001) Another model was used to consider the general dynamics of resistance and 
competition between sensitive and resistant strains in a population. (Blower, Porco et 
al. 1998; Blower and Gerberding 1998) 
The study presented in this chapter adds several novel analyses. First, the 
emergence of a resistant epidemic from within a drug sensitive epidemic is examined. 
Second, the long term dynamics of resistance and the interaction with sensitive strains 
174 
are considered. Third, conditions for the emergence and spread of resistance are 
delineated. Fourth, detailed sensitivity analysis is performed to test the model 
predictions for emergence and spread of resistance to uncertainty in parameter 
estimates. Fifth, the key parameter uncertainties are identified within different control 
environments. Sixth, within the limits of this uncertainty in parameter estimates, the 
resistance prevalence in various control environments is predicted. 
IV. Model Simulations 
IV. A. Under no treatment 
(1) Course of a typical epidemic 
In the absence of treatment, introducing infectious TB cases into a susceptible 
population will allow for the emergence of an epidemic. The course of a typical TB 
epidemic, as used in model simulations throughout this chapter, is depicted in Figure 
6-1. In this simulation, one active infectious case is introduced into a susceptible 
population of size 1x10^. Early in the epidemic, disease levels increase rapidly 
through ongoing cycles of transmission. (Figure 6-lA,B) The prevalence of infection 
continues to increase as the epidemic progresses. (Figure 6-1C) This reduces the 
number of susceptibles in the population, slowing the incidence of new cases until an 
equilibrium level is reached. (Figure 6-1) 
(2) Timescale 
The epidemic timescale, as shown here, is on the order of 100 years. This 
long timescale is a consequence of the slow rate of reactivation disease. The peak of 
endogenous disease may come several decades after the initial peak of primary 
disease, which reflects the rapid progression to disease early after infection. This 
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epidemic timescale is similar to that found in other models. (Blower, McLean et al. 
1995; Blower, Small et al. 1996; Vynnycky and Fine 1997) 
(3) Primary and reactivation disease 
New incident cases are caused by either primary progression from recent 
infection or reactivation of an old infection. Early in the epidemic, a high proportion 
of disease is due to primary transmission. Over the course of an epidemic, the pool of 
latent infections accumulates, increasing the contribution of reactivation disease to 
new cases. As the epidemic progresses a greater proportion of cases are due to 
reactivation of latent infection. (Figure 6-1D) 
(4) Reinfection 
Introducing the possibility of reinfection of previously infected individuals 
into the model changes the course of an epidemic. As defined in the model, the 
reinfection parameter (y) represents the susceptibility of previously infected 
individuals to reinfection and exogenous disease. Increasing the reinfection 
parameter resulted in an increase in incidence and prevalence of disease. As shown in 
Figure 6-2A, increasing the reinfection parameter results in a sharp increase in the 
incidence of exogenous disease and a slight increase in the incidence of primary 
disease. (Figure 6-2) The uncertainty over estimating the reinfection parameter has a 
large impact on the model outcome of disease incidence and prevalence. For the 
remainder of the simulations in this section, the reinfection parameter is set at 60%, in 
accordance with previous estimates. (See parameter estimates section of Chapter 4) 
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Figure 6-1. The course of a typical TB epidemic. The course of an epidemic is followed for 100 years. The simulation is begun by introducing one 
infectious case into a susceptible population. The incidence (A) and prevalence (B) of disease increase rapidly during the early phases of the epidemic, when 
there is a rapid supply of new susceptibles in the population. As a high proportion of the population is infected (C) few susceptibles remain and the incidence 
and prevalence of disease decline, reaching stable equilibrium levels. The incidence of primaiy disease accounts for most new cases early in the epidemic, while 
late in the epidemic the incidence of reactivation cases increases. (D) The incidence rate is shown as new infectious cases per 100,000 (A), and the prevalence 
rate as infectious cases per 100.000. (B) The prevalence of infection is shown as the proportion of the population with either latent infection, active disease, or 
recovered from disease. (C) The incidence rate of primary (solid line) and reactivation (dashed line) disease is shown as new infectious cases per 100,000. (D) 
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Figure 6-2, The impact of reinfection on the model predictions for disease 
levels. Increasing the susceptibility of previously infected individuals to reinfection increases the 
incidence of disease. Increasing the susceptibility to reinfection results in an increase in the incidence 
of ilrst primary disease (solid line), but a greater increase in incidence of exogenous disease (dashed 
line). The reinfection parameter (y), the model parameter reflecting the degree of susceptibility of 
previously infected individuals to reinfection disease, is varied in these simulations from 0% - 100%. 
V. Treatment 
(1) Reduces disease 
Introducing a control program into the model simulations slows the emergence 
of an epidemic. Simulations were begun by introducing one drug sensitive infectious 
case into a susceptible population of size 1x10^, and followed for 200 years. In these 
simulations, it was assumed that the reinfection parameter was 80%. In years 0-100 
of the simulations, disease is allowed to spread and reach endemic levels. In years 
101-200 of the simulations, control is introduced. Introducing treatment reduces the 
incidence of disease. Introducing treatment, with a notification rate of 50%, reduces 
the incidence of disease. (Figure 6-8A) The treatment rate, equal to the proportion of 
incident cases receiving treatment, was varied from 0% to 100%. Increasing the 
treatment rate in these simulations reduces the incidence and prevalence of disease. 
(Figure 6-3B) 
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Figure 6-3. The treatment of a higher proportion of cases reduces incidence 
of disease. 
A. Introducing treatment reduces the incidence of disease. Simulations were begun by introducing 
one infectious drug sensitive case into a susceptible population of size 1x10^, and run to equilibrium 
levels of disease in the absence of any treatment for years 0-100. From years 101-200, 50% of cases 
were treated. The cure rate for drug sensitive cases was set at 80%, for singly drug resistant cases at 
60%, and for MDR cases at 40%. The reinfection parameter was assumed to be 80% in these 
simulations. 
B. Higher notification rates reduce the incidence of disease. Simulations run as for A, with the 
proportion of cases receiving treatment (notification rate) during years 101 -200 varied from 0% to 
100%. Shown is the incidence rate of infectious cases per 100,000 at the end of the simulation. 
(2) Emergence of resistance 
Treatment also allows for the selection of resistance. Resistance emerges from 
tfie treatment of drug sensitive cases. As treatment is begun, resistance emerges in a 
series of linked sub-epidemics from within the initial drug sensitive epidemic. When 
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the conditions allow for resistance to both emerge and form a self-sustaining 
epidemic, resistance levels continue to increase. Simulations were begun by 
introducing one infectious drug sensitive case into a susceptible population of size 
1x1 Ol Infectious cases received treatment at a rate of 50%. New cases of acquired 
resistance emerge from the treatment of drug sensitive cases, and continue a 
resistance epidemic through ongoing cycles of transmission of primary resistance. 
As treatment continues, the incidence of drug sensitive cases is reduced, while the 
incidence of DR and MDR cases increases. (Figure 6-4) 
V. A. Transmission and selection for resistance 
Several factors contribute the transmission and selection for resistance. The 
parameter most significantly associated with resistance is the treatment rate, with 
higher treatment rates correlated to higher resistance prevalence. (Figure 6-5) The 
extent of selection for resistance also depends on parameters for the cure rates, and 
resistance transmission rate. For a given treatment rate in these simulations, 
increasing the cure rate for resistant cases reduces the selection for resistance. (Figure 
6-5A) 
To explore the impact of varying the transmission rates of resistant strains, 1 
first define the relative fitness of strains. The resistant strains are considered to have 
independent transmission rates, as reviewed in Chapter 2 and in the model developed 
in Chapter 5. Here, the fitness cost (/) of a MDR resistant strain is given as the 
transmission rate (c) relative to a wild type drug sensitive strain, as defined here: 
. CMDK 
JMDK = 1 
Cs 
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Thus, if the transmission rate of the MDR strain was 80% that of the drug 
sensitive strain (cg = 0.8 CM), then the MDR strain can be said to have 20% fitness 
cost (fkiDR = 20%). This notation is used in the following simulations. 
When resistant strains have fitness costs that reduce transmission (/WD«) 
relative to drug sensitive strains, the selection for resistance is reduced. The greater 
the fitness cost of resistance, the slower the selection for resistance with increased 
notification rates. This is portrayed in two scenarios- under high or low cure rates. 
When there are high cure rates for both drug sensitive and resistant cases, the 
resistance remains at a low level (below 20%) even at high notification rates. 
Changes in the relative transmission rate of resistant strains have a small impact; 
reducing the relative MDR strain transmission by 50% (/A/D/?=50%) reduces the 
resistance prevalence by 2%, when compared to estimates under equal transmission 
(/^ /£)/?=0%). (Figure 6-5B) 
When there are low cure rates for both drug sensitive and resistant cases, the 
relative fitness of the resistant strain has a greater infiuence on the selection for 
resistance. When the MDR strain has equal transmissibility as the drug sensitive 
(Amr 0%), treating every case can result in a resistance prevalence as high as 80%. 
In comparison, when the MDR strain is 50% as transmissible (f/iioR=50%), treating all 
cases results in 35% resistance. (Figure 6-5C) 
(3) Acquired and primary resistance 
The relative proportion of resistant cases due which are either acquired during 
treatment or resulting from primary transmission reflects on the state of the resistant 
sub-epidemic. When resistance initially emerges within a drug sensitive epidemic, 
most of the resistant cases are those acquired during treatment. As the resistant cases 
transmit infection, the resistance epidemic grows. The relative proportion of resistant 
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cases due to primary transmission increases with the spread of the resistance 
epidemic. (Figure 6-6) 
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Figure 6-4. Treatment selects for the emergence of resistance, which 
continues through ongoing cycles of transmission within the epidemic. The strain-
specific incidence (A) and prevalence (B) are shown over the course of an epidemic under treatment. 
Treatment rapidly reduces the incidence of drug sensitive cases (DS), while allowing for the emergence 
of resistance. As treatment is continued, the incidence of resistant cases (singly resistant, DR, and 
MDR cases) increases. (A) Treatment also increases the prevalence of DR and MDR cases. (B) 
Simulations were begun by introducing one infectious drug sensitive case into a susceptible population 
of size 1x10^, and run to equilibrium levels of disease in the absence of any treatment for years 0-100. 
From years 101-200, treatment of 50% of cases was implemented. The cure rate for drug sensitive 
cases was set at 80%, for singly drug resistant cases at 60%, and for MDR cases at 40%. 
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Figure 6-5. Treatment selects for resistance. This selection depends most 
strongly on the resistant cure rate and fitness. 
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A. Resistant cure rate varied. The cure rates for MDR cases was set at (^ MDR = 10%, 30%, or 50%. 
At lower cure rates for M D R case, increasing the notification rate resulted in a greater increase in 
resistance prevalence. 
B. Under good control. The fitness cost of resistance (/mdr), representing the reduced transmission of 
MDR strain relative to DS, was set to 0%, 20%, or 50%. At greater fitness cost of M D R cases, 
increasing the notification rate resulted in less of an increase in resistance. The cure rate for drug 
sensitive cases was set at 80%, for singly drug resistant cases at 70%, and for MDR cases at 50%. 
C. Under poor control. The cure rate for drug sensitive cases was set at 60%, for singly drug 
resistant cases at 40%, and for MDR cases at 20%. Increasing the fitness cost of resistance, reducing 
the transmission of the M D R strain, limited the selection for resistance with increased notification 
rates. 
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Figure 6-6. The proportion of acquired and primary resistance over the 
course of an epidemic. Early after the start of treatment at year 100, acquired resistance emerges 
from the treatment of drug sensitive cases. As the simulation continues these new cases of acquired 
resistance transmit primary resistance, and a greater proportion of resistant cases comes from primary 
transmission. Shown is the proportion of resistant cases for which resistance was either acquired 
during treatment (solid line) or f rom primary transmission (dashed line). Simulations were begun by 
introducing one drug sensitive case into a susceptible population of size 1x10^, and run to equilibrium 
in the absence of treatment for years 0-100. In year 101, treatment was introduced with a notification 
rate of 50%, a treatment cure rate for drug sensitive cases of 80%, for singly drug resistant cases of 
60%, and for MDR cases of 40%. This treatment was maintained for years 101-200. 
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Figure 6-7. Treatment selects for resistance, which can he reduced by high 
treatment and cure rates. Increasing treatment rates can either control the emerging resistance 
epidemic or select for higher levels of resistance, depending upon the control conditions and relative 
fitness. Simulations were begun by introducing one infectious drug sensitive case into a susceptible 
population of size 1x10^, and run to equilibrium levels of disease in the absence of any treatment for 
years 0-100. The proportion of cases receiving treatment (notification rate) during years 101-200 was 
varied from 0% to 100%. The final incidence of infectious cases is shown as cases per 100,000. 
A. Under good control. The treatment cure rate for drug sensitive cases is set at 80%, for 
singly drug resistant cases at 60%, and for MDR cases at 40%. Increasing the notification rate 
results in a decrease in incidence of disease (total incidence, solid line). This is mostly due to a 
reduction in incidence of drug sensitive cases (DS, dashed line). The incidence of singly 
resistant (DR) and MDR (MDR, circles) cases is increased by increasing the notification rate 
from 0% to 20%. Increasing the notification rate further results in a reduction in incidence of 
resistant cases. 
B. Under poor control. The treatment cure rate for drug sensitive cases is set at 60%, for 
singly drug resistant cases at 40%, and for MDR cases at 20%. Increasing the notification rate 
results in a decrease in incidence of disease (total incidence, solid line). This is mostly due to a 
reduction in incidence of drug sensitive cases (DS, dashed line). The incidence of singly 
resistant (DR) cases is increased by increasing the notification rate from 0% to 20%. Increasing 
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the notification rate further reduces the incidence of DR cases. Increasing the notification rate 
results in an increase of M D R cases (MDR, circles). 
(4) Conditions for emergence and spread resistance 
As shown above, introducing treatment reduces the incidence of disease. In 
Figure 6-7 the affect of treatment on the incidence of each strain is shown. Increasing 
the treatment rate sharply reduces the incidence of drug sensitive cases. The impact 
of treatment on resistant strains is more complex and depends upon the efficacy of 
treatment for both sensitive and resistant cases. When treatment does not provide an 
effective cure for resistant cases, then higher rates of treatment will select for greater 
resistance. This is portrayed in an example of a simulation under poor control, in 
which both the sensitive and resistant cure rates are low. (Figure 6-7B) 
When there is effective cure for both sensitive and resistant cases, increasing 
the treatment rate may result in reduced incidence of resistance. As shown in Figure 
6-7, low rates of treatment allow for the emergence of resistance; as the treatment rate 
is increased from 0 to 30%, there is a sharp rise in the incidence of resistant cases. 
Further increases to the treatment rate result in a decline in resistance incidence. This 
reduction of resistance with higher treatment rates is a result of two combined 
processes. First, at high treatment and cure rates, more cases receive effective 
treatment and are rapidly cured, allowing less opportunity for acquired resistance to 
emerge. Second, the high notification rate allows for a greater proportion of new 
resistant cases to receive treatment, limiting the ongoing spread of resistance. 
(Figure 6-1 A) 
Under good control, high treatment and cure rates limit the emergence of 
resistance. Increasing the treatment rates can contain this emerging resistance. Under 
poor control, there is a greater opportunity for emergence as well as spread of 
resistance. With little effective cure for resistant cases, resistance increases with the 
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propor t ion treated. Increasing the treatment rates can exacerbate a resistance 
problem, increasing resistance prevalence as well as overall incidence. 
VI. Sensitivity analysis 
VI. A. Methods 
In the previous section, the basic dynamics of the model were outlined. The 
direct relationship between several model variables—including the reinfection, 
resistance transmission, notification, and cure rates—and model outcome were 
explored. The analysis presented in this section expands on this sensitivity analysis 
by considering the relationship between each variable and model outcome in the 
context of varying all variables over plausible ranges for each individual variable. 
The correlation between variable and outcome is examined, over the space of possible 
combinations of parameter values, to find which parameters most influence each 
model outcome. The sensitivity scenarios presented in this section are compared in 
Table 6-1. 
Sensitivity analysis was performed on a two-strain version of the model 
presented in chapter 5, with one sensitive and one resistant strain (as given in 
Appendix 1). The sensitivity of model predictions to parameter estimates is examined 
through Monte Carlo simulations. Simulations were run in C++ with RK4 method 
and a time step of one month. In each scenario given below, parameter values were 
varied simultaneously to give the range of possible parameter combinations. A 
normal distribution for parameters values was assumed, with mean and variance as 
given for each scenario. The resulting model outcomes were correlated to each 
parameter in turn. The influence of parameter variance on model outcome is 
portrayed with scatterplots showing the range of parameter values and the resulting 
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model outcomes. In order to further quantify the relative influence of each parameter 
model outcome, the Pearson square coefficient ( / ) is calculated for the proportion on 
of variance in the model outcome which can be explained by the variance in a given 
parameter. A higher coefficient (on a scale of 0 to 1) reflects a larger contribution to 
model outcome. (Full sensitivity analysis and scatterplots found in Appendix 3, 
summary of sensitivity analysis in Table 6-1) 
For the purpose of this sensitivity analysis, the model parameters are classified 
into two general types: intrinsic and treatment parameters. The intrinsic parameters 
are those basic to the strain, transmission, and development of disease. These include 
the contact rate (c), proportion infectious (i), proportion progressing to primary 
disease (p), the mortality rate (JIT), the self-cure rate (K), the relapse rate (if), and the 
reinfection parameter (y). The treatment parameters include the notification (nr) and 
cure rates (O), and the probability of acquiring resistance given treatment failure (r). 
VI. B.Under no treatment 
(1) Basic model, no reinfection 
In scenarios 1-3, the sensitivity of model predictions in the absence of any 
treatment are examined. First, the model sensitivity was considered under a scenario 
where no treatment and no reinfection occur. The results of 1000 Monte Carlo 
simulations, run for 100 years in the absence of treatment, are shown in scenario I A. 
The final incidence of disease ranged from 1-149 (average 81) cases per 100,000. 
(Simulation 1 A) The final incidence of disease was most strongly influenced by the 
variation in the ECR (c), the proportion progressing to primary disease (p) and the 
endogenous reactivation rate (v). There was a positive correlation between each of 
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these input parameters and the model output of final incidence of disease. (Scenario 
1) 
(2) Reinfection sensitivity 
In the second scenario, simulations were run as in scenario 1, but also included 
re infec t ion . The reinfection parameter (y), representing the susceptibility of 
previously infected individuals to exogenous disease, was varied over a wide range 
from 0%-100%. The other intrinsic parameters were the same as for simulation 1. 
Introducing the possibility for reinfection increased the incidence of disease. In these 
simulations, the final incidence of disease ranged from 0-4403 (average 1140). The 
incidence of disease was most strongly influenced by variation in the reinfection 
parameter (y). At low reinfection, the emergence of disease was limited to incidence 
rates below 1000 cases per 100,000, while higher reinfection allowed the opportunity 
for significantly higher levels of disease. The incidence of disease was also 
influenced by the parameters for the ECR and the proportion progressing to primary 
disease. (Scenario 2) 
(3) Reinfection parameter fixed 
In the third scenario, the reinfection parameter was held constant at 60%, the 
value used in subsequent simulations. The other intrinsic parameters were the same 
as for simulations 1 and 2. The final incidence of disease in these simulations ranged 
from 1-3217 (average 1540). The final incidence rate was, as in the previous two 
scenarios, most strongly influenced by the proportion progressing to primary disease 
and the ECR. (Scenario 3) 
1 8 9 
VI. C. Widely varied treatment 
The model sensitivity is next examined in the presence of TB control, where a 
control program is defined as a set of notification, cure, and acquired resistance rates. 
In each scenario, simulations were begun by introducing one infectious drug sensitive 
case into a susceptible population of size 1x10^. For years 0-100, the epidemic was 
allowed to progress, in the absence of treatment, and reach endemic levels of disease. 
Treatment was introduced and maintained with a constant control program during 
years 101-150. In scenarios 4 and 5, the impact of treatment on model outcome is 
examined by widely varying the parameters delineating the control program. 
In scenario 4, the reinfection parameter was also varied, in order to test the 
sensitivity of model behavior under treatment, and in particular on the emergence of 
resistance, to uncertainty in the reinfection parameter. The average final incidence 
rate was 355 (range 31 to 2899) cases per 100,000, with an average resistance 
prevalence of 17% (range 0%-96%). The final incidence of disease was most strongly 
affected by the uncertainty in the reinfection parameter (varied from y=0%-100%), 
accounting for 50.8% of the variation in incidence. Higher reinfection parameters 
resulted in both greater and a wider range of incidence rates. The notification rate, 
also varied from 0%-100%, was the parameter with the second greatest influence on 
the incidence rate, accounting for 9.3% of the variance. Lower notification rates were 
correlated with a higher and greater range in incidence rates, while higher notification 
rates limited the incidence to low levels. (Scenario 4) 
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Figure 6-8. The treatment of a higher proportion of cases reduces incidence 
of disease. 
A. Introducing treatment reduces the incidence of disease. Simulations were begun by introducing 
one infectious drug sensitive case into a susceptible population of size 1x10^, and run to equilibrium 
levels of disease in the absence of any treatment for years 0-100. From years 101-200, treatment of 
50% of cases was implemented. The cure rate for drug sensitive cases was set at 80%, for singly drug 
resistant cases at 60%, and for M D R cases at 40%. 
B- Simulations run as for A, with the proportion of cases receiving treatment (notification rate) during 
years 101-200 varied from 0 % to 100%. Higher notification rates reduce the incidence of disease. 
Shown is the incidence rate of infectious cases per 100,000 at the end of the simulation. 
Varying the reinfection parameter also had a significant impact on the final 
resistance prevalence. The uncertainty in the reinfection parameter had the largest 
impact on resistance, accounting for 23.5% of the variance. At higher reinfection 
parameters, there was a higher and greater range in resistance prevalence. The control 
parameters had the next greatest influence on the resistance prevalence; the DS cure 
1 9 1 
rate a c c o u n t e d for 1 2 . 7 % of the variance, and the D R cure rates accounted for 1 3 . 3 % , 
the acquired resistance rate for 9.1%. (Scenario 4) 
In scenario 5, the reinfection parameter was set to 60%, as in the simulations 
following. The control parameters were widely varied, as in scenario 4. The average 
final incidence rate was 364 (range 63-1582) cases per 100,000, with an average 
resistance prevalence of 18% (range 0%-89%). With the reinfection parameter held 
constant, the greatest influence on the incidence rate came from varying the 
notification rate (from 0% to 100%), accounting for 37.6% of the variance. The final 
prevalence of resistance was most strongly influenced by the control parameters, 
followed by the transmission rate of the resistant strain. The DS cure rate accounted 
for 27.3% of the variance in final resistance prevalence, the DR cure rate for 20.4%, 
the acquired resistance rate for 14.2%, the notification rate for 9.8%, and the fitness of 
the resistance strain for 9.6%. (Scenario 5) 
In scenario 6, the impact of widely varying the treatment rate was examined, 
while the cure rates were held fixed at high levels. The cure rate was set at 80% for 
DS cases and at 50% for DR cases. The average final incidence rate was 320 (range 
23-1601) cases per 100,000, with an average resistance prevalence of 8% (range 0%-
22%). The parameter with the greatest impact on the final incidence rate was the 
notification rate, which when varied from 0%-100% accounted for 52.4% of the 
variance in incidence. The parameters with the greatest influence on the final 
resistance prevalence were those for the control parameters and the fitness of the 
resistant strain. The uncertainty in the acquired resistance rate accounted for 57.8% 
of the variance in final resistance prevalence, the resistance transmission fitness cost 
for 20.4%, and the notification rate for 8.5%. (Scenario 6) 
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VI. D. Good control 
In scenario 7 , the model sensitivity is examined under treatment which is 
varied over a range representing 'good' control, with a high rate and efficacy of 
t reatment . The notification rate was set at 7 5 % , the cure rate for drug sensitive cases 
at 90%, a n d the cure rate for resistant cases at 6 0 % . Simulations were run as in 
scenario 4 , allowing the system to equilibrate in the absence o f treatment for years 0 -
100, and receive a constant control program in years 1 0 1 - 1 5 0 . The final incidence of 
disease in these simulations was an average of 1 5 7 (range 12-299) cases per 1 0 0 , 0 0 0 , 
with an average final prevalence of resistance of 3 % (range 1 - 5 % ) . (Scenario 7 A ) 
With the treatment parameters (aside from the rate of acquired resistance) 
already fixed, the model outcome for disease incidence was most affected by intrinsic 
parameters. The incidence of disease is most strongly affected by the ECR and the 
proportion progressing to primary disease. The final prevalence of resistance was 
most strongly influenced by the control parameter for the acquired resistance rate, as 
well as the intrinsic parameter for the resistance transmission rate. The uncertainty in 
the acquired resistance rate accounted for 54.9% of the variance in the resistance 
prevalence. Higher acquired resistance rates result in greater resistance prevalence. 
The fitness of the resistance strain, as measured by the relative transmission rate, 
accounted for 31.4% of the variance in the resistance prevalence. Increasing the 
fitness cost of resistance (by reducing the relative resistance transmission rate) limited 
the resistance prevalence to low levels. (Scenario 7) When the control program is 
fixed at high rates and efficacy o f treatment, the greatest uncertainty in resistance 
prevalence comes from estimates for the acquired resistance rate, and the resistance 
transmission. 
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VI. E.Poor control 
In scenario 8, the model sensitivity is examined under treatment which is 
varied over a range representing 'poor' control, with a low rate and efficacy of 
t reatment . The notification rate was set at 50%, the cure rate for drug sensitive cases 
at 60%, and the cure rate for resistant cases at 30%. In addition, under poor control 
the rate of acquired resistance amongst treatment failures (r) was set to a higher value 
(and varied over a wider range) than under good control. Simulations were run as in 
scenario 4, allowing the system to equilibrate in the absence of treatment for years 0-
100, and receive a constant control program in years 101-150. The final incidence of 
disease in these simulations was an average of 379 (range 44-791) cases per 100,000, 
while t he final prevalence of resistance was an average of 37% (range 9%-67%). 
(Scenario 8A) 
As in scenario 7, fixing the notification and cure rates leaves the model 
outcome for final disease incidence most strongly influenced by the intrinsic 
parameters of the ECR and the proportion progressing to primary disease. The final 
prevalence of resistance, again as in scenario 7, is most strongly influenced by the 
control parameter for the acquired resistance rate and the intrinsic parameter for the 
resistance transmission. These results appear to be common for fixing the notification 
and cure rates. However, the relative importance of the variation in the fitness of the 
resistant strain on the prevalence of resistance is much higher under poor control, 
while that of the acquired resistance rate is lower. (Scenario 8) 
Table 6-1. 
Simulation Treatment Intrinsic Reinfection Incidence rate Prevalence of resistance 
parameters parameters (Cases per 100,000) (% of cases resistant) 
Average Min Max Average Min Max 
1 None Varied None 81 0.7 149 
2 None Varied Varied 1140 0.1 4 4 0 3 
3 None Varied Constant 1540 0.8 3217 
4 Control Varied Varied 
parameters 
varied 355 31 2899 17% 0% 96% 
5 Control Varied Constant 
parameters 
varied 364 63 1582 18% 0% 89% 
6 Notification 
rate varied 
over wide 
Varied Constant 
range 320 23 1601 8% 0% 22% 
7 Good control Varied Constant 157 12 299 3% 1% 5% 
8 Poor control Varied Constant 379 44 791 37% 9% 67% 
Table 6-1. Comparison of Monte Carlo simulations. Each simulation consists of 1000 Monte Carlo runs of the model, with 
the intrinsic and control parameters varied between runs as given. The results of these simulations are shown as the fmal incidence of 
disease and prevalence of resistance. 
195 
VII. Summary of findings 
VII. A. Basic model dynamics 
The model predicts a course of a typical epidemic to occur on a timescale of 
]00 years. Early in the epidemic most cases are due to primary disease, while later in 
the epidemic there is an increase in endogenous reactivation disease. Increasing the 
reinfection parameter significantly increases disease levels. 
VII. B. Conditions for emergence and spread of resistance 
Introducing treatment reduces the incidence and prevalence of disease, but 
selects for resistance. The highest selection for resistance was seen under high 
notification rates combined with low cure rates. The continued spread of resistance to 
high levels depends upon the fitness of the resistance strain. Good control can limit the 
spread of resistance; increasing the treatment rates with high cure rates can reduce the 
incidence of resistance. Under poor control there is greater opportunity for the 
emergence as well as spread of resistance; increasing the treatment rates when there are 
low cure rates can exacerbate a resistance problem through increased selection as well 
as spread. 
VII. C. Summary of sensitivity analysis 
The sensitivity analysis showed that within the range of parameter uncertainty, 
the model can still make important conclusions. First, as expected, the model shows 
increasing treatment rates reduces disease and selects for resistance. Secondly, this 
depends upon the quality of treatment. Under good control, with high treatment rates 
and efficacy, there is a lower incidence of disease, as well as a limited emergence and 
spread of resistance. In comparison, under poor control there is higher incidence as 
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well as greater range in incidence, reflecting a greater opportunity for spread. Further, 
the low cure and higher acquired resistance rates under poor control result in higher 
resistance levels and greater range in resistance prevalence. Third, the greatest concern 
in terms of resistance emerging to high levels occurs in regions with poor control 
practices. The greatest potential for resistance, as well as the greatest model 
u n c e r t a i n t y in resistance prevalence, occurs under poor control. In order to address 
potentially serious emerging epidemics in such regions, the emergence of resistance 
should first be minimized through improving control practices, focusing first on 
improving quality of treatment and then expanding coverage. 
In the absence of treatment, the model predictions for incidence of disease are 
most strongly influenced by parameters for the intrinsic dynamics of the epidemic. In 
particular, the reinfection parameter, ECR, proportion progressing to primary disease, 
and endogenous reactivation rate show the strongest impact on the final disease 
incidence. (Scenarios 1 , 2 , 3 ) 
When the level of control is varied within a simulation, the control parameters 
have the greatest influence on model outcome for both disease and resistance. Under a 
widely varying level of TB control (Scenarios 5, 6), the control-specific parameters are 
most strongly correlated to model outcome. Once the control strategy has been defined 
and held constant throughout the simulation (Scenarios 7, 8), the parameters for 
intrinsic dynamics show increased influence on model outcome. When control strategy 
is fixed to high (good control. Scenario 7) or low (poor control, Scenario 8) levels, the 
prevalence of resistance is largely determined by variance in control parameters (and 
fitness cost), while disease prevalence is mostly affected by intrinsic parameters. 
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(1) Uncertainty in disease prevalence 
In the absence of treatment, the incidence of disease is most strongly influenced 
by the ECR, the proportion progressing to primary disease, and the reactivation rate. 
(Scenario 1) When the reinfection parameter is varied, this parameter uncertainty has 
the greatest influence on final incidence of disease, with higher reinfection parameters 
resulting in increased incidence. (Scenario 2) When treatment is introduced, the 
incidence of disease is most influenced by the control parameters for the notification 
rate, the cure rate for drug sensitive cases, followed by the intrinsic parameters of the 
contact rate and proportion progressing to primary disease. (Scenario 4) This remains 
the same regardless of control environment. (Scenarios 5, 6) 
VII. D. Uncertainty in resistance prevalence 
The model uncertainty in resistance prevalence is most strongly determined by 
fixing the notification rate, followed by the cure rates for sensitive and resistant cases. 
(Scenarios 5, 6) When the control program is fixed at either high (good control, 
Scenario 7) or low (poor control. Scenario 8) levels, the prevalence of resistance is 
most influenced by the control parameter for the acquired resistance rate, and the 
intrinsic parameter for the resistance strain transmission. Under poor control, there is a 
greater opportunity for the emergence of high levels of resistance. Whether a high 
prevalence of resistance will emerge depends strongly upon the values for the acquired 
resistance rate and the fitness of the resistance strain. (Scenario 8) Thus, the model 
uncertainty in predicting resistance prevalence under a specified control program is 
almost entirely due to uncertainty in estimating the acquired resistance rate and 
resistance transmission, with a greater variance under poor levels of control. 
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VII. E. Uncertainty in key parameter estimates 
(a) Resistance fitness 
There is a great deal of uncertainty as to estimates for the fitness of resistance 
strains, as detailed in chapter 4 (section on parameter estimates). The sensitivity 
analysis presented in this section reveals the impact of this uncertainty in estimating the 
resistance transmission rate on model predictions for resistance prevalence. The 
variance in the resistant transmission rate was a primary cause of model uncertainty in 
resistance prevalence, in particular under poor control. (Scenario 8) 
Under good control, the high treatment and cure rates limit the opportunity for 
the emergence of resistance. With lower emergence of resistance, there is less 
opportunity for spread to high levels, and varying the fitness of the resistant strain 
results in comparatively small fluctuations in resistance prevalence. (Scenario 7) 
This understanding of the importance of the fitness of resistant strains can be 
used to inform control programs as to additional means to reduce resistance. The 
relative resistance transmission parameter, as defined in this model, reflects both 
contact as well as transmission. While the transmission rate is strain-dependent, the 
contact rate is believed to be strain-independent. However, interventions can target 
resistant cases in order to reduce their contact rates, thus reducing the overall resistance 
fitness. Where available, resources for active case detection can be focused on 
diagnosed MDR cases, finding and treating contacts of these cases. Increased isolation 
of these MDR cases can reduce contacts and thus transmission. This effectively occurs 
by sending MDR cases for treatment as specialized regional centers of excellence. 
(Mitnick, Bayona et al. 2003) (Farmer 2001) F i n d i n g a n d testing contacts of MDR 
cases can identify new latent infections or cases of disease for rapid treatment. 
(Loddenkemper, Sagebiel et al. 2002) 
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(b)Acquired resistance rate 
As described in chapter 4 section on parameter estimates, there is significant 
uncertainty in estimating the probability of acquiring resistance during treatment. The 
sensitivity analysis of this section has shown that the model predictions for resistance 
prevalence are very sensitive to the uncertainty in the acquired resistance rate. This 
results in a wide range in resistance prevalence. Again, this is most significant under 
poor control, where there is the potential for the emergence of a high level of 
resistance. Under good control, does have significant impact on model predictions for 
resistance prevalence, but high case detection and cure limit the spread resistance to 
low levels. 
The rate of acquired resistance amongst treatment failures is considered to be 
related to quality of treatment. A lower proportion of treatment failures acquire 
resistance under fully supervised and regulated DOTS programs. (Weis, Slocum et al. 
1994) (Bastian, Rigouts et al. 2000) (Dye, Williams et al. 2002) Further, the 
probability of acquiring resistance has been correlated with errors in treatment, case 
management, and administration. (Mahmoudi and Iseman 1993) High rates of 
acquired resistance are seen in environments with poor control practices, less 
regulation, and other factors which might interfere with regular drug taking, such as 
poverty or war. (Iseman 1999) (Loddenkemper, Sagebiel et al. 2002) Improving these 
control practices can not only improve the treatment cure rates, but also reduce the 
probability of acquiring resistance. This underscores the importance, in regions with 
poor control, of first improving cure rates and reducing the probability of acquired 
resistance. Increasing treatment coverage before the quality of control is ensured can 
select for high levels of resistance. Once the probability of acquired resistance is 
reduced, there is less opportunity for the emergence of resistance, and treatment rates 
can be safely increased. 
200 
In order to restrict the model predictions for resistance prevalence, more 
information is needed regarding the quality of treatment. In localized settings, 
information regarding treatment practices can inform on the relative or probable rates 
of acquired resistance—and this can be used to narrow predictions for the emergence of 
resistance. 
(c) Reinfection 
As shown in the sensitivity analysis, varying the reinfection parameter 
significantly affects the incidence of disease in the model, both in absence (Scenario 2) 
and presence (Scenario 4) of treatment. Under treatment, the reinfection parameter also 
has a significant impact on the prevalence of resistance. Higher reinfection parameters 
allow the opportunity for emergence of greater levels of resistance. (Scenario 4) The 
reinfection parameter has the most influence on model outcomes in areas with high 
incidence and poor control. 
VIII. Conclusions 
1. The model predicts realistic epidemic dynamics. 
2. Resistance emerges under treatment, and the strength of 
selection for resistance is greatest under high notification 
combined with low cure rates, while continued spread of 
resistance depends heavily on the relative fitness of the resistant 
strain. 
3. Sensitivity analyses showed that within range parameter 
uncertainty, the model continues to make useful predictions, and 
highlighted key parameters in representative scenarios. 
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I. Goals 
I. A. To develop a model for control of TB epidemics that 
includes 1 * and 2"^  line treatment regimens. 
I. B. To incorporate into this model realistic progression 
through the course of treatment, with case detection rate, time to 
detection and duration of treatment. 
I. C. To include varying treatment efficacy by resistance status, 
and acquired resistance emerging during the course of 
treatment, depending on regimen and strain. 
II. Abstract 
In this chapter, the model presented for the emergence and transmission of 
resistance is expanded. The components of the model related to treatment are further 
developed, while the rest of the model remains the same as that outlined in chapter 4. 
Several implications of the formulation and parameterization of this model are 
explored. A sensitivity analysis of model results regarding the impact of control 
strategies, presented in the subsequent two chapters, is described. The duration of 
infectiousness (DOl) is defined by strain and treatment regimen. These definitions are 
used to examine the impact of treatment, at different rates and efficacy, on case DOl. 
In addition, the importance of treatment times is examined. Treatment waiting 
times for detection and treatment are included. Each treatment course is divided into 
separate phases during which there are characteristic levels of case infectiousness, 
intensity of treatment, and probability of acquiring resistance. 
III.Methods 
III. A. Simulations 
A compartmental deterministic model was developed, defined by the set of 
ordinary differential equations shown in Appendix 2. These set of equations were 
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solved in Berkeley Madonna using Runge Kutta 4 method with a timestep of 0.01 
m o n t h . The model parameters are defined in Table 7-1 and Appendix 2. 
III. B. Formulating the model 
Individuals are bom into the population susceptible (X). Susceptible 
individuals are infected at a rate equal to the force of infection (X,) and either progress 
directly to infectious disease (sensitive, Is, resistant, IR^  or MDR, IM.) or enter a latent 
state (Ls, LR or LM) from which there is a slow rate of reactivation. The force of 
infection is defined as the effective contact rate multiplied by the proportion of 
infectious individuals in the population. The effective contact rate (cg , CR, CM) is 
defined here as the probability of contact and transmission of infection between an 
infectious and a susceptible individual. The force of infection is defined separately for 
sensitive (Xg) and resistant (A,R or A,M) strains, and is given by: 
9 _ (4 + + 4 ) A. - r _ (Av + Til + Pm) 
' ~ ' N ' " ~ " N ' " ~ N 
A proportion of new infectious cases, equal to the case detection rate (CDR), 
are detected. The CDR is deceptively referred to as a rate (and not a proportion) in 
adapting the terminology of national surveillance definitions. After a time to case 
detection (tco) a proportion (CDR) of new infectious cases are detected and begin a 
course of treatment. The remaining (1-CDR) of new infectious cases are considered 
undetected (Us, UR or DM) and receive no treatment. 
Cases receiving treatment (Ts, TR or TM) are further subdivided according to 
treatment phase and regimen, as well as whether they are infectious. During the initial 
stages of treatment, effective treatment will rapidly reduce the patient's mycobacterial 
load, and will leave the patient non-infectious. Infectious patients (Ty, Th ) can 
transmit infection, while those rendered non-infectious during a course of treatment 
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T™, 7%') continue the course of treatment and may retain symptoms (including 
an increased mortality rate) but cannot transmit disease. After a course of treatment, 
patients who have become non-infectious are cured of disease (Cg, CR or CM), while 
those remaining chronically infectious move into a class for previously treated patients 
(Ps, PR or P M ) . 
IV. Course of treatment 
IV. A. Mycobacterial numbers over course of treatment 
(theory): 
The course of treatment is modeled here as the progression through distinct 
phases of a treatment regimen. The treatment course consists of an initial two week 
phase, followed by phases two and three, each lasting three months and together 
representing the main part of short course chemotherapy (SCC). The fourth phase of 
treatment also lasts three months and represents an extension phase. 
A theoretical representation of the changes in within-host mycobacterial 
numbers over the course of treatment, according to the timing of treatment phases 
defined in the model, is presented in the figure below. Two scenarios are portrayed; 
one in which the patient remains chronically infectious and treatment fails (chronic), 
and one in which the bacterial infection is cleared and the patient is cured (cured). 
(Figure 7-1) 
When the patient is cured by effective treatment, there is a rapid decline in 
mycobacterial load in phase 1. During this initial phase of treatment, effective therapy 
is thought to rapidly decrease the patient's mycobacterial load, corresponding to a 
reduction in symptoms and possibly a shift to be non-infectious, as the patient emits 
fewer viable mycobacteria in sputum. This is depicted in figure 6.1 as a rapid reduction 
in bacterial load below a threshold where the patient is no longer infectious. Treatment 
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is c o n t i n u e d after this initial phase, even if symptoms have abated, to target the 
r e m a i n i n g mycobacterial population. In phases 2 through 4, treatment continues to 
clear the remaining bacteria in the patient. The decline in the bacterial load is modeled 
with two exponentials: a fast exponential decline in the first phase, followed by a 
slower exponential decline in the remaining phases of treatment. (Figure 7-1) 
As direct evidence for typical mycobacterial numbers in human patients, or the 
change in these numbers over the course of treatment, are not available, these estimates 
reflect current qualitative understanding of these processes. The rapid reduction in 
symptoms and conversion of sputum test in the first month of treatment is thought to 
correlate with a clearance of a large proportion of the host's bacterial population. It is 
suggested that only a small bacterial population remains after this initial phase, and that 
possibly these bacteria are more difficult to clear either because of location, or some 
phenotypic resistance to drug action such as a slowed growth rate or dormancy. The 
treatment course must be extended past the initial phase in order to remove these 
remaining bacteria. (Dickinson and Mitchison 1976; Allen B.W 1992; Bloom 1994; 
Gangardharam and Jenkins 1997; Mitchison 2000) 
"Infectious'-
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Figure 7-1. Mycobacterial load versus treatment time. 
Representation of the speculated changes in mycobacterial numbers within a 
patient over the course of treatment. The relative mycobacterial numbers is followed 
from the start of treatment through phases 1 to 4 (Ph 1 - Ph4) of a treatment course. A 
patient failing treatment remains chronically infectious and maintains a high 
mycobacterial load (—). A patient effectively cured by treatment ( — ) is thought to 
experience a rapid decline in mycobacterial numbers in phase 1. followed by a more 
gradual decline in phases 2 - 4 . Theoretical thresholds for the mycobacterial load 
required for case infectiousness and disease clearance are shown. 
IV. B.Treatment patterns 
Three treatment regimens are included in the model: a first line (regimen A) 
effective for drug sensitive (DS) cases, a second line (regimen B) for singly drug 
resistant (DR) cases, and a second line (regimen C) for multiple drug resistant (MDR) 
cases. First-line treatment reflects the typical SCC regimen of four drugs given for six 
months, followed by an extension phase of two drugs taken for three months. Second-
line treatment reflects a specialized regimen given to a patient found to have drug 
resistance, and lasts longer. In the model, both DR and MDR cases receive an extended 
final phase of treatment. 
207 
Possible treatment scenarios include the treatment of a drug sensitive case with 
regimen A and the treatment of a drug resistant case with regimen A, B or C. The cure 
rates are highest for treatment of sensitive cases with regimen A, followed by singly 
resistant cases with regimen B, and MDR cases with regimen C. The treatment of a 
singly resistant case with regimen A is considered to have low effectiveness, as is the 
treatment of a MDR case with either regimen A or B. 
IV. C. Model treatment course 
A proportion of treated cases, equal to the cure rate (O), are effectively cured 
during a course of treatment. These cases become non-infectious after the first phase of 
treatment (T"'). The remaining cases, (1 -O), continue through the course of treatment 
remaining infectious (T') and then move into a class for previously treated (infectious) 
individuals (P). 
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Figure 7-2. The model for treatment of DS cases. 
New incident cases (1) are either detected (1^ "^ ) and begin a course of treatment 
(T) or remain undetected (U). Cases may be cured (C) through self-cure or treatment, 
or may fail a course of treatment and remain infectious (P). Darkened boxes represent 
infectious classes, while clear boxes represent non-infectious classes. The treated 
classes (T) are subdivided according to both treatment time (phases 1-4 shown in 
subscript) and infectious status (infectious (i) or non-infectious (ni) shown in 
superscript). A proportion of treated cases are cured and rendered non-infectious after 
the first phase of treatment: after completing the treatment regimen most of these cases 
(in T"') are transferred to the cured class (C), while a small proportion will relapse to 
disease (and enter P). 
IV. D. Model for acquired resistance 
Acquired resistance is modeled by allowing a proportion of treated DS cases 
which fail treatment to become resistant cases. A proportion (o) of DS cases not cured 
by treatment in phase 1 gain resistance during phase 2, completing the remainder of the 
(first line) treatment course as an infectious case with single drug resistance. This 
represents cases in which treatment has failed to reduce bacterial load and has allowed 
for the selection of resistant bacteria to dominate the infection. In addition, a small 
proportion (r?) of DS cases which become non-infectious after the first phase of 
treatment acquire drug resistance in the second phase. This represents treatment that 
has cleared most of the bacterial population in the first phase, reducing both symptoms 
and infectiousness, but has left a pool of resistant organisms. These resistant bacteria, 
now given a selective growth advantage under drug treatment which has cleared 
competing organisms and freed resources, may now proliferate. 
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Figure 7-3. The model for acquired resistance in the treatment of DS cases. 
A proportion of DS cases failing treatment on regimen A acquire resistance. 
Treated drug sensitive cases (Tg) may be cured, fail treatment and remain drug 
sensitive, or fail treatment and gain resistance becoming a treated resistant case (TR). A 
proportion (r,) of treated drug sensitive cases which remain infectious in phase 2 of 
treatment ( T ' s 2 a ) acquire resistance. A smaller proportion (r?) of treated drug sensitive 
cases which are initially cured and become non-infectious in phase 2 of treatment 
(T"'s2a) also acquire resistance. 
The first character in the subscript denotes strain type, either S or R. Darkened 
boxes represent infectious classes, while clear boxes represent non-infectious classes. 
The treated classes (T) are subdivided according to both treatment time (phases 1 -4 
shown in subscript), infectious status (infectious (I) or non-infectious (Nl) shown in 
superscript), and strain type (sensitive (S) or singly resistant (R) shown in subscript). 
The final character in the subscript denotes the treatment regimen used: either first (a) 
or second line (b) treatment. 
IV. E.Resistance treatment 
Cases with single drug resistance undergo a similar treatment pattern. All cases 
are initially given first line treatment (regimen A), which is effective for drug sensitive 
disease. A proportion of all new incident cases, equal to pDST, receive drug testing. 
These test results are returned after a time (ti^sr), and drug resistant cases are then 
switched to more effective treatment (regimen B for single drug resistance, regimen C 
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for MDR). Previously-diagnosed DR cases which have failed treatment on regimen B 
will, when retreated, all receive drug testing and immediately start a new course of 
regimen B. The repeated drug testing of these cases provides a check of the resistance 
profile and allows for appropriate treatment adjustments where needed. 
The acquisition of multiple drug resistance (MDR) is modeled by allowing for a 
proportion of treated DR cases to move into a treated MDR class. The mistreatment of 
singly drug resistant cases with first line (regimen A) is thought to place a high 
selective pressure for the acquisition of higher levels of resistance. The model also 
provides for an increased probability of acquired MDR with time spent mistreating a 
DR case. This selective pressure results in a high proportion of DR cases treated with a 
first-line regimen developing MDR. 
Cases which are initially resistant to either isoniazid or rifampicin (and are in 
the DR class) may develop resistance to the other drug and become an MDR case. 
Similarly, an initially drug sensitive case may first develop single resistance, and then 
MDR, passing through treated DS, DR, and MDR classes during a single course of 
treatment. 
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Figure 7-4. The model for acquired resistance in the treatment of DR cases. 
A proportion of DR cases failing treatment on regimen A or B acquire 
resistance. Treated singly drug resistant cases (TR) may be cured, fail treatment and 
remain singly drug resistant, or fail treatment and gain higher resistance becoming a 
treated MDR case (TM)- R cases receiving regimen A experience a time-dependent 
selection for acquiring higher levels of resistance, at a rate of ry! month treated. In 
addition, a proportion (r/) of drug resistant cases which fail treatment on regimen B 
remain infectious in phase 2 of treatment (T'R2b) acquire higher resistance. 
The first character in the subscript denotes strain type, either R or M. Darkened 
boxes represent infectious classes, while clear boxes represent non-infectious classes. 
The treated classes (T) are subdivided according to both treatment time (phases 1 -4 
shown in subscript), infectious status (infectious (I) or non-infectious (Nl) shown in 
superscript), and strain type (singly resistant (R) or MDR (M), shown in subscript). 
The final character in the subscript denotes the treatment regimen used: either regimen 
B for single resistance or C for MDR. 
V. Model for acquired resistance during treatment 
regimens 
In this section, the properties and implications of this model for the acquisition 
of resistance during treatment are illustrated. The rates of acquired resistance depend 
upon the treatment regimen, strain, and infectious status. A set proportion of cases 
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failing an appropriate treatment regimen (first-line for DS or second-line for DR cases) 
acquire resistance. However, mistreated cases (first-line for DR cases) are considered 
to be under continuous selective pressure for resistance, such that the proportion 
developing resistance is positively correlated to the duration of incorrect treatment. 
The simulations in this section follow one course of treatment for new cases of 
active disease. Each simulation is begun (at time 0) with 100 new infectious cases of 
the same strain type, either drug sensitive (DS, in simulation 1) or singly drug resistant 
(DR, in simulation 2). These cases are then detected, after an average time to case 
detection, and begin a course of treatment that lasts for 9 Vi months (for DS or DR on 
first-line regimen) or 12 months (for DR on second-line regimen). Assuming an 
average time to case detection of 6 months (and a constant rate of transfer) the 100 
initial cases in this simulation are all detected and have begun treatment by 20 months. 
(Figure 7-5A) These 100 initial cases of active disease are considered in isolation with 
no ongoing transmission, and are removed only through cure or death. The progressive 
detection and treatment of these cases (as well as self-cure and death) reduces disease 
until no cases remain. 
Simulation 1 is begun with 100 drug sensitive cases, which progress through a 
single course of treatment. A proportion of these cases fail treatment, and a proportion 
of treatment failures acquire resistance and transfer to become singly drug resistant 
(DR) cases. As there is no ongoing transmission, any resistant cases present reflect 
acquired resistance. There is a gradual decline in prevalence of disease as DS cases are 
detected and receive treatment. (Figure 7-5B) Simultaneously, there is an increase in 
the number of DR cases, reflecting the acquisition of resistance among treated DS 
cases. By the end of simulation 1, 1.4% of all initial DS cases have acquired DR. 
(Figure 7-5C) 
Simulation 1 
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Figure 7-5. The emergence of acquired resistance in the treatment of drug 
sensitive cases. The simulation is begun with 100 infectious drug sensitive cases, 
which are cleared through treatment, self-cure, or death. (A) The detection and 
treatment of cases reduces the prevalence of drug sensitive cases, but allows for the 
emergence of resistant cases. (B) The number of resistant cases increases over the 
course of the simulation with the treatment of the drug sensitive cases. By the end of 
the simulation, 1.4% of the initial drug sensitive cases have acquired resistance. (C) 
The case detection rate is set at 80% and the treatment cure rate at 90%. 
The same scenario is shown applied to the emergence of MDR from the 
treatment of DR cases in Figure 7-6. Note the more rapid increase in acquired MDR 
(than for acquired DR), reflecting the greater selective pressure assumed to exist for the 
mistreatment of DR cases. 14% of the initial DR cases acquire MDR during the course 
of treatment in simulation 2. (Figure 7-6B) 
Simulation 2 
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Figure 7-6. The emergence of acquired MDR resistance in the treatment of 
singly drug resistant (R) cases. The simulation is begun with 100 infectious singly 
drug resistant (R) cases, which are cleared through treatment, self-cure, or death. The 
detection and treatment of cases reduces the prevalence of DR cases, but allows for the 
emergence of MDR cases. (A) The number of MDR cases increases over the course of 
the simulation with the treatment of the DR cases. By the end of the simulation, 1.4% 
of the initial DR cases have acquired MDR. (B) As in the previous simulation, the 
case detection rate is set to 80% and the treatment cure rate is 90%. In addition, 80% of 
incident cases receive drug testing and switch to a second-line regimen (with cure rate 
of 70%) after one month. 
V. A. The emergence of acquired DR during the treatment of 
DS cases. 
The proportion of DS cases entering treatment which acquire resistance depends 
upon the cure and resistance rates. During the treatment of DS cases, a set proportion 
of cases failing treatment will acquire DR, which includes a proportion /-/ of patients 
who remain infectious and r? of patients who become non-infectious in phase two of 
treatment. As either resistance rate (r/ or r?) is increased, so is the resulting proportion 
of treated DS cases which convert to DR cases. Similarly, as the cure rate for DS cases 
is increased, fewer cases fail treatment and fewer treated cases gain resistance. Thus, 
the proportion of treated DS cases which acquire DR is positively correlated to the 
resistance rate, and negatively correlated to the cure rate. (Figure 7-7) 
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Figure 7-7. The rale of acquired resistance depends upon the model 
parameters for treatment and cure rates. The proportion of treated drug sensitive 
cases which acquire resistance is increased proportional to the probability of acquiring 
resistance given treatment failure (/-/ and 7-?), and inversely proportional to the cure rate. 
In these simulations, unless otherwise indicated, control parameters are set at: Osa = 
90%, rj = 10% and n = 1 % . 
V. B. The emergence of acquired MDR from the treatment of 
DR cases 
The proportion of all treated DR cases that acquire MDR is related to the cure 
rate of second-line treatment, the duration of treatment, the proportion receiving drug 
testing, and the time taken to return these tests. The emergence of higher levels of 
resistance (represented by MDR) during the treatment of DR cases is modeled at two 
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levels. First, DR cases mistreated with first-line regimens are assumed to experience a 
c o n s t a n t selective pressure for acquiring resistance, proportional to the treatment time. 
Second, a set proportion of DR cases which receive an appropriate second-line 
regimen, fail this treatment and develop MDR. 
Drug susceptibility testing of a proportion of treated DR cases allows a switch 
to regimen B (with higher cure rates). Drug testing decreases the proportion of cases 
failing treatment, resuhing in fewer cases transferring to MDR. (Figure 7-8A) The 
longer taken to return results of DST, the more time these cases spend mistreated with 
regimen A, during which there is time-dependent selective pressure to gain resistance. 
Thus, increasing tosr results in greater numbers of acquired MDR cases. (Figure 7-8B) 
The rates for acquired MDR also depend upon the cure rates for DR cases, once 
switched to regimen B. As the DR cure rate is improved, the proportion of treated 
cases acquiring MDR is reduced (Figure 7-8C). At lower cure rates, more treated cases 
remain chronically infectious, and have a higher probability of acquiring MDR. 
The proportion of treated DR cases developing MDR also depends upon the 
resistance rates, as defined in the model for DR cases on either regimen A or B. For 
DR cases on regimen A, there is a time-dependent selective pressure, i'mdr, defined as 
the proportion of cases developing MDR per month of treatment. Increasing i'mdr 
results in higher levels of acquired MDR (Figure 7-8D). For DR cases on regimen B, a 
set proportion of treatment failures (r/) convert to MDR cases. As r/ is increased, so is 
the level of acquired MDR (Figure 7-8E). The proportion of treated DR cases which 
acquire MDR depends on the duration of treatment. In particular, the longer DR cases 
are mistreated with a first^line regimen, the greater the likelihood of developing higher 
levels of resistance. (Figure 7-8F) 
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Figure 7-8. The rate of acquired resistance depends upon the model 
parameters for treatment and cure rates. The proportion of treated singly drug 
resistant (R) cases which acquire higher levels of resistance is increased proportional 
the probability of effective cure. Higher rates of drug susceptibility testing reduce rates 
of acquired MDR (A), while waiting longer for return of these drug tests allows for 
higher rates of acquired MDR (B). Increasing the cure rate for DR cases reduces 
acquired MDR (C), while increasing the probability of acquiring resistance given 
treatment failure {ry and r/) increases acquired MDR (D, E). Increasing the duration 
of treatment also increases acquired MDR. (F) In these simulations, unless otherwise 
indicated, control parameters are set at: pDST = 80%, = 70%, tosi = 1 month, vmor 
= 5%/month (represents the constant selective pressure during treatment of DR with 
regimen A), and /'/ = 10% (represents proportion of treatment failures for DR on 
regimen B acquiring MDR). 
VI. Model for control measures 
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VI. A. Case detection 
Surveillance programs distinguish between active and passive case detection of 
TB disease, with most relying on passive detection. Passive case detection refers to 
patients who report to health authorities with symptoms. Active case detection refers to 
cases found by large scale screening, which may also turn up cases without symptoms. 
Passive case detection is incorporated into the model. The case detection rate is 
defined here as the proportion of new incident cases which are detected, diagnosed, and 
begin TB treatment. A proportion of new incident cases remain untreated, and this may 
occur for several different reasons. First, a proportion of incident infectious cases may 
have fewer symptoms and may therefore be less likely to seek medical attention or be 
tested for TB. Second, a proportion may have less access to medical services. Third, a 
proportion of cases may not be given appropriate and accurate diagnosis. For either of 
the first two possibilities, increasing the population-wide routine access to medical 
services should improve passive case detection, while the latter explanation would 
require improved proficiency in diagnosis. 
VI. B. Re-treatment 
The case detection rate, as defined here, does not include the (re-)detection of 
chronic or relapsed cases. Chronic and relapse cases are assumed to be automatically 
detected for re-treatment, and begin a new course of treatment after being held in a non-
treated class for some time. Patients may also initially become non-infectious during 
the course of treatment, but later relapse to disease. Relapse is incorporated into the 
model by permitting a proportion of cases cured to relapse to active disease after the 
end of treatment. 
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VI. C. Case Detection and DOI 
The duration of infectiousness is defined here as the time a case spends in the 
infectious state. The average case duration of infectiousness accounts both for those 
cases which are detected and receive treatment, and those which remain undetected. 
Chemotherapy reduces the infectious period of TB cases, by providing for more rapid 
cure. 
Untreated cases remain infectious until they either self-cure or die. The average 
duration of infectiousness of an untreated case is inversely proportional to the sum of 
the self-cure and mortality rates (a = |LI + )IIT + K). In this model, the average duration 
of infectiousness for untreated cases is approximately two years, similar to estimates in 
the literature. 
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Figure 7-9. Timescale for removal of untreated cases. Untreated cases remain 
infectious until they either self-cure, or die from natural or TB-associated causes. 50% 
of cases are removed within one year, and 95% within five years. The average duration 
of infectiousness for these untreated cases is two years. 
The duration of infectiousness of a treated case is equal to the time from case 
onset to the initiation of treatment (time to case detection, tco) plus the time from the 
start of treatment to loss of infectiousness (time spent in phase 1, tphi). The average 
duration of infectiousness of an effectively treated case is given in the model as; 
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A proportion of treated cases fail treatment and remain infectious. The average 
duration of treatment for these patients is given as: 
1 , 1 . 1 , 1 1 1 1 
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However, as these cases remain infectious during and after the course of 
treatment, their average DOI is the same as that for untreated cases: 
'^lreol+fail 
a 
VII. Defining duration of infectiousness by strain type 
The case duration of infectiousness is derived here by strain type, assuming an 
epidemic of only one strain. The average duration of infectiousness for patients with 
either sensitive (DOLG) or resistant (DOIR or DOIM) cases is given in the model by 
summing over the time spent in the infectious state. This is calculated as the sum of the 
DOI for undetected, treated and cured, and treated and not cured, and relapse cases. 
Each is weighted by the relative proportion of cases which follow that pathway. 
VII. A. Defining the DOI for drug sensitive (DS) cases 
The average duration of infectiousness for sensitive cases, as defined in the 
model, is equal to the sum of the following components. 
Undetected 
(l-CD/f) ( - ) 
a 
Treated, failures 
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Note: This does not include re-treatment of cases failing a treatment course. Including re-treatment 
would slightly reduce this average DOl, if patients started a new course in less than two years 
(average DOIfor untreated) after infection. As the treatment course itself takes about 10 months, in 
addition to the time to retreatment (an average of one year), this seems a close approximation. 
Treated, cured 
a + - L a + ~ « 
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Note: This is the only component of the overall DOI that is reduced by treatment. 
Treated, cured, relapse 
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VII. B. Defining the DOI for singly drug resistant (DR) 
cases 
Similarly, the average DOI for cases with single drug resistance (DR) includes the 
following components. 
Untreated 
{\-CDR) ( - ) 
a 
Treated, no drug testing (regimen A) 
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VII. C. Defining the DOI for MDR cases 
Untreated 
(] -(ZZIR!) (^-) 
a 
Treated, no drug testing (regimen A or B) 
CDR {\-pDST) { - ) 
a 
Treated, drug testing, regimen C, fail 
COR 
a 
Treated, drug testing, regimen C, cured 
CDR <!>,, pDST (1-w^J (— 
a-\ a-\ orH 
h'D ^Dsr ^pM 
Treated, drug testing, regimen B, cured and relapse 
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VII. D. Higher cure rates reduce infectious period: Cure of 
drug sensitive cases 
The duration of infectiousness is reduced by effective treatment. As more cases 
are detected and given treatment, the average infectious period is shortened. This 
depends on the effectiveness of treatment, represented in the model by the cure rate (9). 
Thus, the average DOI for a DS case depends both on the proportion of cases receiving 
treatment (CDR) and on the cure rate for drug sensitive cases (with regimen 'A', 6sa). 
When the DS cure rate Gsa is set to 0%, treatment does not lead to faster cure, and the 
average DOI for DS cases remains the same as for untreated cases. As the cure rate 9sa 
is increased (shown ranging from 20-100%), more cases are cured at a faster rate, and 
the DOI-DS is reduced in proportion to the level of case detection. (Figure 7-10) 
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Figure 7-10. Effective treatment reduces the duration of infectiousness of 
drug sensitive cases. The DOI of DS cases is reduced by higher levels of case 
detection and treatment (CDR). The cure rate for DS cases on regimen A (Osa) is varied 
from 0% to 100%. When the cure rate is set to 0%, there is no effective cure, and the 
regardless of treatment rate, the DOI remains the same as for untreated cases. Higher 
224 
cure rates allow for effective cure and reduce the DOI of DS cases in proportion to the 
CDR. The average case duration of infectiousness (DOI) for drug sensitive cases is 
shown in months. 
VII. E. Cure of drug resistant cases 
The DOI for resistant cases is similarly reduced by increasing levels of case 
detection and treatment efficacy. Shown below is the average duration of 
infectiousness for MDR cases, over a range of case detection (CDR) and treatment cure 
(treatment of MDR cases on regimen ' C , 9MC) rates. When treatment with regimen ' C 
is completely ineffective at curing MDR cases (9mc= 0%), then the DOI-MDR is the 
same as for untreated cases. As the 6MC cure rate is increased, case detection and 
treatment reduces the DOI of MDR cases. (Figure 7-11) 
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Figure 7-11. Effective treatment reduces the duration of infectiousness of 
MDR cases. The DOI of MDR cases is reduced by higher levels of case detection and 
treatment (CDR). The cure rate for MDR cases on regimen C (6MC) is varied from 0% 
to 60%. Higher rates of treatment and cure reduce MDR case DOI. The proportion of 
incident cases receiving drug susceptibility testing (pDST) is set to 90%. The average 
case duration of infectiousness (DOI) for MDR cases is shown in months. 
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VII. F. Higher levels of drug testing increase effective 
treatment, reduce infectious period 
The average case DOI for resistant cases (DR or MDR) are also reduced by 
increasing levels of drug susceptibility testing. As a higher proportion of incident cases 
are given drug testing and shifted to regimens with higher treatment efficacy, more 
resistant cases are cured, and the DOI is shortened. Shown below is the DOI for MDR 
cases, under varying levels of treatment (CDR, 0% - 100%) as well as proportion of 
treated cases receiving drug testing (DST, 0%, 30%, 60%, 90%). For a given treatment 
rate increasing the DST rate results in further decreases the DOI, as cases are given 
effective regimens that allow for faster cure. (Figure 7-12) 
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Figure 7-12. Drug susceptibility testing (DST) reduces the duration of 
infectiousness of MDR cases. When there is no drug testing (pDST = 0%), the MDR 
case DOI is equal to that of untreated cases, as all incident MDR cases are given first 
line treatment (regimen 'A' for drug sensitive disease). As a higher proportion of 
newly detected cases are given drug testing (range 30-90% shown), the MDR-DOI is 
reduced. With higher levels of case detection and higher levels of drug testing, the 
average MDR-DOI is reduced. An MDR cure rate on regimen ' C (9MC) is set to 50%. 
The average case duration of infectiousness (DOI) for MDR cases is shown in months. 
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VII. G. Comparing strain-specific case DOIs 
The case duration of infectiousness is reduced in proportion to the extent of 
effective treatment. For drug sensitive cases this is a function of case detection and 
cure rates, while for resistant cases, the proportion receiving drug testing must also be 
included. Treatment reduces the case DO! according to the proportion effectively 
cured—highest here for DS cases, followed by DR and then MDR cases. (Figure 7-13) 
MDR 
100% 
Figure 7-13. The average DOI for DS, DR and MDR cases. The detection 
and treatment of cases reduces the average duration of infectiousness. For a given 
treatment rate (CDR), the DOI of sensitive cases are reduced to a greater extent than 
that for either DR or MDR cases. The proportion of new incident cases given drug 
susceptibility testing (pDST) is set to 90%. The cure rates for DR on regimen B (9Rb) = 
70%, and for MDR on regimen B (9MC) = 30%. For DS cases, the reduction in DOI by 
level of treatment depends on 9s. For resistant cases, the reduction in DOI with case 
detection depends on the proportion receiving DST, allowing for switch to a second 
line regimen, as well as the cure rates (9Rb for DR and 9mc for MDR). The average case 
duration of infectiousness (DOI) for sensitive (DS), singly resistant (DR), and MDR 
(MDR) cases is shown in months. 
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VIII. Parameter Table 
Table 7-1. Parameter Table. 
CONTROL PARAMETERS 
Symbol Name Explanation 
CDR Case detection 
rate 
Proportion of incident cases receiving 
treatment 
tCD Time to case detection and 
treatment 
Time from case onset to detection for 
treatment 
OSa TcSa Treatment cure rate for DS cases on 
regimen A 
ORa TcRa Treatment cure rate for DR cases on 
regimen A 
ORb TcRb Treatment cure rate for DR cases on 
regimen B 
OMa TclVia Treatment cure rate for MDR cases on 
regimen A 
OMc TciVIc Treatment cure rate for MDR cases on 
regimen C 
w1 Relsa Relapse rate for DS cases on regimen A 
r1 Acquired 
resistance rate 
Acquired resistance rate for infectious DS 
case under regimen A- or infectious DR 
case under regimen B 
r2 Acquired 
resistance rate 
Acquired resistance rate for non-
infectious DS case under regimen A 
rMDR Acquired 
resistance rate 
Acquired resistance rate for infectious DR 
case under regimen A 
w2 Relrb Relapse rate for DR cases on regimen B 
pDST DST rate Proportion of treated cases receiving drug 
susceptibility testing 
tDST Time to DST Time taken from start of treatment to 
return drug susceptibility tests and start 
second line treatment 
tph1..4 Time each treatment phase 
Phase 1: 2 weeks 
Phase 2: 3 months 
Phase 3: 3 months 
Phase 4: 3 months 
tph5 Time to re-treatment 1 year 
STATE VARIABLES 
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Symbol Explanation Strain type Infectious? 
X Susceptible -
L Latent LS -LR-LM -
Nl Non-infectious disease -
1 New infectious cases IS-IR-IM + 
U Untreated infectious cases US -UR-UM + 
T Treated cases TS -TR-TM + / -
P Previously failed treatment PS - PR- PM + 
C Cured CS-CR-CM -
TREATMENT STATE VARIABLES 
Symbol Description Strain 
type 
Infect-
ious 
Treatment 
regimen 
Tsia Sensitive infectious cases 
receiving treatment a 
S + a 
Tsa Sensitive non-infectious 
cases receiving treatment a 
S - a 
TRIB 
Resistant infectious cases 
receiving treatment a 
R + a 
Tpib Resistant infectious cases 
receiving treatment b 
R + b 
Tpb Resistant non-infectious 
cases receiving treatment b 
R - b 
Tivila MDR infectious cases 
receiving treatment a (or b) 
M + a or b 
T M I C 
MDR infectious cases 
receiving treatment c 
M + 0 
T M I C 
MDR non-infectious cases 
receiving treatment c 
M - c 
IX. Discussion 
IX. A. The costs of poor treatment 
The benefit of treatment, in this model, comes from the reduction in case 
duration of infectiousness. This in turn reduces ongoing transmission and disease 
levels. If the sole effect of treatment is to decrease case DOI, then higher treatment 
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rates would always lead to reductions in disease, as shown in the simulations above. 
While this may generally be true, several possible exceptions are considered below. 
i. Poor treatment and selection for resistance 
First, treatment selects for drug resistance. As more cases receive treatment, the 
rates of drug resistance often increase. A number of studies have suggested 
correlations between poor treatment and acquired resistance. This includes errors in 
patient treatment including delayed diagnosis, use of an inappropriate regimen such as 
adding one new drug to a failing regimen (effective monotherapy), and irregular dosing 
due to limited drug supply. In addition, patient factors including treatment default and 
poor adherence increase rates of resistance. These factors each reduce the overall 
treatment cure rates and may increase the risk of developing resistance. (Iseman I999)( 
Mahmoudi, Jama, 93)(Chaulet and Zidouni 1998) 
In the model developed here, this relationship is modeled by allowing a 
proportion of treatment failures to acquire drug resistance. Thus, increasing the 
treatment cure rates reduces acquired resistance. Because of this assumed association 
between treatment failure and acquired resistance, maintaining low cure rates in a 
population will select for resistance. Further, maintaining these low cure rates while 
expanding treatment coverage may increase the level of acquired resistance. 
ii. The effect of case detection on average case duration of 
infectiousness 
In the absence of second line treatment, drug resistant cases experience the 
same average duration of infectiousness as untreated cases. Accordingly, as the 
resistance prevalence grows within a population under a first line control program, the 
average case DOI will approach that of untreated cases. Consequently, under some 
circumstances adding higher levels of treatment may lead to increases in the average 
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case DOl. This occurs in our model when there is no available second line treatment 
for resistant cases, high case detection, low first line cure rates, and a high probability 
of acquiring resistance. When there is high resistance prevalence, increasing detection 
rates when only first line treatment is available may increase the average case DOI. 
This would increase transmission and exacerbate the resistance problem. 
iii. Poor treatment may increase patient's duration of 
infectiousness? 
Finally, it is may be possible that poor treatment can increase an individual 
patient's duration of infectiousness. Early studies noticed that shortly after introducing 
treatment into a population, case numbers increased. Many of these cases were 
chronically infectious and non-responsive to treatment, but not all appeared to have 
resistance. sSome researchers have suggested that, independent of resistance status, 
poor treatment may increase a patient's duration of infectiousness beyond that of 
untreated cases. The first noticeable impact of treatment is reduction in mortality, 
allowing infectious cases to live longer. It is more difficult to achieve successful cure, 
so under suboptimal treatment regimens, mortality may be reduced with out much 
increase in cure rates. This could result in selection for chronic infectious cases, whose 
lives are prolonged under this suboptimal treatment that does not fully cure cases. 
(Johnston R.F. 1974; Gangardharam and Jenkins 1997; Mitchison 1997) 
Possible explanations for prolonged duration of infectiousness can be found at a 
mycobacterial level, and include selection for persistent mycobacteria. Suboptimal 
treatment regimens may select for semi-dormant bacteria, which would be cleared by 
stronger treatment, but under weak selection are able to survive and replicate at a slow 
rate. This would leave the host still symptomatic, but perhaps with lower 
infectiousness, bacterial load and mortality rates. This explanation is consistent with 
studies that have demonstrated lower rates of transmission from chronically infectious 
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cases after failing multiple courses of treatment. (Lutwick 1995; Davies 1998; Iseman 
2000) 
If the above phenomenon does occur, then treatment with low cure rates would 
incur an additional cost of increasing case duration of infectiousness. The implications 
of this are serious in planning control of epidemics. If the cost of poor treatment is 
significant enough, it is possible that there would be circumstances in which it would 
be better to work on improving the implementation of the program, including 
improvements to treatment completion and reducing relapse rates, before considering 
expansion of coverage to untreated patients. This would also be a reason to favour 
implementation of DOTS programs, which work to ensure standardized regimens and 
high rates of treatment completion. Further experimentation is necessary to explore the 
relationship between the range of possible aspects contributing to poor treatment, and 
the outcome in terms of duration of infectiousness, mortality and cure rates, and 
resistance. 
X. Summary of Findings 
In this chapter, the model for the emergence and transmission of TB was 
expanded to include additional aspects of control and treatment, including case 
detection, treatment times, multiple regimens, and drug susceptibility testing. The 
impact of treatment on duration of infectiousness was examined in terms of strain type, 
treatment regimen and efficacy. Higher rates of treatment and cure were shown to 
reduce the DOl. For drug sensitive cases the case DOl was shown to be inversely 
correlated to the treatment and cure rate. For drug resistant cases, the case DOl is also 
inversely correlated to the drug susceptibility testing rate. 
The dynamics and timescale for emergence of acquired resistance during 
treatment in a population were explored within the model formulation. The proportion 
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of treated drug sensitive cases acquiring resistance is positively correlated to the 
treatment rate and the probability of acquiring resistance given treatment failure, and 
inversely correlated to the cure rate. For the acquisition of MDR during the treatment 
of DR cases, the rate is also inversely correlated to the drug testing rate, and positively 
correlated to the time taken to return drug tests and the duration of treatment. 
In the next two chapters, this model is used to consider the impact of various 
control strategies on the course of TB epidemics, and to formulate priorities for control 
in different settings. 
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VI. S U M M A R Y OF FINDINGS 
I. Goals 
I . A. To examine the impact of elements of first line TB control 
programs on the course of epidemics, including notification and 
cure rates. 
I . B. To examine the importance of treatment waiting times 
within a control program. 
I . C. To examine the impact of drug testing and second line 
resistance treatment on the course of an epidemic. 
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II. Abstract 
Control strategies for TB epidemics are explored using the mathematical models 
defined in Chapter 7. Case detection is shown to be the most important control 
measure required for reduction of disease. A strong first line control program, which 
includes high case detection and cure rates, leads to rapid reduction of disease. 
However, treatment may select for resistance, particularly if low cure rates have been 
maintained while increasing treatment coverage. In order to reduce resistance 
prevalence and prevent further resistant epidemics, a second line control program that 
includes drug susceptibility testing and specialized treatment regimens is required. 
These second line control measures rely on a strong first line program, and should be 
implemented only once a high proportion of all cases are detected and treated 
successfully. 
In previous chapters, dynamics of resistance epidemics, including the 
emergence and transmission of resistance have been explored. In Chapter 7, the model 
was expanded to include additional aspects for control and treatment. In this chapter, 
the model is used to investigate the effects of different TB control strategies. 
III. Results: Simulations for first line control programs 
III. A. Simulations for first line control programs 
In this section, simulations are presented to illustrate the impact of first line 
control measures. In each simulation, an epidemic is begun by the introduction of one 
infectious case into a susceptible population, and run until an equilibrium level of 
disease is reached. In this simulation, the epidemic was first allowed to progress for 
100 years in the absence of any treatment, allowing disease levels to reach equilibrium 
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with an incidence of 110 cases per 100,000 and prevalence of 240 cases per 100,000. 
(Figure 8-1) In the following simulations shown in Figures 8-2 though 8-5, a first line 
control program is introduced after the epidemic has reached equilibrium. These 
simulations vary both by epidemic state (disease burden) and level of control (case 
detection and treatment). 
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Figure 8-1. The impact of treatment on a young epidemic. Simulations 
were begun by introducing one infectious case into a susceptible population of size 10^, and 
allowing an epidemic to emerge in the absence of treatment. The incidence rate (given as new 
cases per 100,000) and prevalence (as cases per 100,000) are followed over the course of the 
simulations. 
III. B. Endemic setting 
In first simulations examine the effect of introducing treatment into an endemic 
setting, in which disease levels have stabilized at an equilibrium level. Shown in 
Figure 8-2 is an example of an epidemic that progressed for 100 years in the absence of 
any treatment, allowing disease levels to reach equilibrium with an incidence of 110 
cases per 100,000. Introducing any curative treatment will disrupt this equilibrium, 
reducing the average case duration of infectiousness and transmission. Even low 
treatment rates, such as case detection of 30% (with a cure rate of 85%), reduces 
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incidence and prevalence of disease. Higher treatment rates results in a faster and 
greater decline in incidence and prevalence. (Figure 8-2) 
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Figure 8-2. Impact of introducing treatment into a high burden 
endemic setting. Treatment is introduced into an epidemic at equilibrium levels with a liigli 
burden of disease. Simulations were first run to allow the epidemic to reach equilibrium in the 
absence of treatment. After 100 years, disease reached equilibrium with an incidence of 120 
cases per 100,000. Treatment was then introduced, with a case detection rate (CDR) ofO%, 
10%, 30%, 60% or 90% of incident cases. This control program was maintained for 60 years. 
When no treatment is introduced (CDR=0%), incidence rate remains at equilibrium levels. As 
higher treatment rates are introduced, there is a reduction in both incidence and prevalence of 
disease over the course of the epidemic. 
The relationship between treatment and disease levels, in the context of this 
high burden endemic setting, is summarized in Figure 8-3. At higher treatment rates, 
the disease levels are reduced over the course of the control phase of the simulations. 
Shown is the final incidence by the treatment level (the case detection rate) used during 
the control phase. Higher treatment rates result in a greater and faster decrease in 
disease. (Figure 8-3) 
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Figure 8-3. Introducing treatment into an endemic setting reduces 
disease. Higher treatment rates result in lower incidence and prevalence of disease. 
Simulations were run as in Figure 8-2. During the control phase of the simulation, the case 
detection rate was set at values ranging from 0% to 100%. The final incidence of disease is 
shown as the new infectious cases per 100,000 after 100 years of treatment is shown. Treatment 
rates are shown as the proportion of incident cases receiving treatment (Case Detection Rate). 
III. c. Treatment benefits; balance treatment and cure 
Treatment reduces disease prevalence by reducing case duration of 
infectiousness and transmission. Successful reduction of disease requires not only 
detection, but also effective treatment and cure. However, there is a balance between 
case detection and treatment cure. In terms of disease prevalence, the major burden is 
in detecting cases—even with only a mildly effective cure, there will be a reduction in 
disease prevalence. Conversely, increasing the cure rates for all treated patients will 
only have a significant impact on the course of the epidemic if a large proportion of 
incident cases are detected. 
Even with low cure rates, wide scale treatment is beneficial in reducing disease 
burden. The impact of varying treatment cure rates is examined in a setting of a high 
incidence epidemic at equilibrium, with an incidence rate of 100 cases per 100,000. 
After the epidemic reached equilibrium levels of disease, treatment was introduced with 
238 
a given case detection rate, and treatment cure rate set at 2 0 , 6 0 , or 9 0 % . Even at the 
low cure rate of 2 0 % , there is a significant decrease in disease. At the higher cure rates 
of 6 0 % or 9 0 % , there is a faster and greater reduction in disease levels. (Figure 8 - 4 ) 
This illustrates that, even at low cure rates, it is beneficial to detect and treat as many 
cases as possible. 
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Figure 8-4. Balance between treatment and cure rates: reduction of 
disease. Introducing treatment with any of the given cure rates results in a notable decrease in 
incidence and prevalence of disease. More disease is prevented at higher case detection rates. 
In addition, at higher detection rates, the treatment cure rate has a more significant impact on 
disease prevented. As more cases receive treatment, improvements to the treatment efficacy 
result in a greater reduction in disease. 
These simulations were run as in Figure 8-2. During the 60 years of control, the case detection 
rate was set at a value between 0% and 100%, and the treatment cure rate was set at 20%, 60%, 
or 90%. The final incidence rate is shown in (C) as new cases per 100,000. 
I I I . D. Selection for resistance under poor treatment and 
high detection 
The relationship between low cure rates and resistance is examined in the 
context of a high burden setting. Simulations were first run to equilibrium in the 
absence of treatment, reaching stable disease levels with an incidence of 100 cases per 
1 0 0 , 0 0 0 . Treatment was then introduced, reducing incidence while selecting for 
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resistance. (Figure 8-5A,B) The highest levels of resistance are seen under high 
detection and low cure. (Figure 8-6) Thus, increasing the case detection rates without 
simultaneously increasing cure rates can promote higher prevalence of resistance and 
possibly disease. 
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Figure 8-5. Selection for resistance under high treatment. 
Higher levels of case detection reduce disease incidence (A), while increasing resistance 
prevalence (B). Simulations were run as in Figure 8-2. During the control phase of the 
simulation, treatment was begun with a case detection rate of 0%, 25%, or 80%. The treatment 
cure rate was set at 90%. The incidence rate is shown as new cases per 100,000 (A) and the 
resistant case rate as cases per 100,000 (B). 
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Figure 8-6. Selection for resistance under high treatment and low cure rates. 
The greatest selection for resistance occurs under high rates of treatment combined with low 
cure rates. The prevalence of drug resistant cases increases with case detection, and declines 
with higher treatment cure rates. At higher rates of case detection, changes in the cure rate have 
a greater impact on resistance prevalence. The highest resistance prevalence occurred under 
high case detection combined with low cure rates. Simulations were run as in Figure 8-2. 
During the 60 years of control, the case detection rate was set at a value between 0% and 100%, 
and the treatment cure rate at 20%, 60%, or 90%. The resistant case rate is shown as the 
number of resistant cases per 100,000 population. 
III. E. Time to case detection (waiting time to treatment) 
The time to treatment, as defined the model, represents the time taken from 
disease onset (and case infectiousness) until the start of treatment. As explained in the 
methods section, this includes the time taken for a new case to enter a health system, 
receive correct diagnosis, and begin tuberculosis treatment. The first depends upon 
onset of patient symptoms, access to medical resources, and willingness to report. The 
second depends upon the passive screening program, including familiarity with 
recognizing symptoms of tuberculosis and using appropriate diagnostic tests, 
availability of these diagnostic tests, and the time taken to return these tests. The third 
depends upon availability and access to appropriate drug regimens as well as 
administrative programs. 
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III. E. 1. Waiting times and case DOI 
The longer patients wait until beginning treatment, the longer their duration of 
infectiousness. Even high rates of treatment and cure will have limited effect in 
reducing case DOI if cases spend long waiting for treatment. The shortest waiting time 
shown in the following simulations is one month. This represents rapid reporting, 
allowing for just a minimum estimated time for patients to recognize symptoms, report 
to a health service, receive diagnostic tests, confirm diagnosis, and begin treatment. In 
our model, an average waiting time of 1 month, combined with a case detection rate of 
80% and treatment cure rate of 90%, the case duration of infectiousness is 8 months. 
As the waiting time is increased to 4 months, the DOI is increased to 10 months. With 
a waiting time of 12 months, the DOI is increased to 13 months. In comparison, the 
average case DOI in the absence of any treatment is 24 months. (Figure 8-7) 
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Figure 8-7. Longer treatment waiting times result in increased average 
duration of infectiousness of treated cases. Shown is the average case duration of 
infectiousness (in months) of treated and untreated cases. Simulations were run as in Figure 
8-2. As the average waiting time to treatment is increased from 1 to 24 months, the average 
duration of infectiousness of treated cases is increased from 7 to 16 months. The average 
duration of infectiousness of untreated cases remains at 24 months. 
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III. F. Waiting times and disease levels 
We examine how treatment waiting times affect the course of an epidemic in a 
high burden setting. In these simulations, the epidemic is run for 100 years with no 
treatment, reaching an equilibrium level of disease with an incidence rate of 100 cases 
per 100,000 and disease prevalence of 0.8%. Then a strong first line treatment 
program, with case detection rate of 80% and treatment cure rate of 90%, is introduced 
and maintained for the next 60 years. While the detection and cure rates are held 
constant, the average waiting time between case infectiousness and treatment is varied 
between simulations. (Figure 8-8) As the treatment waiting time is increased from one 
month to either four or twelve months, the incidence and prevalence of disease over the 
course of the epidemic are increased. (Figure 8-8) 
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Figure 8-8. Decreasing the waiting time to treatment reduces 
incidence of disease. For the same detection and cure rates, shortening the waiting time to 
treatment resulted in reduced incidence of disease over the course of the epidemic. As a control, 
a simulation is shown in which no treatment is introduced (CDR = 0%), and the disease levels 
remain at equilibrium. Simulations were run as in Figure 8-2. A first line control program was 
then introduced after 100 years, with a case detection rate of 80% of incident cases and a 
treatment cure rate of 90%. The average case waiting time to treatment was set at I, 4, or 12 
months. This control program was maintained for 60 years. 
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In Figure 8-9, simulations of the same epidemic are shown, in which the waiting 
times are varied from 1 to 48 months. Longer waiting times allow for increased 
duration of infectiousness and transmission, and result in increased incidence and 
prevalence of disease. ( 
Figure 8-9A) In addition, at longer waiting times, there is less treatment and 
selection for acquired resistance. As expected, increasing the case waiting time slightly 
reduces resistance. This effect is more significant at higher levels of case detection, as 
higher treatment rates provide additional selection for resistance. ( 
Figure 8-9B) 
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Figure 8-9. Wailing time to treatment: increases disease and reduces 
selection for resistance. For a given rate of case detection, increasing the waiting time to 
treatment increases incidence of disease (A) while resulting in lower selection for resistance (B). 
This effect is more pronounced at higher levels of case detection. 
Simulations were run as in Figure 8-8. During the treatment phase of the simulation, the case 
detection rate was set at 20%, 50%, or 90%, and the average case waiting time (Time to Case 
Detection) was set at values between 1 and 48 months. The final incidence of disease (A, new 
cases per 1000,000) or resistance prevalence (B, the proportion cases resistant at end of 
simulation) after 60 years of constant treatment with the given level of detection, is shown 
against the t ime to treatment. 
IV. Simulations for second line control programs 
IV. A. Simulations 
In this section, the impact of second line control for resistance is explored. 
Epidemics were simulated under varying level of control, which includes case 
detection, drug testing, and first and second line treatment. These simulations were run 
in three phases. In the first phase, one infectious drug sensitive case is introduced into 
a susceptible population, and allowed to spread in the absence of treatment for 100 
years, reaching equilibrium with an incidence rate of 100 cases per 100,000. In the 
second phase of the simulation, a strong first line control program is introduced, with a 
case detection rate of 80% and treatment cure rate (for drug sensitive cases) of 90%, 
and maintained for 30 years. In the third phase of the simulation, the first line control 
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program is supplemented with second line, including drug testing and treatment of 
resistant cases. 
IV. B. Second line control effects course of epidemic 
The first line control reduces incidence (Figure 8-1 OA), but allows for the 
selection of resistance (Figure 8-1 OB). When no second line control is introduced 
(pDST=0%, Figure 8-10), the prevalence of resistance continues to increase, in 
comparison, when the first line program is supplemented with drug testing and 
resistance treatment of 40% or 90% of incident cases (pDST= 40%, 90%, Figure 8-10), 
there are further reductions in disease incidence over the course of the epidemic, and 
lower resistance prevalence. (Figure 8-10) 
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Figure 8-10. Introducing second line treatment reduces disease and 
resistance over course of epidemic. 
During the first phase of the simulation, the epidemic was run for 100 years under no 
treatment and reached an equilibrium level of disease with an incidence rate of 100 cases per 
100,000. During the second phase of the simulation, lasting for thirty years, first line control 
was added with a case detection rate of 80% and a drug sensitive cure rate of 90%. The third 
and final phase of the simulation lasted for an additional thirty years. During this final phase 
second line treatment was introduced in addition to the first line control. The prevalence of 
disease is shown in (A) as the number of cases per 100,000 population, and the resistance 
prevalence in (B) as the proportion of cases which are resistant. 
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IV. C. Proportion cases receiving drug testing 
All cases receiving treatment begin with a first line regimen. A proportion of 
treated cases (PDST) receive drug susceptibility testing. Only after drug testing results 
have been returned and show resistance are cases shifted to a second line regimen. 
Drug testing is assumed to be accurate and allows for the correct diagnosis of drug 
resistance patterns with a 100% positive predictive value. Sensitivity of DST is not 
specified as distinct parameters in the model. Rather, the parameter for the DST rate 
reflects the overall "true rate" of detection of resistant cases. This includes the use of 
drug susceptibility tests, and the accuracy and sensitivity of detection. 
The drug testing of new incident cases reduces the prevalence of both disease 
and resistance. Higher levels of drug testing reduce resistance, and to a lesser extent, 
disease prevalence. (Figure 8-1 IB) 
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Figure 8-11. Drug testing and resistance treatment reduce disease and 
resistance. At higher rates of drug testing, both the incidence of disease and resistance 
prevalence was reduced. The rate of drug testing is given as the proportion of incident cases 
receiving drug susceptibility testing and appropriate treatment (pDST). 
Simulations were run as in Figure 8-10. During the third phase of the simulation, the proportion 
of cases receiving drug testing (pDST) was varied from 0%-100%. Shown is the incidence rate 
of new cases per 100,000 (C) and the resistance prevalence (the proportion of cases are 
resistant) (D) at the end of the simulation. 
IV. D. Second line treatment efficacy 
The implementation of drug testing programs can only be useful when 
combined with an effective second line cure for resistant cases. In figure 8, the impact 
of introducing second line control, with a range of resistance cure rates, is examined. 
These simulations were first run to equilibrium levels of disease in the absence of 
treatment. Then a strong first line control program was introduced with a case 
detection rate of 80% and cure rate for sensitive cases of 90%. After 30 years of this 
first line control, a second line program was added, with varying levels of drug testing 
and resistance cure rates. As shown in figure 8A, during the first treatment phase (only 
first line treatment), the prevalence of resistance rapidly increased. The addition of 
second line treatment in the final phase of the simulation resulted in a reduced 
resistance prevalence, compared with that under no second line treatment. 
The treatment cure rates for sensitive and singly resistant cases were set fixed at 
90% and 70%, respectively. The cure rate for multiply resistant cases was set at 50%, 
25%, or 0%. When the cure rate for MDR cases is assumed to be completely 
ineffective (cure=0%), drug testing and treatment of resistant cases still results in a 
reduction in resistance. This reflects the detection and treatment of singly resistant 
cases. This in turn reduces the emergence of MDR. As the cure rate for MDR cases is 
increased to 25% or 50%, the detection of resistant cases results in further reduction in 
resistance. (Figure 8-12) 
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This shows that even with low MDR cure rates, the second line control program 
results in a decrease in resistance prevalence. Drug testing and resistance treatment is 
useful even if can treat only a proportion of resistant cases. This treatment reduces the 
pool of general resistance. This in turn reduces the emergence of MDR. In addition, 
even low MDR cure rates are higher than that under first line treatment, and thus reduce 
case DOl and ongoing resistance transmission. 
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Figure 8-12. The impact of drug testing varies by efficacy of treatment 
for multiply resistant cases. At higher treatment cure rates for multiply resistant cases, 
the implementation of drug testing results in lower resistance prevalence. Even at low cure rates 
for multiply resistant cases, there is some reduction in resistance with greater drug testing. 
Simulations were run as in Figure 8-10. During the first phase of the simulation, the epidemic 
was run for 100 years under no treatment and reached an equilibrium level of disease with an 
incidence rate of 100 cases per 100,000. During the second phase of the simulation, lasting for 
thirty years, first line control was added with a case detection rate of 80% and a drug sensitive 
cure rate of 90%. The third phase, lasting for an additional thirty years, included drug testing of 
a proportion of incident cases (pDST) varied from 0% to 100%. The treatment cure rate for 
sensitive cases was set at 90%, for singly resistant cases at 70%, and for multiply resistant cases 
to 0%, 20%, or 50%. Shown is the final resistance prevalence (the proportion of cases resistant) 
at the end of the simulation. 
IV. E. Built on strong foundations 
The impact of drug testing also depends on the first line control program. In 
particular, cases must be detected before receiving drug testing and second line 
treatment. In the simulations shown in Figure 8-13, second line treatment is introduced 
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into epidemics under varying levels of first line control. At higher levels of case 
detection, the same level of drug testing will result in a greater reduction in resistance. 
At low levels of case detection, implementing drug testing of even a large proportion of 
incident cases may not stop an emerging resistant epidemic. At these low levels of case 
detection, the more effective means to control the epidemic and the emergence of 
resistance would be to increase detection and treatment rates. (Figure 8-13) In these 
simulations, the lowest level of resistance is found under low case detection. 
Conversely, the most resistance occurs under high case detection, which provides more 
opportunity for resistance to emerge. Once resistant epidemics have emerged, higher 
rates of drug testing and second line treatment are required to reduce resistance 
prevalence. (Figure 8-13) 
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Figure 8-13. Impact of drug testing by case detection rate. At higher 
rates of case detection, the implementation of drug testing results in greater reduction in 
resistance prevalence. 
Simulations were run as in Figure 8-10. During the second and third phases of the simulations, 
the case detection rate was set at 20%, 50%, or 80%. During the third phase of the simulation, 
the proportion of incident cases receiving drug testing (pDST) was varied from 0% to 100%. 
The treatment cure rate for sensitive cases was set at 90%, for singly resistant cases at 70%, and 
for multiply resistant cases at 50%. Shown is the final resistance prevalence (the proportion of 
cases resistant) at the end of the simulation. 
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High rates of case detection may select for resistance - particularly if combined 
with low first line cure rates. However, high case detection also provides the 
opportunity to find and treat resistant cases. Thus, introducing drug testing on top of 
high case detection offers a chance to make significant reductions in resistance. In 
comparison, under low case detection it may not be possible to treat a high proportion 
of resistance cases, but lower selection for resistance may mean there is less of a 
resistance problem to repair. 
IV. F.Time to return drug testing results: waiting time to 
resistance treatment 
The time taken to return drug testing results has a limited impact on the level of 
resistance. Longer waiting times to return drug testing results and begin resistance 
treatment results in slight increases in resistance prevalence. The impact of reducing 
the waiting time for drug tests is greatest in situations with high case detection (Figure 
8-MA) and resistance (Figure 8-14B). At higher rates of case detection, the same 
reductions in waiting times results in a greater decrease in resistance prevalence. 
(Figure 8-14) 
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Figure 8-14. Time to return drug susceptibility testing results. Shown is 
the final resistance prevalence (the proportion of cases resistant) at the end of the simulation. At 
longer waiting t imes to switch to appropriate second line regimens, there is an increase in 
resistance prevalence. 
Simulations were run as in Figure 8-10. During the third phase of the simulations, the waiting 
time to return drug susceptibility tests and switch to an appropriate second line regimen was set 
to values between 1 and 12 months. During the third phase of the simulation, the proportion of 
incident cases receiving drug testing (pDST) was set at 0%, 50%, or 90%. The case detection 
rate during the second and third phases was set at 90%. The treatment cure rate for sensitive 
cases was set at 90%, for singly resistant cases at 70%, and for multiply resistant cases at 50%. 
V. Discussion 
253 
V. A. Top priorities in TB control: 
In this chapter, priorities in control of TB epidemics are explored. The first and 
most important control measure for reducing disease burden is ensuring a high level of 
case detection. Second, maintaining high treatment cure rates will reduce disease as 
well as limit the emergence of resistance. Introducing a control program with high 
detection and cure rates will rapidly reduce the disease levels in a population. The 
main findings in this chapter are summarized as follows: 
1. Case detection is the central priority. 
2. There is a balance between treatment and cure—in terms of reducing 
disease burden, higher case detection is a priority. For prevention of resistance, 
ensuring high cure rates is most important, and treatment coverage should not be 
expanded until target cure rates are met. 
3. A strong first line control program, with high case detection and cure rates, 
will rapidly reduce disease levels. 
4. Additional control measures, on top of a strong first line control program, 
will further reduce disease and prevent resistance. 
These findings are supportive of current WHO recommendations for global TB 
control. The WHO's primary priorities in global TB control are increasing global case 
detection and treatment cure rates, and to this end, have set targets to achieve global 
detection of 70% of cases with treatment success rate of 85%. These studies also 
reaffirm that the most important first steps in control are establishing the effective 
treatment of a high proportion of cases in the population. Only after a strong control 
program with high levels of case detection and treatment success is established, should 
further control measures be considered. (WHO 2003; WHO 2003) 
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V. B. Next phase in TB control 
Once this strong first line control has been implemented, and disease burden has 
been reduced, supplementary control measures may be considered. Additional control 
measures will allow for further reductions in disease, as well as treatment and 
prevention of resistance. These programs can be geared towards the next stage in TB 
elimination. 
The other control measures considered in this chapter include: 
1. reducing treatment waiting times 
2. drug susceptibility testing 
3. specialized treatment of resistance cases 
Each of these control measures were shown to be beneficial in situations where 
there was already high case detection and cure rates. Reducing treatment waiting times 
results in further reduction in disease. However, it should be noted that this is small in 
comparison to the reduction in disease caused from increased levels of case detection 
and cure. The benefits of reducing the average case waiting times are highest under 
control that includes high detection and cure, as this leads to the greatest reduction in 
average case duration of infectiousness. 
Introducing these control measures results in reduction of disease, and for the 
latter two, reduction in resistance. Each of these measures provides the most benefit 
when introduced into a control program that includes high detection and cure of drug 
sensitive cases. Further, each of these measures provides only small benefits, in terms 
of reduction in disease, relative to increases in case detection and first line treatment 
cure rates. These control measures should be considered as additions to already strong 
first line control programs, in low incidence regions where there are sufficient 
resources for expansion of control. 
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V. C. Treatment and selection for resistance: striking a balance 
The balance between case detection and cure rates is measured in terms of both 
disease and resistance. When considering the benefit of treatment in preventing 
disease, the most important concern is increasing coverage. The higher the proportion 
of incident cases receiving treatment, the greater the reduction in disease. However, 
when considering the emergence of resistance, the more important consideration 
becomes the quality and efficacy of treatment given. If poor treatment is given to an 
increasing proportion of cases, resistance levels may be exacerbated. 
There are numerous examples of resistance emerging in populations in which 
there may be high rates of treatment, but the quality of treatment is poor in either 
localized or wide scale regions. In particular, prolonged periods of poor control 
practices have resulted in rapid development of high rates of resistance. For example, 
in the Russian Federation, significant resistance has emerged despite high levels of case 
detection. Overall, an estimated 65% of new smear positive cases are detected, with 
over 90% treated under a DOTS program. The treatment success rate is 56.7%. 
Although there remains a reasonably low incidence rate of 23.4 cases per 100,000, 
there has developed a high prevalence of 32.4% single drug resistance and 9% MDR. 
A similar situation is found in Latvia, which has achieved 73.3% case detection, with 
over 90% detected under a DOTS program. With a treatment success rate of 70.2%, 
the estimated smear positive incidence rate has been reduced to a medium level of 37.1 
cases per 100,000. However, there is a high prevalence of 29.9% single drug resistance 
and 9% MDR. (WHO/IUATLD 1997; Iseman 1999; WHO/IUATLD 2000) 
Peru also shows a high prevalence of resistance although control practices have 
improved considerably over the past decade. Recent program improvements have 
reached a case detection rate of 81.9%, with over 90% treated under a DOTS program, 
and an average treatment success rate of 93%. However, a high prevalence of 
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resistance remains, with 18% single drug resistance and 3% MDR. This high resistance 
prevalence may reflect earlier poor treatment practices that have allowed the emergence 
of a continuing resistance epidemic. (Netto, Dye et al. 1999; Espinal, Kim et al. 2000; 
WHO/IUATLD 2000; Raviglione, Gupta et al. 2001) 
V. D. Treatment waiting times 
The waiting time to detection and treatment of infectious cases is another 
important aspect of control. Reducing this waiting time is considered a key element in 
reducing duration of infectiousness and ongoing cycles of transmission. In these 
analyses, shortening the average case waiting time resulted in decreased duration of 
infectiousness, transmission and disease levels. The waiting time to begin treatment 
was most important in scenarios with a strong first line control program. On top of 
strong control, including high case detection and first line cure, shortening waiting 
times results in additional reductions in disease. 
In regions with poor control, which have low rates of case detection, reducing 
waiting times results in slight reductions in disease. However, in this scenario far more 
disease would be prevented by first increasing case detection. Under programs with 
low average cure rates, reducing the waiting times may provide even less benefit. 
Reducing the time to treatment, when treatment itself provides only a marginal 
reduction in duration of infectiousness, has a limited impact on reducing disease. In 
this scenario, the priority would lie in first improving control through higher cure rates. 
V. E. Reducing waiting time to treatment 
The waiting time to treatment can be reduced at several levels. First, new cases 
must receive medical attention. Second, these patients are seen by a medical 
practitioner and considered to have symptoms that allow suspicion of a case. Third, 
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these cases are properly diagnosed as an active case of TB. Fourth, confirmed cases 
wait to begin a course of treatment. 
V. E. 1. delays in patient reporting 
The time from onset of symptoms until a patient reports to a health authority is 
referred to as the patient delay. Studies have considered any time over one month as a 
delay in patient reporting. Patients may delay seeking for a number of reasons. First, 
they may have few symptoms and not recognize the need for medical attention. This 
may occur for biological reasons—a proportion of cases will have lower severity of 
disease and develop fewer symptoms. Second, there may be social, cultural, or 
economic barriers to routine medical access. (Asch, Leake et al. 1998; Needham, 
Foster et al. 2001) In developing country settings, studies have found that delays in 
patient reporting were correlated to poor health infonnation, and lack of information 
regarding the symptoms and treatment of tuberculosis. These patient delays were 
found to be longer in rural areas, in patients with lower education levels, and for 
patients who did not have prior information regarding tuberculosis. (Salaniponi, 
Harries et al. 2000; Wandwalo and Morkve 2000; Lienhardt, Rowley et al. 2001; 
Needham, Foster et al. 2001) Improving general awareness on the symptoms of 
tuberculosis, available treatment, and how to access health care services are important 
measures to both increase case detection rates and reduce the delay in patient reporting. 
Even under strong control programs in developed countries, there may be 
significant patient delays in seeking care. Studies examining the reasons patients delay 
in reporting include concern over cost of treatment, difficulties in access to health 
services, misunderstanding of tuberculosis, and fearing immigration authorities. Patient 
delay was correlated to unemployment, uncertainty about where to seek care, and a 
belief that they could treat themselves. Conversely, the severity of the illness and 
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symptoms were not seen to significantly affect patient delay. (Asch, Leake et al. 1998) 
These findings suggest a lack of equity in treatment, such that groups with lower 
education and knowledge about seeking health care and tuberculosis disease itself are 
less likely to receive treatment. 
Active screening programs, including contact tracing and screening of high-risk 
groups, may detect these cases and bring them in for treatment faster. In addition, 
population-wide (or within high-risk groups) measures to increase education about TB 
symptoms and where to seek treatment may increase detection and reduce reporting 
times. Education can also seek to reduce possible stigma associated with seeking 
treatment. Similarly, improving routine medical access, particularly in high-risk groups 
which often experience social or economic barriers, may decrease reporting times. 
V. E. 2. institutional delay in recognizing symptoms / suspecting case 
Improvements in education of TB symptoms and diagnosis amongst medical 
practitioners are of key importance in decreasing the time to suspicion of active TB. 
This time is often the most critical, as after suspicion many health authorities will seek 
to isolate patients, or at least reduce potential contacts, until diagnostic tests are 
returned. Increased medical education is particularly important in areas of low 
incidence, where practitioners may be unfamiliar with recognizing symptoms and the 
appropriate guidelines for diagnosis and treatment. 
Patients may experience delays once in hospital, waiting either for diagnosis or 
to start treatment. These delays may include intervals for referral, diagnosis, and 
initiation of treatment. Both doctor and clinic delays have been shown to contribute to 
overall institutional delays. (Salaniponi, Harries et al. 2000; Yilmaz, Boga et al. 2001) 
Clinical delays in treatment are often associated with atypical presentation, lack of 
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symptoms, and waiting for culture results. Older patients and those without respiratory 
symptoms are more often initially misdiagnosed. (Mathur, Sacks et al. 1994) 
Delays in treatment are associated with admittance to a hospital with a low 
incidence of tuberculosis, and atypical clinical presentation. In hospitals with low TB 
admission rates, cases were more likely to be initially misdiagnosed. Further, the rate 
of TB admissions was inversely proportional to the successful treatment outcome. At 
lower rates of TB admissions, cases were more likely to fail treatment, die, and transmit 
infection. Treatment delays amongst patients in a hospital may lead to nosociomal 
transmission. (Greenaway, Menzies et al. 2002) 
V. E. 3. diagnostic delay 
Faster and more effective diagnostic tests would allow cases to begin treatment 
earlier. Diagnostic tests with improved sensitivity may also allow detection of cases at 
earlier stages, when patients may have fewer disease symptoms. (Heymann, Brewer et 
d. 19197) 
V. E. 4. diagnosis to treatment 
Delays from the time of confirmed diagnosis to the start of treatment are usually 
the shortest, and reflect administration and medical delays. The delay from confirmed 
diagnosis to treatment tends to range from one to two days in industrialized countries. 
Significant delays may be caused by administration, referral to specialized centers, or 
lack of appropriate regimens. In addition, if patients are not hospitalized after 
diagnosis, further delays may occur if patient does not return as expected. 
V. E. 5. An alternative: presumptive treatment 
Treatment waiting times can also be reduced by lowering the threshold needed 
for positive diagnosis. One alternative is starting presumptive treatment without 
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bacteriological confirmation of mycobacterial infection. Confirmation of disease may 
come either from subsequent sputum culture test, or simply from patient response to 
chemotherapy. Such presumptive treatment is used in a variety of situations, including 
high suspicion of disease, and limited resources for diagnostic testing. (Kennedy and 
Fallon 1979; Brewer, Heymann et al. 1998) 
Reducing times from suspicion of TB to treatment can also be reduced by 
beginning therapy before confirmation by culture test. In the USA, national guidelines 
recommend beginning treatment on all patients with positive smear tests. However, 
studies of practice in hospitals that rarely see active TB cases show that most patients 
did not begin treatment until after mycobacterial diagnostic confirmation by culture 
test. This delay, past the requirements of the national guidelines, may reflect on the 
physician's lack of familiarity with procedures for treating TB cases. Indeed, the time 
to treatment is faster in hospitals with a higher TB caseload. It remains unclear the 
effect of treating uninfected patients, and it is believed that this is outweighed by the 
benefits of reducing time treatment in infectious patients, and reducing the extent of 
nosociomal transmission. This is less applicable in regions with high environmental 
and non-tuberculosis mycobacteria, which cannot be distinguished by smear test. In 
these regions, confinnation by culture test is still needed to signal active TB. 
V. F. Drug resistance 
V. F. 1. Emergence and control 
In the simulations presented here, drug resistance is seen to emerge under first 
line control programs. As the prevalence of resistance increases, first line control alone 
is not sufficient to control resistance. Implementation of second line control, on top of 
strong first line programs, can reduce resistance that may have emerged under earlier 
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control, and prevent further emergence of resistance. In order to be successful in 
reducing resistance, the second line control program should include drug testing of a 
high proportion of cases and offer effective resistance cure. 
This is also observed in program conditions. Traditional DOTS programs 
recommend treating ail presenting cases with first line regimens. Poor program 
practices may allow for the emergence of high levels of resistance. While the first line 
regimens offered under DOTS may achieve high cure rates for drug sensitive cases, 
even under the best program conditions, to both INH and RIF (MDR) results in high 
failure rates. In addition, mistreatment of resistant cases may lead to amplification of a 
patient's resistance to higher levels. (Mitchison and Nunn 1986; Shimao 1998; Espinal, 
Kim et al. 2000; Raviglione, Gupta et al. 2001) 
The cost and difficulties in implementing wide-scale drug testing and resistance 
regimens limits the feasibility of these control measures in many parts of the world. 
However, the good news is that even partial implementation of these second line 
control measures will still have positive effects. In order to reduce and prevent further 
resistance, resources available after ensuring high detection and first line cure rates 
should be invested in second line control. 
V. F. 2. DOTS-plus and resistance treatment guidelines 
In order to address the growing prevalence of resistance, and in particular MDR, 
the WHO has considered extending the DOTS program in some regions. The DOTS-
plus program incorporates a standardized system for second line control, including drug 
susceptibility testing, and specialized regimens for treatment of general resistance and 
MDR. The WHO control guidelines recommend implementation of these additional 
control measures only in areas that have already achieved targets for DOTS control, 
maintaining high levels of detection and treatment success. These programs are 
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particularly important in regions with high prevalence of MDR. Under traditional 
D O T S , all cases are treated with first line regimens, and the low cure rates of MDR on 
these regimens may only exacerbate the resistance problem. (Farmer and Kim 1998; 
WHO 1999; Bastian, Rigouts et al. 2000) (Bahrmand, Velayati et al. 2000) 
(Loddenkemper, Sagebiel et al. 2002) 
Regions that lack the resources for wide-scale drug testing and expensive MDR 
treatments, but do have a growing resistance problem, have other alternatives. Some 
programs offer a general resistance treatment by default: cases failing one or more 
subsequent courses of treatment receive a standardized re-treatment regimen that shows 
higher cure rates for some resistant cases. (WHO 1997; Bahrmand, Velayati et al. 
2000; Loddenkemper, Sagebiel et al. 2002) 
VI. Summary of Findings 
In this chapter, the optimal control strategies for regional TB epidemics were 
explored, incorporating historical trends in TB treatment and following the course of 
epidemics through incremental improvements in control programs, including both first 
and second line chemotherapy. The effects of introducing elements of first and second 
line control programs on the dynamics of the epidemic, as well as the benefits in terms 
of reducing disease and preventing resistance, were compared. 
While treatment will generally reduce disease levels, this depends upon the 
efficacy of treatment and the probability of acquiring resistance. Even treatment with 
low cure rates will reduce disease, by reducing the case DO I below that of untreated 
cases. However, if there is a high probability of acquiring resistance, then increasing 
treatment under low cure rates will select for higher levels of resistance and possibly 
disease. 
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Treatment also brings a cost by selecting for drug resistance. This selection is 
greater under higher treatment and lower cure rates. Treating a high proportion of 
cases with low cure rates will allow for the emergence and spread of resistance. If low 
cure rates are maintained while treatment coverage is expanded, it is possible to 
develop a serious resistance problem, in which additional treatment leads to greater 
resistance and possibly disease. 
Introducing a second line treatment program, including the drug testing and 
specialized treatment regimens, reduces prevalence of both disease and resistance. The 
success of a second line treatment program depends upon the proportion of cases 
receiving drug susceptibility treatment and the efficacy of resistance treatment, as well 
as the strength of the first line treatment program, including the case detection and 
(drug-sensitive case) cure rates. 
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I. Goals 
I. A. To consider control priorities for TB epidemics in high 
and low disease burden settings. 
II. Abstract 
The control measures outlined in the previous chapter are further explored by 
examining the benefits of implementing these measures within different settings. The 
relative benefits of different control measures are considered and priorities for the 
development of control programs recommended. Current global targets for increasing 
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case detection and cure rates are appropriate for the high burden countries, where over 
80% of cases are found. In these conditions, the control of epidemics is hindered by 
low case detection and treatment rates. In regions where a high prevalence of 
resistance has already developed, special care must be taken to improve program 
conditions before considering expansion. In low incidence regions, control priorities 
can expand to include additional measures, specifically, active case detection and 
treatment of latently infected individuals. 
III.Introduction 
In this chapter, the relative priorities in control of local TB epidemics are 
considered. Three representative settings were selected that differ by disease burden, 
level of control, and resistance prevalence. The relative benefits of implementing 
elements of first and second line control on reducing incidence of disease and 
resistance were tested. 
These settings are: 
1. A high burden country with low resistance prevalence and strong 1®' line 
control but low detection rates. 
2. A high burden country with poor treatment practices, high rates of 
acquired resistance, and weak 1^ ' line control. 
3. A low incidence setting with medium levels of resistance and strong 1^ ' line 
but no l"** line control. 
The disease burden and level of control simulated in each of these three scenarios is 
summarized in Table 9-1. (Table 9-1) 
Scenario 1 2 3 
HBC 
Low resistance 
HBC 
High resistance 
Low incidence, 
elimination phase 
Disease burden 
Incidence rate 62 85 21 
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Incidence rate 
DR 
4.5 26 1.5 
Prevalence 
DR 
9% 33% 6.7% 
Control program 
CDR 40% 40% 80% 
Cure rate, DS 60% 40% 80% 
DST 0% 0% 0% 
Table 9-1. Summary of disease burden and control parameters used in the three 
scenarios described in this chapter. 
IV. Scenario 1: High Burden 
IV. A. Description scenario 1 
The first scenario reflects a high burden country with a low level of resistance. 
The disease levels are high, with an annual incidence rate of 62.5 cases per 100,000. 
Resistance is at a low level, with under 10% resistance prevalence amongst cases. A 
first line control program, with a case detection rate of 40% and treatment cure rate of 
60%, has been maintained for twenty years. 
IV. B.Trends 
In these simulations, an epidemic was first begun by introducing a drug 
sensitive case into a susceptible population of size 10 .^ After 100 years in the absence 
of treatment, the epidemic reached equilibrium levels of disease with an annual 
incidence rate of 163 cases per 100,000. Control was then introduced with a case 
detection rate of 40% and an average cure rate of 60%. Under 20 years of this control, 
disease levels were reduced to an annual incidence of 62.5 cases per 100,000. This 
control program also led to an increased resistance prevalence of 8.7% (resistance 
incidence of 4.5 cases per 100,000). (Figure 9-1) 
If this control program is continued for an additional 10 years, the disease 
prevalence will continue to decrease to an incidence rate of 61 cases per 100,000. The 
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resistance prevalence will also continue to increase to reach resistance incidence rate of 
6.5 cases per 100,000 (12% resistance prevalence). (Figure 9-1) If the control 
program is improved over the next 10 years of control, through increased case detection 
and/or treatment cure rates, the prevalence of disease will be further reduced. 
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Figure 9-1. Trends in incidence for simulations in scenario 1. 
Simulations were run as described in the text for Scenario 1. For the first 100 years of the 
simulation, the epidemic was allowed to equilibrate in the absence of treatment, reaching final 
annual incidence rate of 163 cases per 100,000. For years 101- 120, a control program 
including case detection rate of 40% and cure rate of 60% was implemented. For the final years 
121-130, this same control program was maintained. This control reduced the incidence rate to 
61 cases per 100,000, but allows for an increase in resistance incidence to 6.5 cases per 100,000. 
Shown is the annual incidence rate of total and resistant cases (as cases per 100,000) at the end 
of the simulation. 
IV. c. Relative Priorities 
The control parameter that had the greatest influence on the prevalence of 
disease was the case detection rate. Increasing the case detection rate from 40% to 50% 
resulted in a reduction in annual incidence from 63.6 to 53.8 cases per 100,000. A 
further increase to 60% case detection resulted in a further decrease to 45.9 cases per 
100,000. (Figure 9-2, Table 9-1) Increasing the case detection rate resulted in reduced 
incidence of drug sensitive cases. Increasing the case detection rate to 60% reduced the 
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incidence of sensitive cases from 55.2 to 38.1 cases per 100,000. The incidence of 
resistant was slightly reduced from 8.4 to 7.9 cases per 100,000. (Figure 9-2, Table 9-2) 
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Figure 9-2. Increases to the case detection rate reduce the incidence 
oj drug sensitive cases. Increasing the case detection rate from 40% to 90% resulted in a 
reduction in incidence of sensitive cases. Simulations were run as described in the text for 
Scenario 1. During the final ten years of the simulations, the case detection rate was set at 
values from 40% to 90%, while the treatment cure rate was held constant at 60%. No drug 
testing or resistance treatment was included. Shown is the annual incidence rate of drug 
sensitive and resistant cases (as cases per 100,000) at the end of the simulation. 
The control parameter with the second greatest influence on disease levels was 
the cure rate. Increasing the average treatment cure rate from 60% to 80% reduced the 
annual incidence from 63.6 to 55.1 cases per 100,000. Increasing the cure rate to 90% 
reduced the annual incidence to 51.9 cases per 100,000. As shown in Figure 9-3, 
increasing the case detection and cure rates simultaneously results in further decreases 
in incidence. (Figure 9-3) 
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Figure 9-3. Increases 1o the case detection and cure rates reduce 
incidence. Higher treatment and cure rates result in lower rates of incidence. Simulations 
were run as described in the text for Scenario I. During the final ten years of the simulations, 
the case detection rate was set at values from 40% to 90%, while the treatment cure rale was 
held constant at either 60% or 80%. N o drug testing or resistance treatment was included. 
Shown is the annual incidence rate (as cases per 100,000) at the end of the simulation. 
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Figure 9-4. Increases to the case detection rate reduce the incidence oj 
cases caused by primary disease and reinfection. Higher levels of case detection and 
treatment reduce the incidence of primary and reinfection cases, but leave nearly constant the 
incidence of reactivation cases. Simulations were run as described in the text for Scenario I. 
During the final ten years of the simulations, the case detection rate was set at values from 40% to 
90%, while the treatment cure rate was held constant at 60%. No drug testing or resistance 
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treatment was included. Shown is the annual incidence rate (as cases per 100,000) at the end of 
the simulation, by type of case. Reactivation cases are due to reactivation of an earlier infection, 
primary cases are due to direct progression after infection, and reinfection is due to direct 
progression after reinfection. 
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Figure 9-5. Increasing the treatment cure rate for sensitive cases 
reduces the incidence of drug sensitive and resistant cases. The improved treatment 
cure rates reduce the incidence of both drug sensitive and resistant as cases. Simulations were run 
as described in the text for Scenario I. During the final ten years of the simulations, the first line 
cure rate was set at values from 60% to 90%, while the case detection rate was held constant at 
40%. N o drug testing or resistance treatment was included. Shown is the annual incidence rate of 
drug sensitive and resistant cases (as cases per 100,000) at the end of the simulation. 
The first-line control parameter that had the greatest influence on the resistance 
prevalence was the cure rate. Increasing the cure rate from 60% to 80% (while keeping 
the case detection rate at 40%) reduced the annual incidence of resistant cases from 8.4 
to 6.5 cases per 100,000. Increasing the cure rate to 90% further reduced resistance to 
5.9 cases per 100,000. (Figure 9-5, Table 9-2) Other first-line control measures had 
comparatively low impact on disease levels and resistance prevalence. 
Introducing drug testing and resistance treatment resulted in only slight 
reductions in resistance. Introducing drug testing and resistance treatment ol 50% of 
incident cases resulted in a reduction of annual incidence of resistance cases from 8.4 to 
8.2 cases per 100,000. Testing of a higher proportion of incident cases resulted in 
further decreases in incidence of resistance cases. (Table 9-2) However, in order to 
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achieve significant reduction of overall disease, as well as the remaining resistance, the 
case detection and cure rates must also be increased. For example, increasing the case 
detection rate to 60%, the DS cure rate to 80%, and the DST rate to 100%, the 
resistance incidence rate is reduced to 4.8 cases per 100,000. This increase in DST 
does not significantly affect the incidence of sensitive cases, which stays near 32 cases 
per 100,000. (Figure 9-5, Table 9-2) Further reductions to remaining resistance require 
higher levels of case detection, in order to find and treat new resistant cases, and to 
reduce the pool of sensitive cases from which new resistance arises. 
Introducing drug testing resulted in a reduction in the incidence of resistance 
amongst primary cases, but left that amongst reactivation cases nearly constant. 
(Figure 9-6) This shows that the instituted drug testing and resistance treatment 
reduced the ongoing transmission of resistance, lowering the incidence of resistance 
amongst primary cases. 
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Figure 9-6. Increases to the drug susceptibility testing rate (DST) reduces the 
incidence of resistant cases. Simulations were run as described in the text for Scenario I. During 
the final ten years of the simulations, the case detection rate was set at 60%, the cure rate for DS cases at 
80%. The proportion of incident cases receiving DST and resistance treatment was set at values between 
0% and 100%. The cure rate for singly resistant and MDR cases is set at 60% and 40%, respectively. 
Shown is the annual incidence rate (as cases per 100,000) at the end of the simulation, by resistance 
status. 
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Figure 9-7. Increases to the DST rate reduce the incidence of 
resistant cases caused by primary disease. Simulations were run as described in the 
text for Scenario I. During tlie final ten years of the simulations, the case detection rate was set 
at 60% and cure rate (of drug sensitive cases) was set at 80%. The drug testing rate of new 
incident cases was set at values between 0 % and 100%, as shown. The cure rale for singly 
resistant and MDR cases is set at 60% and 40%, respectively. Shown is the annual incidence 
rate (as cases per 100,000) at the end of the simulation, by type of case. Reactivation cases are 
due to reactivation of an earlier infection, primary cases are due to direct progression after 
infection. 
Shortening the average case waiting time to detection and treatment also 
provided a small reduction in incidence. The waiting time to treatment was set at 4 
months during the first twenty years of control in the simulations shown in Figure 9-7. 
During the final ten years of control, the waiting time was reduced to values between I 
and 3.5 months. Reducing the treatment waiting time from 4 months to I month 
resulted in a decrease in incidence rate from 65 to 60 cases per 100,000. While the 
incidence of drug sensitive cases was reduced from 57.2 to 51.8, the drug resistant 
incidence rate stayed fairly constant at near 8.2 cases per 100,000. (Figure 9-8) While 
shortening the time to treatment does slightly reduce the incidence of disease, the 
benefits are small compared to other measures. A higher case detection and cure rates 
are needed before treatment waiting times has a more significant impact in preventing 
disease. 
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Figure 9-8. Reducing the time to treatment reduces incidence. Shortening the 
average waiting time to case treatment from 4 months to 1 month reduced the incidence of sensitive 
cases from 57.2 to 51.8 cases per 100,000, while the incidence of resistance was only slightly reduced 
from 8.2 to 8.1 cases per 100,000. 
Simulations were run as described in the text for Scenario 1. During the first twenty years of 
control, the waiting time to treatment was set at 4 months. The treatment waiting time was either kept at 
4 months, or reduced to values from 1 to 3.5 months for the final ten years of the simulations. 
Throughout the simulations, the case detection rate was set at 40% and the treatment cure rate at 60%. 
No drug testing or resistance treatment was included. Shown is the annual incidence rate (as cases per 
100,000) of drug sensitive and resistant cases at the end of the simulation. 
V. Scenario 2: High burden region, high resistance 
V. A. Description 
The second scenario presented here is of a high burden country with a high 
prevalence of resistance. In these simulations, there is an annual incidence rate of near 
100 cases per 100,000, with a resistance prevalence of 33%. There is a first line control 
program in place, with a case detection rate of 40% and cure rate of 40%. fhere is no 
second line control in place. Treatment practices and low cure rates have allowed lor 
the emergence of high rates of resistance, which are not effectively treated under the 
current program. In addition, the ability to control the still rising epidemic is limited by 
a low case detection rate. This scenario reflects those HBCs which have medium to 
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low first line control practices, with variable treatment efficacy and practices, and have 
developed a high prevalence of resistance. 
V. B. Trends 
In these simulations, an epidemic was first run to equilibrium levels of disease, 
reaching an annual incidence rate of 280 cases per 100,000 after 100 years. Control 
was then introduced, with a case detection rate of 40% and cure rate of 40%. This 
control was maintained for twenty years, reducing incidence to 85 cases per 100,000. 
This control also resulted in an increase in incidence of resistance to 26 cases per 
100,000 (a resistance prevalence of 33%). In the final ten years of the simulations, this 
control program was improved in some way, and the results of these simulations are 
shown in the tables below. (Figure 9-9) 
First we examine the impact of maintaining the same control program for the 
final ten years of the simulation, with a case detection rate of 40% and a cure rate of 
40%, and no drug testing or resistance treatment. This results in a continued decrease 
in drug sensitive cases to an annual incidence rate of 53 cases per 100,000. The 
resistance rate, at the same time, will continue to increase to an incidence rate of 
approximately of 37 cases per 100,000 (a resistance prevalence of 41%). Due to this 
continued growth in resistance, the total incidence rate has increased slightly to 90 
cases per 100,000. (Figure 9-9) Improving the control, over the final ten years of the 
simulation, results in further decreases in disease as well as resistance. 
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Figure 9-9. Trends in incidence for simulations in scenario 2. Simulations were 
run as described in the text for Scenario 2. For the first 100 years of the simulation, the epidemic was 
allowed to equilibrate in the absence of treatment, reaching final annual incidence rate of 170 cases per 
100,000. For years 100- 130, a control program including case detection rate of 40% and cure rate of 
40% was implemented. This reduces the total incidence rate to 85 cases per 100,000, while allowing an 
increase of resistance incidence to 26 cases per 100,000. For the final years 131-140, this same control 
program was maintained. This continued control reduces the drug sensitive incidence rate to 53 cases 
per 100,000, while allowing the resistance incidence to increase to 37 cases per 100,000, combining to a 
slightly increased total incidence of 90 cases per 100,000. Shown is the annual incidence rate of total 
and resistant cases (as cases per 100,000) at the end of the simulation. 
V. C. Relative Priorities 
The control parameter that had the greatest influence on the prevalence of 
disease was the case detection rate. Increasing the case detection rate from 40% to 50% 
resulted in a reduction in annual incidence from 90.2 to 81.9 cases per 100,000. A 
further increase to 60% case detection reduced incidence to 7 5 . 4 cases per 100,000. 
(Figure 9-10) Comparing the numbers of sensitive and resistant amongst the new 
incident cases in Figure 9-10, shows that increasing the case detection rate reduced the 
incidence of drug sensitive cases, while allowing resistance to increase. Increasing the 
case detection rate to 60% reduced the incidence of sensitive cases from 52.4 to 36.5 
cases per 100,000. At the same time, the incidence of resistant cases increased slightly 
from 37.8 to 38.8 cases per 100,000. (Figure 9-10, Table 9-3) Taking another look at 
the components of new incident cases in Figure 9-11, shows that increasing the case 
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detection rate reduces the incidence of primary and reinfection cases, but leaves nearly 
constant the incidence of reactivation cases. (Figure 9-11, Table 9-3) 
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Figure 9-10. Increases to the case detection rate reduce the incidence 
of drug sensitive cases. Higher rates of case detection reduced the incidence of drug 
sensitive cases, while slightly increasing the resistance incidence. Simulations were run as 
described in the text for Scenario 2. During the final ten years of the simulations, the case 
detection rate was set at values from 4 0 % to 90%, while the treatment cure rate was held 
constant at 40%. N o drug testing or resistance treatment was included. Shown is the annual 
incidence rate of drug sensitive and resistant cases (as cases per 100,000) at the end of the 
simulation. 
0) 
05 
o : 
100 
9 0 
80 
7 0 
60 
o 5 0 
o 4 0 
;o 
o 30 
20 
10 
0 
• Primary 
S Reinfection 
• Reactivation 
40% 50% 60% 70% 80% 90% 
CDR 
Figure 9-11. Increases to the case detection rate reduce the incidence 
of cases caused by primary disease and reinfection. Higher levels of case detection 
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and treatment reduce the incidence of primary and reinfection cases, but leave nearly constant 
the incidence of reactivation cases. Simulations were run as described in the text for Scenario 2. 
During the final ten years of the simulations, the case detection rate was set at values from 40% 
to 90%, while the treatment cure rate was held constant at 40%. No drug testing or resistance 
treatment was included. Shown is the annual incidence rate (as cases per 100,000) at the end of 
the simulation, by type of case. Reactivation cases are due to reactivation of an earlier 
infection, primary cases are due to direct progression after infection, and reinfection is due to 
direct progression after reinfection. 
The control parameter with the second greatest influence on disease levels was 
the cure rate. When the average treatment cure rate was increased from 60% to 70%, 
the annual incidence was reduced from 97.2 to 89.6 cases per 100,000. Increasing the 
cure rate to 80% or 90% further decreased the annual incidence to 83.4 or 78.3 cases 
per 100,000, respectively. (Figure 9-12) 
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Figure 9-12. Increases to the treatment cure rate for sensitive cases 
reduce the incidence of drug sensitive cases. Increasing the cure rates for first line 
treatment reduces the incidence of both drug sensitive and resistant cases. Simulations were run 
as described in the text for Scenario 2. During the final ten years of the simulations, the lirst 
line cure rate was set at values from 40% to 80%, while the case detection rate was held 
constant at 40%. No drug testing or resistance treatment was included. Shown is the annual 
incidence rate of drug sensitive and resistant cases (as cases per 100,000) at the end of the 
simulation. 
The first-line control parameter with the greatest influence on resistance was the 
cure rate. Increasing the cure rate from 40% to 80% (while keeping the case detection 
rate at 40%) reduced the annual incidence of resistant cases from 37.8 to 25.5 cases per 
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100,000. (Figure 9-12, Table 9-3) Other first-line control measures had comparatively 
low impact on disease levels or resistance prevalence. 
V. D. Importance of DST and resistance cure 
In this scenario, introducing drug testing and resistance treatment under the 
current first line control program results in a slight increase in resistance. When drug 
testing is introduced on top of the current first line program with a CDR of 40% and DS 
cure rate of 40%, introducing drug testing increases resistance; when 50% of treated 
cases receive drug testing the incidence of resistance is increased from 37.8 to 40.3 
cases per 100,000. (Figure 9-13, Table 9-3) 
In this scenario, the case detection and cure rates are too low for widespread drug 
testing to be beneficial. In addition, there may be a danger in offering second line 
treatments when there are low cure rates for both sensitive and resistant cases. 
Introducing second line drugs with regimens that have low cure rates allows for further 
selection for higher levels of resistance, as well as increasing the number of drugs to 
which cases are resistant. 
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Figure 9-13. Increases to the drug susceptibility testing rate (DST) 
reduces the incidence of resistant cases. Simulations were run as described in the text 
279 
for Scenario 2. During the final ten years of the simulations, the case detection rate was set at 
40%, the cure rate for DS cases at 40%. The proportion of incident cases receiving DST and 
resistance treatment was set at values between 0% and 100%. The cure rate for singly resistant 
and MDR cases is set at 40% and 30%, respectively. Shown is the annual incidence rate (as 
cases per 100,000) at the end of the simulation, by resistance status. 
The proportion of resistance found in primary and reactivation cases is next 
examined. The implementation of drug testing and resistance treatment allows for an 
increased incidence of resistance amongst primary cases, but does not significantly 
affect that amongst reactivation cases. When 100% of incident cases receive drug 
testing, the incidence of resistance amongst primary disease cases is increased from 
35.9 to 40.6 cases per 100,000. The incidence of resistance amongst reactivation cases 
is increased slightly from 1.9 to 2.0 cases per 100,000. (Figure 9-14, Table 9-3) In 
these simulations, the inclusion of drug testing has increased the ongoing transmission 
of resistance, as reflected by the increase in resistance incidence amongst primary 
cases. 
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Figure 9-14. Increases to the DST rale reduce the incidence of resistant 
cases caused by primary disease. Simulations were run as described in the text for 
Scenario 2. During the final ten years of the simulations, the case detection rate was set at 40% 
and cure rate (of drug sensitive cases) was set at 40%. The drug testing rate of new incident cases 
was set at values between 0% and 100%, as shown. The cure rate for singly resistant and MDR 
cases is set at 40% and 30%, respectively. Shown is the annual incidence rate (as cases per 
100,000) at the end of the simulation, by type of case. Reactivation cases are due to reactivation 
of an earlier infection, primary cases are due to direct progression after infection. 
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Shortening the average case waiting time to detection and treatment also 
provided a small reduction in incidence. The waiting time to treatment was set at 4 
months during the first twenty years of control in the simulations shown in Figure 
9-15. During the final ten years of control, the waiting time was reduced to values 
between 1 and 3.5 months. Reducing the treatment waiting time from 4 months to 1 
month resulted in a decrease in incidence rate from 90 to 85 cases per 100,000. While 
the incidence of drug sensitive cases was reduced from 52.4 to 47.6, the drug resistant 
incidence rate stayed fairly constant at near 38 cases per 100,000. (Figure 9-15) 
While shortening the time to treatment does slightly reduce the incidence of disease, the 
benefits are small compared to other measures. A higher case detection and cure rates 
are needed before treatment waiting times has a more significant impact in preventing 
disease. 
100 
80 (D 
TO 
cc 60 
o 
o 
c 
0) 40 
;a 
u 
c 20 
0 
2 3 
Time to Treatment (months) 
• Sens 
• Res 
Figure 9-15. Reducing the time to treatment reduces incidence. 
Simulations were run as described in liie text for Scenario 2. During tlie first twenty years of 
control, the waiting time to treatment was set at 4 months. The treatment waiting time was 
either kept at 4 months, or reduced to values from 1 to 3.5 months for the final ten years of (lie 
simulations. Throughout the simulations, the case detection rate was set at 40% and the 
treatment cure rate at 40%. No drug testing or resistance treatment was included. Shown is the 
annual incidence rate (as cases per 100,000) of drug sensitive and resistant cases at the end of 
the simulation. 
VI. Scenario 3: Low Incidence Region 
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VI. A. Description 
This scenario reflects a low burden country, with an annual incidence rate 
below 20 cases per 100,000. The resistance prevalence is at a medium level of 5-15%. 
There is a strong first line control program, with a case detection rate of 80% and cure 
rate of 80%, but no second line control in place. The first line control program is 
strong and has reduced disease to low levels; however, if resistance remains unchecked 
will continue to increase. 
VI. B.Trends 
For the first 100 years of the simulations shown in this section, an epidemic was 
begun by introducing one drug sensitive case into a susceptible population, and allowed 
to run to equilibrium, reaching an annual incidence rate of 45 cases per 100,000. 
Control was then introduced, with a case detection rate of 80% and cure rate of 80%, 
and maintained for thirty years. This control reduced the incidence to 20 cases per 
100,000, while allowing for an increase in resistance to an incidence of 2.5 cases per 
100,000 (a resistance prevalence of 6.7%). In the final ten years, this control program 
was improved in some way, and the results of these simulations are shown in the 
following figures and tables. 
First we examine the impact of maintaining the same control program for the 
final ten years of the simulation, with a case detection and cure rates each at 80%, and 
no drug testing or resistance cure. This results in a continued decrease in d r u g sensitive 
cases to an annual incidence rate of 18 cases per 100,000. The resistance rate continues 
to increase to an incidence rate of approximately 2.5 cases per 100,000 (a resistance 
prevalence of 20%). Due to growing resistance, the total incidence rate has slightly 
increased over the course of these ten years of continued treatment, to reach 21 cases 
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per 100,000. (Figure 9-16) Improving the control, over the final ten years of the 
simulation, results in further decreases in disease as well as resistance. 
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Figure 9-16. Trends in incidence for simulations in scenario 3. 
Simulations were run as described in the text for Scenario 3. For the first 100 years of the 
simulation, the epidemic was allowed to equilibrate in the absence of treatment, reaching final 
annual incidence rate of 46 cases per 100,000. For years 100- 130, a control program including 
case detection and cure rates each of 80% was implemented. This reduces the incidence rate to 
20.8 cases per 100,000, but allows for an increase in resistance incidence to 1.3 cases per 100,000. 
For the final years 131-140, this same control program was maintained. This control reduces the 
incidence rate of drug sensitive cases to 18.6 cases per 100,000, but allows for an increase of 
resistance to 2.4 cases per 100,000, resulting in a slightly increased combined incidence rate of 
21.3 cases per 100,000. Shown is the annual incidence rate of total and resistant cases (as cases 
per 100,000) at the end of the simulation. 
VI. c. Relative Priorities 
The control parameter that had the greatest influence on the prevalence of 
disease was the case detection rate. Increasing the case detection rate from 80% to 90% 
resulted in a reduction in annual incidence from 21.3 to 18.9 cases per 100,000. The 
final incidence of sensitive cases was reduced from 18.6 to 16.1, while the resistance 
incidence stayed nearly constant at 2.7 cases per 100,000. (Figure 9-17) 
283 
• Res 
92% 96% 100% 
Figure 9-17. Increases to the case detection rate reduce the incidence 
of drug sensitive cases. Simulations were run as described in the text for Scenario 3. 
During the final ten years of the simulations, the case detection rate was set at values from 80% 
to 100%, while the treatment cure rate was held constant at 80%. No drug testing or resistance 
treatment was included. Shown is the annual incidence rate of drug sensitive and resistant cases 
(as cases per 100,000) at the end of the simulation. 
Increases to the cure rate, above the already high average of 80% treatment 
success, results in further decreases in disease levels. As shown in Figure I 8, 
increasing the cure rate to 90% (while keeping the CDR at 80%) reduces the disease 
incidence from 21.3 to 19.5 cases per 100,000. (Figure 9-18) It is further apparent 
from Figure 18 that increases to the already high case detection and cure rates do not 
result in the quick eradication of remaining levels of disease. Even at the highest levels 
of detection and cure (of drug sensitive cases), there remain a fairly constant level of 
annual incidence. 
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Figure 9-18. Increases to the case detection and cure rates reduce 
incidence. Simulations were run as described in the text for Scenario 3. During the final ten 
years of the simulations, the case detection rate was set at values from 80% to 100%, while the 
treatment cure rate was held constant at either 80% or 90%. No drug testing or resistance 
treatment was included. Shown is the annual incidence rate (as cases per 100,000) at the end of 
the simulation. 
(1) Relative importance of primary and reactivation 
disease 
In these simulations, increasing the case detection rate even to very high levels 
(above 90% of incident cases) does not result in the eradication of disease. In order to 
understand the nature of this continuing base level of incidence, the proportion of new 
cases caused by progression to primary disease, reinfection, or reactivation of a 
previous infection, is explored. Increasing the case detection rate from 80% to 100%, 
while keeping the cure rate constant at 80%, results in a reduction of incidence, as seen 
above. Increasing the case detection rate reduced the incidence of primary and 
reinfection cases, but left the incidence rate of reactivation cases nearly constant at I 1 
cases per 100,000. (Figure 9-19) Case detection combined with rapid and effective 
cure reduce the transmission of disease, and so the numbers of primary disease decrease 
soon after these are implemented. However, detection and treatment of active eases 
285 
does not reduce the incidence rates of reactivation cases, which continue to emerge 
from the pool of latently infected individuals. 
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Figure 9-19. Increases to the case detection rate reduce the incidence 
of cases caused by primary disease and reinfection. Simulations were run as 
described in the text for Scenario 3. During the final ten years of the simulations, the case 
detection rate was set at values from 80% to 100%, while the treatment cure rate was held 
constant at 80%. N o drug testing or resistance treatment was included. Shown is the annual 
incidence rate (as cases per 100,000) at the end of the simulation, by type of case. Reactivation 
cases are due to reactivation of an earlier infection, primary cases are due to direct progression 
after infection, and reinfection is due to direct progression after reinfection. 
In order to reduce remaining cases due to reactivation of earlier infection, other 
control measures need to be implemented. This includes active screening to detect 
individuals with latent infection, and chemoprophylaxis treatment to reduce the rates of 
progression to active disease. Targeting latent infections to prevent new cases may 
have more impact than simply detection of new incident cases, since in this scenario 
ongoing transmission accounts for less of new cases than does reactivation of old 
infection. 
In these simulations, the detection and treatment of new cases ol active disease 
was implemented at high levels, resulting in a reduction of disease to low levels. 1 he 
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remaining incidence results largely from reactivation of latent infections obtained many 
years earlier. The next control challenge in this scenario is reducing the final incidence 
of disease and seeking elimination. In order to accomplish this, active screening to 
detect and treat latently infected individuals is needed. In addition, the already high 
levels of case detection and treatment cure need to be maintained and where possible 
increased. 
(2) Importance of DST and resistance cure 
Increasing the rates of drug testing and resistance treatment reduces the 
incidence of resistant cases. As seen in Figure 9-20, higher rates of drug testing results 
in a reduction in the resistance incidence. Increasing the proportion of incident cases 
receiving drug testing and resistance treatment (pDST) from 0 to 100% results in a 
decrease in final resistance incidence from 3 to 1 cases per 100,000. This improvement 
in detection and treatment of resistance does not significantly affect the incidence of 
sensitive cases, which stays constant at near 18 cases per 100,000 in these simulations. 
(Figure 9-20) 
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Figure 9-20. Increases to the drug susceptibility testing rate (DST) 
reduces the incidence of resistant cases. Simulations were run as described in the text 
for Scenario 3. During the final ten years of the simulations, the case detection rate was set at 
80%, the cure rate for DS cases at 80%. The proportion of incident cases receiving DST and 
resistance treatment was set at values between 0% and 100%. The cure rate for singly resistant 
and MDR cases is set at 70% and 50%, respectively. Shown is the annual incidence rate (as 
cases per 100,000) at the end of the simulation, by resistance status. 
(3) Resistance from primary and reactivation cases 
The proportion of resistance found in primary and reactivation cases is next 
examined. When no drug testing or resistance treatment is offered, 90% of the drug 
resistance incidence is due to ongoing transmission of primary cases. The 
implementation of drug testing and resistance treatment reduces the incidence of 
resistance amongst primary cases, but does not significantly affect that amongst 
reactivation cases. When 100% of incident cases receive drug testing, the incidence of 
resistance amongst primary disease cases is reduced from 2 to 0.2 cases per 100.000. 
The incidence of resistance amongst reactivation cases is reduced from 0.2 to 0.1 cases 
per 100,000. After 10 years of 100% DST, 65% of the resistant incidence is due to 
ongoing primary transmission. ( 
Figure 9-21) 
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Figure 9-21. Increases to the DST rale reduce the incidence of resistant 
cases caused by primary disease. Simulations were run as described in the text for 
Scenario 3. During the final ten years of the simulations, the case detection and cure (of drug 
sensitive cases) rate was set at 80%. The drug testing rate of new incident cases was set at 
values between 0 % and 100%, as shown. The cure rate for singly resistant and MDR cases is 
set at 70% and 50%, respectively. Shown is the annual incidence rate (as cases per 100,000) at 
the end of the simulation, by type of case. Reactivation cases are due to reactivation of an 
earlier infection, primary cases are due to direct progression after infection. 
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Table 9-2. Scenario 1: First-line Control Measures: Impact of improvements to 
control parameters on incidence in high burden country 
Incidence rate Incidence DS 
cases 
Incidence DR 
cases 
Control measure Incidence rates after 10 years this control 
CDR Cure rate 
40%, 60% 636 55.2 8 .4 
50%s 60% 53 .8 45 .7 8.2 
60%s 60% 4 6 . 0 380 7.9 
70%s 60% 39 .7 32 0 7.7 
80%% 60% 34.7 272 7.5 
90%,, 60% 308 23 .4 7 .3 
Control measure Incidence rate Incidence DS 
cases 
Incidence DR 
cases 
CDR Cure rate Incidence rates after 10 years this control 
40%, 80% 55.1 48 .5 6 .6 
50%^ 80% 45 .6 3&3 6 .3 
60%, 80% 383 322 6.1 
70%, 80% 32 8 2&8 5.9 
80%, 80% 285 227 5.8 
90%s 80% 25 .2 19.5 5.7 
Control measure Incidence rate Incidence DS 
cases 
Incidence DR 
cases 
CDR Cure rate Incidence rates after 10 years this control 
40%, 90% 51.9 45 .9 5.9 
50%^ 90% 426 36 9 5.7 
60%, 90% 356 30.1 5.5 
70%,, 90% 303 25.0 5.4 
80%, 90% 264 21.1 5 .3 
90%^ 90% 234 18.1 5.2 
Scenario 1: Second-line Control Measures: Impact of improvements to control 
Control measure Incidence rate Incidence 
DS cases 
Incidence 
DR cases 
CDR Cure 
rate 
DST Incidence rates after 10 years t lis control 
40%,, 60% 0% 636 55 .2 8.4 
40%, 60% 50% 6 3 . 4 55 .2 8.2 
40%,, 60% 100% 6 3 . 4 55 .2 8.2 
60%^ 80% 0% 38 .3 32 .2 6.1 
60%, 80% 50% 37 .4 322 5.2 
.60%, 80% I0&% 37.0 32 .2 4.8 
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Table 9-3. Scenario 2; First-line Control Measures: Impact of improvements to control 
parameters on incidence in high burden and resistance region 
Control measure Incidence rate Incidence DS 
cases 
Incidence DR 
cases 
CDR Cure rate Incidence rates after 10 years this control 
40%^ 40% 90 .2 52.4 37 .8 
50%, 40% 81.9 43 5 38 .4 
60%, 40% 75 .4 36.5 38 .8 
70%, 40% 70 .2 31.1 39.1 
80%, 40% 66.1 268 39 .3 
90%, 40% 6 3 . 0 23.4 39 .5 
Control measure Incidence rate Incidence DS 
cases 
Incidence DR 
cases 
CDR Cure rate Incidence rates after 10 years this control 
40%^ 60% 78 .2 47 .7 30 .5 
50%, 60% 69 .6 39.0 30.6 
60%, 60% 63 .0 32.4 30 .6 
70%, 60% 580 27.3 30 .7 
80%, 60% 54 .3 23 5 30.8 
90%, 60% 51 .4 20.5 30 .9 
Control measure Incidence rate Incidence DS incidence DR 
cases cases 
CDR Cure rate Incidence rates after 10 years this control 
40%^ 80% 695 44.0 25 .5 
50%^ 80% 60 .9 35.5 25 .4 
60%^ 80% 54.6 29 3 25 .4 
70%, 80% 50.1 24.6 2 5 . 4 
80%, 80% 46 .7 21.1 25 .6 
90%, 80% 44.1 18.4 25 .8 
Scenario 2: Second-line Control Measures: Impact of improvements to control 
Control measure Incidence rate Incidence 
DS cases 
Incidence 
DR cases 
CDR Cure 
rate 
DST Incidence rates after 10 years t lis control 
40%, 40% 0% 90 .2 52.4 37 .8 
40%, 40% 50% 92 .4 52.1 4 0 . 3 
40%, 40% 100% 94.5 51.8 42 .7 
40%^ 80% 0% 69 .5 44 .0 2 5 . 5 
40%^ 80% 50% 68 .7 44 .0 24 .7 
40%, 80% 100% 68 .2 44 .0 24 .2 
90 .2 52.4 37 .8 
Table 9-4. Scenario 3: First-line Control Measures: Impact of improvements to control 
parameters on incidence in low burden region 
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Control measure Incidence rate Incidence DS 
cases 
Incidence DR 
cases 
CDR Cure rate Incidence rates after 10 years this control 
80% 80% 2 1 3 18.6 2 .7 
85% 80% 19.8 17.1 2 .8 
90%s 80% 18.9 16.1 2 .8 
95%, 80% 17.7 14.9 2 .8 
Control measure Incidence rate Incidence DS 
cases 
Incidence DR 
cases 
CDR Cure rate Incidence rates after 10 years this control 
80% 90% 19.5 17.2 2.31 
85% 90% 18.1 15.7 2 .34 
90%^ 90% 17 .3 14.9 2 . 3 5 
95%s 90% 16.1 13.8 2 .36 
Control measure Incidence rate Incidence 
primary 
cases 
Incidence 
reinfection 
cases 
Incidence 
reactivation 
cases 
CDR Cure rate Incidence rates after 10 years this control 
80% 80% 21^ 8.7 1.16 11.4 
85% 80% 19 8 7.5 0 .99 11.3 
90%s 80% 18.9 6.8 0.88 11.3 
95%^ 80% 17.7 5 .8 0.74 11.2 
Scenario 3: Second-line Control Measures: Impact of improvements to control 
Control measure Incidence rate Incidence 
DS cases 
Incidence 
DR cases 
CDR Cure 
rate 
DST Incidence rates after 10 years t lis control 
80%, 80% 0% 2 1 . 3 18.6 2 .7 
80% 80% 50% 19 .6 18.7 0 .9 
80% 80% 100% 19.2 18.7 0 .5 
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VII. Discussion: 
VII. A. High Burden Countries 
The WHO has classified 30 countries as high burden countries, which together 
account for over 90% of all TB cases globally. The incidence rates in these countries 
range from about 60 to over 200 cases per 100,000. (WHO 2003) (Netto, Dye et al. 
1999) Only several of these countries were represented in recent drug resistance 
surveillance studies, allowing limited estimates of resistance prevalence amongst the 
HBC. Amongst the countries participating in the resistance surveillance studies, 
resistance prevalence ranged from 1 to 37%. Several countries reported a high 
incidence rate but low resistance (under 10%), including Malaysia, Nepal, Botswana, 
South Africa (Mpumalanga district), and Morocco (Casablanca). Other high burden 
countries showed drastically high resistance levels of 30-37%, including the Russian 
Federation, Latvia, Estonia, and China (Henan Province). (WHO/IUATLD 2000) 
VII. B. Scenario 1: High incidence low resistance 
In this scenario, there is a high burden of disease and a low level of drug 
resistance. The institution of control at the level of 40% case detection with a 60% cure 
rate has led to a gradual reduction in disease, while selecting for resistance. In order to 
continue to reduce disease in this scenario, the case detection and cure rates need to be 
increased. These two control parameters have the greatest influence on the course of 
the epidemic in this scenario. Increasing other parameters, including time to treatment, 
drug testing, and resistance cure, has a comparably small impact on disease levels. 
This scenario has some similarities to regions with high disease and low 
resistance levels. These include parts of South Africa (Mpumalanga province). 
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Botswana, Malaysia, Nepal, Singapore, Barcelona Spain, Korea, and Guinea. 
(WHO/IUATLD 2000) 
(1) CDR and cure rates: Limits to case detection in 
developing country settings 
Increasing the case detection rate in a developing country setting involves a 
number of challenges. Barriers to increasing case detection may include health 
infrastructure and limited access to health care. Only individuals who have routine 
access to heath services are likely to be detected through passive screening, in which 
cases are diagnosed from amongst patients who report with symptoms. In addition, 
there may be inappropriate diagnosis due to lack of familiarity with recognizing the 
symptoms and treatment of TB. Diagnosis may also be affected by the effectiveness 
and use of diagnostic methods. (Shimao 1998) Furthermore, in many developing 
country settings, cases may be diagnosed by haphazard methods. Often practitioners, 
outside of regulated DOTS programs, will begin treatment after recognizing symptoms 
through routine physical examination. Such presumptive treatment is given without 
mycobacterial confirmation or chest x-ray. (Shimao 1998) 
There may also be some real or program limits to case detection. Most new 
cases detected under DOTS programs reflect those previously detected under non-
DOTS programs. As a global average, case detection rates under any program have 
remained near 40% of estimated incidence for nearly 20 years. (WHO 2002; WHO 
2003) Programs need to address how to reach new, currently undetected, cases that 
may be beyond reaches of the health care systems in these countries. Increasing the 
case detection rate in the high burden countries will mean reaching sectors of the 
population currently beyond the reach of general health services. 
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An alternative theory is that there is a higher true case detection rate, but that 
current estimates of incidence are limited. First, the estimates of the proportion of 
cases detected depend in turn on estimates of the true incidence rate. If incidence rates 
have been overestimated, then the predicted undetected cases may not exist. Second, 
these cases may exist, and receive treatment, but not be reported to national programs. 
This may be of particular concern in private sector treatment removed from national 
regulation and surveillance. (WHO 2002; WHO 2003) 
(2) Constraints to expansion 
The most common constraints to expanding DOTS coverage in high burden 
countries have been identified as lack of technical support, health infrastructure, 
decentralization of health services and private sector treatment. (WHO 2003) Thus, 
increases to case finding in these settings should include improvements to health 
infrastructure, expansion of coverage of access to health care as well as NTP programs, 
and education of practitioners on symptoms and diagnosis of active cases. 
Increasing the average treatment cure rate will similarly require a number of 
challenges to be met. These may include improvements to health care, NTP programs, 
patient management, and steady supply of quality drugs. In addition, strong training of 
medical officers and technical support is required. Much of this is achieved through 
expansion of DOTS, which provides structure for a regulated and coordinated global 
treatment program. 
In addition, bringing cases which are usually detected and treated in the private 
sector into public NTP programs is important. Throughout the high burden countries, 
the treatment success rates are higher amongst cases treated under DOTS programs 
than non-DOTS. Cases treated in the private sector generally have shown lower cure 
rates. 
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Another useful measure is reporting to organized centers of excellence, which 
offer proficient diagnosis and treatment, as well as a high level of supervision and 
management. This is particularly important for cases which have failed previous 
courses of treatment, have suspected resistance, or are at high risk for failure. 
(3) Treatment waiting time 
Reducing the time to treatment, in this scenario, results in only a small 
reduction in incidence. This is limited by the still low case detection and cure rates. 
Increasing the case detection and cure rates has far greater impact on the course of the 
epidemic than changing the waiting time to treatment. 
A number of studies have proposed introducing faster diagnostic methods, 
suggesting that wide scale availability of faster diagnosis would significantly improve 
the control of TB in HBCs. The possible benefits of large scale faster diagnosis have 
been suggested, but not analyzed in models of TB control. For example, using a PCR-
based diagnostic test could conceivably reduce the time to diagnosis from 3+ weeks to 
less than 1 week. (Heymann, Brewer et al. 1997) Other means to reducing the time to 
treatment include improved general access to medical resources, improvements to 
overall health infrastructure, and education on symptoms and treatment of TB. Again, 
each of these measures may result in reduced average case time to treatment, thus 
reducing ongoing transmission and disease incidence. 
VII. C. Scenario 2: High burden high resistance 
This second scenario represents the most serious of public health concerns, in 
which a high prevalence of resistance has already emerged, and if left unchecked, may 
continue to increase and develop into self-sustaining cycles of a resistant epidemic. 
The most important concern in this scenario is first improving program conditions. 
Program coverage should not be expanded or wide-scale second line regimens offered, 
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until these conditions have improved to the extent that new drug sensitive cases are 
treated effectively with a low risk of developing resistance. 
The largest uncertainty in model predictions comes from parameter estimates 
for the probability of acquiring resistance given treatment failure and the relative 
transmission rate of resistant strains. If the resistant strains have equal transmission to 
the drug sensitive, the emerging resistant epidemic will be even more difficult to 
control, and continuing or expanding first line treatment under current program 
conditions will increase selection for resistance and exacerbate the situation. 
(1) Improving program conditions 
Increasing the treatment cure rates and reducing the probability of acquiring 
resistance is likely to involve many factors outside the scope of national TB treatment 
programs. This may include improvements to general health care infrastructure and 
access. Poor socio-economic conditions have also been associated with higher rates of 
acquired resistance. Higher rates of resistance have also been found in regions with 
otherwise strong NTPs, which maintained high detection and cure rates, but which were 
torn by war or other social and political conflicts. Such turmoil may facilitate 
conditions in which optimal treatment patterns are far more difficult to obtain, and may 
lead to haphazard drug usage. (Chaulet and Zidouni 1998) (WHO/IUATLD 2000) 
One of the most important considerations in reducing rates of acquired 
resistance is providing a steady supply of quality drugs for the duration of patient 
treatment. Without assurances of a steady supply needed to complete a course of 
treatment, patients may end up on a sub-optimal regimen in order to conserve drug 
resources, or may take drugs intermittently or only for a shortened duration. Each of 
these could rapidly select for resistance, particularly if cases continue on effective 
monotherapy. (Iseman 1999) (Chaulet and Zidouni 1998) R a t e s of acquired resistanc
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have also been correlated with program errors, including misdiagnosis, effective 
monotherapy, and delayed treatment. Improvements to patient supervision and care 
may decrease the rate of treatment errors and with this the probability of acquired 
resistance. (Janmeja and Raj 1998) (Mahmoudi and Iseman 1993; Chaulet and Zidouni 
1998) Referring cases to specialized centers, which are able to provide a standardized 
high level of care, may both increase the cure rates and reduce the probability of 
resistance. 
(2) Drug resistance treatment 
Surveillance of drug resistance on a regional and individual case basis is an 
important consideration in this scenario. However, this may not be feasible given 
limitations on financial and technical resources. Drug testing requires additional 
technical expertise and laboratory resources. Second line regimens are also 
prohibitively expensive and because of longer duration, increased toxicity and side 
effects, these regimens are more difficult to manage. Programs that are unable to 
achieve high cure rates on the shorter first line SCC regimens are unlikely to offer even 
reasonable success rates with the second line regimens. In addition, offering second 
line regimens with low levels of regulation and management allows the opportunity for 
rapid selection of higher levels of resistance. This would select for resistance to all of 
the current drugs, increasing the prevalence of cases that are untreatable under these 
conditions. (Loddenkemper, Sagebiel et al. 2002) (Bastian, Rigouts et al. 2000) 
(Bahrmand, Velayati et al. 2000) (Dye, Williams et al. 2002) 
Some programs have been able to include specialized MDR treatment within 
existing program conditions. High levels of success have been achieved in Peru, where 
MDR cases are refeired to separate treatment centers of expertise, where cases receive 
high level of care and supervision. Establishing such regional centers for resistance 
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treatment is a plausible alternative that may prove useful in other high burden settings. 
(Loddenkemper, Sagebiel et al. 2002) (Bastian, Rigouts et al. 2000) 
VII. D. Scenario 3: Low incidence 
The third scenario presented is of a relatively low incidence region with a 
medium level of drug resistance, which has implemented high levels of first line 
control. The greatest benefits in this scenario would come from control measures not 
included in our model, which would involve the active detection and treatment of 
latently infected individuals. 
Increasing the case detection rate slightly reduces disease levels. Similarly, 
improving the cure rate for drug sensitive cases results in a small decrease in disease 
levels. Even when both the case detection and cure rate are at very high levels (above 
90%), there remains a continual base incidence of new drug sensitive cases. More than 
90% of these incident cases were caused by reactivation of an earlier infection. 
Increases to case detection and case cure rate reduce the incidence of cases caused by 
primary progression and reinfection, but do not significantly influence the incidence of 
reactivation cases on the timescale of ten years examined here. 
In order to reach the elimination phase o fTB disease, control measures must be 
targeted to reduce the incidence of cases caused by reactivation of an earlier infection. 
Such measures include active screening for latent infection and chemoprophylaxis 
treatment to reduce the rate of progression to active disease. In addition, control 
priorities should be to maintain, and where possible increase, the already high levels of 
case detection and cure. Instituting drug testing of new incident cases, concomitant 
with effective resistance treatment, results in a decrease in resistance. However, as 
resistance accounted only for a small proportion of incidence, even a strong second line 
program will not affect the continuing incidence of drug sensitive cases. 
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(1) Priority setting 
The priorities in this setting are to move from a focus on treatment to 
prevention. In order to enter the elimination phase of the TB epidemic, the base level 
of incidence caused by reactivation of latent infections must be reduced through active 
case finding and chemoprophylaxis treatment. Active screening programs are best 
targeted to high risk groups, of which the most significant are immigrants from high 
burden regions and contacts of infectious cases. (Lillebaek, Andersen et al. 2001) 
(Gilpin and Hammond 1987; CDC 1998; Dasgupta, Schwartzman et al. 2000; Marks, 
Taylor et al. 2000; Society 2000; Broekmans, Migliori et al. 2002) 
These recommendations are in line with those in many of the low incidence 
developed countries. In Europe, the recommendations include active screening 
programs, particularly amongst high-risk groups. (Broekmans, Migliori et al. 2002) In 
the United States, recommendations for control also focus on increased active case 
finding and preventative treatment. This includes screening within high-risk groups 
such as foreign-born, contacts of infectious cases, and AIDS cases. (CDC 1998) 
(2) Reducing incidence of reactivation disease 
The best means to target new reactivation cases is through active screening to 
detect latently infected individuals and chemoprophylaxis treatment to reduce the rate 
of progression to active disease. Such active screening programs have been 
implemented in various degrees throughout much of the developed world. In 
particular, screening amongst contacts of infectious cases and high risk groups have 
been effective means of finding newly infected and disease cases. 
Contact tracing, combined with chemoprophylaxis treatment for infected 
individuals and full treatment for new cases, has been shown to reduce disease levels. 
(Styblo, van Geuns et al. 1984) Models have been used to illustrate the benefits of 
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active screening programs. Other models have shown the cost effectiveness of contact 
tracing in terms of preventing new cases, which would have to undergo full medical 
treatment. Models have also shown the benefit, in terms disease reduction, of contact 
tracing and chemoprophylaxis treatment. (Murray and Salomon 1998; Murray 2002) 
Cost effectiveness studies have shown the benefits of active screening programs 
amongst immigrants. Chemoprophylaxis treatment of immigrants from regions of high 
resistance reduces health costs. In addition, using regimens appropriate to these 
patterns, and not using INH when there is high RIF prevalence, reduces selection for 
MDR and concomitant increased health costs. (Khan, Muennig et al. 2002) 
Difficulties in expanding case finding programs in low incidence countries may 
include several obstacles. First, general knowledge about TB disease and symptoms in 
the general population may not be sufficient. This is central to maintaining rapid case 
reporting, and becomes increasingly important in areas where TB is uncommon and 
failure to recognize symptoms may cause delays in case detection. Second, as case 
numbers drop, local authorities may become less familiar with detecting and treating 
cases, and treatment standards may fall. If necessary, regional centres may be 
established which maintain the technical expertise for diagnosis and treatment of cases. 
Local authorities and health practitioners must still be educated and alerted to recognize 
the symptoms of active TB and the procedures for handling cases. (American Thoracic 
Society 2000; Society 2000; Broekmans, Migliori et al. 2002; Blumberg, Burman et al. 
2003) 
(3) Relative importance of ongoing transmission 
In this scenario, a high proportion of incidence was due to reactivation of latent 
infections. The relative importance of ongoing transmission to the continuation of the 
epidemic in such settings has been discussed in numerous studies. High levels of 
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primary disease have been found under strong control programs, as estimated by 
contact tracing and strain testing. 
VIII. Summary of Findings 
In this chapter, priorities in control of local TB epidemics are further explored. 
Three scenarios, with representatively different levels of disease burden and control, 
were examined. The impact of implementing the first and second line control 
measures, as described in the previous chapter, is tested in each of these settings. 
The first setting is a high burden country with a low prevalence of resistance. 
There is a medium level of control, with a case detection rate of 40%, treatment cure 
rate of 50%, and no drug testing or resistance regimens. In this scenario, the control 
priorities lie with reducing the disease burden through increasing case detection and 
treatment cure rates. 
The second setting is a high burden country with a high prevalence of 
resistance. There is a high level of case detection, but poor treatment, which has led to 
a growing resistance problem. In this scenario, the control priorities are two-fold: 
reduce disease burden through increasing case detection, and control the emerging 
resistance epidemic by improving program conditions and increasing treatment cure 
rates. The availability of resources will be a key factor in determining how control 
should be improved. First, program conditions should be improved ensuring high rates 
of treatment success with low rates of acquired resistance. Second, case detection rates 
should be expanded. And third, resistance regimens should be given either 
automatically to cases failing first line regimens, or to cases confirmed to have 
resistance after drug susceptibility testing. 
The third setting is a low burden country, with strong first line control, entering 
the elimination phase of TB. The control priorities in this setting are markedly 
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different: with a strong control program already in place and a low incidence rate, 
priorities may now change to those consistent with an elimination phase. This includes 
improvements to all elements of the first and second line program. While high rates of 
case detection and cure have reduce the incidence of primary disease, a low base level 
of disease due to reactivation of previous infection. In order to reduce incidence 
towards final elimination, additional control measures are needed. These should be 
targeted towards detection of latently infected individuals and chemoprophylaxis 
treatment to reduce rates of progression to primary disease. 
The two high burden settings, typically found in developing countries, generally 
have limited financial and technical resources. As the disease burden is still high, 
priorities lie with reducing disease levels through detection and treatment of cases. 
There is unlikely to be remaining resources available for introducing second line 
control in these settings; and doing so would bring only small benefits in terms of 
disease reduction compared to increased rates of detection. Further, introducing second 
line drugs under poor conditions allows for selection for resistance to more drugs, 
resulting in accumulation of cases increasingly difficult to treat under any program 
conditions. Rather, limited resources should be focused on reducing disease burden by 
increasing coverage and cure rates of the first line program, as much as possible. 
IX. Conclusions 
1. In high burden countries priorities should lie with increasing case detection 
and treatment cure rates. 
2. In high burden countries, resistance may emerge rapidly, particularly if 
there have been poor program conditions for a prolonged period. In these 
situations, the priorities lie with first improving program conditions such 
that new drug sensitive cases are treated effectively with a low rate of 
303 
acquired resistance. Only once the first line program has been 
strengthened should DST and resistance treatment be included in order to 
reduce the resistance prevalence. 
3. In low incidence countries, priorities lie with eliminating disease and 
reducing resistance. In order to accomplish both, improved case detection 
(above already high levels) as well as drug susceptibility testing of all 
incident cases should be implemented. In addition, active screening to 
detect latently infected individuals and chemoprophylaxis treatment are 
needed to reduce incidence of reactivation cases. 
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10. Conclusions: 
The emergence, transmission and control of 
resistance within TB epidemics 
In this thesis, mathematical models are used to inform on the process for the 
emergence, transmission, and control of resistant tuberculosis epidemics. This work 
contributes to the understanding of the conditions under which resistance emerges and 
reaches high levels, providing insight as to why there is such variability in the rates of 
resistance found in surveillance. The balance of priorities in control of resistance is 
also considered within the context of continuing epidemics and under existing program 
conditions. In this concluding chapter, 1 highlight key questions for future research, 
including mathematical analyses, experiments, and control. 
In tenns of control for overall control for epidemics and resistance, the priorities 
continue to lie with increased case detection and treatment, particularly in the 22 High 
Burden Countries. The analysis presented here should alert additional concern over 
control of resistance in regions with poor treatment practices and the possibility for 
increases in the resistance prevalence to alarming levels. Despite the range of 
difficulties presented to control in these regions, efforts need to be focused on 
improving the conditions for case detection, management, and efficacy of treatment. It 
is further hoped that the guidelines for control of resistance presented here will inform 
policy, showing the need for tuberculosis control programs in all environments to 
address resistance, and to assist the process of deciding how to best include the 
management of resistance within current programs. 
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I. Global burden of TB resistance 
Resistance to the commonly used anti-mycobacterial drugs was first observed 
shortly after the introductive of effective chemotherapy in the 1950s. (Mitchison 1950; 
Buck 1952; Hobby 1952; Middlebrook 1952; Steenken 1952; Szybalski 1952; Barnett 
1953) Studies throughout the 1960s and 1970s showed that resistance emerged rapidly 
under the common regimens of the day, which often involved the use of only one drug. 
(Mitchison 1969; Mitchison 1970) Such monotherapy reduced mortality rates, 
prolonging the life of patients, although a high proportion remained infectious. Such 
chronically infectious cases, were at high risk of developing resistance. When these 
limitations of monotherapy were realized, regimens began to be improved to include 
two drugs, and were shown to reduce the rates of acquired resistance to either of the 
drugs used. (Medical Research Council 1955; Crofton 1960; Barry 1964; Hobby, 
Johnson et al. 1969; Tripathy, Menon et al. 1969) With the introduction of rifampicin 
in the 1970s and the establishment of short course chemotherapy regimens involving at 
least four drugs, significantly higher cure rates were achieved and resistance appeared 
to be less of a problem. (Dickinson and Mitchison 1970; Fox and Mitchison 1975; Fox 
and Mitchison 1976; Mitchison 1979) 
In global surveys of TB drug resistance over the past decade, resistance has 
been found in every region of the world surveyed. It remains unclear, however, 
whether resistance poses a serious problem to the control of TB epidemics. In some 
localized regions, the prevalence of resistance has risen to high levels, contributing to 
over 30% of the case incidence. In other regions, resistance remains at low levels and 
is largely managed by programs based on first line treatment of drug sensitive cases. 
(WHO/IUATLD 1997; WHO/IUATLD 2000; WHO 2003) What distinguishes these 
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scenarios, in terms of where resistance will emerge to high levels? And, under what 
conditions does resistance pose a serious threat to the control of local TB epidemics? 
II. Summary of main findings 
The understanding of the spread, persistence, and control of M tuberculosis has 
been assisted at many levels by analysis based on mathematical models. Over the past 
decade a number of studies have used mathematical models to explore the dynamics of 
TB epidemics, as was reviewed in Chapter 4. In this thesis, mathematical models have 
been developed and used to investigate the dynamics of the emergence of resistance 
within TB epidemics and strategies for their control. This work contributes to the 
understanding of tuberculosis epidemics and the evolution of resistance on several 
levels. First, the model developed here offers a framework for considering the 
emergence and persistence of resistant TB epidemics, and insight into the conditions 
that favor the emergence of resistance. Second, these models have been used to 
consider priorities for control of resistance. 
II. A. Emergence of resistance 
The conditions for the emergence of resistance within TB epidemics have been 
examined in this thesis, using the model for the emergence and transmission of resistant 
TB presented in Chapter 5. The model presented here incorporates both acquired and 
primary resistance, as well as interaction between sensitive and resistant strains, which 
as outlined in Chapter 4, are important points not included in previous models. This 
allows for consideration of the conditions for emergence of resistance during treatment, 
as well as for competition with other strains and transmission through the population. 
On a local level, the emergence of resistance occurs through inadequate treatment that 
allows for the selection of resistance. These practices influence the rates oi acquired 
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resistance. On a regional level, the ability of the emerging resistant strains to transmit 
infection, compete with other strains, and continue an epidemic will determine the 
success of the resistant pathogens and the levels of primary resistance. 
As for all modeling studies, the robustness of the conclusions are limited by the 
quality of parameter estimates. The sensitivity analysis presented in Chapter 6 provides 
an understanding of how the model outcome depends on the parameter estimates, and 
showed that within the range of parameter uncertainty, the model can still delineate 
important conclusions. As expected, the model shows increasing treatment rates 
reduces disease and selects for resistance, dependent on the quality of treatment. Under 
good control, with high treatment rates and efficacy, there is a lower incidence of 
disease, as well as a limited emergence and spread of resistance. In comparison, under 
poor control there is higher incidence as well as greater range in incidence, reflecting a 
greater opportunity for spread. Further, the low cure and higher acquired resistance 
rates under poor control result in higher resistance levels and greater range in resistance 
prevalence. In order to address potentially serious emerging epidemics in such regions, 
the emergence of resistance should first be minimized by improving control practices, 
focusing on quality of treatment and then expanding coverage. 
Examining model behavior at equilibrium brought further understanding as to 
the conditions under which resistant epidemics would emerge. Solving the model at 
equilibrium also allowed for the definition of the basic and effective reproductive 
numbers for each strain in terms of model parameters. This analysis provided insight 
into the conditions for the emergence of resistance within TB epidemics. This can best 
be understood by comparing the effective reproductive numbers, which reflect on the 
strain fitness. First, competition between sensitive and resistant strains depends upon 
their relative fitness. Second, resistance cannot be eradicated unless all sensitive strains 
are also eradicated, as resistance will continue to emerge from the treatment of sensitive 
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cases. Third, treatment has a differential impact on the fitness of each strain, with the 
implication that the conditions for eradication of each strain will differ, making it 
possible for one strain to succeed while another is removed under the same program. 
Maintaining low cure rates over a high proportion of the population may allow for the 
clearance of sensitive strains, while allowing resistance to increase. In order to reduce 
the prevalence of all strains, high notification and cure rates are required. 
II. B. Control of resistance 
In the final chapters of this thesis, the control practices for resistant tuberculosis 
were considered. In Chapter 7, a model for the control of tuberculosis is presented, 
based on the model for emergence and transmission developed in Chapter 4. The 
model accounts for control practices including case detection, drug susceptibility 
testing, and treatment with different regimens. The model also incorporates treatment 
times, including time to treatment, the duration of treatment, and time to return drug 
testing results. 
Using this model, the control of resistance is explored in Chapter 8. Introducing 
treatment into a population is beneficial in terms of reducing disease levels, even if the 
treatment offered attains only low cure rates. Treatment also selects for drug 
resistance, which is more prevalent under high treatment and low cure rates. Increasing 
treatment rates within a population shortens case duration of infectiousness, allows for 
faster cure, and reduces ongoing cycles of transmission, leading to reduced incidence 
and prevalence of disease. However, caution is necessary if there are high rates of 
acquired resistance, as may occur under poor control practices. The flame of an 
emerging resistance epidemic may be fanned by increasing the treatment rates whilst 
the quality of treatment remains poor. 
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Introducing a second line control program, including the drug testing of a 
proportion of treated cases and specialized regimens, reduces resistance as well as 
disease levels. The success of the second line program rests upon the strength of the 
first line program; resistant cases can only be treated once detected, and ensuring high 
first line cure rates reduces the emergence of new resistant cases. 
In Chapter 9, the priorities for control of resistance are further developed by 
considering epidemics in several representative scenarios. The first two settings 
represent high burden countries (HBC), differentiated based on the level of resistance 
and control. In HBCs with low resistance, priorities should focus on increased case 
detection and first line cure rates. These control measures have the greatest impact on 
both disease and resistance levels. HBCs with high levels of resistance, which may 
have poor health infrastructure, low levels of DOTS, and low cure rates, face the most 
serious of global TB challenges. In the absence of immediate and drastic 
improvements in provision of TB care, treatment, and case detection, preferably 
supplemented by specialized treatment for resistant cases, the situation here grows 
more serious. As poor treatment practices are maintained, the resistance epidemic 
continues to grow unchecked by 2"^ line control measures. The resistance problem 
becomes more serious with time, as highly resistant cases are produced which are not 
easily treated or controlled by the current system. In this scenario, the control priorities 
are two-fold: reduce disease burden through increasing case detection, and control the 
emerging resistance epidemic by improving program conditions and increasing 
treatment cure rates. The availability of resources will be a key factor in determining 
how control should be improved. First, program conditions should be improved 
ensuring high rates of treatment success with low rates of acquired resistance. Second, 
case detection rates should be expanded. And third, resistance regimens should be 
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given either automatically to cases failing first line regimens, or to cases confirmed to 
have resistance after drug susceptibility testing. 
Overall, in high burden regions the priorities lie with reducing disease levels 
through detection and treatment of cases. As most high burden regions are found in 
developing countries with limited health resources, resources should be focused on 
improving the quality of treatment, ensuring high cure rates, and then expanding first 
line treatment programs. There are unlikely to be remaining resources available for 
introducing second line control in these settings; and doing so would bring only small 
benefits in terms of disease reduction compared to increased rates of detection. 
Further, introducing second line drugs under poor conditions allows for selection for 
resistance to more drugs, resulting in accumulation of cases which are increasingly 
difficult to treat under any program conditions. 
In those settings with low incidence, which have already established strong 
levels of control, priorities can move beyond the 1 '^ and 2"^ line control measures 
examined here. In particular, active screening for the detection and treatment of latent 
cases, which are a cause of a high proportion of annual incidence, has the most 
significant impact in reducing disease. Implementing or improving 2"'' line control of 
resistant cases is important for reducing resistance. Reductions to treatment waiting 
times also reduce incidence, but again this effect is small compared to that brought 
about by prevention of new reactivation cases. 
III. Previous work 
Here, 1 briefly review studies within the field that have led up to or addressed 
similar work as that in this thesis, and consider how the work and conclusions compare. 
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A. Models 
The relevant literature on mathematical modeling studies of tuberculosis is 
reviewed in Chapter 2. Several key points brought out through the modeling analyses 
developed in this thesis have also been made in previous modeling studies. 
For example, previous modeling studies of infectious diseases have shown that 
resistance develops under poor treatment programs. In the models developed within 
this thesis, as shown in Chapters 5 and 6, it is shown that resistance develops under 
poor treatment conditions. This work goes further than previous in showing the 
dynamics for the emergence of resistance over time within TB epidemics, as well as 
showing how the level of acquired resistance is a reflection on the treatment state of 
program. 
The modeling of competition between multiple strains is also a theme in this 
thesis, and the basis of the model developed here. Previous modeling studies have 
examined different types of multiple strains within an epidemiological context. For 
example, studies have modeled the competition between drug sensitive and resistant 
strains within epidemics. (Lipsitch and Levin 1997; Schrag, Perrot et al. 1997; Lenski 
1998; Andersson and Levin 1999) A few studies have also considered spread of 
sensitive and resistant strains within a TB epidemic. (Levin, Lipsitch et al. 1997; 
Blower and Gerberding 1998) The current work adds to field the first comprehensive 
analyses of multiple sensitive and resistant strains. In particular, this is the tlrst model 
to incorporate together emergence of acquired drug resistance as well as spread of 
primary resistance, competition with muhiple sensitive and resistant strains allowing 
for different fitness. In addition, these dynamics are considered on a historical 
timescale, including not only treatment, but realistic improvements to control programs 
that have occurred over the past century. 
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The work presented in Chapters 7-9 also provides the first examination of 
waiting times in TB epidemics. This is of particular interest given the considered 
importance of waiting times in treatment, in particular the time to present to health care 
services, and time to diagnosis and start of treatment. Previous studies have examined 
waiting times in the context of other epidemics. One study has examined the influence 
of using different distributions for waiting times during parts of traditional (S-I-R) 
epidemiological models. (Lloyd 2001) One of the suggestions from this work, to use 
an alpha distribution to more realistically model treatment times, is also incorporated 
into the model developed in Chapter 7. Here, inclusion of multiple sequential 
compartments of infectious cases, untreated and during treatment, effectively allows the 
distribution of waiting time from onset of case infectiousness, until case detection and 
treatment, as well as duration of treatment, to be non-exponential. This is important... 
B. Epidemiological studies 
The recent epidemiology surveys and studies of TB are reviewed in Chapter 1. 
Of particular relevance to this thesis are the reports from the TB Global Resistance 
surveys conducted over the past decade. These have shown that resistance is found in 
all regions surveyed, with a high degree of variability in the prevalence of resistance by 
region. Some of the high burden countries showed higher resistance prevalence, as did 
regions with lower levels of DOTS program implemented. Yet such surveys of 
resistance prevalence could not address what differentiates regions which develop 
strikingly high levels of resistance, such as those found in a few regions with over 3-5% 
resistance prevalence. (Raviglione, Dye et al. 1997; WHO 1999; WHO 2003) 
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C. Control priorities 
These epidemiological surveys of resistance, combined with annual reports of 
regional burden of TB, allows consideration of what control has shown effective in 
reducing TB resistance levels. As mentioned above, WHO resistance surveys have 
shown overall lower levels of resistance found under DOTS programs, suggesting that 
the standardized treatment program is effective at preventing or reducing resistance. 
WHO studies have recommended focusing on reaching global targets for case 
detection and cure rates. These studies prioritize the detection of new cases and 
bringing them under standardized treatment programs as DOTS, and suggest that these 
are the primary impediments to control of TB epidemics worldwide. 
In some local area epidemics, there have been examples under which outbreaks 
of MDR-TB have been shown to be effectively controlled through improvements to the 
control practices and first-line treatment, without widespread second line treatment 
programs. For example, during the NYC MDR outbreak in the 1990s, improvements to 
the first line treatment program was shown to rapidly reduce and control the epidemic. 
(Eltringham and Drobniewski 1998; Bleed, Dye et al. 2000; Dye, Fengzeng et al. 2000; 
Espinal, Kim et al. 2000; Espinal, Laszlo et al. 2001; Raviglione, Gupta et al. 2001) 
(Alland, Kalkut et al. 1994; Friedman, Stoeckle et al. 1995; Bifani PJ 1996; Munsiff, 
Bassoff et al. 2002) 
Other studies have examined the effectiveness of introducing standardized 
second-line treatment programs, such as DOTS+, within existing control programs. 
The WHO currently recommends introducing such DOTS+ programs in areas which 
have already achieved high levels of control under DOTS program, maintaining target 
case detection and first line cure rates. (WHO 1997; WHO 1999) 
These recommendations for control priorities are similar and in agreement with 
those emerging from the work in this thesis. It is clear from the modeling studies 
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developed here, that the most important consideration in terms of controlling disease 
levels is the detection and effective treatment of new cases. This was shown most 
clearly in Chapter 6, with sensitivity analyses that showed the case detection and then 
the cure rates had the biggest effect on the disease as well as resistance levels. This 
was shown in more detail in Chapter 9, that within each of three TB epidemics varying 
in disease and resistance levels, increasing the case detection and cure rates were the 
most important considerations in reducing disease and resistance levels. 
The work developed in this thesis also adds a few additional points to help 
understand the dynamics of control of resistance within TB epidemics. For example, it 
was shown in Chapter 7 that introducing second line control, with the first line program 
still has suboptimal case detection and cure rates, can lead to a rapid exacerbation of 
resistance. This suggests how introducing second line control (such as a DOTS+ 
program) before the basic DOTS program implemented detection and effective 
treatment of a high proportion of new drug sensitive cases, can lead to increases in 
resistance prevalence, as well as amplification of resistance due to mistreatment. This 
suggests, again in agreement with current WHO guidelines, that DOTS+ programs not 
be introduced in areas which have not met the DOTS targets for case detection and cure 
rates. 
IV. Future directions: Experimental priorities 
In this section, the experimental priorities in tuberculosis research are 
considered. As examined in Chapter 6, the model predictions are sensitive to 
uncertainty in estimating key parameters. In particular, the resistance prevalence 
depends heavily on the variation in estimates of the relative fitness of the resistance 
strain, and the probability of acquiring resistance during treatment. 
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For progress in the field of mathematical models for tuberculosis, refining key 
estimates of resistance transmission and the probability of acquiring resistance during 
treatment are central. In addition, the next generation of models should be expanded to 
include aspects of network based models, HIV coinfection, and within host properties 
of mycobacterial infection. 
A. Resistance transmission and fitness 
Strain fitness, as defined in this thesis, includes the probability of transmission 
of infection to a susceptible host given contact (defined as the effective contact rate) 
and the probability of progression to active disease given infection (known as strain 
virulence). Both transmission of infection and strain virulence are components of the 
overall strain fitness, as measured by the basic reproductive number defined here. 
Measurement of mycobacterial strain fitness is more complicated than providing 
estimates from mathematical models. As shown in Chapter 6, the relative fitness of 
resistant strains is of great significance in model predictions for the dynamics of 
resistance within epidemics. The variance in the resistant transmission rate was a 
primary cause of model uncertainty in resistance prevalence, in particular under poor 
control. 
However, the relative transmission rate of resistant, and in particular MDR, 
strains remains a source of significant uncertainty. Experiments have suggested a wide 
range of transmission rates for resistant strains— from strains with reduced fitness to 
'super fit' MDR strains with greater transmissibiiity than drug sensitive strains. 
Strain fitness can be measured through contact tracing studies. One approach is 
to examine the proportions of contacts of sensitive and resistant cases which convert 
and develop active disease. This can then be compared to studies estimating the same 
for contacts of sensitive cases. A number of such studies have been performed, largely 
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in low incidence developed country settings, as reviewed in Chapter 4. Studies have 
also investigated the proportion of resistant cases due to ongoing transmission. This 
can be estimated as the prevalence of resistance amongst new and previously treated 
cases, assuming that new cases are caused by transmission of a resistant strain, while 
acquired resistance during treatment is found amongst previously treated strains. 
More recently, convention has led towards using molecular epidemiological 
studies to examine transmission. In these studies, clustering of strains with similar 
genetic markers is used as a surrogate for recent transmission, and such analysis has 
been used to estimate the relative proportion of resistant strains in a population due to 
ongoing transmission. In an area of high incidence (Capetown, South Africa), the 
proportion of resistance due to primary transmission, as detected by RFLP strain 
typing, was high; over 50% of MDR cases were clustered. (Van Rie, Warren et al. 
2000) In Denmark, over 70% of resistant strains were found to be clustered. (Thomsen, 
Bauer et al. 2000) There have also been reports of 'super fit' resistant strains which 
have been found more frequently in clusters and are believed to have greater 
transmission. (Agerton, Valway et al. 1999; Kruuner, Hoffner et al. 2001; 
Toungoussova, Sandven et al. 2002) 
Interventions can also be designed to specifically or preferentially target 
resistant cases in order to reduce their contact rates, thus reducing the overall resistance 
fitness. Where available, resources for active case detection can be focused on 
diagnosed MDR cases, finding and treating contacts of these cases. This can be 
implemented by sending MDR cases for treatment at specialized regional centres of 
excellence. (Farmer 2001; Mitnick, Bayona et al. 2003) Finding and testing contacts of 
MDR cases can identify new latent infections or cases of disease for rapid treatment. 
(Loddenkemper, Sagebiel et al. 2002) 
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B. Acquired resistance rate 
As described in Chapter 4, there is significant uncertainty in estimating the 
probability of acquiring resistance during treatment. The sensitivity analysis has shown 
that the model predictions for resistance prevalence are very sensitive to the uncertainty 
in the acquired resistance rate. This is most significant under poor control, when there 
is the potential for the emergence of a high level of resistance. Under good control, the 
uncertainty in estimates for the acquired resistance rate does have significant impact on 
model predictions for resistance prevalence, but high case detection and cure rates limit 
the spread of resistance. 
Studies have suggested that acquired resistance accounts for only a small 
proportion of treatment failures, and that cases are more likely to fail treatment for 
other reasons. One method of estimating from surveillance has suggested that 
resistance arises amongst treatment failures at a rate of 13% for isoniazid, 8% for 
rifampicin, and 7% for MDR. (Dye and Espinal 2001) In this thesis, using the model 
presented in Chapter 5, the rate of acquiring resistance given treatment failure was 
estimated at approximately 5-15%, and depended upon the control program and disease 
levels. These estimates of the proportion of acquired resistance have been made 
assuming that there is a constant rate of acquiring resistance during treatment. 
However, there is also evidence that this statistic should vary with the quality of 
treatment. Under good control measures, there is a low rate of acquired resistance. 
When the control is poor, higher levels of resistance are found, particularly when there 
are lower rates of DOTS implementation. (WHO/IUATLD 2000) 
For example, the probability of acquiring resistance has been correlated with 
errors in treatment, case management, and administration. (Mahmoudi and Iseman 
1993) Poor treatment practices correlated to increased resistance rates include adding 
one drug to a failing regimen, using an inadequate regimen, not diagnosing initial 
318 
resistance, and poor patient adherence. (Iseman 1999) Use of supervised standardized 
treatment and a regulated drug supply has been shown to reduce the proportion of cases 
developing resistance. (Weis, Slocum et al. 1994) Under fully supervised and 
regulated DOTS programs, a lower proportion of treatment failures are seen to acquire 
resistance. (Weis, Slocum et al. 1994; Bastian, Rigouts et al. 2000; Dye, Williams et al. 
2002) High rates of acquired resistance are seen in environments with poor control 
practices, less regulation, and other factors which might interfere with regular drug 
taking, such as poverty or war. (Iseman 1999; Loddenkemper, Sagebiel et al. 2002) 
Improving these control practices can not only improve the treatment cure rates, but 
also reduce the probability of acquiring resistance. 
Experiments focused on the within host dynamics of a mycobacterial infection 
are crucial to unveiling the mysteries associated with acquired resistance. Useful 
studies include observing the selection for resistance within a patient through a 
timecourse of treatment. The means to undertake such experiments may be within 
reach; already, the use of PGR tests for resistance have allowed improvements in 
quantification of the relative proportion of resistant mycobacteria present in sputum. 
Such studies could begin to address the questions of what treatment conditions allow 
for the selection of acquired resistance. 
V. Future directions: Implications for tuberculosis 
control 
Tuberculosis remains a leading public health concern. With over one third of 
the world's population infected, an annual incidence of 9 million new cases, and nearly 
3 million deaths to tuberculosis each year, tuberculosis continues to pose a health 
emergency. (Dye, Scheele et al. 1999; WHO 2000; Mathers, Stein et al. 2002; WHO 
2003) There is still much work to bring tuberculosis epidemics under control. This 
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includes several frontiers, including increasing coverage of DOTS programs and case 
detection rates, improving and maintaining quality of treatment, and managing and 
treating resistance. 
The first, and most important, next step is increasing coverage of current 
programs. An estimated 60% of annual cases remain undetected. The greatest number 
of cases is found in developing countries, with over 80% occurring in the 22 high 
burden countries (HBC). Global control efforts should focus on increasing and 
improving programs in these high burden areas. These efforts need to be centered 
around new means for detecting cases which otherwise would remain untreated. In 
particular, cases which occur amongst high risk groups and parts of the population 
which have reduced access to health services. 
Second, global control priorities should focus on improving overall treatment 
conditions to ensure high level of cure. DOTS offers manageable and cost-effective 
programs which have been repeatedly shown to achieve high cure rates even under 
difficult conditions. Increasing the reach of DOTS programs provides improved 
conditions for patient care and treatment. This in turn leads to better patient outcomes, 
including higher cure rates and lower rates of acquired resistance. These efforts may 
involve the introduction of standardized DOTS programs into new regions, as well as 
the extension of DOTS coverage to parts of populations currently seeking private care. 
Third, the problem of emerging resistance must be handled proactively. 
Knowing that resistance emerges under every treatment program, strategies for control 
of these resistance cases should be incorporated into program strategies. These 
strategies should be fitting to the local environment, based on an understanding of the 
state of the local epidemic, the control practices, and the likelihood for resistance. The 
analysis presented in this thesis can provide initial guidelines for setting priorities. 
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Of pressing concern is the treatment of resistance in those high burden countries 
in which there has already emerged a high prevalence of resistance. This includes 
regions such as the Russian Federation, Latvia, Estonia, and China. These high burden 
regions each show drastically high levels of resistance, of over 30%, in recent 
surveillance. (WHO/IUATLD 2000) Unfortunately, control in these areas may also be 
the most difficult to improve. Due to consistently poor treatment practices, resistance 
has developed to high levels in this area. In many of these areas, there are severely 
limited resources for health care and often only a fraction of the population has routine 
access to these services. 
In regions with a high burden of disease and a low prevalence of resistance, 
concentrating on increasing coverage and quality of treatment under first line DOTS 
programs should be the first priority. These measures should also manage resistance. 
However, particular caution should be taken to ensure overall high cure rates and 
quality of care before expanding coverage. This should include measures for 
surveillance of treatment, patient outcomes, and resistance. In addition, continual 
surveillance for resistance will allow for rapid alerts if there are local or regional 
increases in resistance that could warrant changes in treatment protocols. Countries 
which have reported a high incidence rate but low resistance (under 10%) include parts 
of South Africa (Mpumalanga province), Botswana, Malaysia, Nepal, Singapore, 
Spain, Korea, and Guinea. (WHO/IUATLD 2000) 
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APPENDIX 
11. Appendix 1 
Model for Chapter 5 
Figure 1: Model Equations 
Figure 11-1. The partial differential equations representing the three-strain model presented in Chapter 5. This model includes a drug sensitive 
(S), a singly drug resistant (R), and a multiply drug resistant (M) strain. 
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Figure 2: Model flow chart 
Figure 11-2. The three-strain model for the emergence and transmission of drug resistant and MDR tuberculosis is represented in this diagram. 
The equations for this model are given in Appendix 1. Individuals are born into the population (kept at a constant size) as susceptibles (X), and are 
subject to infection by the drug sensitive (S), singly drug resistant (R), or multiply drug resistant (M) strain. Infected individuals either progress directly 
to infectious (1) or non-infectious (Nl) disease, or enter a latent state from which there is a slow reactivation rate. Infectious cases receive drug treatment 
and either recover (T), fail treatment and remain drug sensitive, or fail treatment and acquire drug resistance. Individuals previously infected with TB (L 
and T classes) may be reinfected with any of the three strains (for simplicity, lines representing reinfection are not shown here). 
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Parameter Explanation Estimated values Source 
X Per capita rate of 
infection 
c Effective contact rate 5-15 (average 10) 
infections/ infectious case -
year 
(Styblo, 1991), 
(Blower, McLean et al. 1995), 
(Porco and Blower 1998), (Dye 
and Williams 2000; Dye and 
Espinal 2001) 
/ Proportion infectious 0.4 - 0.6 (Fishman and Elias 1998) 
(Davies 1998) 
P Proportion infected 
progress to primary 
disease 
5 ^ 5 % (Sutherland, Svandova et al. 
1982; Sutherland, Bleikeret al. 
1983) (Vynnycky and Fine 1997) 
V Rate latent infected 
progress to infectious 
0.03% (Sutherland, Svandova et al. 
1982; Sutherland. Bleiker et al. 
1983), (Vynnycky and Fine 
1997) 
K Self-cure rate for DS 10% (Chaulet and Zidouni 1998) 
(Enarson and Hopewell 1998), 
Estimates in this chapter. 
n Notification rate for 
sputum smear positive 
(jis treatment cure rate of 
DS cases 
Developed: 70-95%. 
developing: 50-75% 
(WHO/IUATLD 2000: WHO 
2003), (Chaulet and Zidouni 
1998) 
(|R Treatment cure rate of 
single DR cases 
Developed: 70-95%, 
developing: 50-75% 
(similar to DS cure rates) 
(Espinal. Kim et al. 2000) 
I'M Treatment cure rate of 
multiple DR cases 
developed: 50-80%) 
developing: 4-60%> 
(reduced cure rates) 
(Espinal. Kim et al. 2000) 
r Prob. of acquiring 
resistance mutation 
during drug treatment 
of DS case 
Developed: low(5%) -
high(]0%) 
Developing: high (]0-15%) 
(Chaulet and Zidouni 1998), 
(Dye and Espinal 2001) 
Mortality rate (not 0.015 Average life expectancy 80 years 
Ht Mortality rate due to 
TB 
15-30 (mean 20)% (Grzybowski 1991; Chaulet and 
Zidouni 1998; Davies 1998; 
Enarson and Hopewell 1998), 
Estimates in this chapter. 
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w relapse rate 2-5% (Chaulet and Zidouni 1998) 
Figure 11-3. Estimates of values for model parameters. Unless otherwise 
indicated, parameter values are given as rate per year. For control parameters (including 
the notification, cure, and acquired resistance rates) ranges of values found in developed 
and developing countries are given. 
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Figure 4: Two strain model 
Figure 11-4. The partial differential equations representing the two strain version of the model presented in Chapter 5. This model includes one 
drug sensitive (S) and one drug resistant (R) strain. 
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Figure 5: Two strain model flow chart 
Figure 11-5. The two-strain model for the emergence and transmission of drug resistant tuberculosis is represented in this 
diagram. The equations for this model are given in Appendix 3. Individuals are born into the population (kept at a constant size) as 
susceptibles (X), and are subject to infection by either the drug sensitive (S) or drug resistant (R) strain. Infected individuals either 
progress directly to infectious (I) or non-infectious (NI) disease, or enter a later state from which there is a slow reactivation rate. 
Infectious cases receive drug treatment and are either cured (T), fail treatment and remain drug sensitive, or fail treatment and acquire 
drug resistance. Individuals previously infected with TB may be reinfected with either strain (reinfection shown in dotted lines). 
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12. Appendix 2 
Model for Chapter 7 
Force of infection, by strain and overall: 
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New active infectious TB cases waiting for case detection after time tCD (for bookkeeping convenience), by 
strain type: 
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Treated drug sensitive cases, undergo treatment course for phases 1 - 4 , and either remain infectious (I) or 
become non-infectious (NI): 
Infectious (I) DS cases (S) on treatment regimen a (a), by treatment phase (1, 2 ,3 , 4): 
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Non-infectious (NI) DS cases (S) on treatment regimen a (a), by treatment phase (1, 2, 3, 4): 
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DS cases which are either cured (C) or have failed treatment (P, previously treated) 
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Singly drug resistant cases (DR), treated with regimen B, continue infectious and fail treatment: 
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Singly drug resistant cases (DR), treated with regimen B, become non-infectious through effective treatment: 
dt 
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Multiple drug resistant cases (MDR), treated with regimen A or B (for convenience, notation only includes 
'a'), continue infectious: 
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Multiple drug resistant cases (MDR), treated with regimen C, continue infectious and fail treatment: 
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Multiple drug resistant cases (MDR), treated with regimen C, become non-infectious through effective 
treatment: 
d f ' 
^ [ 1 1 = 0 
dt 
d f ' 
340 
d f ' 
ywc*- -" 
d f ' 
Mc 
M - tpb 
^ 3 i - t 
6 / r " 
MDR cases which are either cured (C) or have failed treatment (P, previously treated): 
( 1 - ^ ; C M i + < C < D - 4 + 0 i . 5 | < t i . . 4 | + 4 + [ { , + % ) - ( / / + r M q L 
t M t M + < : C M ] - & + / , + / f + , r ) ^ 
L = 
/ = 
r = 
N 
h + ^r+ hi 
^ ^ + tm 
— ^ + Z/ + / + 3" 
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Table 12-1. Parameter values for model presented in chapter 7. Rates are given in per 
month unless otherwise indicated. 
Parameter Explanation Range Source 
INTRINSIC PARAMETERS 
c Contact rate, 
strain specific 
1 - 1 . 5 About I eflectivc 
contact / case-
mornli 
P Probability 
direct 
progression 
0.10 
V Reactivation 
rate 
0.0015 / year 
u Mortality rate 0.015 / year 
UT TB-mortality 
rate 
0.05 / year 
k Self-cure rate 0.5 /year 
ri AR rate 5^ 15% Acquired resistance 
rale for infectious 
DS case under 
regimen A. or 
infectious DR case 
under regimen B 
r2 AR rate 0-3% Acquired resistance 
rale for non-
infectious DS case 
under reoimen A 
•"MDR AR rate 20-60% Acquired resistance 
rate for infectious 
DR case under 
regimen A 
Y Reinfection 
susceptibility 
-50% 
/»/ ' Proportion 
developing 
infectious disease 
40-60% 
CONTROL PARAMETERS 
$ S A T^^a 
^ R A TcRa Assume 0% 
^Rb TcRb 
TcMa Assume 0% 
TcMc 
W] Relsa 
Wi Relsal 
Relrb 
W4 Relrbl 
CDR Case detection 
rate 
tCD Time to detect 
P O S T Proportion new IR 
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cases receiving 
DST 
tnsT Time to DST 0 - 2 months 
ti For bookkeeping: 
time to remove 
from new 
incidence class 
1 week 
t p h l . . 4 Time each 
treatment phase 
Phase 1 : 2 weeks 
Phase 2: 3 months 
Phase 3: 3 months 
Phase 4: 3 months 
t p h S Time to re-
treatment 
1 year 
STATE VARIABLES 
Symbol Explanation By strain type Infectious? 
X Susceptible -
L Latent Ls 5 L R , L M -
N1 Non-infectious 
disease 
-
1 New infectious 
cases 
Is , IR, 1M + 
U Untreated 
infectious 
cases 
U s ,UR,UM + 
T Treated cases + / -
P Previously 
failed 
treatment 
Ps, PR, PM + 
C Cured Cs , CR, CM -
TREATMENT STATE VARIABLES 
Symbol Description Strain type Infectious Treatment 
regimen 
T s i a 
Sensit ive infectious 
cases receiving 
t reatment a 
S 4- a 
Tsa Sensit ive non-infect ious cases 
receiving treatment a 
S - a 
TRIO Resistant infectious 
cases receiving 
treatment a 
R -f a 
T R I b 
Resistant infectious 
cases receiving 
t reatment b 
R 4- b 
Tab Resistant non-
infect ious cases 
receiving treatment b 
R - b 
Tivila M D R infectious cases 
receiving treatment a 
(or b ) 
M 4- a or b 
TM IC 
M D R infect ious cases 
receiving treatment c 
M 4- c 
T M I C 
M D R non-infect ious 
cases receiving 
t rea tment c 
M c 
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13. Appendix 3 
Sensitivity Analysis Scenarios for Chapter 6 
Simulation Treatment Intrinsic Reinfection Incidence rate Prevalence of resistance 
parameters parameters (Cases per 100,000) (% of cases resistant) 
Average Min Max Average Min Max 
1 None Varied None 81 0.7 149 
2 None Varied Varied 1140 0.1 4 4 0 3 
3 None Varied Constant 1540 0.8 3217 
4 Control Varied Varied 
parameters 
varied 355 31 2 8 9 9 17% 0% 96% 
5 Control Varied Constant 
parameters 
varied 364 6 3 1582 18% 0% 89% 
6 Notification 
rate varied 
over wide 
Varied Constant 
range 320 2 3 1601 8% 0% 22% 
7 Good control Varied Constant 157 12 299 3% 1% 5% 
8 Poor control Varied Constant 379 4 4 791 37% 9% 67% 
Table 13-1. Summary of sensitivity analysis simulations. Comparison of Monte Carlo simulations in sensitivity analysis. Each simulation consists 
of 1000 Monte Carlo runs of the model, with the intrinsic and control parameters varied between runs as given. The results of these simulations 
are shown as the final incidence of disease and prevalence of resistance. 
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SCENARIO 1: No treatment, no reinfection 
A. 
B. 
o 100 
Q> 80 
20 4* 
200 400 600 
S i m u l a t i o n 
800 
Model 
Outcome Average Min Max 
Incidence 81 1 149 
Prevalence 
Resistance 0% 0% 0% 
DOI-DS 82 1 150 
Parameter Parameter explanation Mean Variance 
Intrinsic parameters 
n Mortality rate 0.015 0.01 
HT 
TB disease specific mortality 
rate 0.2 0.01 
k Self-cure rate 0.1 0.005 
ECR Effective contact rate 10 1 
/ 
Proportion progress to 
infectious disease 0.55 0.01 
P 
Proportion progress to primary 
disease 0.1 0.01 
V Endogenous reactivation rate 0.03% 0.001% 
Y Susceptibility to reinfection 0 0 
f 
Resistance transmission 
reduced by 0 0 
VJ Relapse rate 0.05 0.01 
Treatment parameters 
nr Notification rate 0 0 
Os 
Treatment success rate for DS 
cases 0 0 
OR 
Treatment success rate for DR 
cases 0 0 
r Acquired resistance rate 0 0 
C. 
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Parameter Parameter explanation 
Prevalence 
disease 
Intrinsic parameters 
n Mortality rate 3.0% 
UT 
TB disease specific mortality 
rate 0.1% 
k Self-cure rate 0.0% 
ECR Effective contact rate 2.1% 
/ 
Proportion progress to 
infectious disease 0.0% 
P 
Proportion progress to primary 
disease 7.1% 
V Endogenous reactivation rate 9.5% 
w Relapse rate 0.0% 
Y Susceptibility to reinfection 0.0% 
D. 
160 
140 
<D 120 -i 
100 
80 
60 
40 
20 
0 
o 
c 
0) 
•ja 
"o 
c 
0% 5% 10% 
Primary progression 
15% 
0) 120 
0.00% 0.01% 0.02% 0.03% 0.04% 0.05% 
Reactivation rate 
346 
140 -
<D 120 
100 -
Scenario 1. Model sensitivity under no drug treatment. The results of 1000 
Monte Carlo simulations run for ten years under no treatment (notification rate set 
to 0) are shown as the final incidence of infectious disease (A). Model parameters 
were randomly generated in each simulation, assumed to have a normal 
distribution with mean and variance as given in (B). The Pearson squared 
correlation (r )^ calculated in (C) reflects the proportion of variance in model 
outcome explained by variance in each parameter. Scatterplots for the input 
parameters which most influenced the model outcome of disease incidence (as 
new cases per 100,000) are shown in (D). 
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SCENARIO 2: No treatment, reinfection varied 
A. 
4500 
200 400 600 
S i m u l a t i o n 
800 1000 
Model 
Outcome Average Min Max 
Incidence 1140 0 4403 
Prevalence 
Resistance 0% 0% 0% 
DOl-DS 2.21 1.95 2.46 
B. 
Parameter Parameter explanation | Mean Variance 
Intrinsic parameters 
u Mortality rate 0.015 0.01 
UT 
TB disease specific mortality 
rate 0.2 0.01 
k Self-cure rate 0.1 0.005 
ECR Effective contact rate 10 1 
/ 
Proportion progress to 
infectious disease 0.55 0.01 
P 
Proportion progress to primary 
disease 0.1 0.01 
V Endogenous reactivation rate 0.03% 0.001% 
Y Susceptibility to reinfection 0.5 0.2 
f 
Resistance transmission 
reduced by 0 0 
w Relapse rate 0.05 0.01 
Treatment parameters 
nr Notification rate 0 0 
Os 
Treatment success rate for DS 
cases 0 0 
<t>R 
Treatment success rate for DR 
cases 0 0 
r Acquired resistance rate 0 0 
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c. 
Parameter Parameter explanation Incidence 
Intrinsic parameters 
u Mortality rate 0.0% 
Ht 
TB disease specific mortality 
rate 2.2% 
k Self-cure rate 0.0% 
ECR Effective contact rate 8.8% 
/ 
Proportion progress to 
infectious disease 0.3% 
P 
Proportion progress to primary 
disease 11.0% 
V Endogenous reactivation rate 0.0% 
w Relapse rate 1.3% 
y Susceptibility to reinfection 62.7% 
D. 
5000 
4000 
0) 
c 3000 
o 
•v 
o 
c 
0% 20% 40% 60% 80% 100% 
Reinfection rate 
0) 
o 
c 
w ;g 
o 
c 
5000 
4000 
3000 
2000 
1000 
0 
10 15 
ECR 
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5000 
4000 
o 
c 3000 
o 
3 2000 
o 
— 1000 
• • 
0% 5% 10% 15% 
Primary progression 
Scenario 2. Model sensitivity under no drug treatment, and widely varied 
reinfection rate. The results of 1000 Monte Carlo simulations run for ten years 
under no treatment (notification rate set to 0) are shown as the final incidence of 
infectious disease (A). Model parameters were randomly generated in each 
simulation, assumed to have a normal distribution with mean and variance as 
given in (B). The Pearson squared correlation (r") calculated in (C) reflects the 
proportion of variance in model outcome explained by variance in each parameter. 
Scatterplots for the input parameters which most influenced the model outcome of 
disease incidence are shown in (D). 
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SCENARIO 3: No treatment, reinfection constant 
A. 
B. 
3500 
3000 
<D 2500 
o 
400 600 
Simulation 
800 1000 
Model 
Outcome Average Min Max 
Incidence 1540 1 3217 
Prevalence 
Resistance 0% 0% 0% 
DOI-DS 2.21 1.95 2.50 
Parameter Parameter explanation | Mean Variance 
Intrinsic parameters 
n Mortality rate 0.015 0.01 
TB disease specific mortality 
rate 0.2 0.01 
k Self-cure rate 0.1 0.005 
ECR Effective contact rate 10 1 
;• 
Proportion progress to 
infectious disease 0.55 0.01 
P 
Proportion progress to primary 
disease 0.1 0.01 
V Endogenous reactivation rate 0.03% 0.001% 
T Susceptibility to reinfection 0.60 0.01 
f 
Resistance transmission 
reduced by 0 0 
w Relapse rate 0.05 0.01 
Treatment parameters 
nr Notification rate 0 0 
<t>s 
Treatment success rate for DS 
cases 0 0 
0 R 
Treatment success rate for DR 
cases 0 0 
r Acquired resistance rate 0 0 
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c. 
Parameter Parameter explanation Incidence 
Intrinsic parameters 
Mortality rate 0.0% 
l-lT 
TB disease specific mortality 
rate 4.5% 
k Self-cure rate 0.0% 
ECR Effective contact rate 40.4% 
/• 
Proportion progress to 
infectious disease 0.5% 
P 
Proportion progress to primary 
disease 48.4% 
V Endogenous reactivation rate 0.3% 
w Relapse rate 1.7% 
y Susceptibility to reinfection 1.6% 
g 2500 
2000 
3500 
3000 
® 2500 
S 2000 
; g 1500 
E 1000 
~ 500 
0 
0% 5% 10% 
Primary progression 
15% 
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SkeiiaiTk):;. wnder Mo<drwg /rea/rnen,, ctw%sAzMYjT?H,/ecf,()n 
rate. The results of 1000 Monte Carlo simulations run for ten years under no 
treatment (notification rate set to 0) are shown as the final incidence of infectious 
disease (A). Model parameters were randomly generated in each simulation, 
assumed to have a normal distribution with mean and variance as given in (B). 
The Pearson squared correlation (r") calculated in (C) reflects the proportion of 
variance in model outcome explained by variance in each parameter. Scatterpiots 
for the input parameters which most influenced the model outcome of disease 
incidence are shown in (D). 
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SCENARIO 4: Varied control, varied reinfection 
A. 
3 5 0 0 n 
3 0 0 0 
• • • 
(1) 2 5 0 0 
o • 
c 2 0 0 0 - • • • (D • • 
• o 
"o 
1 5 0 0 -• • 
c 1 0 0 0 -
* 
• 
5 0 0 1 »• 
0 ' 
200 4 0 0 6 0 0 
Simulation 
1000 
0) 
o 
c 
(0 (g 
tfi 
CD 
1 0 0 % 
90% 
80% 
70% 
60% 
50% 
40% 4 
30% 
20% 
10% 
0% 
• 
• 
• 
• • ^ 
• '• v ' 
. • * 
• 
• 
• • 
• • 
• 
• • • 
: I : v ' • ' . ; 
0 2 0 0 4 0 0 6 0 0 
Simulation 
8 0 0 1000 
Model 
Outcome Average Min Max 
Incidence 
Rate 355 31 2899 
Prevalence 
Resistance 17% 0% 96% 
Incidence 
Rate- Drug 
sensitive 335 29 4106 
Incidence 
rate- Drug 
resitant 135 0 5594 
DOI-DS 1.03 0.55 2.22 
354 
DOI-DR 1.61 0.91 2.25 
B. 
Parameter Parameter explanation Mpan Variance 
Intrinsic parameters 
u Mortality rate 0.015 0.001 
HT 
TB disease specific mortality 
rate 0.2 0.01 
k Self-cure rate 0.1 0.1 
ECR Effective contact rate 10 0.5 
/• 
Proportion progress to 
infectious disease 0.55 0.01 
P 
Proportion progress to primary 
disease 0.1 0.005 
V Endogenous reactivation rate 0.0003 0.00005 
Y Susceptibility to reinfection 0.5 0.3 
f 
Resistance transmission 
reduced by 0.1 0.1 
w Relapse rate 0.03 0.005 
Treatment parameters 
nr Notification rate 0.5 0.2 
<Ps 
Treatment success rate for DS 
cases 0.9 0.2 
OR 
Treatment success rate for DR 
cases 0.25 0.1 
r Acquired resistance rate 0.08 0.03 
C. 
Prevalence of 
Parameter Parameter explanation Incidence Resistance 
Intrinsic parameters 
Mortality rate 02% 0.4% 
TB disease specific mortality 
rate 03% 0.3% 
k Self-cure rate 0^% 0.1% 
ECR Effective contact rate 0^% 0.3% 
i 
Proportion progress to 
infectious disease 02% 0.3% 
p 
Proportion progress to primary 
disease 16% 0.7% 
V Endogenous reactivation rate 0^% 0.2% 
Y Susceptibility to reinfection 50.8% 23.5% 
f 
Resistance transmission 
reduced by 1.0% 6.2% 
w Relapse rate 1.0% 0.0% 
Treatment parameters 
nr Notification rate 9^% 4.7% 
Os 
Treatment success rate for DS 
cases 1.3% 12.7% 
OR 
Treatment success rate for DR 
cases 0.8% 13.3% 
r Acquired resistance rate 0.1% 9.1% 
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Scenario 4. Model sensilivity under widely varied control and reinfenction rates. 
The results of 1000 Monte Carlo simulations run for ten years under no treatment 
(notification rate set to 0) are shown as the final incidence of infectious disease 
(A). Model parameters were randomly generated in each simulation, assumed to 
have a normal distribution with mean and variance as given in (B). The Pearson 
squared correlation (r )^ calculated in (C) reflects the proportion of variance in 
model outcome explained by variance in each parameter. Scatterplots for the 
model outcome of incidence are shown in (D) and resistance prevalence in (E). 
358 
SCENARIO 5: Varied control 
A. 
3 0 0 0 
2500 
<D • 
O 2000 - • 
c • • 
o 
"O 1500 -
• • 
• 
' o a 
c 1000 
5 0 0 
• • 
• 
• 
200 400 600 
Simulation 
800 1000 
(0 15% H 
2 10% 
200 400 600 
Simulat ion 
800 1000 
Model 
Outcome Average Min Max 
Incidence 
Rate 364 63 1582 
Prevalence 
Resistance 18% 0% 89% 
Incidence 
Rate- Drug 
sensitive 357 59 2241 
Incidence 
rate- Drug 
resitant 75 0 1189 
DOI-DS 1.04 0.55 2.22 
DOI-DR 1.62 0.92 2.33 
359 
B . 
Parameter Parameter explanation Mean Variance 
Intrinsic parameters 
Mortality rate 0.015 0.001 
HT 
TB disease specific mortality 
rate 0.2 0.01 
k Self-cure rate 0.1 0.1 
ECR Effective contact rate 10 0.5 
/ 
Proportion progress to 
infectious disease 0.55 0.01 
P 
Proportion progress to primary 
disease 0.1 0.005 
V Endogenous reactivation rate 0.0003 0.00005 
Y Susceptibility to reinfection 0.6 0.01 
f 
Resistance transmission 
reduced by 0.1 0.1 
w Relapse rate 0.03 0.005 
Treatment parameters 
nr Notification rate 0.5 0.2 
CPs 
Treatment success rate for DS 
cases 0.9 0.2 
<PR 
Treatment success rate for DR 
cases 0.25 0.1 
r Acquired resistance rate 0.08 0.03 
C. 
Parameter Parameter explanation Incidence 
Prevalence of 
Resistance 
Intrinsic parameters 
Mortality rate 06% 0.0% 
HT 
TB disease specific mortality 
rate 24% 0.4% 
k Self-cure rate 0.2% 0.2% 
ECR Effective contact rate 82% 0.3% 
i 
Proportion progress to 
infectious disease 0.0% 0.0% 
P 
Proportion progress to primary 
disease 10.0% 1.2% 
V Endogenous reactivation rate 0.6% 0.1% 
Y Susceptibility to reinfection 0.6% 0.1% 
f 
Resistance transmission 
reduced by 09% 9.6% 
w Relapse rate 4.4% 0.3% 
Treatment parameters 
nr Notification rate 37 6% 9.8% 
0s 
Treatment success rate for DS 
cases 7^% 27.3% 
Treatment success rate for DR 
cases 0.8% 20.4% 
r Acquired resistance rate 0.0% 14.2% 
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Scenario 5. Model sensitivity under widely varied control, with a constant 
reinfenction rate. The results of 1000 Monte Carlo simulations run for ten years 
under no treatment (notification rate set to 0) are shown as the final incidence of 
infectious disease (A). Model parameters were randomly generated in each 
simulation, assumed to have a normal distribution with mean and variance as 
given in (B). The Pearson squared correlation (r )^ calculated in (C) reflects the 
proportion of variance in model outcome explained by variance in each parameter. 
Scatterplots for the input parameters which most influenced the model outcome of 
incidence are shown in (D) and resistance prevalence in (E). 
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SCENARIO 6: Varied treatment rate 
A. 
0) 
u 
c 
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A A 
0 200 400 600 800 1000 
Simulation 
Model 
Outcome Average Min Max 
Incidence 
Rate 320 23 1601 
Prevalence 
Resistance 8% 0% 22% 
Incidence 
Rate- Drug 
sensitive 352 23 2027 
Incidence 
rate- Drug 
resitant 26 0 166 
DOI-DS 1.02 0.62 2.16 
DOI-DR 1.27 0.85 2.22 
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B. 
Parameter Parameter explanation | Mean Variance 
Intrinsic parameters 
Mortality rate 0.015 0.001 
HT 
TB disease specific mortality 
rate 0.2 0.01 
k Self-cure rate 0.1 0.1 
ECR Effective contact rate 10 0.5 
/ 
Proportion progress to 
infectious disease 0.55 0.01 
P 
Proportion progress to primary 
disease 0.1 0.005 
V Endogenous reactivation rate 0.0003 0.00005 
Y Susceptibility to reinfection 0.6 0.01 
f 
Resistance transmission 
reduced by 0.1 0.1 
w Relapse rate 0.03 0.005 
Treatment parameters 
nr Notification rate 0.5 0.2 
Os 
Treatment success rate for DS 
cases 0.8 0 
OR 
Treatment success rate for DR 
cases 0.5 0 
r Acquired resistance rate 0.08 0.03 
C. 
Parameter Parameter explanation Incidence 
Prevalence of 
Resistance 
Intrinsic parameters 
u Mortality rate 0.1% 0.0% 
l-^ T 
TB disease specific mortality 
rate 3.7% 0.5% 
k Self-cure rate 0.2% 0.2% 
ECR Effective contact rate 8.2% 0.5% 
/ 
Proportion progress to 
infectious disease 0.3% 0.1% 
P 
Proportion progress to primary 
disease 6.1% 1.9% 
V Endogenous reactivation rate 0.1% 0.1% 
Y Susceptibility to reinfection 0.7% 0.3% 
f 
Resistance transmission 
reduced by 0.0% 20.4% 
w Relapse rate 4.6% 1.0% 
Treatment parameters 
nr Notification rate 52.4% 8.5% 
CDs 
Treatment success rate for DS 
cases 
OR 
Treatment success rate for DR 
cases 
r Acquired resistance rate 0.0% 57,8% 
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Scenario 6. Model sensitivity under a varied treatment rates. The results of 
1000 Monte Carlo simulations run for ten years under no treatment (notification 
rate set to 0) are shown as the final incidence of infectious disease (A). Model 
parameters were randomly generated in each simulation, assumed to have a 
normal distribution with mean and variance as given in (B). The Pearson squared 
correlation (r") calculated in (C) reflects the proportion of variance in model 
outcome explained by variance in each parameter. Scatterplots for the input 
parameters which most influenced the model outcome of incidence are shown in 
(D) and resistance prevalence in (E). 
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SCENARIO 7: Good control 
A. 
350 
300 
o 250 
o 
c 200 
<D 
T3 150 
O 
_C 100 
50 
0 
0 200 400 600 800 1000 
Simulation 
o 4% 
200 400 600 800 1000 
Simulation 
Model 
Outcome Average Min Max 
Incidence 
Rate 157 12 299 
Prevalence 
Resistance 3% 1% 5% 
Incidence 
Rate- Drug 
sensitive 175 12 400 
Incidence 
rate- Drug 
resitant 4 0 14 
DOI-DS 0.70 0.68 0.73 
DOI-DR 0.91 0.87 0.95 
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B. 
Parameter Parameter explanation | Mean Variance 
Intrinsic parameters 
n Mortality rate 0.015 0.001 
HT 
TB disease specific mortality 
rate 0.2 0.01 
k Self-cure rate 0.1 0.1 
ECR Effective contact rate 10 0.5 
/ 
Proportion progress to 
infectious disease 0.55 0.01 
P 
Proportion progress to primary 
disease 0.1 0.005 
V Endogenous reactivation rate 0.0003 0.00005 
Y Susceptibility to reinfection 0.6 0.01 
f 
Resistance transmission 
reduced by 0.1 0.1 
w Relapse rate 0.03 0.005 
Treatment parameters 
nr Notification rate 0.75 0 
(Ps 
Treatment success rate for DS 
cases 0.9 0 
OR 
Treatment success rate for DR 
cases 0.6 0 
r Acquired resistance rate 0.05 0.01 
C. 
Parameter Parameter explanation Incidence 
Prevalence of 
Resistance 
Intrinsic parameters 
V- Mortality rate 0.6% 0.2% 
UT 
TB disease specific mortality 
rate 8.4% 2.0% 
k Self-cure rate 0.2% 0.8% 
ECR Effective contact rate 25.1% 0.9% 
/ 
Proportion progress to 
infectious disease 1.5% 0.3% 
P 
Proportion progress to primary 
disease 34.0% 2.7% 
V Endogenous reactivation rate 1.0% 0.0% 
Y Susceptibility to reinfection 1.1% 0,5% 
f 
Resistance transmission 
reduced by 0.1% 31.4% 
w Relapse rate 19.4% 7.5% 
Treatment parameters 
nr Notification rate 
Cl)g 
Treatment success rate for DS 
cases 
0 R 
Treatment success rate for DR 
cases 
r Acquired resistance rate 0.0% 54.9% 
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Scenario 7. hdodel sensitivily under a good control program. The results of 1000 
Monte Carlo simulations run for ten years under no treatment (notification rate set 
to 0) are shown as the final incidence of infectious disease (A). Model parameters 
were randomly generated in each simulation, assumed to have a normal 
distribution with mean and variance as given in (B). The Pearson squared 
correlation (r )^ calculated in (C) reflects the proportion of variance in model 
outcome explained by variance in each parameter. Scatterplots for the input 
parameters which most influenced the model outcome of resistance prevalence are 
shown in (D). 
A . 
369 
SCENARIO 8: Poor control 
A. 
TJ 400 
8 0 0 -
U 300 
0 200 400 600 800 1000 
Simulation 
70% 
60% 
2 50% 
^ 20% 
0 200 400 600 800 1000 
Simulation 
Model 
Outcome Average Min Max 
Incidence 
Rate 379 44 791 
Prevalence 
Resistance 37% 9% 67% 
Incidence 
Rate- Drug 
sensitive 287 33 780 
Incidence 
rate- Drug 
resitant 159 11 754 
DOI-DS 1.13 1.07 1.20 
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DOI-DR 1.49 1.40 1.63 
B. 
Parameter Parameter explanation Mean Variance 
Intrinsic parameters 
Mortality rate 0.015 0.001 
HT 
TB disease specific mortality 
rate 0.2 0.01 
k Self-cure rate 0.1 0.1 
ECR Effective contact rate 10 0.5 
/ 
Proportion progress to 
infectious disease 0.55 0.01 
P 
Proportion progress to primary 
disease 0.1 0.005 
V Endogenous reactivation rate 0.0003 0.00005 
Y Susceptibility to reinfection 0.6 0.01 
f 
Resistance transmission 
reduced by 0.1 0.1 
w Relapse rate 0.03 0.005 
Treatment parameters 
nr Notification rate 0.5 0 
® s 
Treatment success rate for DS 
cases 0.6 0 
OR 
Treatment success rate for DR 
cases 0.3 0 
r Acquired resistance rate 0.15 0.04 
c. 
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Parameter Parameter explanation Incidence 
Prevalence of 
Resistance 
Intrinsic parameters 
n Mortality rate 0.3% 0.0% 
TB disease specific mortality 
rate 98% 2.9% 
k Self-cure rate 0.4% 1.1% 
ECR Effective contact rate 23 6% 1.2% 
; 
Proportion progress to 
infectious disease 1.5% 0.3% 
P 
Proportion progress to primary 
disease 343% 3.5% 
V Endogenous reactivation rate &3% 0.0% 
Y Susceptibility to reinfection 1J% 0.6% 
f 
Resistance transmission 
reduced by &9% 45.9% 
w Relapse rate 12.5% 1.2% 
Treatment parameters 
nr Notification rate 
0s 
Treatment success rate for DS 
cases 
O r 
Treatment success rate for DR 
cases 
r Acquired resistance rate 0.1% 44.1% 
D. 
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Scenario 8. Model sensitivity under a poor control program. The results of 1000 
Monte Carlo simulations run for ten years under no treatment (notification rate set 
to 0) are shown as the final incidence of infectious disease (A). Model parameters 
were randomly generated in each simulation, assumed to have a normal 
distribution with mean and variance as given in (B). The Pearson squared 
correlation (r") calculated in (C) reflects the proportion of variance in model 
outcome explained by variance in each parameter. Scatterplots for the input 
parameters which most influenced the model outcome of resistance prevalence are 
shown in (D). 
373 
14. Appendix 4 
Drugs used in chemotherapy 
14. Appendix 4 
Drugs used in chemotherapy 
I. Isoniazid 
l.A. Bacterial targets 
I.B. General effects: bacteriostatic and bacteriocidal 
I.e. Pharmacokinetics 
I.D. In vivo: human treatment 
I.E. Emergence of resistance 
I.F. Summary 
II. Rifampicin 
II.A. Mode of Action 
11.B. Bactericidal activity 
11.C. Mechanism 
11.D. In human action/ dosing 
II.E. Emergence of resistance 
III. Streptomycin 
III.A. Mode of Action 
IIl.B. In vitro studies 
III.C. Dosing 
III.D. Emergence of resistance 
I. Isoniazid 
Isonicotinic acid hydrazide, or isoniazid (INH), is one of the most commonly 
used drugs for the prophylaxis and treatment of mycobacterial diseases. (Rattledge 
1999) Isoniaizd is selective for mycobacteria. (Goodman 1996) M. tuberculosis and 
M. bovis are both very susceptible to INH, with MICs ranging from 0.02 to 0.2 ug/ml. 
(Rattledge 1999) Other mycobacterial species are less susceptible, with MICs of 5 to 
50 ug/ml. (Pansy 1952) Non-mycobacterial bacteria are fairly resistant to INH action. 
E. coli, for example, is resistant to at least 500 ug/ ml. (Rattledge 1999) 
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LA. Bacterial targets 
Isoniazid is thought to exert a bactericidal action on mycobacteria by inhibiting 
synthesis of mycolic acids, a component of the mycobacterial cell envelope. INH has 
been shown to inhibit mycolate synthesis in vitro within six hours, at levels of 0.1 ug/ml 
(equal to the MIC for M tuberculosis) for human strain H37Ra and 0.5 ug/ml for M. 
bovis-BCG. (Takayama, Wang et al. 1972) In vivo evidence has also implicated mycolic 
acid synthesis as a downstream effect of isoniazid on tubercle bacilli. The rate of 
mycolic acid synthesis inhibition has been shown to increase with the rate of uptake of 
INH.(Wang and Takayama 1972) The inhibitory action of isoniazid has been shown to 
be reversible, if washed out before 10 hours. (Takayama, Wang et al. 1972) 
The strong specificity that isoniazid shows for mycobacterial species was 
explained with the discovery of the drug's cellular target. Mycolic acid is a cell wall 
component of all mycobacterial species. The considerable variability of MlCs amongst 
mycobacterial species is generally accounted for by differential cell wall permeability to 
isoniazid. (Rom 1996) Recent studies have also explained this difference by the lack of 
a functional oxyR gene in M. tuberculosis. OxyR encodes a transcriptional activator of 
aphC transcription, which itself encodes a subunit of alkyl hydroperoxide reductase. 
AphC and oxyR are both stimulated in response to oxidative stress. Mutations in the 
promoter of the aphC gene have appeared as compensatory mutations in INH-resistant 
bacilli with a mutation in the katG gene. KatG encodes a protein with catalase-
peroxidase activity. The overexpression of the aphC hydroperoxidase is thought to 
compensate for this reduced activity in katG mutants. (Rattledge 1999) 
LB. General effects: bacteriostatic and bacteriocidal 
INH can exert both a bacteriostatic and bactericidal activity on tubercle bacilli. 
The bactericidal action is generally exerted on growing cells, and the bacteriostatic action 
on resting cells. (Goodman 1996) Isoniazid kills cells in lag or logarithmic, but not 
stationary phase. In the first 24 hours after exposure to the drug, only young cells are 
killed. (Barry 1964) The tubercle bacilli generally undergo 1-2 divisions after treatment 
with isoniazid, before cellular multiplication is arrested. (Goodman 1996) The 
bactericidal action of INH is almost independent of concentration, at doses above 0.1 
ug/ml. (Mackaness and Smith 1953; Barry 1964) 
M. tuberculosis strains exposed to isoniazid show a period of delay between the 
time of exposure and the observation of a bactericidal effect. The length of this delay 
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period depends on bacterial growth rate, but is largely independent of drug concentration. 
There is usually a delay of 1 - 4 days before bactericidal action is seen, corresponding to 
about 1 1/2 generations. (Mackaness and Smith 1953; Barry 1964) 
INH penetrates easily penetrates into sensitive cells. (Goodman 1996) Thus, the 
drug is equally effective for intracellular and extracellular bacilli. (Goodman 1996) The 
mechanism of cellular uptake is believed to involve active transport. (Gangardharam 
1997) The process of INH uptake has been shown to require oxygen (uptake is inhibited 
under anaerobic conditions) and is largely inhibited by heating. (Gangardharam 1997) 
Not surprisingly, INH has also been shown to be inactive in anaerobic conditions. (Barry 
1964) 
Tubercle bacilli treated with INH undergo morphological changes. The bacilli 
turn in shape to appear as tapering rods. The internal cellular structure lost within 24 
hours. (Barry 1964) INH causes the loss of acid-fast property of mycobacteria, as the 
cell wall becomes permeable to the decolorizing agent used in the test. (Rattledge 1999) 
This occurs at same time as the onset of bactericidal action (one to two generations). 
(Barry 1964) 
I . e . Pharmacokinetics 
1. /?? v/Z/'o studies 
The minimal tuberculostatic concentration in vitro is 0.025 to 0.05 ug/ml. 
(Goodman 1996) The concentration needed to inhibit the tubercle bacilli multiplication 
is little affected by the size of the inoculum, suggesting that only a small proportion of 
the drug is adsorbed onto cells. (Barclay 1964; Barry 1964) 
I.D. In vivo: human treatment 
The small molecular size of INH allows wide distribution, and INH diffuses 
readily into all body fluids and tissues. (Chamgers 1998) Isoniazid can be found 
detected in serous membranes, caseous foci, tubercle cavities, and macrophages. 
(Dannenberg 1998) 
The metabolism of INH is genetically determined, and depends on the rate of 
acetylation of the drug. (Chamgers 1998) INH is metabolised in the liver by both 
acetylation and oxidation. (Dannenberg 1998) For rapid acetylators, the average 
concentration of INH in plasma is about 1/3 to /a of that in slow acetylators and the 
average half-lives are less than 1 hr and 3 hrs, respectively. The more rapid clearance 
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rate by rapid acetylators is an important consideration in therapy if the drug is not taken 
on a daily basis. Following an average adult oral dose of 5 mg/kg (300 mg), peak serum 
concentrations of INH reach 3 - 5 ug/ml in 1- 2 hours. (Chamgers 1998; Dannenberg 
1998) The inactive metabolites of INH are excreted in the urine. Approximately 75 — 
95% of a dose is removed within 24 hours. (Dannenberg 1998) 
Studies have suggested a two-phase action for INH, consisting of: 1) a reversible 
uptake in sensitive cells (whether actively growing or not), and 2) an irreversible binding 
(occurring only in growing cells). (Barry 1964) In the first phase, isoniazid uptake by 
sensitive growing bacilli occurs easily, peaking one day after exposure. The rate of 
uptake then falls, and subsequently slowly increases to a plateau level at 7 days, by 
which time the bactericidal action has been completed. (Barry 1964) Resistant strains 
show much lower ability to uptake isoniazid, suggesting the failure to accumulate drug as 
a mechanism of resistance. In the second phase of INH action, the binding of INH to 
cells is irreversible; a 10 day incubation in drug free medium does not reverse INH action 
on cells. (Barry 1964) 
I.E. Emergence of resistance 
M. tuberculosis shows a mutation rate to isoniazid of 1 - 3 X 10'^/ bacterium / 
generation. The endogenous frequency of mutants resistant to 0.2 - 5 ug/ml INH, 
observable in a sensitive population, is 1/10^ to 1/10^. Such resistance mutants lack the 
catalase enzyme, occur in single step mutation, and are considered high resistance 
(growing on 20 ug/ml or greater of INH) mutants. (Barry 1964) 
The current hypothesis for the molecular basis of isoniazid action is that the drug 
is oxidized by catalase-peroxidase (encoded by the katG gene) to an active compound, 
which binds to the inhA gene product (an enoyl-ACP reductase). (Rattiedge 1999) 
Resistance to INH action arises in two main fashions; either mutations in the katG gene 
prevent conversion of INH to the active form of the drug, or mutations in the structural 
gene inhA prevent its action. (Rattiedge 1999) Low level of resistance is seen in mutants 
that overexpress the inhA gene product. Highly resistant isolates usually show a 
missense or complete deletion of the katG gene. (Dannenberg 1998) 
Most commonly, resistance is due to a change in the katG gene; 50 to 75% of 
INH-resistant isolates have a W G missense mutation or deletion. (Rattiedge 1999) The 
role of katG mutation in causing resistance to INH has been further verified by studies 
showing that the insertion of a wild type copy of katG into an INH resistant mutant with 
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a A:o/G mutation does restore drug sensitivity. (Gangardharam 1997) Sequence analysis 
oikatG mutants resistant to INH has showed the development of a compensatory 
mutation in the promoter region of the aphC gene. Such a compensatory mutation is 
likely to counteract the loss of catalase/peroxidase activity by hyperexpressing the alkyl 
hydoperoxidase encoded by ahpC. (Rattledge 1999) Strains producing catalase are more 
virulent then WG-deficient mutants in immunocompetent mice. (Rattledge 1999) 
Two factors—INH uptake and enzyme activity—have been shown important in 
resistant mutants. One category of resistant mutants clearly shows a deficiency in their 
ability to take up INH from the environment. Isoniazid resistant cells exposed to '""C-
INH have taken up much less radioactivity than corresponding sensitive cells. 
(Gangardharam 1997) Studies have also shown that in mutants with a high level of 
resistance to INH, the primary mechanism of resistance is the decreased permeability to 
the drug. The resistant mutants appear to have acquired a cell wall factor impermeable to 
isoniazid. (Gangardharam 1997) 
I.F. Summary 
Isoniazid is one of the leading anti-mycobacterial drugs used in the treatment of 
tuberculosis. Experimental studies, both in vitro and in vivo, have elucidated the 
mechanisms and dynamics of INH action on mycobacteria. Genetic studies on M. 
tuberculosis have suggested the genetic basis of resistance to INH action, as well as 
identifying the molecular drug targets. This understanding of INH drug action on M. 
tuberculosis provides us important information in modelling the interaction between the 
drug and the bacteria. In previous sections we have provided initial models of the drug 
treatment of a tuberculosis infection. In the following section we add upon these basic 
models of drug treatment, incorporating the specifics from this literature review of 
isoniazid action. 
II.Rifampicin 
II.A. Mode of Action 
Rifampin is a large (MW 823) complex that serves as an antituberculosis drug. 
Rifampin is in the class of rimacyins, a group of structurally similar, highly lipophilic, 
antibiotics. Rifampin is a semi-synthetic derivative of rifamycin B. RIF inhibits most 
gram positive, as well as many gram negative bacteria. Is active equally well on 
mycobacterial and nonmycobacterial organisms. Because of its high versatility, 
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rifampin is also used to treat other mycobacterial diseases, including leprosy. 
(Rattledge 1999) (Goodman 1996; Gangardharam 1997; Chamgers 1998) 
RIF acts by inhibiting RNA polymerase enzymatic activity and thus blocking 
RNA synthesis. Rifampin binds directly to the DNA-dependent RNA polymerase, 
forming a stable complex. The drug acts on the process of transcription, prior to the 
formation of the first phosphodiester bond. (Gangardharam 1997) The maximal levels 
of inhibition are achieved in vitro assays by incubating the drug and enzyme prior to 
the addition of other necessary assay components. (Gangardharam 1997) RNA 
polymerase from M. tuberculosis is lOOOX more sensitive then from E. coli. 
(Gangardharam 1997) 
II.B. Bactericidal activity 
Rifampin is bactericidal for mycobacteria. (Goodman 1996) RIF readily 
penetrates most tissues and into phagocytic cells, easily diffuses across the hydrophobic 
mycobacterial cell envelope, and is bactericidal for intracellular organisms. (Chamgers 
1998) Rifampin is considered a sterilizing agent in the chemotherapy of tuberculosis, 
in that it is active against slowly metabolising organisms. (Dannenberg 1998) 
II.C. Mechanism 
RNA polymerase consists of two parts: the core enzyme, (which has four 
subunits, including one called beta), catalyses transcription elongation. The holoenzyme 
includes the core and sigma factors that show specific affinity for different promoters, 
and function at the level of transcription initiation. (Rattledge 1999) Rifampicin binds 
the beta subunit, inhibiting transcription. (Goodman 1996; Gangardharam 1997) 
Rifampin exerts its bactericidal effect on cells by inhibiting the production of 
RNA synthesis. Rifampin binds strongly to the beta subunit of the bacterial DNA-
dependent RNA polymerase, forming a stable drug-enzyme complex. (Chamgers 
1998) Rifampin requires the presence of the entire RNA polymerase complex in order 
to bind; but the drug site of action is the beta subunit. The formation of this complex 
suppresses the initiation of chain formation of RNA synthesis. Rifampin is unable to 
bind to the nuclear RNA polymerase found in eukaryotic cells, and therefore does not 
inhibit RNA synthesis in these cells. (Goodman 1996) 
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II.D. In human action/ dosing 
The growth of M tuberculosis is inhibited in vitro by 0.005 to 0.2 ug/ml RIF. 
(Goodman 1996) For myobacterial infections, RIF used 600 mg/d/ (10 mg/kg/d) orally. 
(Goodman 1996) In some short-course therapies, use 600 mg given twice weekly. 
Rifampicin is well absorbed after oral administration, excreted mainly through the liver 
into bile. Usual doses result in serum levels of 5-7 ug/mL. Rifampicin is widely 
distributed in body fluids and tissues and is found to be highly protein-bound. 
(Chamgers 1998) Rifampin penetrates into tissue, caseous foci, serous membranes, and 
macrophages. (Dannenberg 1998) Oral dosing gives peak concentrations in plasma 2-4 
hours. After 600 mg, peak serum concentration is 7 ug/ml, but there is much variability 
amongst patients. The half-life varies from 1.5 to 5 hours, longer in case of hepatic 
dysfunction. (Goodman 1996) Half life progressively shortened by 40% during first 
14 days of treatment; induction of hepatic microsomal enzymes with acceleration of 
drug deacetylation. (Goodman 1996) 
Rifampin is metabolised in the liver and excreted in the bile. Rifampin can be 
detected in body fluids including urine, tears, and sweat, colouring them orange-red. 
(Dannenberg 1998) Use of rifampicin shows a low incidence of bad side effects, and is 
generally well tolerated, with less then 4% adverse reactions. (Goodman 1996) 
lI.E. Emergence of resistance 
Resistant mutants are present in all microbial populations at frequency of about 
1 in lO' to 10^ bacilli. Resistance results from one of several possible point mutations, 
which prevent RIF binding to RNA polymerase. Resistance is seen to develop rapidly 
in vitro in a one step process. As the human RNA polymerase is not able to bind to 
rifampin, it is also unable to be inhibited by the drug. (Chamgers 1998) (Goodman 
1996) 
The gene coding for the beta subunit of RNA polymerase is rpoB. Mutations in 
this gene give a high level resistance to rifampicin. Over 90% of rifampicin resistant 
bacilli have a mutation in rpoB. These are typically missense point mutations occurring 
in a region of 27 codons near the centre of the gene. These mutations do not appear to 
confer any significant growth disadvantage. 5% of clinically isolated resistant strains do 
not have a mutation in rpoB, suggesting that there exists an alternative mechanism of 
resistance. A likely possibility is thought to be the inactivation of rifampicin, as is seen 
in other species of mycobacteria. RIF inhibits uridine-C14 uptake in sensitive, but not in 
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resistant strains. Mutants that have the rifampicin mutation in both the alpha and beta 
subunits are resistant overall; bacteria which have only the beta subunit with a resistant 
mutation still show resistance to drug action. (Aboshkiwa, al-Ani et al. 1992; Telenti, 
Imboden et al. 1993; Aboshkiwa, Rowland et al. 1995; Gangardharam 1997; Telenti, 
Honore et al. 1997; Rattledge 1999; Morlock, Plikaytis et al. 2000) 
Most of all isolated rifampicin resistant mutants show mutation located in rpoB 
gene, in a 69bp region. This small region in rpoB has a higher potency for mutation to 
resistance. Most of clinically isolated resistant mutants have shown mutations in a short 
region of 27 codons in the center of the rpoB coding sequence. These mutations are 
mostly missense mutations, although some small in-frame insertions and deletions have 
also been found. (Honore and Cole 1993; Telenti, Imboden et al. 1993; Gangardharam 
1997; Telenti, Honore et al. 1997) 
III. Streptomycin 
III. A. Mode of Action 
Streptomycin, a member of the aminoglycoside family of antimicrobial agents, 
exerts a bacteriocidal action on mycobacteria. Streptomycin is specific to M. 
tuberculosis, and non-tuberculous mycobacteria are resistant to its action. The drug acts 
by interfering with protein synthesis, targeting the bacterial ribosome. (Goodman 1996) 
The bactericidal action of streptomycin is exerted only on growing organisms. The 
completeness of the killing action appears proportional to the rapidity of replication. 
(Barry 1964) Streptomycin action is related to the size of the inoculum. The proportion 
of SM bound to bacteria is usually small compared to the amount free in solution. (Barry 
1964) 
After a dose of streptomycin near the MIC (1 to 10 ug/ml for M. tuberculosis), 
the tubercle bacilli can continue to grow for several generations. This is referred to as a 
delay period, in which growth continues until the bactericidal effect of the drug 
commences. During this delay period, for about two days after treatment with 
streptomycin, the bactericidal action of the drug can be prevented by washing off the 
drug. After this time, bacterial lysis begins to take place, reducing the bacterial number 
to about the level at the start of treatment. While during this delay period the number 
of bacteria continues to increase, the number of viable units decreases. After the 
induction of bactericidal activity, the number of viable units continues to decrease. At 
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higher dosages of streptomycin, at concentrations of over 10 ug/ml, the progression to 
bactericidal action is much more rapid. Once the drug is administered to tubercle 
bacilli at such a dose, the effects are non-reversible, and will result in the death of the 
bacilli. (Ban-y 1964) 
Streptomycin shows both bacteriostatic and bacteriocidal activity. The 
determination of which activity predominates in any given interaction with a bacterium is 
related to drug concentration used, contact period, targeted organism, growth rate, 
medium used, and inoculum size. For the treatment of M. tuberculosis in human 
patients, the bactericidal action of streptomycin usually prevails. (Barry 1964) 
Tubercle bacilli treated with streptomycin show morphological changes. The 
immediate change is the elongation and swelling of the bacteria. The secondary 
morphological change, seen after four days exposure, is the loss of cytoplasmic structure 
and the disintegration of the cytoplasm. (Barry 1964) 
III.B. In vitro studies 
Streptomycin, because of its highly polar nature, penetrates into cells poorly. 
The drug is therefore primarily active against extracellular tubercle bacilli. (Chamgers 
1998) Studies have shown poor action against intracellular bacilli. (Chamgers 1998) 
In vitro studies have shown that relatively low concentrations (on the order of 2.5 
X 10"' M) of streptomycin can inhibit protein synthesis. And in theory, only one 
molecule of SM per ribosome is needed to inhibit the protein synthesis of a cell. 
(Gangardharam 1997) However, a larger dose is needed for effective bactericidal action 
against bacterium such as M. tuberculosis, for which there exist barriers to cellular 
uptake of the drug. Excess concentrations must be used in such cases, to account for the 
relative pemieability of the targeted cells. (Gangardharam 1997) Most tubercle bacilli 
are inhibited by a dose of 1 - 10 ug/ml in vitro. (Chamgers 1998) A sensitive population 
of M. tuberculosis can be expected to be about 80% inhibited by such a dose of 
streptomycin. (Gangardharam 1997) 
IILC. Dosing 
Streptomycin is administered by intermittent intracellular injections. For the 
treatment of tuberculosis, SM is usually given at a dose of 15 mg/kg per day with a 
single intramuscular injection. (Goodman 1996) 
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An intramuscular injection is absorbed well, giving peak blood concentrations 
within 30 - 9 0 minutes. Streptomycin is usually given in human therapy intravenously, 
as a 30 - 60 minute infusion. Such treatment yields a brief distribution phase, followed 
by serum concentrations identical to those seen after an intramuscular injection. 
Therapy is usually given in 1 to 3 equal daily doses (for patients with normal renal 
function). (Chamgers 1998) 
The dose of streptomycin is cleared by the kidney. After an oral dose, virtually 
entire dose is excreted in feces. The drug excretion rate is directly proportionate to 
creatinine clearance. The normal half-life of the drug in serum is 2-3 hours, increasing to 
24-28 hrs in patients w/ significant impaired renal fxn. (Chamgers 1998) 
III.D. Emergence of resistance 
On average, 1 in 10^ tubercle bacilli can be expected to show natural resistance 
to streptomycin, growing on media containing 10 - 100 ug/mL streptomycin. 
(Chamgers 1998) The most common mechanism of streptomycin resistance is 
mutation of genes affecting the bacterial ribosome, which prevent the enzymatic 
inhibitory action of streptomycin. The primary mutation found in human tuberculosis 
cases resistant to streptomycin is a point mutation that alters the ribosomal binding site. 
(Meier, Kirschner et al. 1994; Chamgers 1998) Other types of resistant mutants are 
found, including those resulting from the acquisition of enzymes that can metabolize or 
prevent the up-take of streptomycin. (Goodman 1996) 
Three categories of single step mutants are typically obsei-ved in a sensitive 
population: low resistance (at a frequency of 10"''), medium resistance (10'^), and high 
resistance (10"^). (Ban y 1964) One also observes resistance emerging through a series 
of steps in succession. The frequencies for such multiple-step mutants vary greatly by 
strain. Spontaneous mutation of tubercle bacilli to a high level of resistance to 
streptomycin has been observed at a rate of about 10 / bacterium. (Barry 1964) 
Mutants showing a high level of resistance to steptomycin require a 10,000 fold 
higher concentration then used for sensitive strains, to achieve a 50% inhibition. 
(Gangardharam 1997) The mutations conferring such high levels of resistance have been 
found to reside in the genes for the bacterial ribosome. In contrast, M tuberculosis 
mutants showing low levels of resistance appear to use an alternative mechanism for 
resistance. Such mutants show similar in vitro inhibition of protein synthesis, showing 
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that the mutation conferring cellular resistance to SM does not reside in ribosome 
function. (Gangardharam 1997) 
DRUG 
CELL INHIBITS Requires ACTIVE Environ Sterilizing Mechanism Mutation Endemic 
TARGET Growth? AGAINST -ment Activity In 
vivo? 
Resistance Rate Resistance 
FIRST LINE DRUGS 
ISONIAZID 
(INH) 
Enzyme 
required for 
mycolic acid 
synthesis 
Cell wall 
synthesis 
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dividing; weakly 
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multiplying 
Extracellul 
ar 
None Inactivatio 
n of 
catalase-
peroxidase 
gene, katG 
] 0-8 1 in 106 
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(RMP) 
B- subunit 
RNA 
polymerase 
RNA 
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rapidly) growing 
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Intra + 
Extracellul 
ar 
Sterilizing 
(acts on 
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RpoB 
mutation 
(j3-subunit 
pol) 
10-10 1 in 108 
STREPTOMYCl 
N 
(SM) 
ribosome Protein 
synthesis 
Yes Rapidly dividing Extracellul 
ar 
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Sterilizing 
10-8 1 in 107 
PYRAZINAMID 
E 
(PZA) 
9 9 Bacterios 
tatic 
Can kill in acid 
environment 
Intra + 
extracellul 
ar 
Sterilizing 10-3 1 in 106 
ETHAMBUTOL 
(EMB) 
Arabinogaia 
ctan 
synthesis 
Cell wall 
synthesis 
Yes BACTERID 
-STATIC 
Weakly 
active 
against 
Intra + 
Extracellul 
ar bacilli 
None Mutation 
of target 
enzyme 
10-7 1 in 105 
SECOND LINE DRUGS 
ETHIONAMIDE Inhibits 
mycolic acid 
BACTERIO-
STATIC 
Mutation 
of target 
10-3 
synthesis enzyme 
Thiacetazone BACTERIO-
STATIC 
10-3 
P-aminosalicyclic 
acid 
(PAS) 
Folate 
biosynthesis 
BACTERIO-
STATIC 
10-8 
Oxfloxacin DNA gyrase Rapidly 
dividing; 
Neutral or 
alkaline pH 
gyr A&B 9 
QUINOLONE DNA 
Gyrase 
DNA 
replication 
Mutation 
of target 
enzyme 
? 
Table 14-1. The properties of drugs used in the treatment of tuberculosis. Sources: (Mackaness and Smith 1953; Mitchison and Fox 1969; 
Mitchison 1974; Mitchison 1979; Goodman 1996; Gangardharam and Jenkins 1997; Mitchison 1997; Peloquin, Jaresko etal. 1997; Mitchison 
2000) 
DRUG Dose Cmax (mg/L) 
Tmax tl/9 MI 
C 
Protein 
binding Inhibits 
Requires 
growth? 
Active 
against 
ISONIAZID 
(slow acetylator) 
(fast acetylator) 
300 5 1.0 
(Peloqui 
n, 
Jaresko 
et al. 
1997) 
3 0.1 0 Cell wall 
synthesis 
Yes Rapidly dividing; 
weakly on slowly 
multiplying 
4 1.3 
RIFAMPICIN 600 12 1-2 
(Peloqui 
n, 
Jaresko 
et al. 
1997) 
3 0.3 85 RNA 
synthesis 
Yes acts against 
slowly (+ rapidly) 
growing 
organisms 
STREPTOMYCIN 750 40 3-5 2 35 Protein 
synthesis 
Yes Rapidly dividing 
PYRAZINAMIDE 2000 40 8 20 0 ? Bacteriostat 
ic 
Can kill in acid 
environment 
ETHAMBUTOL 1200 3 3 1.5 0 Yes Low activity 
Table 14-9. The pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of tuberculosis. 
Sources: (Mackaness and Smith 1953; Mitchison and Fox 1969; Mitchison 1974; Mitchison 1979; Goodman 1996; 
Gangardharam and Jenkins 1997; Mitchison 1997; Peloquin, Jaresko et al. 1997; Mitchison 9000) 
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IV. Estimating in vivo growth of TB strains 
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VI. Discussion 
I. Introduction 
We consider here a model of a tuberculosis infection in order to better 
understand the dynamics of the within-host mycobacterial population. 
In particular, we are interested in quantifying the in vivo growth rate of 
Mycobacterium tuberculosis, as this directly affects the rate of progression to infectious 
tuberculosis disease, as well as the time needed to treat and clear an infection and the 
rate of emergence of drug resistance. Each of these points is crucial to understanding 
current issues in the treatment of tuberculosis, in particular the epidemics of drug 
resistance and the need for a long duration of treatment. 
We know from in vitro experiments that mycobacteria tuberculosis is slow 
growing, dividing on the order of once per 20-24 hour period, depending on conditions 
used. (Fishman and Elias 1998; Colston 1999) However, it has been difficult to infer 
from these experiments an in vivo growth rate, as the environment within-host is 
difficult to characterize and replicate in an in vitro setting. 
In particular, the multi-compartmental nature of a mycobacterial population 
within an infected tuberculosis patient, including sub-populations that may have 
differential access to nutrients as well as drug, confound these interpretations. In 
addition, the host immune system plays a role in suppressing mycobacterial growth, 
limiting the population size. 
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While it is widely accepted that mycobacteria grow more slowly within-host 
than in optimal in vitro conditions, experiments have not been able to disentangle host 
effects on bacterial death from inhibition (or slowing) of growth. In the terms of 
population dynamics, this means we cannot differentiate between an increased death 
rate and a decreased division rate. However, we can comment on the relationship 
between the birth and death rate. In particular, we can estimate the bacterial growth 
rate, defined as the birth rate divided by the death rate. 
Previously, the in vivo growth rate of mycobacteria remained fairly elusive due 
to limited quantitative bacteriologic data from tuberculosis patients. Recent studies 
measuring the colony forming units (CPU) of mycobacteria over the course of patient 
treatment provide us the opportunity to estimate the growth rate. (Nunn 1992; Brindle 
1993; Desjardin 1999) 
We examine previously reported data on the timecourse of CPU during the first 
28 days of treatment of infectious tuberculosis patients with a daily regimen of 
streptomycin (S), thiacetazone (T), and isoniazid (H). (Brindle 1993) We propose a 
model to explain the decrease in mycobacterial CPU over this treatment time. 
In particular, we propose the existence of two distinct sub-populations of 
mycobacteria within the host, which differ only in their effective growth rates. 
Purther, we add to previous population dynamic models of bacterial infection by 
including specific pharmacodynamic parameters to account for the mode of drug action 
on bacteria. As the drugs used in this treatment (S, T, and H) each require growth to 
exert bactericidal activity, we suggest that the drug-induced death rate is proportional to 
the mycobacterial growth rate. 
We estimate these bacterial population dynamic parameters by fitting our model 
to the described data set, using maximum likelihood. We find that our model of two 
bacterial populations with equal drug susceptibility but different growth rates can 
explain the observed data and variance with a high level of significance (p<0.001), and 
suggest interpretations of the parameters as well as alternatively plausible models. 
II. The Data Set 
We examine the counts of mycobacteria present in sputum of patients 
undergoing the first month of a standard regimen of tuberculosis treatment. This data 
was part of a study to compare the chemotherapeutic effect of two particular TB 
regimens in HIV-positive and a control HIV-negative patient group, in Nairobi, Kenya. 
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All patients in the study were confirmed TB positive, had not received previous TB 
treatment, and showed no initial drug resistance to the drugs used. Two different TB 
regimens were compared in this study—STH and SHRZ (streptomycin, isoniazid, 
rifampicin, and pyrazinamide)—in both HIV positive and negative patient groups. 
(Brindle 1993) 
Brindle compares these treatment regimens and concludes that HIV status does 
not significantly change the effectiveness of chemotherapy, as measured by the rate of 
decrease of mycobacterial counts in the sputum. This suggests that drug bactericidal 
activity is similar in HIV-positive and negative patients, even though the difference in 
immune system response to the mycobacteria must differ significantly. (Brindle 1993) 
In the second phase of this study, patients were given a continuation treatment 
regimen (of TH) for an additional 11 months and mortality rates and causes of death in 
the four treatment groups were compared. (Nunn 1992) 
Mitchison's statistical analysis of the Nairobi data suggested experimental and 
biological explanations for the variance seen in patient drug response. (Mitchison, in 
press). 
We focus on the patients receiving STH treatment, as we are interested in 
understanding the effects of bactericidal drugs requiring growth. The second treatment 
includes two drugs—rifampicin and pyrazinamide—that are considered 'sterilizing' 
drugs and are shown v//ro to be active on slow growing mycobacteria. 
The patients are given daily doses of streptomycin, thiacetazone, and isoniazid. 
Sputum samples are taken at unequal intervals during a 28-day period after the 
beginning of treatment. Mycobacterial numbers present in sputum are measured by 
colony counts, and reported as logiocounts. 
III. Methods of fitting model to data 
We tested the distribution of CPU counts for normality, using SPSS K-Wallis 
test. We found that the bacterial counts did not significantly conform to the normal 
distribution. In addition, we found that the variation changed with time. We 
transformed the data in order to work with a normal distribution and to normalize the 
variation. 
We found that the mean of the CPU counts is approximately equal to the 
standard deviation. As this is a property of the log normal distribution, we considered 
transforming the data by taking the natural logarithm of the counts. We find that the LN 
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(counts) for timepoints 2 to 28 does indeed more significantly (by the K-Wallis test) 
resemble a normal distribution. However, the counts at timepoint t=0 did not conform 
to normality. 
In order to get around the high variance present during the rapid kill phase of 
the first two days of treatment, we examined the relative kill in each patient. We 
plotted the relative LN(counts) at each time point, defined as the LN N(t) / LN N(0). 
We found that the relative LN counts did significantly fit a normal distribution. 
We fit our model (see above) to this data set, and estimated parameters by 
maximum likelihood. We find, for the log normal distribution, that the variance (a~ = 
0.035) is constant over time. We use the sample estimate of the variance from the 
patient data set as the MLE of the variance in our model. 
We find the MLE for our model parameters by minimizing the negative log 
likelihood for a normal distribution, calculated as; 
— \ 2 M , (/' - /") 
- Log likelihood - n log(cr) + — !og(2n) + 
2 2 o ^ 
We minimize this function and fit parameters with a C+4- program using powell 
minimization. We found powell to be more efficient and reliable method than Newton 
or conjugate minimization. 
We found confidence intervals for each parameter by refitting the model at each 
point, holding the parameter of interest constant. The 95% confidence interval is found 
for maximum likelihood estimates that fall within a x" with 1 d.f , reflecting the one 
parameter that is held fixed. 
Zhy = 3 . 8 4 
Change in log likelihood < 3.84 
A change in log likelihood less than 3.84 falls within the 95% confidence interval. 
We found the parameter confidence intervals using powell minimization in C++, 
through repetitive calls to minimize the negative log likelihood function as one 
parameter was given a fixed value and the remainder were allowed to vary. 
IV. Estimating in vivo growth of TB strains 
We are interested in quantifying population parameters that describe the within-
host mycobacterial growth rates, as a template to measure drug action. For viruses, the 
convention is a parameter known as RQ, which describes the number of secondary cell 
infections by a primary infected cell, in the absence of constraints on viral population 
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growth. This parameter is useful in describing populations growing primarily 
intracellularly, and as such, is less applicable to studies of active infectious 
tuberculosis. 
We consider an environment in which mycobacteria are at equilibrium with any 
host-induced growth restraints, particularly immune response. In addition, we focus 
our attention on the mycobacterial population that grows extracellular. While early 
after infection the mycobacterium is primarily growing within macrophages, by the 
time there has been progression to active, smear positive tuberculosis disease, the 
mycobacteria are primarily extracellular. The liquefied caseous material found in the 
now aerated foci seem to inhibit macrophages, and for the first time since the start of 
infection, the tubercle grows in an extracellular environment. 
We therefore assume that the mycobacterial population grows extracellularly. 
A relevant parameter to describe the extracellular growth of a bacterial population is 
the intrinsic population growth, r, which describes the potential for growth in the 
absence of constraints. 
We measure here the intrinsic population growth in the presence of specific-
activated host immune response. We also measure the intrinsic growth rate in the 
presence of drug, during the first 28 days after treatment. The drug acts, as expected, to 
bring the intrinsic growth below 0, (r<0), such that the drug reduces the mycobacterial 
population size, already found at equilibrium with the host immune response. 
V. Estimating r 
We model two bacterial strains growing exponentially and independently. We 
assume here that the growth rates are density-independent and do not attempt to apply 
an upper limit to the population size. We feel these assumptions are appropriate for this 
model, as we are considering a bacterial population that begins at t = 0 at drug-free 
equilibrium. We then introduce drug treatment and observe the change in population 
size during short intervals. During this time, the bacterial population can be assumed to 
be adjusting to the addition of drug and (far from equilibrium) undergoing exponential 
decline. We assume constant drug concentration over time. 
Model \ \ N , = N ^ e ' " + N ^ e ' 
We first estimate the intrinsic mycobacterial growth rate in the presence of drug, 
r*. We consider a model in which two mycobacterial strains are present. We estimate 
the growth rate of each strain, and find that the two growth rates are distinct (r*, 7^  r'z) 
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with p<0.05. We estimate the death rate of strain 1 to be O.I 1 (95% CI [0.06, 0.14]) that 
of strain 2. We estimate that 9% of the total mycobacterial population is being killed at 
this slower rate. 
We fit model 1 to the data set using maximum likelihood estimation, and found 
that the maximum likelihood estimate for model 1 was 263.28. To test whether this 
model can significantly represent the data, we compared the ML (itself a chi-squared 
distribution) to a%^ with 4 d.f.. We found that this model can predict the data with a p-
value of p<0.01. 
Our estimation of the growth rate of two strains during this treatment suggests 
that approximately one in ten mycobacteria is cleared at a rate of 6 - 14% of the 
remaining mycobacteria. This estimate of r* represents the mycobacterial growth rate in 
vivo in the presence of drug treatment. This reflects a combination of the intrinsic 
mycobacterial growth rate (births), the death (or decreased birth) rate due to host 
immune response, and the death rate from drug action. 
r = births - deaths 
We then seek to understand the two components of the growth rate, the birth and 
death rates. We propose three models for the combination of birth and deaths that can 
explain the dynamics for the clearance of the two mycobacterial populations under drug 
treatment. We find that each of these models (models 2 - 4 ) can predict the variance 
seen in the data with greater than 99% confidence, but that none is significantly better 
explanation of the data (p<0.01). 
In models two and three, we present two strains which share either a common 
birth or death rate. In model four we consider a situation where the death rate is directly 
proportional to the birth rate, and this proportionality constant is shared between two 
strains with distinct birth and death rates. 
M o d e l 2 : = AT, 
We model here two strains (N| and N2) growing with a birth rate (p.) but distinct 
death rates (D, and D2). This is meant to represent bacterial strains that either have 
differential drug susceptibility or drug access. We estimate that the initial population 
consists of 91.1% strain 1 and 9.9% strain 2. We estimate the birth rate p. as 0.91 
divisions/ day, D| as 1.09 deaths/ day, and D2 as 1.99 deaths/ day. We then estimate the 
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dimensionless ratio births / deaths, representing the strains growth capacity. We find the 
best estimate for )j,/D| to be 0.84, approximately twice the best estimate of 0.39 for ^/Dz. 
Model 3: = TV, 
We model here two strains (N, and N?) with distinct birth rates (|_i| and p.?) but a 
common death rate (D). This represents strains growing at different rates due to either 
differential access to nutrients required for growth or the extent of immune inhibition. 
Model 4: VV, = TV, 
where D = d p. 
We model here two strains (N1 and N2) with both distinct birth rates (pi and 
1^ 2) and death rates (D1 and D2). We assume that the drug-kill rate is directly 
proportional to the bacterial growth rate. D is the proportionality constant for drug 
action on the dividing bacteria. This relationship allows us to model drug action that is 
dependent on the growth rate, requiring division in order to kill the bacteria. 
Organisms that do not divide (p = 0) will not be killed by drug (drug-kill rate = 0). The 
faster a bacterial strain divides, the faster it will be killed by drug. 
This model incorporates our intended requirement for bacterial division in order 
for the drug to exert its bacteriocidal activity. In addition, we assume here that all 
bacteria are killed with the same rate per cell division. The difference seen in growth 
rates between the two bacterial strains is due solely to the relative rates of division. 
Drug - kill rate = d 
— M f' 
Drug-induced deaths — - ' ' o ^ 
If D = 1, then birth rate = death rate, and strain size will stay constant. 
If D>1, then drug will decrease the population size If D<1, then growth rate will exceed drug-
death rate, and population will grow 
We estimate the initial population to consist of 5% strain 1, with a birth rate ()j.|) 
of 0.13 divisions/day. Strain 2 was estimated at 95% of the initial population, with a 
birth rate (p,;) of 1.2 births/day. The common drug death rate constant (d) was estimated 
as 1.99. The drug death rate (D = d p.) for strain 1 (D|) was 0.08-0.51 deaths/day, and 
for strain 2 (D2) 1.27-4.00 deaths/day. We also estimate the birth / death ratio as 0.41 -
0.63, a narrower interval than we obtained in the above models. 
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We find that these three proposed models of bacterial growth rates are equally 
likely and thus we cannot reject any of these models. If we made assumptions about 
the relation between the birth and death rates, including the extent of variation within 
the bacterial population and the ratio between birth / deaths, we could estimate these 
rates as well. However, a better biological understanding is required to distinguish 
which assumptions are valid and which model is most applicable. 
VI. Discussion 
While the nature of dormant or persisting mycobacteria remains elusive, the 
existence of slow growing strains able to evade the host immune response is believed to 
be an important component in treatment failure. Our within-host model of the 
dynamics of TB growth predicts that one strain is cleared at a significantly slower rate, 
reinforcing this notion. 
M tuberculosis has the ability to remain dormant for extended periods of time. 
(Colston 1999; Koch 1997) The biological nature of this dormancy is not well 
understood. However, this feature is central to allowing bacteria to remain in a host for 
years following the initial infecfion, a state referred to as latent tuberculosis. (Colston 
1999) This makes bacterial sterilization of a host very difficult, particularly since many 
of the antituberculosis drugs are active only on dividing cells. (Smith 1994) Drug 
treatment will usually kill most of the mycobacteria! population within several weeks; 
however, the mycobacterial persisters will evade the drug by entering into a dormant 
state and remain in the host. These remaining bacilli can later lead to reactivation of 
the infection and post-primary tuberculosis. (Colston 1999) 
Our model predicts that one strain is cleared at a significantly slower rate. This 
reinforces the idea that the mycobacterial population is not of equal drug susceptibility, 
and that long-term treatment is required in order to clear the persisting mycobacteria. 
Our model predicts, based on the observations during the first month of drug 
treatment, how long it will take to clear the infection. We also predict what proportion 
of the initial bacterial population is cleared at a slower rate. Unfortunately, as we are 
not able to distinguish mathematically between a strain that has a decreased death rate 
and one with an increased birth rate, we cannot precisely estimate the birth and death 
rate of these strains. Instead, we offer several plausible models that give a range of 
values for these rates. A more precise estimation of the in vivo mycobacterial birth and 
death rates requires further experimentation. S 
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Figure 15-1. Model parameters. 
Model 1: e"'' + 
Parameter Explanation Estimation 95% Confidence 
Interval 
Nt population size at 
time= t 
N, (A3) Proportion strain ] at 
t=0 
0 .09 [0.044, 0.18] 
N2 (5E7-
N l ) 
Proportion strain 2 at 
t=0 
0.91 [0.82, 0.95] 
r , CAO growth rate strain 1 
0.166/day 
[-0.2,-0.1] 
r z (A2) growth rate strain 2 -1.4 / day [-3.2, -0.7] 
Model 2: N, = 
Parameter Explanation Estimation 95% Confidence 
Interval 
N, Population size at 
time= t 
NJ / NQ (A1) Proportion strain lat 
t=0 
0.911 (0.79, 0.95) 
Proportion strain 2 at 
t=0 
0 .099 (0.05. 0.21) 
Birth rate 0.91 (0.86, 0.96) 
D/ Death rate strain 1 1.09 (1.02, 1.12) 
Death rate strain 2 1.99 (1.13,+) 
/ / / D , 0 .84 (0.81,0.89) 
yU/D, 0 .39 (0 ,0 .77) 
Model 3: W, = #, + N,e""-"" 
Parameter Explanation Estimation 95% Confidence 
interval 
N, Population size at 
time= t 
N! / A'O Size strain ] at t=0 0 .05 
Size strain 2 at t=0 0 .95 
/^I Birth rate strain 1 0.01 
/^2 Birth rate strain 1 1.24 
D Death rate 1.41 
Model 4: N, = A^, 
Parameter Explanation Estimation 95% Confidence 
Interval 
N, Population size at 
time= t 
396 
Proportion strain 1 at 
t=0 
0 . 0 5 [0, 0.15] 
N2/N0 (5e7 Proportion strain 2 at 
t=0 
0.95 [0.85, 1] 
Birth rate strain 1 0.13 / day [0.05, 0.21] 
Birth rate strain 2 1.2 / day [0.81,1.64] 
Death rate constant 1.99 fi [1.58, 2.44] 
D , = ( 0 . 0 7 9 , 0 . 5 1 ) 
D 2 = ( 1 . 2 7 , 4 . 0 0 ) 
^ / D = ( 0 . 4 1 , 0 . 6 3 3 ) 
Model 1. 
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A. 
C. 
4)^ -0.70 
GroAih Rale Strain 1 (A1) 
4)^  -0.4 -OjO %L20 4110 0.00 
B. 
OfMhR#l#af#lm2 (A2) 
.4 90 -4.00 3 50 -3 00 2 90 -2.00 1.90 100 OjO 0.00 
^ OM MO ^ 0# ^ ^ 
Figure 15-2. Model 1. 95% Confidence intervals for Model 1 parameters. 
Growth rates of strain 1 (r , , A) and strain 2 (r , , B), and the proportion of initial 
population which is cleared at a slower rate (Ni/No , C). 
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Predicted vs. observed values for model 1. 
SHT Treatment HIV-
1 ,E+05 
M 1.E*04 
u- 1.E+03 
1.E+02 
-MODEL !! 
lO'OATA 11 
Treatment Time (Days) 
Figure 15-3. Mean data and model 1 predicted values. The mean values of 
patients in the SHT, HIV- treatment group at each time point are shown above (solid 
triangles) against the values predicted by model 1 (solid line). The parameters used in 
model 1 are the best fit parameters from the estimation, as shown in Figure 15-2. 
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Residuals for Model 1. 
A. 
SHT Treatment, HIV-
Residuals: Predicted - Observed 
B. 
SHT Treatment, HIV-
RESIDUALS: (Model - Data)*2 
1.00E+10 
1.00E*0@ 
i.ooE+oe 
1.00E+07 
1.00E406 
1.00E+05 
1.00E*04 
1.00E+03 
1 006*02 
1.00E+01 
1.00E+00 
I.OOE^  
1.006-04 
1 00EO6 
Figure 15-4. Residuals for model 1. The model 1 residuals (predicted - observed), are 
shown in (A) and the square of these residuals in (B). 
4 0 0 
Model 2 
A. 
oa 07 08 w 
B. 
• 
• 
OM 0» 0* Oa 0# 
c. 
MO WW OM OW 0# 1#l 
D. 
am AM am im 
F i g u r e 15-5. M o d e l 2. C o n f i d e n c e intervals for model 2 parameters . 
Proportion of initial population which is slow growing, Ml/No (A), birth rate p. (D), and 
the ratio of birth rate to death rate of strain 1 (p /Dl , B) and strain 2 (|_i/.D2, C). 
Model 4. 
A. 
06 M 08 Ml 
B. 
• 
• 
ow 0% o# OM iM 
c. 
om 0^ OM OW OM DM 
D. 
F igure 15-6. M o d e l 4. C o n f i d e n c e intervals for model 4 parameters . 
Proportion of initial population which is slow growing, N l / N o (A), birth rate p (D), and the 
ratio of birth rate to death rate of strain 1 (p /Dl , B) and strain 2 (p/.D2, C). 
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